Search by Journal
- HOME
- > Search by Journal
- > Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Volume , Issue suppl.1 / 2020
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
We improve a pharmacist power supporting medical care with patients 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 101-101, 2020. |
|---|
|
|
Efforts and problem for the further development of the Japanese cure association 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 102-102, 2020. |
|---|
|
|
SL1. Medical therapy of the gastric cancer to examine in gastric cancer treatment guidelines 小寺泰弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 103-103, 2020. |
|---|
|
|
SL3. Contribution to society of the pharmaceutical company which fixed its eyes on the medical future 手代木功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 105-105, 2020. |
|---|
|
|
SL4. We regard the present and the future of pharmacologic - AI as medical care 池谷裕二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 106-106, 2020. |
|---|
|
|
EL1. The current situation of the genomic medicine and future directionality 尾崎紀夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 107-107, 2020. |
|---|
|
|
EL2. Personalized medicine: TDM vs. genomic medicine 谷川原祐介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 108-108, 2020. |
|---|
|
|
EL3. Pharmacist duties of one day are not everlasting pharmacist duties 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 109-109, 2020. |
|---|
|
|
EL4. The current situation and the future of the Alzheimer therapeutic drug 服部光治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 110-110, 2020. |
|---|
|
|
EL5. It is ... with ... pharmacist protecting patients from mishaps in medical practice 長尾能雅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 111-111, 2020. |
|---|
|
|
ES1-1. From the situation of the physician who was the practice of COVID-19 忽那賢志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 113-113, 2020. |
|---|
|
|
ES1-2. From the position of the pharmacist of the medical institution which gave medical care of COVID-19 梅村拓巳1, 武藤義和2, 太田愛子1, 伊藤雄紀1, 伊藤晴也1, 小崎耕自1, 位田陽史2, 石原誉志美2, 小林有里2, 須川真規子2, 市原利彦2, 山田哲也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 114-114, 2020. |
|---|
|
International Symposium 1. Efficient and productive pharmacist profession in the future - Point of view of Pharmaceutical Care, Education, Research and Social Contribution-1 Yasuo Takeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 121-121, 2020. |
|---|
|
|
IS01-3. Pharmacist Education and Professionalism in Japan and the United States Misuko Onda1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 123-124, 2020. |
|---|
|
|
IS01-4. Role of Pharmacist in Primary Care Setting During Covid-19 Pandemic : Thailand's Experience Jatuporn Thong-Im1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 125-126, 2020. |
|---|
|
|
IS02-SP. Establishment of the Clinical Pharmacist Okayama Simulation Training for Next - generation Pharmacists Toshiaki Sendo1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 127-128, 2020. |
|---|
|
|
IS02-1. Pharmaceutical GS1 barcodes for patient safety: preventing picking error and improving traceability Koichi Uemura1, Takao Orii2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 129-129, 2020. |
|---|
|
|
IS02-2. Developing a Japanese version of the "Scale of Attitudes Toward Pharmacist-Physician Collaboration" Kanayuki Kitahara1, Takeshi Uchikura1, Yuta Nio1, Satoko Katsuragi1, Keinosuke Okazaki1, Yoshiko Nishi2, Takashi Kawaguchi3, Takuhiro Yamaguchi4, Tadanori Sasaki1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 130-130, 2020. |
|---|
|
|
IS02-3. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database Shiori Hasegawa1,2, Hiroaki Ikesue1, Satoshi Nakao2, Kazuyo Shimada2, Ririka Mukai2, Mizuki Tanaka2, Kiyoka Matsumoto2, Misaki Inoue2, Riko Satake2, Yuu Yoshida2, Fumiya Goto2, Tohru Hashida1, Mitsuhiro Nakamura2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 131-131, 2020. |
|---|
|
|
Symposium 1. [practice] How do you make use of infection measures cooperation common platform (J-SIPHE) in drug-resistant (AMR) measures? 北原隆志, 大曲貴夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 132-132, 2020. |
|---|
|
|
S01-1. A summary of J-SIPHE and future directionality 村木優一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 134-134, 2020. |
|---|
|
|
S01-2. The utilization situation in the Nagoya district 加藤善章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 135-135, 2020. |
|---|
|
|
S01-3. Inflection report of J-SIPHE about the improvement in hand hygiene in JCHO 片山歳也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 136-136, 2020. |
|---|
|
|
S01-4. The utilization situation between the national and public universities Hospital 浦上宗治1, 加賀谷英彰1, 山崎伸吾1, 沖畠里恵1, 丹羽隆1, 冨田隆志1, 徳江豊1, 高山和郎1, 村上啓雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 137-137, 2020. |
|---|
|
|
S01-5. Activities by the cooperation between areas in capital disease medicine, Shinjuku-ku 木村利美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 138-138, 2020. |
|---|
|
|
Symposium 2. [Medical care] Onco-Cardiology Let's learn science - task sharing, demonstrating pharmacist power to manage in the shift era - 向井幹夫, 藤堂真紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 139-139, 2020. |
|---|
|
|
S02-1. With the tumor angiocardiology? Demand it from a pharmacist in clinical settings 向井幹夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 141-141, 2020. |
|---|
|
|
S02-2. Result report of the research of the field of Onco-Cardiology where a pharmacist sends it to 平出誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 142-142, 2020. |
|---|
|
|
S02-3. About the side effect regime of the anticancer medicine which a setup and a pharmacist can play for Onco-Cardiology team 藤堂真紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 143-143, 2020. |
|---|
|
|
S02-4. How can the pharmacist play an active part in the settings of Onco-Cardiology? We think about this 中埜信太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 144-144, 2020. |
|---|
|
|
Symposium 3. [practice] ... which learns which renal function you should use for administration plan from a ... pit fall case 平田純生, 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 145-145, 2020. |
|---|
|
|
S03-1. Evaluation of the renal function of frailty sarcopenia elderly people 平田純生1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 147-147, 2020. |
|---|
|
|
S03-2. Pit fall of the renal function notation of the package insert 竹内裕紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 148-148, 2020. |
|---|
|
|
S03-3. Usefulness and pit fall of the serum creatinine level 浦田元樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 149-149, 2020. |
|---|
|
|
S03-4. Use and pit fall of estimation CCr, eGFR 川上倫子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 150-150, 2020. |
|---|
|
|
S03-5. Usefulness and pit fall of cystatin C 津下遥香1, 田中遼大1, 龍田涼佑1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 151-151, 2020. |
|---|
|
|
S03-6. Usefulness and pit fall of the round up method 大谷知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 152-152, 2020. |
|---|
|
|
Symposium 4. [practice] How should the pharmacist work to prevent the becoming severe of the immune-mediated adverse event? 渡邊裕之, 池田宗彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 153-153, 2020. |
|---|
|
|
S04-1. Relation of the pharmacist in the irAE management 藤堂真紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 155-155, 2020. |
|---|
|
|
S04-2. Multicenter collaboration aimed at safe cancer treatment practiced by pharmacists - Kagoshima Cancer Immunotherapy Support Network KISnet - 上原友美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 156-156, 2020. |
|---|
|
|
S04-3. The need of regional alliances of the irAE management that we were able to see by an activity of Kyushu University Hospital team ICI 南晴奈1, 池田宗彦1, 秦晃二郎1, 渡邊裕之1, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 157-157, 2020. |
|---|
|
|
S04-4. "Thing - "which is necessary for ... drugstore pharmacist to support ICI proper use 古賀友一郎1, 村田峰生1, 林田諭1, 加藤周子1, 石橋正次1, 川本健司1, 高木淳一1, 鷲山厚司1, 田中泰三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 158-158, 2020. |
|---|
|
|
Symposium 5. [education] Upbringing of the next-generation leader solving a clinical problem in the cancer chemotherapy 橋本浩伸, 河添仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 159-159, 2020. |
|---|
|
|
S05-1. The study achievements that are demanded from a pharmacist specialized in a cancer 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 160-160, 2020. |
|---|
|
|
S05-2. Difference between study and clinical studies that the 6-year pharmacist who is a graduate feels that is a graduate 馬場楓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 161-161, 2020. |
|---|
|
|
S05-3. Importance of rationale in the instruction of the study (the study that is a graduate) by the pharmacy student 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 162-162, 2020. |
|---|
|
|
S05-4. That the purpose studying creates evidence and returns it to future patients 河添仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 163-163, 2020. |
|---|
|
|
S05-5. Step ... to fight ... weak conquest without the end with English presentation, the English article 大谷壽一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 164-164, 2020. |
|---|
|
|
Symposium 6. [study] For the creation of the innovative therapeutic drug which rose in the viewpoint of drug discovery study - clinical pharmacy that academic hospital automation pharmacy challenged - 齋藤秀之, 石澤啓介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 165-165, 2020. |
|---|
|
|
S06-1. Study on uric acid transporter and uric acid descent medicine found by genome analysis 高田龍平1, 宮田大資1, 豊田優1, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 167-167, 2020. |
|---|
|
|
S06-2. Creation of the high affinity chaperone compound which is optimal for lysosomal disease treatment to function as a structure stabilizer of the mutation enzyme 加藤敦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 168-168, 2020. |
|---|
|
|
S06-3. Strategy for prophylactic/therapeutic drug development for cancer chemotherapy-induced peripheral neuropathy 中川貴之1, 荻原孝史1, 小柳円花1, 今井哲司1, 松原和夫1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 169-169, 2020. |
|---|
|
|
S06-4. Search of the renal failure extension inhibition therapeutic drug which assumed production responsibility enzyme SULT1A1 of the sulfuric acid conjugation type urine toxin a target 齋藤秀之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 170-170, 2020. |
|---|
|
|
S06-5. Drug repositioning study utilizing medical big data 座間味義人1,2, 新村貴博1, 石澤有紀3, 合田光寛2, 濱野裕章2, 岡田直人2, 八木健太4, 中馬真幸4, 桐野靖2, 中村敏己2, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 171-171, 2020. |
|---|
|
|
Symposium 7. [contribution to society] The clinical reasoning in the acute intoxication medical care 堀寧, 峯村純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 172-172, 2020. |
|---|
|
|
S07-1. Nearby caffeinism! The appropriate management is a duty of the pharmacist 今井徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 174-174, 2020. |
|---|
|
|
S07-2. Diphenhydramine poisoning to feel from clinical manifestations 佐藤智人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 175-175, 2020. |
|---|
|
|
S07-4. The clinical reasoning of the acute methanol poisoning with the unidentified metabolic acidosis 波多野亘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 177-177, 2020. |
|---|
|
|
S07-5. Toxic side effect to assume kidney origin 平田純生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 178-178, 2020. |
|---|
|
|
Symposium 8. [education] To build rehabilitation nourishment and the knowledge ... elderly people with rehabilitation drug society which want to know full of life; ... 中村直人, 東敬一朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 179-179, 2020. |
|---|
|
|
S08-1. About sarcopenia frailty - elderly people society and medical therapy - 中村直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 181-181, 2020. |
|---|
|
|
S08-2. - to make use from - tomorrow in duties about rehabilitation nourishment, a rehabilitation drug 東敬一朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 182-182, 2020. |
|---|
|
|
S08-3. Mainly on activity place and multi-type of job cooperation - polypharmacy efforts example of the pharmacist - 中道真理子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 183-183, 2020. |
|---|
|
|
S08-4. Than the workshop of the practice rehabilitation drug - country bionomics classification working in an area ... 久保田恵理1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 184-184, 2020. |
|---|
|
|
S08-5. We expect it of rehabilitation nourishment and fine-view - pharmacist of the rehabilitation drug 若林秀隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 185-185, 2020. |
|---|
|
|
Symposium 9. [study] The clinical application of the mechanism elucidation of the internal change change by fundamental researches: When we end it in phenomenalism, it is a waste! 内田信也, 工藤敏之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 186-186, 2020. |
|---|
|
|
S09-1. Fundamental researches of the internal change change mechanism aiming at clinical application 工藤敏之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 187-187, 2020. |
|---|
|
|
S09-2. Clinical practice and basic pharmaceutic integration study aiming at an interaction mechanism elucidation of the polypharmacy 黄倉崇1, 志保美月1, 中谷絵理子1, 赤下学1, 山田静雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 188-188, 2020. |
|---|
|
|
S09-3. Quantitative analysis based on the mechanism of drug interactions: Inflection of OATP substrate medicine (probe) and the internal substrate 吉門崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 189-189, 2020. |
|---|
|
|
S09-4. Factor elucidation of the individual difference to give the effectiveness, safety of the fentanyl percutaneous absorption type preparation 嶋田努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 190-190, 2020. |
|---|
|
|
S09-5. Application to medical treatment of the internal change information 乾直輝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 191-191, 2020. |
|---|
|
|
Symposium 10. [Social contribution] New knowledge required for pharmacists in cancer and reproductive medicine - Up to date Oncofertility for Pharmacist - 米村雅人, 網野一真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 192-192, 2020. |
|---|
|
|
S10-1. The support system about the generative function preservation of patients with children, AYA generation cancer, Mainly on importance of the multi-type of job cooperation 古井辰郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 194-194, 2020. |
|---|
|
|
S10-2. Viewpoint ... from the current situation of the guidelines on patients receiving anticancer medicine development in the contraception and the difference between problem - country 米村雅人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 195-195, 2020. |
|---|
|
|
S10-3. Knowledge ... from change - fundamental researches of the sexual function after the treatment with anticancer agent 片岡智哉1, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 196-196, 2020. |
|---|
|
|
S10-4. It is ... from the viewpoint of bridge - pregnant woman, nursing mother medical therapy authorization pharmacists from "the pregnancy and medicine consultation are foreign" to "fecundity preservation is foreign" 長谷川まゆみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 197-197, 2020. |
|---|
|
|
Symposium 11. [practice] Progress of inflammatory bowel disease - medical therapy and role of the pharmacist, problem ... 八木澤啓司, 中村健志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 198-198, 2020. |
|---|
|
|
S11-1. Expectation - to importance and a pharmacist of progress - MDT of the medical therapy in the inflammatory bowel disease 新崎信一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 200-200, 2020. |
|---|
|
|
S11-2. Relation ... current situation and problem ... of the pharmacist to the IBD patients 八木澤啓司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 201-201, 2020. |
|---|
|
|
S11-3. Relation of the pharmacist to an inpatient 中村健志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 202-202, 2020. |
|---|
|
|
S11-4. Relation of the pharmacist to an outpatient 宇田川雄也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 203-203, 2020. |
|---|
|
|
S11-5. Relation of the IBD patients and the pharmacist of the childhood onset nemaline myopathy 笠原沙耶香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 204-204, 2020. |
|---|
|
|
Symposium 12. [education] Ring - of the childhood medical therapy to widen in other types of job from importance and current situation - pharmacist of the pediatric medical therapy education 冨家俊弥, 石川洋一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 205-205, 2020. |
|---|
|
|
S12-1. Education to a physician 詫間梨恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 206-206, 2020. |
|---|
|
|
S12-2. It is the instructional activity for other types of job, the patients family from a pharmacist in university hospital NICU, GCU 若林仁美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 207-207, 2020. |
|---|
|
|
S12-3. From the position of the nurse of the NICU: Wanting a pharmacist to tell, being taught it, and being helpful 井出由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 208-208, 2020. |
|---|
|
|
S12-4. Education from the pharmacist in the university hospital public children to other types of job 松岡順子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 209-209, 2020. |
|---|
|
|
S12-5. Education from the pharmacist in the children in general hospital domain to other types of job 鈴木秀明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 210-210, 2020. |
|---|
|
|
Symposium 13. [study] Next-generation medical care ... which drug discovery, Ikuyaku study - clinical pharmacist from approach of the clinical pharmacy opens up 城野博史, 兒玉幸修 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 211-211, 2020. |
|---|
|
|
S13-1. Creation of a nucleic acid, gene medicine which assumes the multifunctional type DDS preparation which we designed by a viewpoint of the clinical pharmacy a base 兒玉幸修1, 佐々木均1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 214-214, 2020. |
|---|
|
|
S13-2. Creation of next-generation multitarget type super molecule RNAi medicine based on clinical needs of intractable disease treatment 城野博史1,2, 安東由喜雄3, 齋藤秀之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 215-215, 2020. |
|---|
|
|
S13-3. Drug repositioning study for the side effect of drug resistant bacterium therapeutic drug prevention which obtained an idea from clinical studies 中馬真幸1, 座間味義人2,3, 合田光寛3, 八木健太1, 濱野裕章3, 岡田直人3, 近藤正輝1, 楊河宏章1, 石澤啓介2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 216-216, 2020. |
|---|
|
|
S13-4. Search of the new treatment, preventive preparation based on biomarker of anticancer agent-induced peripheral neuropathy and the pathogenesis 今井哲司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 217-217, 2020. |
|---|
|
|
Symposium 14. [contribution to society] We regard the way of the intelligence as the reporting activity under "the guidelines about the sale reporting activity on ethical drug" 林昌洋, 後藤伸之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 218-218, 2020. |
|---|
|
|
S14-1. Process and aim of the guidelines development 江野英夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 220-220, 2020. |
|---|
|
|
S14-2. Original role, mission of the significance of existence and the MR of the MR which we saw by the enforcement of guidelines 近澤洋平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 221-221, 2020. |
|---|
|
|
S14-3. A reporting activity and intelligence under the sale reporting activity guidelines judging from the position of the pharmacist specialized in drug information 冨田隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 222-222, 2020. |
|---|
|
|
S14-4. - From the position of the hospital duty pharmacist - 坂田洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 223-223, 2020. |
|---|
|
|
Symposium 15. [practice] Pit fall of the elderly people medical treatment 大井一弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 224-224, 2020. |
|---|
|
|
S15-2. Precaution in the infection medical therapy in elderly people 榎屋友幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 226-226, 2020. |
|---|
|
|
S15-3. A way of thinking and evaluation of the elderly people cancer medical therapy 松尾宏一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 227-227, 2020. |
|---|
|
|
S15-4. It is ... from the current situation than prescription suggestion ... "suit of the symptom" of the pharmacist in the elderly people medical therapy with much "test value" prescription intervention that we started from 柴田ゆうか1, 松尾裕彰2, 伊藤英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 228-228, 2020. |
|---|
|
|
S15-5. As for the basis of the pressure sore treatment medicine for external application, ... basis characteristic to have the effect that is equivalent to medicinal properties is associated with extracellular matrix complexation; and is promotion ... for healing 古田勝経1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 229-229, 2020. |
|---|
|
|
Symposium 16. [practice] The patients support that is seamless until after a discharge before PFM (Patient Flow Management), hospitalization 竹内正幸, 大木剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 230-230, 2020. |
|---|
|
|
S16-1. A role and problem of the ethical pharmacy in PFM 永井尭範1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 232-232, 2020. |
|---|
|
|
S16-2. Hospitalization and release information cooperation ... utilizing efforts - ICT of Yao-shi toward PFM 小川充恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 233-233, 2020. |
|---|
|
|
S16-3. Medicine medicine cooperation using Dr.JOY 林信至1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 234-234, 2020. |
|---|
|
|
S16-4. Problems and problem of the drug summary judging from MSW 青木美典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 235-235, 2020. |
|---|
|
|
Symposium 17. [practice] Proposal about drug duties of the heart failure palliative care 高井靖, 寺崎展幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 236-236, 2020. |
|---|
|
|
S17-1. Role ... of process, the pharmacist of process of heart failure palliative care - making about drug duties 高井靖1,10, 芦川直也2,10, 櫻下弘志3, 志方敏幸4,10, 寺崎展幸5,10, 土岐真路6,10, 前田朱香7,10, 吉国健司8, 佐藤幸人9,10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 239-239, 2020. |
|---|
|
|
S17-2. The current situation and directionality of the heart failure palliative care 佐藤幸人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 240-240, 2020. |
|---|
|
|
S17-3. About process of heart failure palliative care - breathing pain, lassitude about drug duties - 寺崎展幸1,10, 高井靖2,10, 芦川直也310, 櫻下弘志4,10, 志方敏幸5,10, 土岐真路6,10, 前田朱香7,10, 吉国健司8, 佐藤幸人9,10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 241-241, 2020. |
|---|
|
|
S17-4. About process of heart failure palliative care - delirium, sleeplessness about drug duties - 前田朱香1,10, 土岐真路2,10, 芦川直也3,10, 櫻下弘志4, 志方敏幸5,10, 高井靖6,10, 寺崎展幸7,10, 吉国健司8, 佐藤幸人9,10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 242-242, 2020. |
|---|
|
|
S17-5. About process of heart failure palliative care - pain, inappetence about drug duties - 志方敏幸1,10, 高井靖2,10, 芦川直也3,10, 櫻下弘志4, 寺崎展幸5,10, 土岐真路6,10, 前田朱香7,10, 吉国健司8, 佐藤幸人9,10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 243-243, 2020. |
|---|
|
|
Symposium 18. [study] Use and application does real world data for database investigation/study after the production and sales 青木事成, 折井孝男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 244-244, 2020. |
|---|
|
|
S18-2. The reliability of data: Efforts - of standardization and the validation - Kagawa University Hospital 樋口和子1, 谷川雅俊2, 横井英人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 248-248, 2020. |
|---|
|
|
S18-3. Conducting data management to secure high quality 高田敦史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 249-249, 2020. |
|---|
|
|
S18-4. Is Class B gourmet? Cookery ... of ... real world data 青木事成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 250-250, 2020. |
|---|
|
|
Symposium 19. [practice] Know-how of the medical cooperation to support of the medical diversification 室井延之, 荒木隆一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 251-251, 2020. |
|---|
|
|
S19-1. From an advanced example of know-how - whole country of the hospitalization and release support task by the pharmacist connecting to the living of patients - 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 252-252, 2020. |
|---|
|
|
S19-2. We think about the regional alliances that fixed their eyes on 2040 荒木隆一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 253-253, 2020. |
|---|
|
|
S19-3. From medical cooperation - inside the hospital that a pharmacist sends to the area - 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 254-254, 2020. |
|---|
|
|
Symposium 20. [practice] You evaluate what, and, at which antithrombotic therapy ... point in time in the perioperative period, how do you cope? ... 柴田ゆうか, 芦川直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 255-255, 2020. |
|---|
|
|
S20-1. Catheterization and antithrombotic therapy of the ischemic heart disease 前田朱香1, 入江利行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 256-256, 2020. |
|---|
|
|
S20-2. Cardiac Surgery and antithrombotic therapy 鈴木正論1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 257-257, 2020. |
|---|
|
|
S20-3. After all, is it new that a pharmacist supports by intervention and antithrombotic therapy - new treatment to arrhythmia and heart structural disease (SHD)? - 土岐真路1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 258-258, 2020. |
|---|
|
|
S20-4. The neutralization medical treatment that is used at the emergency surgery of the use of antithrombotic drug patients 原直己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 259-259, 2020. |
|---|
|
|
S20-5. Around way of thinking and antithrombotic drug management - Noncardiac Surgery of bleeding and the clot risk of the perioperative patients - 柴田ゆうか1, 松尾裕彰2, 伊藤英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 260-260, 2020. |
|---|
|
|
Symposium 21. [study] - Japan and China medical society cosponsorship symposium - to regard proper use as science of the Chinese medicine 礒濱洋一郎, 本間真人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 261-261, 2020. |
|---|
|
|
S21-1. Pharmacologic action of the Chinese medicine and close relations of the aquaporin: Mainly on Goreisan 礒濱洋一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 264-264, 2020. |
|---|
|
|
S21-2. Side effect of the Glycyrrhiza, search of the cause ingredient of the pseudoaldosteronism 牧野利明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 265-265, 2020. |
|---|
|
|
S21-3. The use actual situation and adverse event of the Chinese medicine 本間真人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 266-266, 2020. |
|---|
|
|
S21-4. About package insert information to contribute to proper use of the Chinese medicine 袴塚高志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 267-267, 2020. |
|---|
|
|
Symposium 22. [study] Pit fall in a theory and the pharmacy study of the signal detection 漆原尚巳, 後藤伸之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 268-268, 2020. |
|---|
|
|
S22-1. A fact and problem of the safety of medicine report 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 271-271, 2020. |
|---|
|
|
S22-2. Spontaneous report (side effect report) in the pharmaceutical company and database - scenery and utilization - 宮崎真1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 272-272, 2020. |
|---|
|
|
S22-3. The signal detection, starting farming for the year 漆原尚巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 273-273, 2020. |
|---|
|
|
S22-4. The matter which should note it in a data mining study using JADER 酒井隆全1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 274-274, 2020. |
|---|
|
|
Symposium 23. [study] We think and let's tie it! The way of the pharmacy education which university, a hospital, a drugstore cooperates and should aim at 高橋一栄, 平田收正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 275-275, 2020. |
|---|
|
|
S23-1. About nature and before graduation, postgraduate education sought by a pharmacist engaged in emergency care 今井徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 279-279, 2020. |
|---|
|
|
S23-2. Nature and education of the pharmacist sought by emergency intensive care, disaster medical care 吉川博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 280-280, 2020. |
|---|
|
|
S23-3. About the cooperation of university in the before graduation pharmacy education and the clinical pharmacist 佐古守人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 281-281, 2020. |
|---|
|
|
S23-4. Pharmacy student and - to think, and to support community medical care as role - medical care person of the hospital pharmacist to "a cancer, palliative care" 辻井聡容1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-282, 2020. |
|---|
|
|
S23-5. From a prescription proposer to a corporate strategy planner 野崎歩1, 堀内望1, 奥川寛1, 馬橋美由季1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 283-283, 2020. |
|---|
|
|
S23-6. Hospital, drugstore cooperation business training by the pharmacist training program to take local team approach in medical care on 平田收正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 284-284, 2020. |
|---|
|
|
Symposium 24. [study] ... that the use and application of ... AI/ICT to make use of a next-generation ICT technique in pharmacist duties advances to here 神崎浩孝, 千堂年昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 285-285, 2020. |
|---|
|
|
S24-1. Work-style reform (patients correspondence, drug information management edition) of the pharmacist utilizing AI/ICT 望月伸夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 287-287, 2020. |
|---|
|
|
S24-2. The example of efforts - Tokushukai group to improvement in medical quality using data for the cause - 野村浩子1,2, 藤村義明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 288-288, 2020. |
|---|
|
|
S24-3. It is effectively utilized pharmacist X programming inside the hospital information assets 佐古卓人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 289-289, 2020. |
|---|
|
|
S24-4. Use and application - of - pharmaceutical products information management system "AI-PHARAMA" sharing knowledge, the pharmacist's experience using ICT 神崎浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 290-290, 2020. |
|---|
|
|
Symposium 25. [contribution to society] One or ... which there is what for approach ... people from the situation of each ALL pharmacist for the current situation of the regulation pharmaceutical products in foreign countries 石原千春, 橋本直弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 291-291, 2020. |
|---|
|
|
S25-1. About the response of the pharmacist in the regulation pharmaceutical products of the current situation report and the foreign tour of the member investigation of the Japanese mild cure association 石原千春1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 294-294, 2020. |
|---|
|
|
S25-2. Invention at efforts - application to conduct drug carrying import and export permission application for the medical care smoothly and problem ... which was seen 橋本直弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 295-295, 2020. |
|---|
|
|
S25-3. Prescription situation of corresponding - regulation pharmaceutical products in the dispensing pharmacy with much use of visit to Japan foreigner patients and future problem - 鈴木渉太1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 296-296, 2020. |
|---|
|
|
S25-4. About a system of the export by the carrying of drug for the medical care and medical psychotropic drugs and the import 竹内大輔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 297-297, 2020. |
|---|
|
|
S25-5. We work on the proper use promotion of the drug for the medical care 鈴木勉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 298-298, 2020. |
|---|
|
|
Symposium 26. [practice] In Patient Empowerment a breakthrough! : New keyword in the cancer practice of the Reiwa era 森田一, 小室雅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 299-299, 2020. |
|---|
|
|
S26-1. Process of the Patient Empowerment Program (PEP) setup 東光久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 301-301, 2020. |
|---|
|
|
S26-2. Thing to bring for an implication, treatment for cancer of Patient Empowerment 石井均1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 302-302, 2020. |
|---|
|
|
S26-3. "Workshop for improvement in "patients power" whom a medical person leads" case introduction 下村昭彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 303-303, 2020. |
|---|
|
|
S26-4. Practice of "Patient Empowerment" from tomorrow participates in "the improvement in patients power workshop whom a medical person leads" as ... pharmacist 堀之内藍1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 304-304, 2020. |
|---|
|
|
S26-5. Participate in PEP workshop as thing - facilitator that there is a pharmacist to give medical care with high satisfaction; and ... 小室雅人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 305-305, 2020. |
|---|
|
|
Symposium 27. [practice] It is ... in the times to aim at the symbiosis with cancer by ... evolving cancer treatment to realize effective treatment by security by the intervention of the pharmacist specialized in a cancer 河原昌美, 中多陽子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 306-306, 2020. |
|---|
|
|
S27-1. About the pharmacist examination situation and a trend specialized in a cancer of 2019 河原昌美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 307-307, 2020. |
|---|
|
|
S27-2. Pharmaceutical intervention for patients with gastric cancer with suspected 5-FU encephalopathy 内谷加江1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 308-308, 2020. |
|---|
|
|
S27-3. Pharmaceutical intervention for peripheral neuropathy of patients with progress gastric cancer 金子忍1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 309-309, 2020. |
|---|
|
|
S27-4. Intervention to patients with lung cancer that it is hard to take 木村滋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 310-310, 2020. |
|---|
|
|
S27-5. Picture of the future ... which activity and efforts ... specialists of the subcommittee aiming at the improvement of the pharmacist specialized in a cancer of the cancer medical therapy to develop describe it in 三宅知宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 311-311, 2020. |
|---|
|
|
S27-6. Efforts of the training subcommittee for pharmacist upbringing and the skill up specialized in a cancer 中多陽子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 312-312, 2020. |
|---|
|
|
Symposium 28. [practice] Expectation to a pharmacist in the treatment that we gave priority to the quality of life of patients with breast cancer over 寺町ひとみ, 平井みどり Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 313-313, 2020. |
|---|
|
|
S28-1. We can do it, and what should do what for diversifying breast cancer treatment, patients? 二村学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 316-316, 2020. |
|---|
|
|
S28-2. The effect that pharmacist intervention gives to patients quality of life and medical economy 田中和秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-317, 2020. |
|---|
|
|
S28-3. It is ... through ... other types of job cooperation for a smile of patients 大野(川井)朋子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 318-318, 2020. |
|---|
|
|
S28-4. About formulation of basic knowledge and the Mohs paste of the cancerous wound care 重山昌人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 319-319, 2020. |
|---|
|
|
S28-5. It is education ... full of a sense of reality in ... University for the pharmacist who can suggest prescription 寺町ひとみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 320-320, 2020. |
|---|
|
|
Symposium 29. [practice] About the role emergency response of the pharmacist prospective for securing of patients security and the activity of the time of peace 梅村朋, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 321-321, 2020. |
|---|
|
|
S29-1. About the current situation including role - law revision of the medical (patients) pharmacist sought safely, the revision of medical service fees - 舟越亮寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 324-324, 2020. |
|---|
|
|
S29-2. The pharmaceutical products safety management system in the Mie University Hospital: Unlicensed drug, contraindicated medicine out of the adaptation 水谷栄梨1,2, 向原里佳1, 兼児敏浩2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 325-325, 2020. |
|---|
|
|
S29-3. Efforts of the municipal hospital about the medical safe system 菅野浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 326-326, 2020. |
|---|
|
|
S29-4. It is the role of the pharmacist in (emergency) at medical accident occurrence 山本崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 327-327, 2020. |
|---|
|
|
S29-5. The relation of an emergency in the patients security and the pharmacist in the time of peace and the future prospects 梅村朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 328-328, 2020. |
|---|
|
|
Symposium 30. [education] We reconsider small and medium size hospital drug duties from a point of view of running it 荒川隆之, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 329-329, 2020. |
|---|
|
|
S30-1. With the directionality that future ... small and medium size hospital pharmacist of small and medium size hospital drug duties should advance to? 樋島学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 331-331, 2020. |
|---|
|
|
S30-2. In "form by the attractive duties of the small and medium size hospital! - The making of structure which also produces the securing of pharmacist and outcome in the hospital management now! -" 新井克明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 332-332, 2020. |
|---|
|
|
S30-3. Efforts for the realization of pharmacist duties expected in Itsukaichi memorial hospital 荒川隆之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 333-333, 2020. |
|---|
|
|
S30-4. Policy suggestion ... to the hospital administration that visualization and PBPM utilization technique - sustained growth of the medical information by the hospital pharmacist are possible 関利一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 334-334, 2020. |
|---|
|
|
S30-5. Expectation to small and medium size hospital pharmacist judging from a viewpoint of the community medical care cooperation 木佐貫篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 335-335, 2020. |
|---|
|
|
Symposium 31. [contribution to society] Let's talk now; is baton ... to professionalism - next generation of the pharmacist 細谷治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 336-336, 2020. |
|---|
|
|
S31-1. What is the element necessary for the professionalism of the pharmacist? 細谷治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 337-337, 2020. |
|---|
|
|
S31-3. A college of pharmacy, a pharmacy school having to change now 杉林堅次1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 338-338, 2020. |
|---|
|
|
S31-4. Professionalism of the pharmacist in the medical management 赤瀬朋秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 339-339, 2020. |
|---|
|
|
S31-5. Specialty of the pharmacist judging from a law 赤羽根秀宜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 340-340, 2020. |
|---|
|
|
S31-6. Structural conversion from the professionalism thing of the pharmacist to a person 永田泰造1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 341-341, 2020. |
|---|
|
|
Symposium 32. [Social Contribution] Don't Lose to Disasters! Receiving Aid and Countermeasures Learned from the Disaster Chronicle - To protect ourselves and save you in the event of a disaster - 小林政彦, 高山和郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 342-342, 2020. |
|---|
|
|
S32-1. We think from an unexpected disaster record 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 343-343, 2020. |
|---|
|
|
S32-2. Step ... from description of heavy rain disaster experience - damage to revival 角南敦史1, 本島和典1, 谷本ひとみ1, 佐藤友里加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 344-344, 2020. |
|---|
|
|
S32-3. Attempt for importance of drugstore BCP in the local support at disaster that it showed from a support authorization pharmacist system at a disaster and the effectiveness-related BCP development that there is 北川太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 345-345, 2020. |
|---|
|
|
S32-4. Experiencing receiving support for the 2016 Kumamoto earthquake 岡村直樹1, 宮田昭1, 陣上祥子2, 下石和樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 346-346, 2020. |
|---|
|
|
Symposium 33. [practice] To show a pharmacist power at the place of ... clinical nutrition to reconsider clinical application of the intravenous lipid microsphere; ... 井上真, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 347-347, 2020. |
|---|
|
|
S33-1. We think about utilization of the intravenous lipid microsphere: Problems and measures at the clinical place 千葉正博1, 中山泰葉2, 若林仁美2, 杉沢諭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 348-348, 2020. |
|---|
|
|
S33-2. Clinical application of the intravenous lipid microsphere for haemodialysis patients 藤谷竜磨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 349-349, 2020. |
|---|
|
|
S33-3. Should be usable more; the lipid microsphere for the IV infusion! - Efforts - at the acute phase hospital 茂木孝裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 350-350, 2020. |
|---|
|
|
S33-4. ... which makes use of ... inquiry content in clinical practice to use intravenous lipid microsphere appropriately 岩原良晴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 351-351, 2020. |
|---|
|
|
S33-5. Individualization rate of application design by the pharmacokinetic analysis of the lipid microsphere 福島恵造1, 大村健二2, 合志聡3, 岡田章1,4, 田中求2, 辻本貴江1, 入山圭二5, 杉岡信幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 352-352, 2020. |
|---|
|
|
Symposium 34. [education] Efforts to problem and the Pharmacist-Scientist training of ... pharmacy education thinking about a pharmacist image of the new age 北市清幸, 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 353-353, 2020. |
|---|
|
|
S34-1. The current situation and the prospects of hospital pharmacist duties judging from the public welfare labor science study and an investigation of the Japanese Society of Hospital Pharmacists 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 356-356, 2020. |
|---|
|
|
S34-2. A challenge and the current situation to a new six years system in the Osaka University pharmacy school 堤康央1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 357-357, 2020. |
|---|
|
|
S34-3. Newly 6-year introduction in Gifu Pharmaceutical University and the significance 北市清幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 358-358, 2020. |
|---|
|
|
S34-4. Can a pharmacy, the pharmacist survive? ... which thinks about ... some other time 6-year pharmacy education 政田幹夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 359-359, 2020. |
|---|
|
|
Symposium 35. [study] We think about a trial and the relation of the pharmacist 池田龍二, 城野博史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 360-360, 2020. |
|---|
|
|
S35-1. It is ... including the correspondence to a ... open-label pharmacist setting test about the role of the pharmacist in the clinical experimental medicine administrative work 黒田智1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 363-363, 2020. |
|---|
|
|
S35-2. About a relation to the ethic examination as the pharmacist 寺元剛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 364-364, 2020. |
|---|
|
|
S35-3. Relation ... of role ... Dr. of the pharmacist in the clinical development-led investigational enforcement system construction, trial adjustment secretariat administration and the pharmacist 二川俊隆1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 365-365, 2020. |
|---|
|
|
S35-4. It is efforts ... of our hospital in ... Kumamoto earthquake correspondence and the subsequent system construction from the situation of the pharmacist CRC 成田さわな1, 上田泰子1, 伊藤祐子1, 川瀬美紀1, 城野博史1,2, 松岡雅雄2,3, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 366-366, 2020. |
|---|
|
|
S35-5. About the relation of the pharmacist in the trial of the antitumor agents 大野梨絵1,2, 池田龍二1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 367-367, 2020. |
|---|
|
|
Symposium 36. [education] About the way of the after graduation initial training of the pharmacist 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 368-368, 2020. |
|---|
|
|
S36-1. Problem of the postgraduate training of the pharmacist thinking from the clinical practice system of the physician or an American pharmacist resident system 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 370-370, 2020. |
|---|
|
|
S36-2. The current situation and problem judging from a national survey about the postgraduate training 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 371-371, 2020. |
|---|
|
|
S36-3. We think about the way of the training from the situation of the drugstore in the early period of after graduation of the pharmacist 宮崎長一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 372-372, 2020. |
|---|
|
|
S36-4. Expectation and request from the pharmacy school 中村明弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 373-373, 2020. |
|---|
|
|
Symposium 37. [practice] Essential specialty of the pharmacist who can contribute to psychiatry clinical practice 賀勢秦子, 梅田賢太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 375-375, 2020. |
|---|
|
|
S37-1. Expect it of a pharmacist in psychiatry clinical practice 園部漢太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 378-378, 2020. |
|---|
|
|
S37-2. The past, the present, the future of psychiatry pharmacist duties 天正雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 379-379, 2020. |
|---|
|
|
S37-3. Local shift and pharmacist of the psychiatric practice 長浜恭史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 380-380, 2020. |
|---|
|
|
S37-4. Point of view ... of treatment participation ... sustained-release parenteral injection utilization of the pharmacist who makes possibility of continuing it 横森順1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 381-381, 2020. |
|---|
|
|
S37-5. It is the idea making use of the pharmacist from the viewpoint of mind and body both sides in the psychiatry domain 梅田賢太1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 382-382, 2020. |
|---|
|
|
Symposium 38. [education] Strategic - tissue management leadership, personnel training - to show a pharmacist power in the clinical study 吉村知哲, 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 383-383, 2020. |
|---|
|
|
S38-1. The leadership and the management in the non profit organization 赤瀬朋秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 386-386, 2020. |
|---|
|
|
S38-2. The pharmacy management to realize an organizational reform 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 387-387, 2020. |
|---|
|
|
S38-3. Fusion ... of drug department management - Toyota ism utilizing the Toyota way and the medical person mind 遠山幸男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 388-388, 2020. |
|---|
|
|
S38-4. The leadership competency which is pursued in the medical domain 相馬孝博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 389-389, 2020. |
|---|
|
|
Symposium 39. [study] It is ... expecting development of a clinical question and the TDM by creation - clinical pharmacist of the evidence which a TDM study finds 三浦昌朋, 尾田一貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 390-390, 2020. |
|---|
|
|
S39-1. TDM study aiming at the conquest of the clinical problem of the oral multi-kinase inhibitor 野田哲史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 391-391, 2020. |
|---|
|
|
S39-2. We challenge the clinical question of the infection in antimicrobial TDM 浦上宗治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 392-392, 2020. |
|---|
|
|
S39-3. To send Clozapine more safely; approach - from - TDM 北川航平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 393-393, 2020. |
|---|
|
|
S39-4. Usefulness of TDM and the genetic polymorphism information of the immunosuppressive drug in the kidney transplantation domain 加賀谷英彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 394-394, 2020. |
|---|
|
|
S39-5. For the further development of the TDM study by the clinical pharmacist 榎屋友幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 395-395, 2020. |
|---|
|
|
Symposium 40. [contribution to society] Let's get on in the current of the times of the task share shift! - - to make the new age by utilizing a pharmacist power to a change of society, the medical environment 松尾宏一, 林稔展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 396-396, 2020. |
|---|
|
|
S40-1. Promotion of task shifting by pharmacists 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 397-397, 2020. |
|---|
|
|
S40-2. Clinical problem solution to pharmacist specialty - by display - pharmaceutical intervention in response to a task shift 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 398-398, 2020. |
|---|
|
|
S40-3. Achievement - of a pharmacist and the pharmacist of role allotment - life 100 years times of the physician 中井清人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-399, 2020. |
|---|
|
|
Symposium 41. [Medical] Intensive care, ready! - Let's start with the completion of the position paper Let's expand the intensive care unit work - 入江利行, 柴田啓智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 400-400, 2020. |
|---|
|
|
S41-1. Position paper and efforts of the pharmacist in the local support hospital 立石裕樹1, 宮津大輔1, 後藤貴央1, 宮内善豊2, 江田陽一2, 平川雅章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 401-401, 2020. |
|---|
|
|
S41-2. Position paper and efforts (from a university hospital) of the own institution 橋本麻衣子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 402-402, 2020. |
|---|
|
|
S41-3. Stare at the future of the pharmacist in the intensive care 今浦将治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 403-403, 2020. |
|---|
|
|
S41-4. Thought of the corporate strategy to cultivate by polishing a skill in an intensive care domain 野崎歩1, 堀内望1, 奥川寛1, 馬橋美由季1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 404-404, 2020. |
|---|
|
|
S41-5. The expectation to the pharmacist in the intensive care unit: From the position of the specialist in intensive care 志馬伸朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 405-405, 2020. |
|---|
|
|
Symposium 42. [study] For the establishment of the study support system of the pharmacist in the cancer medical therapy [cure association academic third subcommittee plan] 板倉由縁, 久田達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 406-406, 2020. |
|---|
|
|
S42-1. For the establishment of the study support platform in the cancer domain efforts - of - Aichi 宮崎雅之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 409-409, 2020. |
|---|
|
|
S42-2. To keep study support system and problem ... limited human resources in the cancer medical therapy of Mie alive; ... 三宅知宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 410-410, 2020. |
|---|
|
|
S42-3. Efforts of personnel training and the study support system in the Gifu cancer-related training institution 宇佐美英績1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 411-411, 2020. |
|---|
|
|
S42-4. Activity and result - of the pharmacist team specialized in construction - Ishikawa cancer of education, the study support system in Ishikawa 菅幸生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 412-412, 2020. |
|---|
|
|
S42-5. It is efforts ... of ... Saitama cancer medical therapy workshop for the construction of the study support system in Saitama 佐野元彦1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-413, 2020. |
|---|
|
|
Symposium 43. [education] The current situation of the pharmacy common use study OSCE in the pharmacy education and future problem 野田幸裕, 橋詰勉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 414-414, 2020. |
|---|
|
|
S43-1. Pharmacy common use study OSCE and pharmacy education 福島哉史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 416-416, 2020. |
|---|
|
|
S43-3. A pharmacy education: New problem and OSCE 橋詰勉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 418-418, 2020. |
|---|
|
|
S43-4. It is efforts - aim and problem of the OSCE (Post-CC OSCE) after the practice participation type bedside teaching of the Showa University faculty of medicine 土屋静馬1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 419-419, 2020. |
|---|
|
|
Symposium 44. [study] With the clinical pharmacy study found in the times of the Reiwa 内藤隆文, 三浦昌朋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 420-420, 2020. |
|---|
|
|
S44-1. The improvement of medical technology that is necessary at a drug administration design for becoming it 三浦昌朋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 422-422, 2020. |
|---|
|
|
S44-2. Significance and importance of research activities 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 423-423, 2020. |
|---|
|
|
S44-3. - to forge a study to become the base of contribution - clinical power to the team approach in medical care utilized the pharmacist power 石澤啓介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 424-424, 2020. |
|---|
|
|
S44-4. Of the clinical pharmacy study "have just begun" "until now": Efforts of the Hamamatsu University School of Medicine hospital pharmacy 内藤隆文1, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 425-425, 2020. |
|---|
|
|
Symposium 45. [practice] The perioperative medical therapy management that we catch in patients security viewpoint again 舟越亮寛, 柴田ゆうか Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 426-426, 2020. |
|---|
|
|
S45-1. Expectation from an anesthesiologist to a pharmacist 齋藤繁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-428, 2020. |
|---|
|
|
S45-2. Approach about the medical security in the perioperative period as GRM 柴田みづほ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 429-429, 2020. |
|---|
|
|
S45-3. Efforts of the perioperative pharmacy management 島田雅人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 430-430, 2020. |
|---|
|
|
S45-4. Patients security by the perioperative care team pharmacist 竹之内正記1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 431-431, 2020. |
|---|
|
|
S45-5. Consideration about the discontinuation failure case of the cancellation medicine before surgery, examination 和地徹1, 佐賀利英2,3, 柳田真樹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 432-432, 2020. |
|---|
|
|
Symposium 46. [practice] Scrummaging with aggravation prevention - multi-type of job of diabetes and the chronic kidney disease to work on in ONE TEAM 井上岳, 三宅健文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 433-433, 2020. |
|---|
|
|
S46-1. Expectation to a pharmacist in chronic kidney disease (CKD) and the diabetic kidney disease (DKD) team approach in medical care 安田宜成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 434-434, 2020. |
|---|
|
|
S46-2. Problem future with going in a hospital and an area to prevent that diabetes is aggravated 古田麻衣子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 435-435, 2020. |
|---|
|
|
S46-3. Explore cooperation with diabetes aggravation prophylactic role - medical institution as the health insurance pharmacy pharmacist; and ... 森貴幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 436-436, 2020. |
|---|
|
|
S46-4. Being carried out in a hospital and an area that diabetic nephropathy is aggravated and prevents a shift to artificial dialysis 大岩拓馬1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 437-437, 2020. |
|---|
|
|
S46-5. Going in a drugstore and an area that diabetic nephropathy is aggravated and prevents a shift to artificial dialysis 松下智侑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 438-438, 2020. |
|---|
|
|
S46-6. What a pharmacist scrummaging with the multi-type of job for the aggravation prevention of diabetes in the area and the chronic kidney disease should do 三宅健文1, 辻芙美1, 植村有加1, 谷崎泰広1, 安田早織1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 439-439, 2020. |
|---|
|
|
Symposium 47. [practice] The management promotion (the academic fourth subcommittee) utilizing "the relation guide to the drug interactions in the healthcare setting" 米澤淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 440-440, 2020. |
|---|
|
|
S47-1. Public announcement of "the relation guide to the drug interactions in the healthcare setting" 伊藤清美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 442-442, 2020. |
|---|
|
|
S47-2. Way of thinking of evasion and the management of drug interactions 大野能之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 443-443, 2020. |
|---|
|
|
S47-3. A report and problem of the drug interactions management in the healthcare setting 木村丈司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 444-444, 2020. |
|---|
|
|
S47-4. The drug interactions management for patients with the specific background 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 445-445, 2020. |
|---|
|
|
S47-5. The drug interactions study that a clinical pharmacist conducts 百賢二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2020. |
|---|
|
|
S47-6. A prediction and inspection of drug interactions 樋坂章博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 447-447, 2020. |
|---|
|
|
Symposium 48. [education] Sailing of the new specialty pharmacist system 奥田真弘, 寺田智祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 448-448, 2020. |
|---|
|
|
S48-1. An idea and system design of the new specialty pharmacist system 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 449-449, 2020. |
|---|
|
|
S48-2. Need ... of pharmacist - clinical results specialized in clinical pharmacy 百瀬泰行1, 青山隆夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 450-450, 2020. |
|---|
|
|
S48-3. Pharmacist ... further directional ... specialized in a cancer 河原昌美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 451-451, 2020. |
|---|
|
|
S48-4. Development of the pharmacist specialized in medical therapy 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 452-452, 2020. |
|---|
|
|
S48-5. The foundation of the pharmacist system specialized in local pharmacy care and future expectation 宮崎長一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 453-453, 2020. |
|---|
|
|
Symposium 49. [practice] Pharmacist duties and the risk management which transform with the extension of AI and the robot 斎藤寛子, 築山郁人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 455-455, 2020. |
|---|
|
|
S49-1. For information management and the joint ownership of the pharmacist development - of - pharmaceutical products information management system "AI-PHARAMA" using the digital technology 神崎浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 458-458, 2020. |
|---|
|
|
S49-2. Challenge to development - formulations mistake zero of the smart dispensary (robot drugstore), waiting time zero 渡部正之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 459-459, 2020. |
|---|
|
|
S49-3. Drug duties to transform by the inflection of AI, the robot 青森達1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 460-460, 2020. |
|---|
|
|
S49-4. With the knowledge that the next-generation pharmacist who can play an active part in the AI era comes to need? ! 宮川隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 461-461, 2020. |
|---|
|
|
Symposium 50. [practice] Medicine medicine cooperation to promote patients-oriented separation of pharmacy and clinic 賀川義之, 植兆満 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 463-463, 2020. |
|---|
|
|
S50-1. Efforts of the medicine medicine cooperation about proper use of the drug for the medical care 伊藤譲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 465-465, 2020. |
|---|
|
|
S50-2. Hospital pharmacist is ... through technique and an example of the effect - Kagawa west inscription area "joining community medical care together" 篠永浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 466-466, 2020. |
|---|
|
|
S50-4. About education - model core curriculum - before graduation education and the future 平田收正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 468-468, 2020. |
|---|
|
|
Symposium 51. [education] Regional alliances for upbringing of the pharmacist as the healthy manager of the town 平松正行, 牛田誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 469-469, 2020. |
|---|
|
|
S51-1. The way of a drugstore, the pharmacist whom a dispensing fee revision turns in notice of 0402, revised medicine machine method, 2020 狭間研至1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 472-472, 2020. |
|---|
|
|
S51-2. - From position of the hospital pharmacist - 坂田洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 473-473, 2020. |
|---|
|
|
S51-3. The system of the Furukawa model that we thought about the solution to local problem from multi-type of job collaboration type - goal by all drugstore participation is made one or ... how 宇田和夫1,2,3, 高橋真吾1,4, 吉田聡1,5, 田村美帆1,6, 樅山徳幸1,7, 加藤大貴1,8, 川島与輝1,8, 坂本希実1,9, 山下美妃1,10, 赤荻榮一11,12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 474-474, 2020. |
|---|
|
|
S51-4. Upbringing (approach at university) of the pharmacist as the healthy manager of the town 牛田誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-475, 2020. |
|---|
|
|
Symposium 52. [study] A pharmacist being sought now by mild medical study promotion 佐藤淳也, 宮崎雅之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 476-476, 2020. |
|---|
|
|
S52-1. A Pharmacist's Perspective Utilized in Research on Palliative Medicine 槙原克也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 479-479, 2020. |
|---|
|
|
S52-2. Intervention - of the pharmacists from the normal business routine of the health insurance pharmacy to the at-home palliative care case using observational study - PCA pump which we originated 田邉一尊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 480-480, 2020. |
|---|
|
|
S52-3. From the situation of collaboration - relaxation care physician in mild medical clinical studies and the guidelines making 森雅紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 481-481, 2020. |
|---|
|
|
S52-4. Participate in the revision of latest evidence - respiratory symptom guidelines on medical therapy for dyspnea; and ... 山本泰大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 482-482, 2020. |
|---|
|
|
Symposium 53. [study] Development to discovery and the clinical studies of the clinical question in pharmacist specialties 鈴木昭夫, 中馬真幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 483-483, 2020. |
|---|
|
|
S53-1. Know-how and invention to push forward the clinical studies of the intensive care domain 中馬真幸1, 座間味義人2,3, 合田光寛3, 八木健太1, 岡田直人3, 濱野裕章3, 近藤正輝3, 楊河宏章1, 石澤啓介2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 484-484, 2020. |
|---|
|
|
S53-2. To show specialty by clinical studies - team approach in medical care to solve an on-site problem; ... 川田敬1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 485-485, 2020. |
|---|
|
|
S53-3. Observational study ... which plays for embodiment - idea of the clinical question in the relaxation domain 佐藤淳也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 486-486, 2020. |
|---|
|
|
S53-4. Rearward clinical studies based on the drug duties for clinical question solutions in the cancer chemotherapy 藤井宏典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-487, 2020. |
|---|
|
|
S53-5. Statistical analysis in the observational study 吉田寿子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 488-488, 2020. |
|---|
|
|
Symposium 54. [Social Contribution] Recommending Regional Formularies to Support Patients and Medical Care in the Integrated Community Care System with Evidence 岸本真, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 489-489, 2020. |
|---|
|
|
S54-1. Discussions and Basic Ideas Concerning Formularies 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 491-491, 2020. |
|---|
|
|
S54-2. Efforts for a local formularies in the Awa region of Chiba Prefecture 舟越亮寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 492-492, 2020. |
|---|
|
|
S54-3. Formulation of in-hospital formularies and future developments at regional medical support hospitals - Aiming for interlocking with PBPM and regional collaboration paths - 小枝伸行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-493, 2020. |
|---|
|
|
S54-4. Role and future prospects of pharmacists in formularies 磯部総一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 494-495, 2020. |
|---|
|
|
Symposium 55. [study] We create new diagnosis, therapy and challenge the conquest of the intractable disease 永井拓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 496-496, 2020. |
|---|
|
|
S55-1. Development of the rare cancer cell high sensitivity detecting method by the microdroplet culture 寺薗英之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 498-498, 2020. |
|---|
|
|
S55-2. Application to the basics, the clinical studies of all new phosphatide class high sensitivity assays 森田真也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-499, 2020. |
|---|
|
|
S55-3. Challenge of the behavioral pharmacology researcher to dementia early detection and drug discovery 溝口博之1, 山中宏二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 500-500, 2020. |
|---|
|
|
S55-4. Development of the new therapy for schizophrenia based on the objective diagnosis 永井拓1,2, 尾崎紀夫3, 山田清文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 501-501, 2020. |
|---|
|
|
Symposium 56. [practice] For construction of the medical therapy for the comeback to normal life of schizophrenia 亀井浩行, 野田幸裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 502-502, 2020. |
|---|
|
|
S56-1. Summary of the medical therapy for the comeback to normal life of schizophrenia 野田幸裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 504-504, 2020. |
|---|
|
|
S56-2. The condition of a patient elucidation and diagnostic technique development of schizophrenia 吉見陽1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-505, 2020. |
|---|
|
|
S56-3. A choice and proper use of antipsychotics to think about from dosage form 波多野正和1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 506-506, 2020. |
|---|
|
|
S56-4. Polypharmacy of the multi-type of job and patients with cooperation, schizophrenia to face each other while supplementing it 定岡邦夫1, 定岡摩利1, 沖村里咲1, 加藤秀明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 507-507, 2020. |
|---|
|
|
S56-5. The schizophrenia medical therapy that fixed its eyes on a long term prognosis 岩本邦弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-508, 2020. |
|---|
|
|
S56-6. We think about a stigma 亀井浩行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 509-509, 2020. |
|---|
|
|
Symposium 57. [practice] Multifaceted ability of the pharmacist shown by kidney disease medical treatment instruction 山田成樹, 田中章郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 510-510, 2020. |
|---|
|
|
S57-1. Pit fall of the medicine to use frequently in the decreased renal function patients 伊藤さおり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2020. |
|---|
|
|
S57-2. Kidney disease medical treatment instruction to practice in an alimentary division gastrointestinal division ward 宗山真梨奈1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 512-512, 2020. |
|---|
|
|
S57-3. We try to make use of the skill of the kidney disease medical treatment instruction person in an urologic ward 荒川悠樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 513-513, 2020. |
|---|
|
|
S57-4. Story of the medicine about the kidney transplantation that a pharmacist wants to know 安田知弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-514, 2020. |
|---|
|
|
S57-5. Precaution when we take the medicine for the circulatory organ to patients in CKD 富田敏章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 515-515, 2020. |
|---|
|
|
Symposium 58. [practice] Heart failure pandemic - exercise and nourishment and drug ... to face by the multi-type of job cooperation 吉国健司, 入江利行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 516-516, 2020. |
|---|
|
|
S58-1. Role to fulfil of the condition of a patient and the heart rehabilitation of the heart failure 井澤英夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 518-518, 2020. |
|---|
|
|
S58-2. From the position of - physical therapist who understand other types of job, and practices the multi-type of job cooperation - 佐藤憲明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 519-519, 2020. |
|---|
|
|
S58-3. Efforts ... in nourishment management and multi-type of job cooperation - heart failure team in patients with heart failure 吉内佐和子1,5, 田中雅幸2,3, 森下瞬4, 田中千春4, 宮内拓史5, 藤井彩5, 大北亜紀6, 久保田ナナ6, 伊藤駿7, 木村穣8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2020. |
|---|
|
|
S58-4. A drug and nourishment in the intensive care 野崎歩1, 堀内望1, 奥川寛1, 馬橋美由季1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 521-521, 2020. |
|---|
|
|
S58-5. About the role of the pharmacist in the heart rehabilitation team 太田友樹1, 山本達郎1, 松本麻里1, 孝田佳子1, 渡部裕紀1, 衣笠良治2, 加藤雅彦3, 山本一博2, 島田美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 522-522, 2020. |
|---|
|
|
S58-6. Rehabilitation nourishment and rehabilitation drug 中村直人1, 若林秀隆2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-523, 2020. |
|---|
|
|
Symposium 59. [study] The basics and practice to work on a clinical pharmacy study 伊藤清美, 田崎嘉一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 524-524, 2020. |
|---|
|
|
S59-1. A pharmacist think through past clinical studies - article making in the municipal hospital ninth year 篠田康孝1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 525-525, 2020. |
|---|
|
|
S59-2. It is ... for study support ... senior pharmacist who can rely in the general hospital which learns together, and accompanies it 池末裕明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-526, 2020. |
|---|
|
|
S59-3. It is multi-type of job cooperation ... with education, research activities - student to perform as a clinical system teacher 林秀樹1,2,3,4,5, 廣瀬智恵美4,5, 飯原大稔1,4,5, 鈴木昭夫1,4,5, 河合琢良2,5, 生木庸寛2,5, 小原道子2,5, 小林篤史3,5, 甲斐絢子3,5, 日比野靖5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 527-527, 2020. |
|---|
|
|
S59-4. The beginning is a beginner of the study in anyone 杉山雄一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 528-528, 2020. |
|---|
|
|
Symposium 60. [study] It is ... from the study of ... these days to think about lower urinary tract dysfunction to treatment 木村和哲, 堀田祐志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-529, 2020. |
|---|
|
|
S60-1. Relation of the urologic ward exclusive duty pharmacist for the lower urinary tract dysfunction 杉山洋介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 530-530, 2020. |
|---|
|
|
S60-2. Recent treatment for the lower urinary tract dysfunction 濱川隆1, 窪田泰江2, 安井孝周3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 531-531, 2020. |
|---|
|
|
S60-3. Search of the functional ingredient that an effect is expected for an urination disorder 伊藤由彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-532, 2020. |
|---|
|
|
S60-4. Intracerebral molecules group - associated with the urination control that we were able to see from effect - stress reaction study that stress gives to an urination function 清水孝洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 533-533, 2020. |
|---|
|
|
Symposium 61. [contribution to society] We think about the career path of word no hearing - pharmacist in a gender equality genuinely 塚本有子, 三宅健文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 534-534, 2020. |
|---|
|
|
S61-1. About the promotion of the gender equality in technology, the arts and sciences 福田明美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 535-535, 2020. |
|---|
|
|
S61-2. About the workplace environment that is necessary about the stability of improvement in consciousness and the duties of the field of clinical pharmacy being attractive as a pharmacist 吉田紀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 536-536, 2020. |
|---|
|
|
S61-3. The workplace and hope and anxiety that are easy to act in the future 荒川真萌1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 537-537, 2020. |
|---|
|
|
S61-4. I continue carrier in this way in a renal disease domain 林八恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 538-538, 2020. |
|---|
|
|
S61-5. I continue carrier in this way in a cancer domain 後藤愛実1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 539-539, 2020. |
|---|
|
|
S61-6. Gap between a gender equality plan and the store in the company 川原哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 540-540, 2020. |
|---|
|
|
S61-7. "Ikubo's declaration" to work on work-life balance 三宅健文1, 國枝亜矢香1, 辻芙美1, 安田早織1, 東野公亮1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 541-541, 2020. |
|---|
|
|
Symposium 62. [education] For improvement in quality of clinical pharmacy education - pharmacy business training to bring up a pharmacist supporting the future - 鈴木匡, 長谷川洋一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 542-542, 2020. |
|---|
|
|
S62-1. Look back on business training of 2019; and - result and problem - 伊東明彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 545-545, 2020. |
|---|
|
|
S62-2. Invention and problem of the business training in the university hospital 津川透1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 546-546, 2020. |
|---|
|
|
S62-3. Oldness and training to be carried out by regional alliances 小林潤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 547-547, 2020. |
|---|
|
|
S62-4. Consideration from the business training University in conformity with the revision model core curriculum 鈴木匡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 548-548, 2020. |
|---|
|
|
Symposium 63. [contribution to society] Jump out of an own institution, and is a pharmacist associated with how local infection measures? 高山和郎, 高田勝利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 549-549, 2020. |
|---|
|
|
S63-1. Pharmacist Law Article 1 at the cut end called infection measures 高山和郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 550-550, 2020. |
|---|
|
|
S63-2. Activity of the school pharmacist for the purpose of the infection measures in the area 荒川隆之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 551-551, 2020. |
|---|
|
|
S63-3. Let's turn our eyes to the community from within the hospital - Actions aimed at local AMR countermeasures thought by a pharmacist - 上ノ段友里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 552-552, 2020. |
|---|
|
|
S63-4. Participation in local infection measures to be possible in the position of the university teacher 継田雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 553-553, 2020. |
|---|
|
|
S63-5. Antimicrobial proper use support team (AST) to bring up in an area 國島広之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 554-554, 2020. |
|---|
|
|
A workshop. It is the pharmaceutical approach to the patients with the compound disease (2) - practice to improve the pharmacist power as ... generalist 日本医療薬学会 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 555-555, 2020. |
|---|
|
|
O1-1. Effective and safe compounding of medicines duties improvement by the construction of the drug assistant educational program 松田貴子1, 鈴木慎二1, 渡辺智美1, 山田恭子1, 齊藤暢子1, 鈴木孝幸1, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-557, 2020. |
|---|
|
|
O1-2. Effect about prescription mention of test value for the pharmaceutical products proper use and the check item 依光奈津美1, 梅村晃子1, 平野公美1, 宮本康敬1, 川口千香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 558-558, 2020. |
|---|
|
|
O1-3. Usefulness evaluation of the prescription suggestion support system for the promotion of the proper use of the renal excretion type drug 薗田晃弘1, 近藤悠希2, 岩下佳敬1, 中尾承司1, 石田和久1, 石塚洋一2, 入江徹美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 558-558, 2020. |
|---|
|
|
O2-1. In-hospital formulary introduction of oral proton pump inhibitors in general hospitals and examination of its effects 後藤健志1, 竹尾恵理子1, 酒井欣嗣2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 559-559, 2020. |
|---|
|
|
O2-2. The setting of the pharmaceutical products ward placement standard and the effect 大竹慶尭1, 菅野ゆみか1, 大谷美子1, 丸山智弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 560-560, 2020. |
|---|
|
|
O3-1. Examination of the usefulness of the open clean bench (super clean generation device KOACH) in the parenteral injection no bacteria preparation 佐東未咲1, 菅原拓也1, 延川正雄1, 松田圭一郎1, 西村孝一郎1, 木村東子2, 長岡純二2, 荒井浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 561-561, 2020. |
|---|
|
|
O3-2. For the further spread of simple suspension methods: Development of the tablet crush technology with the rotation, the revolution mixer 長井紀章1, 後藤涼花1, 宇野樹1, 東尚希1, 中尾元紀2, 橋本直文3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 562-562, 2020. |
|---|
|
|
O4-2. Education effect of the audit enforcement aiming at improvement in quality of ward duties 真志田絵美子1, 吉川博1, 片岡達夫1, 佐伯康之1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-564, 2020. |
|---|
|
|
O4-3. Analysis - using effect - tendency score matching that a pain-killer after the total prostatectomy gives for renal function after the operation 西村文宏1, 牛島智子1, 原一正2, 門脇大介3, 宮村重幸3, 鬼木健太郎4, 猿渡淳二4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-564, 2020. |
|---|
|
|
O4-4. Evaluation of the intervention effect of the ward pharmacist in the blood medical service 金子憲太郎1, 川口文誉1, 内藤たから1, 杉本誠1, 豊田茂雄2, 土井路子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 565-565, 2020. |
|---|
|
|
O4-5. Fact-finding about the subjective adherence evaluation of patients by Visual analogue scale 宮崎元康1, 小野千花1, 内山将伸1, 松尾宏一1, 鵜木亜矢子1, 中島章雄1, 後藤美和1, 今給黎修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 565-565, 2020. |
|---|
|
|
O4-6. An investigation about the efforts for the polypharmacy reduction in the digestive organ surgery ward: Single institution rearward observational study (the second report) 岡野愛子1, 吉廣尚大1, 小野塚和人1, 礒貝明彦1, 中光篤志2, 橋本佳浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-566, 2020. |
|---|
|
|
O4-7. The multi-type of job conference for patients with symptomatic heart failure shows the main harmful cardiovascular events protective efficacy after the discharge 櫻下弘志1, 石井聡一郎1, 佐伯康之1, 畝井浩子1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-566, 2020. |
|---|
|
|
O5-1. Activity in the pre-hospital automation of the emergency resident pharmacist for the abuse of the nonprescription drug 広瀬正幸1,2, 平川昭彦3, 田島康介4, 山田成樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 567-567, 2020. |
|---|
|
|
O5-2. The case that patients who received plasma exchange and haemodialysis underwent TDM of VCM, and control came to have good 赤羽理也1, 福井里佳1, 下村春奈1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 568-568, 2020. |
|---|
|
|
O5-3. Efforts utilizing the ICT in the super acute phase stroke primary care 平岩歳久1, 加藤貴大1, 岩崎仁志1, 廣瀬正幸1, 松本省二2, 中原一郎2, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 568-568, 2020. |
|---|
|
|
O5-4. Examination about the intervention effect of the pharmacist in the nutrition therapy in the intensive care domain 中川貴弘1, 北庄司敦久1, 西井拓人1, 西田愉可利1, 若林里絵1, 森朝紀文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 569-569, 2020. |
|---|
|
|
O6-1. Validity evaluation of the confirmation before hospitalization of the antirheumatic drug by the pharmacist for the orthopedics surgery planned patients 中西一志1, 安島秀友1, 美馬朱美1, 杉本涼佳1, 松崎貴志1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 570-570, 2020. |
|---|
|
|
O6-2. The current situation and pharmacist sleep consultation foreign efforts of the sleeping drug prescription 今井圭介1, 黒飛謙次1, 藤川亜衣1, 富田哲夫1, 古野孝明1, 川口健1, 半田寛1, 難波康男2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 571-571, 2020. |
|---|
|
|
O6-3. Effect of the foreign inhalational instruction by the pharmacist in the acute phase hospital 平山優花1, 内田有紀1, 廣澤達哉1, 松永康二郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 571-571, 2020. |
|---|
|
|
O6-4. Usefulness of the pharmacist outpatient department mainly on the drug for the medical care 辻村行啓1, 荒川大輔1, 古橋侑樹1, 飯塚美有1, 清水真弓1, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-572, 2020. |
|---|
|
|
O6-5. Examination about the effect of the Chinese medicine improving going emptiness 上野良夫1, 眞鍋聡太3, 小原依里3, 玉木真紀子2, 伊原木沙智代1, 三枝貢1, 眞鍋伸次1, 飯原なおみ3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-572, 2020. |
|---|
|
|
O7-1. Usefulness of the medical information system training 山中理1,2,3, 山村篤史1, 中村真樹4, 横幕香織4, 中山英夫1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 574-574, 2020. |
|---|
|
|
O7-2. Activity of the pharmacist in the JCHO Nankai medical center eating deglutition support team 道野南風1, 葉田昌生1, 川勝美里1, 北村仁1, 佐々木達也1, 海部真代1, 谷口公章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-575, 2020. |
|---|
|
|
O7-3. Contents and the result that received the medical information system training by the medical information engineer pharmacist 中村真樹1, 山中理2,3,4, 山村篤史2, 横幕香織1, 茂籠茂彦1,5, 近藤博紀1, 中山英夫2,4, 大野勝則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-576, 2020. |
|---|
|
|
O7-4. Medicine review meeting ... by the information sharing of the post of post of construction - pharmacist, nursing of the multi-type of job cooperation model who aimed at the appropriate medical treatment of the nursing facility resident, care 石坂優奈1, 柳奈津代2, 佐藤宏樹2, 三木晶子2, 馬来秀行3, 川村耕平3, 西川英里3, 木村貴史3, 小西ゆかり3, 岡本勝樹3, 雨宮潤美3, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 576-576, 2020. |
|---|
|
|
O7-5. Cooperation possibility - of examination - child-care facility and the drugstore of the support to expect of the difficult feeling and drugstore pharmacist of the administration of the nursery staff in the nursery school institution 柳奈津代1, 佐藤宏樹1,2, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 577-577, 2020. |
|---|
|
|
O8-1. The detection of excessive quantity, the too few order of pharmaceutical products using the machine learning 永田健一郎1, 辻敏和1, 村岡香代子1, 渡邊裕之1, 金谷朗子1, 江頭伸昭1, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 578-578, 2020. |
|---|
|
|
O9-1. Analysis of the nonsteroidal antiinflammatory drug using the domestic adverse event spontaneous report database and the acetaminophen-related thrombo embolic event 菅原英輝1, 有馬太陽1, 寺薗英之1, 武田泰生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 579-579, 2020. |
|---|
|
|
O9-2. Efforts for problem grasp and the improvement for improvement in customer satisfaction in the inquiry correspondence, and the like 太田和人1, 大町成樹1, 有和泰子1, 平松理郁子1, 中井徹1, 京井由加利1, 吉實弘樹1, 高野修一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2020. |
|---|
|
|
O9-3. Examination - about the risk factor of the pseudoaldosteronism in evaluation (the first report) - Yokukansan user of safety of medicine, the effectiveness using the medical information 石田智滉1, 川田敬1,2, 森沢惇平1,2, 常風興平1, 森田靖代1, 宮村充彦1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2020. |
|---|
|
|
O9-4. Analysis results ... of side effect database FEARS of ... world's largest of hiccups and nicotine concerned 細谷龍一郎1,2, 日野斉一1, 野澤(石井)玲子2, 植沢芳広3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 581-581, 2020. |
|---|
|
|
O9-5. Investigation about the use situation of the use according to a good use standard 川崎裕貴1, 和田良浩1, 谷田彩1, 小川恵美子1, 吉川一吾1, 池田和之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 581-581, 2020. |
|---|
|
|
O9-6. Fact-finding about package insert mention about the effect on transitivity and infants to human mother's milk by the medication of the antidepressant 久保野尚子1, 相曽明日香1, 佐野慎亮1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-582, 2020. |
|---|
|
|
O9-7. Onset of dysfunction thyroid situation evaluation with the molecular target anticancer medicine using the adverse drug reaction database 松井頌明1, 石原慎之2, 玉木宏樹2, 矢野貴久2, 幸田恭治1, 直良浩司2, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-582, 2020. |
|---|
|
|
O9-8. Construction and evaluation of the injection drug incompatibility search system which is browsable on an electronic medical chart 樽野麻依1, 梶田貴司1,2, 西島美佳2, 戎浦規文1, 雪矢良輔1, 黒松誠1, 西川豊1, 奥野智之1, 金子嘉志2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 583-583, 2020. |
|---|
|
|
O9-9. Exhaustive examination of the drug-related necrosis of the jaw bone based on JADER 鳥海真也1,2, 小林明信1, 植沢芳広2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 583-583, 2020. |
|---|
|
|
O10-1. Experience and attitude survey about clinical studies of the hospital pharmacist 高武嘉道1, 川俣洋生1, 大石裕樹1, 福石和久1, 高島伸也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 584-584, 2020. |
|---|
|
|
O10-2. Identification of the factor involved in the secession of the disseminated intravascular coagulation syndrome with the administration of the thrombomodulin alfa 小武和正1, 田平明啓1, 新見奈々1, 羽井佐郁恵1, 川上恭弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 585-585, 2020. |
|---|
|
|
O10-3. Multicenter large-scale fact-finding of the medication adherence of the direct action type oral anticoagulant drug for patients with non-valvular atrial fibrillation 三浦誠1, 尾濱直子1, 関利一2, 秋山裕史2, 杉山哲大3, 翁長真一郎4, 宮里弥篤4, 新谷歩5, 吉田寿子5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 585-585, 2020. |
|---|
|
|
O10-4. The use situation investigation for the proper use of the dry concentration person prothrombin complex preparation 花田聖典1, 鶴崎泰史1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 586-586, 2020. |
|---|
|
|
O10-5. Validity evaluation of the third generation cephalosporin antimicrobial deletion of the cataract surgery clinical path 杉本涼佳1, 安島秀友1, 美馬朱美1, 中西一志1, 松崎貴志1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 586-586, 2020. |
|---|
|
|
O10-6. How the pharmacist can be concerned in a long-term viewpoint for the pharmaceutical products after formulations; is ... through the expiration date of ... nitro pen sublingual tablet 木元英之1, 鴨田健1, 阿部真也3, 丸谷晴子2, 谷口智則4, 今村かおり5, 正木匠6, 茨目彩耶7, 河野慈子7, 佐藤卓也8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 587-587, 2020. |
|---|
|
|
O10-7. Adherence and drug economics investigation of the use of liquid patients for the Efinaconazole movement of the feet 徳山智治1, 磯尾優子1, 穴見江梨子2, 坂本豊伸3, 塚本賢児4, 天方奉子5, 稲葉一郎5, 宮野恭彰6, 木戸宏幸6, 湯川栄二6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 587-587, 2020. |
|---|
|
|
O10-8. Examination of the usefulness by clinical test value mention to outside Parliament prescription 吉永光辰1, 尾之江剛樹1, 谷口潤1, 迫田英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-588, 2020. |
|---|
|
|
O10-9. Effect on prescription situation and blood toxicity investigation of the silver sulfadiazine cream 山根靖弘1, 山根紗希子1, 梅田清隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-588, 2020. |
|---|
|
|
O10-10. Attitude survey for the role of the drugstore of the health insurance pharmacy pharmacist and the family pharmacist 長沼敬子1, 木下隆市1, 染谷光洋1, 谷口亮央1, 中島史雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 589-589, 2020. |
|---|
|
|
O10-11. Grasp and content analysis of the use situation of the contraindicated medicine in the Mie University Hospital 白石ちひろ1, 杉本浩子1, 水谷栄梨1, 向原里佳1, 加藤千佳1, 篠木優里1, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 589-589, 2020. |
|---|
|
|
O11-1. Cost effectiveness of the Japanese progress, nivolumab in recurrence cancer of the esophagus second treatment 近藤有1, 榊原崇芳1, 加藤潤1, 渡邊雅史1, 西村栄輝1, 實安健市1, 下野大貴1, 間瀬悟1, 三宅芳男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 590-590, 2020. |
|---|
|
|
O11-2. Outcome evaluation of the proper use guideline (rea formula) introduction in the antiinfluenza medicine 片田佳希1,2, 米澤淳1, 杉本充弘1, 木全柾典1, 吉田優子1, 糸原光太郎1, 中川俊作1, 北田徳昭1, 今井哲司1, 池見泰明1, 深津祥央1, 中川貴之1, 松村康史2,3, 長尾美紀2,3, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 591-591, 2020. |
|---|
|
|
O11-3. Evaluation of the drug economic usefulness by the sleeplessness indicator standardization 税所篤行1,2, 高砂美和子1, 若林和貴1, 秋山真里1, 幸田恭治1, 松永和人2, 石田博3, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 591-591, 2020. |
|---|
|
|
O11-4. Drug costs reduction effect by the storage period extension of the multiple use vial 藤本俊祐1, 中村はづき1, 多賀允俊1, 野崎香於利1, 中田早音1, 高橋喜統1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2020. |
|---|
|
|
O11-5. Evaluation of the impact of warning display at the time of prescription order on formulary promotion 安島秀友1, 松崎貴志1, 美馬朱美1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2020. |
|---|
|
|
O11-6. Factorial experiments about medication of the patients whom cerebral infarction developed in during anticoagulant remedy 赤木祐貴1, 池滝晶子1, 中村玲子1, 高橋竜哉2, 遠藤美乃里3, 盛川敬介3, 太田貴洋4, 及川瞬5, 辰己晋平6, 鈴木隆史7, 水島淳裕8, 山村重雄9, 小井土啓一1, 高橋省三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 593-593, 2020. |
|---|
|
|
O11-7. Examination of the usefulness of the use of perioperative statin using the National receipt database 黒田侑花1, 落部達也2, 秋田彩佑1, 頭金正博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 593-593, 2020. |
|---|
|
|
O11-8. Medical economic effect by DVO and the Dose Banding introduction simulation of the injection anticancer medicine 本永正矩1, 板村亮1, 小林遼平1, 寺谷祐亮1, 佐伯康之1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 594-594, 2020. |
|---|
|
|
O12-1. Functions and usefulness of the polypharmacy system made by Yuyama Co., Ltd. 上田宏1, 細田未紀1, 畑将弘1, 石谷理紗1, 山根正也1, 千原里美1, 伊東範尚2, 三宅建郎3, 野村俊至4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 595-595, 2020. |
|---|
|
|
O12-2. Examination about the construction of the prescription adequacy support system and the effect 竹村有美1, 濱崎千尋1, 山田健一1, 塚原邦浩1, 小倉秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 596-596, 2020. |
|---|
|
|
O13-1. About reporting about the safety of the health food in the anti-doping education for the professional athlete 武山和也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 597-597, 2020. |
|---|
|
|
O14-1. "A healthy fair" utilizing obesity, the alcohol metabolism-related genetic screening for citizens 池田佳代1, 細井徹1, 三浦常代2,3, 島崎一郎4, 春日真由5, 高畑真由子5, 島田和美5, 田中信江5, 龍春花3, 幾田美紀3, 谷口智昭3, 天崎あゆみ3, 吉井美智子1, 杉山政則6, 大谷純一3, 重留佳代子5, 若生あき5, 中野真豪7, 野村祐仁7, 豊見雅文8, 小澤光一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-598, 2020. |
|---|
|
|
O15-1. The effectiveness and safety of the breast cancer trastuzumab follower product in real world data 佐々木俊則1, 水谷三浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 599-599, 2020. |
|---|
|
|
O16-1. One case of the diffuse scleroderma that resulted in a pulmonary oedema by bosentan administration 今井雄介1, 田中雅幸1,2, 打谷和記1, 諏訪惠信3, 村中達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 600-600, 2020. |
|---|
|
|
O16-2. Development of the onset of non-expression side effect prediction law using the distance between drug - side effects and inspection of the validity 渡部輝明1, 川上準子1, 星憲司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-601, 2020. |
|---|
|
|
O16-3. The establishment of the onset of fatal adverse event risk rating system with the immune checkpoint inhibitor in patients with lung cancer: Risk assessment of the interstitial lung disease 岡田直人1, 松岡里英1, 櫻田巧1, 合田光寛1, 中馬真幸2, 武智研志3, 座間味義人1,4, 桐野靖1, 中村敏己1, 西岡安彦5, 石澤啓介1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-601, 2020. |
|---|
|
|
O16-4. One case that presented a serious neutropenia in the FOLFIRI + bevacizumab therapy of Lacosamide treated patients 松沼悟1, 輿石徹1, 川辺千苗美1, 須永茂樹2, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 602-602, 2020. |
|---|
|
|
O16-5. 1 case with suspected vasculitis with duloxetine 中川義浩1, 鶴崎泰史1, 花田聖典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 602-602, 2020. |
|---|
|
|
O16-6. Study on risk factor analysis of the blood eosinophil count ratio increase for the early detection of eosinophilic pneumonia through daptomycin 梅村晃子1, 早川慎哉1, 平野公美1, 宮本康敬1, 川口千香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-603, 2020. |
|---|
|
|
O16-7. Association between expression of Infusion Reaction and allergic disease and allergy history with rituximab 深田耕司1, 宮本真由1, 犬飼萌乃1, 前田真一郎1,2,3, 前田真貴子1,2,4, 藤尾慈1,2,4, 廣部祥子1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-603, 2020. |
|---|
|
|
O16-8. Examination about the effect on CK with the daptomycin high dose 上田真也1, 田代匠1, 早川裕二3, 深見和宏1, 近藤芳皓4, 朝居祐貴5, 鈴木亮平6, 細江慎吾7, 薄雅人4, 間瀬広樹3, 山本吉章2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2020. |
|---|
|
|
O16-9. Risk factor evaluation of the checkpoint inhibitor-related fatal adverse event of immunity 新村貴博1, 座間味義人1,2, 合田光寛2, 中馬真幸3, 八木健太3, 福島圭穣4, 石澤有紀5, 藤野裕道4, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2020. |
|---|
|
|
O16-10. Effect on cognitive function of the non-ergot system dopamine agonist in the Parkinson's disease patients 中村友紀1, 重面雄紀1, 中川貴之1, 今井哲司1, 樽野陽亮2, 澤村正典2, 大村友博3, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 605-605, 2020. |
|---|
|
|
O16-11. Case of the complete atrioventricular block by the azelnidipine that an eternal pacemaker shrubbery was evaded by pharmaceutical intervention 井出直仁1, 望月彩加1, 伊藤政治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 605-605, 2020. |
|---|
|
|
O16-12. Two cases of the pulmonary thromboembolism that occurred during antipsychotics remedy 甲斐真己都1, 山村亮太1, 河野浩之1, 田中遼大1, 龍田涼佑1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-606, 2020. |
|---|
|
|
O16-13. The combination of the P-glycoprotein inhibitor giving it to a bleeding risk of the dabigatran and nephropathic effect (the third report) 横田裕之1, 川上智恵子1, 土岐浩介1,2, 青沼和隆2, 家田真樹2, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-606, 2020. |
|---|
|
|
O16-14. About side effect collection based on the law such as pharmaceutical products medical equipment, and the like in the Aichi Medical University Hospital 宇野英理子1, 野々垣知行1, 佐久間晶基1, 近藤あゆみ1, 深谷さおり1, 竹内正幸1, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-607, 2020. |
|---|
|
|
O16-15. Evaluation of the bleeding-related adverse event in Avastin and the DOAC combination 中村宗一郎1, 坂野博紀1, 町支優和1, 石川元章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-607, 2020. |
|---|
|
|
O16-16. Does the Donepezil raise a side effect risk of amantadine? 薄井健介1,2, 岡田浩司1,2, 宇野尭2, 小塚脩平3, 高瀬照人3, 大内竜介1,2, 鈴木映二3, 渡辺善照1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 608-608, 2020. |
|---|
|
|
O16-17. The onset of tubulointerstitial nephritis situation with the immune checkpoint inhibitor: Analysis using Japanese Adverse Drug Event Report database 岡田浩司1,2, 薄井健介1,2, 大内竜介1,2, 宇野尭2, 高橋将典2, 菊池大輔2, 渡辺善照1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 608-608, 2020. |
|---|
|
|
O17-1. Construction of the physiologic pharmacokinetics model in consideration of a complicated non-linear internal change of the hepatitis C therapeutic drug Grazoprevir 志田紗恵子1, 吉門崇1,2, 年本広太2, 杉山雄一2, 千葉康司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 609-609, 2020. |
|---|
|
|
O17-2. Examination of the species difference in the oxidative metabolism response of the regorafenib 曽我部鮎果1, 加藤美紀2, 小島綾華1, 榊原有季子2, 灘井雅行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2020. |
|---|
|
|
O17-3. The effect that a multi-kinase inhibitor gives to the expression of human skin drug transporter 小島綾華1, 加藤美紀1, 榊原有季子1, 灘井雅行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2020. |
|---|
|
|
O18-1. Consideration - case report about the index to guess a cerebral fluid extraction rate of vancomycin at meningitis 山形真一1, 狩野亘平2, 白澤宏美3, 原田正公2, 鶴崎泰史3, 中川義浩3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 611-611, 2020. |
|---|
|
|
O18-2. Do pharmacokinetic-related genetic polymorphisms affect inter-individual variability in trough concentrations of oral factor Xa inhibitors? 中川潤一1, 金城貴彦2, 飯塚芽依1, 上野桂代1, 富田泰史2, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2020. |
|---|
|
|
O18-3. The peripheral blood lymphocyte counts in patients with advanced cancer, serum IgG behavior and anticipatory evaluation of serum nivolumab concentrations that paid their attention to the cachectic condition of a patient 阿部一樹1, 柴田海斗1, 内藤隆文1, 柄山正人2, 大塚篤史3, 前川真人4, 山田康秀2, 三宅秀明3, 須田隆文5, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2020. |
|---|
|
|
O18-4. Effect on arbekacin clearance due to the febrile neutropenia 中山貴裕1, 中馬真幸1, 栃倉尚広1, 岩渕聡1, 鈴木慎一郎1, 松本千明1, 今井徹1, 吉田善一1, 濱田高志2, 中川優2, 高橋宏通2, 内野慶人2, 三浦勝浩2, 入山規良2, 八田善弘2, 武井正美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-613, 2020. |
|---|
|
|
O18-5. Rationalization of very high blood flecainide levels in patients with cirrhosis merger end stage renal failure using the physiologic pharmacokinetics model 土岐浩介1, 久賀圭祐2, 青沼和隆2, 家田真樹2, 本間真人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-613, 2020. |
|---|
|
|
O18-6. The diabetes medical therapy that is optimal for an individual 富岡節子1, 山崎直毅2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 614-614, 2020. |
|---|
|
|
O18-7. Population pharmacokinetics/genome pharmacologic analysis of the edoxaban in patients with atrial fibrillation 上島智1, 平大樹1,2, 道籏梨央1, 田淵陽平2, 伊藤英樹3,4, 小澤友哉3, 中川義久3, 堀江稔3,5, 寺田智祐2, 桂敏也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 614-614, 2020. |
|---|
|
|
O19-1. Effect of the dihydropyridine-based calcium-channel blocker on side effect expression of the Ramucirumab/Paclitaxel therapy 川口萌実1, 友松拓哉1, 青山剛1, 川上和宜1, 平出誠1, 山口研成2, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 615-615, 2020. |
|---|
|
|
O19-2. Effect - that the enzyme induction of patients with refractory epilepsy and polypharmacy - antiepileptic drug gives to antipsychotics 福島悠太郎1, 山本吉章1,2, 賀川義之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-616, 2020. |
|---|
|
|
O19-3. Examination about drug interactions and the polypharmacy during cancer pain treatment 鈴木訓史1, 齋藤一樹1, 一戸集平1, 後藤達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-616, 2020. |
|---|
|
|
O19-4. Effect on effect of treatment of the rosuvastatin by the taking magnesium oxide timing 小山勝真1, 税所篤行1, 幸田恭治1, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 617-617, 2020. |
|---|
|
|
O19-5. Examination by in vitro of the interaction through cytochrome P450 of voriconazole and aprepitant 石田真紗子1, 熊谷健2, 進藤佐和子2, 鈴木裕之3, 山本達郎1, 森木邦明1, 永田清2, 島田美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 617-617, 2020. |
|---|
|
|
O20-1. Examination of the renal function evaluation method using the serum creatinine level in patients with amyotrophic lateral sclerosis 野々内裕紀1, 眞継賢一1, 王宏維1, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 618-618, 2020. |
|---|
|
|
O20-2. Association between age-related body composition change and metabolism of the liver metabolism type drug in elderly people 蕪木素代子1, 吉村恵理2, 宮本康史2, 今井俊吾3, 柏木仁3, 上野英文2, 菅原満3,4, 武隈洋4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 619-619, 2020. |
|---|
|
|
O20-3. Assay establishment of high sensitive free form Lenvatinib concentrations using UPLC-MS/MS 末繁嘉朗1, 白岩健1, 田中遼大1, 本田浩一2, 齋藤衆子2, 岩尾正雄2, 荒川光江2, 遠藤美月2, 龍田涼佑1, 村上和成2, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 619-619, 2020. |
|---|
|
|
O20-4. We look at the rear about Teicoplanin maintenance doses aiming at 15-30 μg/mL of trough values and examine a mark 近藤昭志1, 尾田一貴1,2, 片野田朋美1,2, 成田勇樹1, 岩村耕次1, 野坂生郷2, 城野博史1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-620, 2020. |
|---|
|
|
O20-5. Construction of the blood level simultaneous analytical procedure of CDK4/6 inhibitor in the breast cancer and the hormonal therapies medicine 佐藤裕1, 重田健介2, 平澤天晴2, 菊地正史1,2, 佐藤紀宏1, 小倉次郎1, 前川正充1,2, 江幡明子3, 濱中洋平3, 多田寛3, 石田孝宣3, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-620, 2020. |
|---|
|
|
O20-6. Search of the optimal loading dose of the Teicoplanin in patients with hypoalbuminemia 吉瀬絵理1, 小松敏彰1, 宮坂優人1, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 621-621, 2020. |
|---|
|
|
O20-7. Examination about the blood level at the amiodarone continuous intravenous infusion for children 牧野宏美1, 諏訪淳一1, 植村明日香1, 鹿山祐梨1, 藤田幹生1, 山口智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 621-621, 2020. |
|---|
|
|
O20-8. The LC-MS/MS assay development of human serum tocilizumab concentrations using the trypsin digestion to immobilize and the clinical application 望月啓志1, 柴田海斗1, 内藤隆文1, 下山久美子2, 小川法良2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-622, 2020. |
|---|
|
|
O20-9. Exploratory evaluation of the change factor of the plasma GlcNAc concentration in patients with rheumatoid arthritis 今江陽1, 坪井声示1,2, 松本拓也2, 南雲達1, 谷澤康玄1, 大澤隆志1, 賀川義之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-622, 2020. |
|---|
|
|
O20-10. In-hospital algorithmic compliance and evaluation in the TDM of vancomycin 瀬戸良教1, 奥脇達也2, 小松敏彰2, 高山陽子1, 厚田幸一郎2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-623, 2020. |
|---|
|
|
O20-11. Establishment of the simultaneous assay of the each optical isomer of plasma tolvaptan in patients with heart failure and the hydroxylated metabolite 阿久津駿太1, 内藤隆文1, 星川昂平1, 早乙女雅夫2, 前川裕一郎2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-623, 2020. |
|---|
|
|
O21-1. The construction method of the examination for NUDT15 genetic polymorphism measurement 磯野哲一郎1, 平大樹1,2, 中村吉伸1, 辻徳治1, 赤羽理也1, 河原真大3, 森田真也1, 安藤朗3, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 624-624, 2020. |
|---|
|
|
O21-2. Usefulness of the microRNA as the effect prediction biomarker of the Benralizumab in patients with severe asthma 上原星輝子1, 平井啓太1, 良知優花1, 木村朋起1, 白井敏博2, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 625-625, 2020. |
|---|
|
|
O22-1. Examination of optimal non-duration of use becoming the freeze standard of the registration regimen in the cancer chemotherapy, Multicenter investigation 渡邊裕之1, 槙原克也2, 中野寛之3, 倉橋基尚4, 近藤篤5, 村上賢次6, 中尾將彦7, 足立充司8, 萱野勇一郎9, 平井三保子10, 尾上雅英5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 626-626, 2020. |
|---|
|
|
O22-2. Examination of medication adherence and the effect of treatment of TAS102 奥田泰考1, 三瓶祐貴1, 品田誠1, 齋藤賢宏1, 毛塚ちひろ1, 星ちはる1, 小林直人1, 山口博紀2, 藤井博文2, 須藤俊明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 627-627, 2020. |
|---|
|
|
O23-1. Approach at the drugstore for the HBOC patients 宇田雅実1, 松久知由1, 金澤哲也1, 坂川興規2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-628, 2020. |
|---|
|
|
O23-2. Efforts to foreign cancer chemotherapy with high quality through the cancer medicine medicine cooperation 基村佳世1, 槙原克也1, 福井梨乃1, 奥澤文敏1, 井上聖夜子1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 629-629, 2020. |
|---|
|
|
O24-1. The anticancer medicine exposure situation investigation before and after the closed system anesthesia drug transportation system introduction 立原茂樹1, 大神正宏1, 市塚亜由美1, 石川洋輔1, 島田浩和1, 小島友恵1, 柴このみ1, 山下真以1, 坪山勝平1, 千葉布季子1, 鈴木麻紗子1, 鈴木美加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 630-630, 2020. |
|---|
|
|
O24-2. Translocation of Anticancer Drugs to Drainage by Hemodialysis and Continuous Hemodiafiltration in Patients Administered with Pomalidomide and Cyclophosphamide 古賀和馬1, 田頭尚士1, 山本宏1, 中尾亮太2, 有安祥訓2, 大野開成2, 吉田磨2, 太田康介3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-631, 2020. |
|---|
|
|
O24-3. Examination about the attitude survey in anticancer medicine exposure measures and the use expansion of the closed system anesthesia drug transportation system 横山雄一1, 井上潔1, 古谷頼和1, 植木亮磨1, 吉村仁志1, 江崎翔平1, 宇野由紀子1, 篠原義剛1, 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-631, 2020. |
|---|
|
|
O24-4. Analysis of the factor influencing the anxiety to injectable anticancer agent preparation duties in the hospital pharmacist 柳澤友希1,2, 黒須智博1, 夏目義明4, 清野敏一2, 伊佐間和郎2, 西村哲治3, 山下敦志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 632-632, 2020. |
|---|
|
|
O24-5. Evaluation of the occupational exposure measures at preparation by the anticancer agent exposure investigation 佐藤由美子1, 諸角一成1, 恒川有里1, 權田結乃1, 長水正也1, 日比陽子1, 森下修行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 632-632, 2020. |
|---|
|
|
O25-1. Regional alliances for irAE measures 坂川興規1, 金澤哲也1, 松久知由1, 宇田雅実1, 村上通康2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 633-633, 2020. |
|---|
|
|
O25-2. Efforts to the making of information sharing base of the medicine medicine cooperation in the cancer medical care 中村久美1,2, 淺野未代子2, 有井太郎2, 井出貴之2, 大輪武司2, 鬼窪利英2, 小野里直彦2, 野村充俊2, 平林克博2, 松澤直樹2, 松原重征2, 三浦篤史2, 向山百合2, 村田稔弥2, 吉澤貴代美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2020. |
|---|
|
|
O25-3. Efforts ... of the education, duties support activity - Aichi hospital pharmacist society cancer sectional meeting tool making group to a pharmacist engaged in cancer medical therapy 鈴木大介1,2, 朝岡裕樹2, 伊藤友哉2, 伊藤文香2, 鵜飼麻由2, 越智富美江2, 加藤奈波2, 神谷幸江2, 切畑麻那2, 小杉菜々子2, 嶋洋将2, 末松菜月2, 玉置彩奈2, 袴田杏紗2, 山田卓摩2, 高木麻衣2, 冨田庸介2, 川合甲祐2, 板倉由縁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2020. |
|---|
|
|
O25-4. Examination of the factor having an influence on the improvement of the understanding degree for the cancer medical therapy in the outpatient department 豊里星来1, 安藤洋介1, 小出菜優1, 松田日出三1, 辻井奈保1, 柘植雅大1, 河田健司2, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-635, 2020. |
|---|
|
|
O25-5. It is the current situation investigation about the tolerability of S-1 in the adjuvant chemotherapy after the pancreatic cancer technique 野口裕介1, 加藤良隆1, 大坪達弥1, 鹿浦香織1, 神田英一郎1, 小林大祐1, 眞釼彩子1, 江島智彦1, 豕瀬諒2, 村木優一2, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-635, 2020. |
|---|
|
|
O26-1. Comparison of the antiemesis effect of granisetron and palonosetron under the NK1 receptor blocker combination on chemotherapy of the moderate emetic risk 三好孝法1, 松尾尚美1, 小田原真希1, 堀南奈子1, 平木洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 636-636, 2020. |
|---|
|
|
O27-1. Device of the light subtraction of the liquid preparations gemcitabine-induced vascular pain which paid their attention to a dilution 内山数貴1, 齋藤佳敬1, 坂本達彦1, 菅野亮太1, 小松嘉人2, 武隈洋1, 菅原満1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 637-637, 2020. |
|---|
|
|
O27-2. Search of the patients background to be associated with the onset of the adverse event of the MPB therapy for the multiple myeloma 坂部彩1, 亀位涼1, 中嶋琢人1, 頭金正博1, 李政樹2, 飯田真介2, 丸山大2, 大佐賀智2, 飛内賢正2, 福原規子2, 宮崎香奈2, 南陽介2, 塚本憲史2, 辻村秀樹2, 吉満誠2, 宮本憲一2, 塚崎邦弘2, 永井宏和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-638, 2020. |
|---|
|
|
O27-3. Basic examination about the usefulness of the cystine theanine oral administration for oxaliplatin-induced peripheral neuropathy 川尻雄大1, 小林大介1, 江頭伸昭2, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-638, 2020. |
|---|
|
|
O27-4. It is ... for the early detection of telephone follow-up ... serious cardiovascular system adverse event for patients with multiple myeloma during IMiDs administration 西垣賢1, 生川賀代2, 米田勝晃2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 639-639, 2020. |
|---|
|
|
O27-5. Basic and clinical evaluation about the usefulness of the proton pump inhibitor for the cisplatin origin-related renal failure 平松駿一1, 池村健治2, 藤澤豊3, 岩本卓也1, 奥田真弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 639-639, 2020. |
|---|
|
|
O27-6. Investigation about the nasal meatus irritative symptom at the cyclophosphamide administration in the breast cancer chemotherapy 桑村恒夫1, 上津沙織1, 小笠裕斗1, 末松文博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2020. |
|---|
|
|
O27-7. About neutropenia and the patient background factor with bendamustine 大谷豊司1, 南目祐希1, 河角康1, 渡辺美恵子1, 新宮行雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2020. |
|---|
|
|
O27-8. Examination about the onset of thrombocytopenia with nutritional status and the oxaliplatin + S-1 therapy of patients with gastric cancer 中澤佑介1, 影山明1, 北村正樹1, 三森教雄2, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-641, 2020. |
|---|
|
|
O27-9. The effectiveness of the mirogabalin for peripheral neuropathy in the gynecologic TC therapy and safe examination 馬場華菜1, 谷口潤1, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-641, 2020. |
|---|
|
|
O27-10. Inspection of the effectiveness of the naldemedine in the poor Performance Status group of patients 加藤信太郎1, 小野田紘子1, 齋藤佳敬1, 今井俊吾2, 熊井正貴1, 敦賀健吉3, 渡辺祐子1, 武隈洋1, 菅原満1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 642-642, 2020. |
|---|
|
|
O27-11. Fact-finding of the administration cancellation by irAE of the ICI combination chemotherapy in the lung cancer 早坂州生1, 岩本浩史1, 北山秀則1, 竹内公美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 642-642, 2020. |
|---|
|
|
O27-12. Investigation about the onset of the interstitial lung disease associated with the immune checkpoint inhibitor using the adverse drug reaction database and the outcome 横井茉里1,2, 米澤淳2, 中川俊作2, 半田知宏3,4, 老本名津子1,2, 北田徳昭2, 中川貴之2, 松原和夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2020. |
|---|
|
|
O27-13. Patients with postmenopausal breast cancer have high onset, aggravation risk of paclitaxel-induced peripheral neuropathy 宮本朋佳1,3, 富士谷昌典1, 畑中重克2, 小泉祐一1, 川畑篤史3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2020. |
|---|
|
|
O27-14. Inspection of GARG Toxicity SCORE of elderly people cancer treatment in Japanese 藤村浩司1,9, 伊藤夕貴1,9, 大島有美子2,9, 平松久典3,9, 向山直樹4,9, 佐々木俊則5,9, 山口智江3,9, 佐藤由美子6,9, 堀田和男7,9, 久田達也1,9, 板倉由縁8,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-644, 2020. |
|---|
|
|
O27-15. Serum beta 2 - microglobulin is a risk factor of the cisplatin-induced acute renal failure onset for patients with cancer of the esophagus 古原優也1, 高橋克之1, 豕瀬諒1, 高橋正也1, 永山勝也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-644, 2020. |
|---|
|
|
O27-16. About onset of electrolyte abnormality to occur after Cetuximab administration 山城海渡1,2, 平田敦士2, 太田涼介2, 緒方文彦1, 中村武浩1, 川崎直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 645-645, 2020. |
|---|
|
|
O27-17. Extension of the no oxaliplatin association hypersensitivity reaction survival period with the antihistamine pre-medication 板倉祥嗣1, 土手賢史2, 古田祐美子2, 塩飽英二2, 金子忍2, 津田正博1, 小林由佳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 645-645, 2020. |
|---|
|
|
O27-18. The effectiveness, safe examination of precedent biomedicine of the filgrastim for the salvage chemotherapy of the malignant lymphoma and the following article 島野玲菜1, 那須いずみ1, 内田ゆみ子1, 柏村友一郎1, 藤井博之1, 谷口修一2, 伊藤忠明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2020. |
|---|
|
|
O27-19. Fact-finding about the administration timing of the peg filgrastim in patients with gynecologic cancer 小島友恵1, 大神正宏1, 谷中敦美1, 立原茂樹1, 市塚亜由美1, 石川洋輔1, 島田浩和1, 柴このみ1, 渡邊雅明2, 花井誠2, 島田浩明2, 鈴木嘉治2, 本田真人2, 鈴木美加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2020. |
|---|
|
|
O27-20. Prospective clinical study of the steroid prophylaxis for the eruption by the pemetrexed 櫻田巧1, 柴田高洋1, 濱野裕章1, 山川祐介1, 合田光寛1, 座間味義人1,2, 桐野靖1, 中村敏己1, 軒原浩3, 西岡安彦3, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-647, 2020. |
|---|
|
|
O27-21. Examination of the adverse event risk by ICI and the chemotherapy combination 金永進1, 南貴之1, 若月淳一郎1, 小林寛明2, 松本香織1, 筒井俊晴2, 柿崎有美子2, 花輪和己3, 小林みつ恵1, 宮下義啓2, 小林義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-647, 2020. |
|---|
|
|
O27-22. Examination of the onset risk of venous thromboembolism (VTE) in patients with cancer which received bevacizumab (BEV) 西村明莉1,2, 満間綾子2, 池田義明1, 安藤雄一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 648-648, 2020. |
|---|
|
|
O28-1. Use fact-finding of the opioid-induced constipation therapeutic drug naldemedine tosyl acid salt 戸田温子1, 飛鷹範明2, 坂本宣俊1, 田中守2, 田中亮裕2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 649-649, 2020. |
|---|
|
|
O28-2. Examination of the effectiveness of the midazolam a little sustained administration for the nausea symptom of patients with end-stage cancer 鈴木のどか1, 打田佑人2, 松本篤季3, 山本孝枝1, 河内若代1, 三宅浩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-650, 2020. |
|---|
|
|
O28-3. Examination about the use situation of bringing medicine and the rescue medicine for patients with cancer 江草徳幸1, 萬光沙紀1, 井口奈美1, 安原昌子1, 堀川俊二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-650, 2020. |
|---|
|
|
O28-4. Relations of the quantity of drug application for disease severity of oral mucositis every irradiation part of the radiation in patients with head and neck cancer and the pain 山本和輝1, 星川昂平1, 堀雄史1, 八木達也2, 神谷正貴3, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 651-651, 2020. |
|---|
|
|
O29-1. One case that performed a dose design of induction therapy and the consolidation chemotherapy of the acute promyelocytic leukemia in haemodialysis patients, and succeeded 林田颯志1, 佐道紳一1, 岩村直也1, 對馬秀樹1, 一瀬将広1, 樋口則英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-652, 2020. |
|---|
|
|
O29-2. Attenuation effect of the nicorandil for high blood pressure and the antitumor effect with the neovascularisation inhibitor 海老名一樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-653, 2020. |
|---|
|
|
O29-3. Look at TPS in the use of Pembrolizumab patients and the rear about the autoimmune disease-related side effect; a mark multicenter study 水上皓喜1, 北本真一2, 武良卓哉3, 妹尾啓司1, 阪田安彦1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-653, 2020. |
|---|
|
|
O29-4. An effect of EGFR-TKI in the EGFR mutation in the gene-positive non-small cell lung cancer and effect of the body-surface area on side effect 小田桐功武1, 高木香菜子2, 鷲巣晋作1, 細谷幸紀1, 内池明博1, 坪井伸也1, 葉山達也1, 権寧博3, 林宏行2, 木村高久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 654-654, 2020. |
|---|
|
|
O29-5. Antitumor effect and antimicrobial ... of effect - immunity checkpoint inhibitor to give to cancer immune therapy of the non-small cell lung cancer 貝野裕也1, 北澤文章1, 前野有紀1, 大井隆広1, 坂野玲子1, 中藏伊知郎1, 中村孝人2, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 654-654, 2020. |
|---|
|
|
O29-6. Relative examination with a survival period and the onset of patients with extensive-stage small-cell lung cancer of neutropenia: Multicenter study 宮城壮裕1, 辻大樹1, 川崎洋平2, 石川寛3, 中尾將彦4, 中垣繁5, 林稔展6, 原田知彦7, 鮎原秀明8, 玉木慎也9, 前田章光10, 大橋養賢11, 藤田行代志12, 荒川雄一郎13, 山本圭祐14, 矢野琢也15, 宮本康敬16, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-655, 2020. |
|---|
|
|
O29-7. Examination - interim report - about the effect factor of the diarrhea by the Abemaciclib 杉山理奈1, 嘉屋道裕1, 大滝由美1, 坂田茂代1, 杉山恭平1, 鈴木麻里子1, 冨士野ひより1, 堤正人1, 相磯佳歩1, 平野桂子1, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-655, 2020. |
|---|
|
|
O29-8. The warfarin combination case that we were thought to need for the recovery of the CYP2C9 conduction by the Enzalutamide for several months 山田麻衣子1, 奈良克彦1, 大野能之1, 田中雄大1, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 656-656, 2020. |
|---|
|
|
O29-9. Examination of the effect that PPI at the Cetuximab administration in patients with craniocervical part cancer gives to a low Mg blood symptom 谷本憲哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 656-656, 2020. |
|---|
|
|
O29-10. Examination about a weight loss before the administration in the administration of immune checkpoint inhibitor and the association of the survival period 槙原克也1, 松村友和1, 紙森隆雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 657-657, 2020. |
|---|
|
|
O29-11. A CDDP-induced nephropathic reduction effect by Caffeine and elucidation of the enhancement of the antitumor effect 菊池優貴乃1, 河野洋平1, 小池翼1, 野原萌1, 齋藤めぐみ1, 上原佳奈枝1, 青山隆夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 657-657, 2020. |
|---|
|
|
O29-12. The severe immune-mediated adverse event with the immune checkpoint inhibitor is high, and it develops in patients without a previous history of treatment 冨士原あゆみ1, 土手賢史1, 塩飽英二1, 古田祐美子1, 金子忍1, 松原菜美1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2020. |
|---|
|
|
O29-13. Fatigue, lassitude by the Lenvatinib, examination of the anorectic expression risk factor 土屋直彦1, 佐野周生2, 若林雅人1, 中田伸司2, 森宏光3, 和田秀一3, 浜善久4, 牛山利昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2020. |
|---|
|
|
O29-14. The effectiveness and safety of the checkpoint inhibitor combination therapy of immunity 濱武清範1, 小西史子1, 松田ちひろ1, 野間敏也1, 奥村優介1, 橋本浩明1, 北英夫2, 菅理晴3, 小島一晃1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-659, 2020. |
|---|
|
|
O29-15. The effect that BMI gives for expression and effect of treatment of the serious thrombocytopenia of the Carboplatin + etoposide 根來寛1, 重森美奈1, 小島すみれ1, 山下慎司1, 渡邉享平1,2, 矢野良一3, 塚本仁1, 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-659, 2020. |
|---|
|
|
O30-1. Establishment of use of standardization carbapenem system medicine metrics based on DPC data, Correlation with predictive DDDs and the usability test coefficient 前田真之1, 村木優一2, 安濃侑桂1, 佐和章弘3, 日馬由貴4, 石金正裕4, 大曲貴夫4, 大毛宏喜5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 660-660, 2020. |
|---|
|
|
O30-2. The linezolid-resistant enterococcal new detection decrease and drug costs reduction effect by the linezolid consumption drop 岡冨大輔1, 山西紀子1, 片山雄太2, 谷口雅敏1, 松田裕之3, 石野敬子4, 福地邦彦5, 二木芳人6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-661, 2020. |
|---|
|
|
O30-3. The effect that the feedback of the culture sampling rate before the wide area antimicrobial administration gives for narrowing of the antimicrobial 下平智秀1,2, 町田征己1, 藤田裕晃1, 奥川麻美1, 中村造1, 添田博1,2, 前彰2, 渡邉秀裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-661, 2020. |
|---|
|
|
O30-4. Drug costs reduction effect by the intervention of the pharmacist to the use of all injectable antimicrobial patients 大橋健吾1, 篠田康孝1, 松岡知子1, 新井かおり1, 西村未紗1, 長瀬泉1, 森卓之1, 吉田真也1, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-662, 2020. |
|---|
|
|
O30-5. Efforts of the education to the resident by the antibacterial chemotherapy authorization pharmacist 中田一孝1, 冨田有香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-662, 2020. |
|---|
|
|
O30-6. Evaluation of the AST activity led by the pharmacist judging from antimicrobial consumption investigation 星野僚介1, 木村繁和1, 松本智史1, 林貴子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 663-663, 2020. |
|---|
|
|
O30-7. Report - infective endocarditis surgical treatment case - of the cooperation situation of AST and the cardiovascular surgery in the Tomigusuku center Hospital 小杉卓大1, 姫野智子1, 運天雅1, 中島里奈1, 新垣淑大1, 大嵩昌子2, 石川美根子2, 西平守邦3, 山内昭彦4, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 663-663, 2020. |
|---|
|
|
O30-8. Consideration about the dose at renal failure of favipiravir and liver damage from literatures 池谷修1, 高野八百子1, 長谷川直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-664, 2020. |
|---|
|
|
O31-1. Effect of the antimicrobial proper use support activity at the small and medium size scale hospital 中村聡志1,2, 有馬隆司1,3, 田代良一1,4, 安水里美1,5, 愛甲隼人2, 渡邉恵美2, 中島隆司2, 長友優歩2, 柿元郁代2, 本屋敏郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 665-665, 2020. |
|---|
|
|
O31-2. Spreading effect to the education effect of the hand hygiene on ward pharmacist and the pharmacy school business trainee as the reviewer 柴田京香1, 飯田真之1, 宇田篤史1,3, 出田理恵2,3, 八幡眞理子2,3, 大本暢子1, 山本和宏1, 大村友博1, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 666-666, 2020. |
|---|
|
|
O31-3. About the usefulness of the study session about the infection for the purpose of the pharmacist education 佐々木暢琢1, 川口奈緒美1, 近藤健太1, 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 666-666, 2020. |
|---|
|
|
O31-4. Comparison between cefazolin and surgical-site infections protective efficacy of the cefmetazole in the orthopedics domain 中島一1, 桑村恒夫1, 芳賀由美2, 土屋邦善3, 末松文博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-667, 2020. |
|---|
|
|
O31-5. Examination about the consumption change of the beta-lactam system medicine accompanied with the adoption review of the oral antimicrobial 多賀允俊1, 高瀬文超1, 中村はづき1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-667, 2020. |
|---|
|
|
O31-6. Usefulness of the AST activity utilizing MALDI-TOFMS 石塚友一1, 本田勝亮1, 柏原道志1, 長岡翔1, 石原冬馬2, 釋悦子2, 齊藤一仁5, 武地大維5, 真壁利枝3, 宮木祐一郎4, 澤昇平1, 山本圭祐1, 松川陽央1, 鈴木真理子1, 石野清亮1, 渡邊卓哉5, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-668, 2020. |
|---|
|
|
O31-7. Evaluation of the effect that bacteremia due to drug-resistant Escherichia coli gives for clinical outcome 三村亘1, 佐藤夏津1, 福田治久2, 庄野あい子3, 赤沢学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-668, 2020. |
|---|
|
|
O31-8. Allied analysis of the UTIs in the SGLT2 inhibitor using adverse drug reaction database (JADER) 角真太郎1, 久保利樹1, 祖川倫太郎1, 江本晶子1, 田崎正信1, 入江裕之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 669-669, 2020. |
|---|
|
|
O31-10. An example of the enforcement situation and the problem of the infection management strategy in the health insurance pharmacy 玉城武範1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-670, 2020. |
|---|
|
|
O31-11. Examination of the usefulness using practice support system "Vitalook" online for the medical treatment support of patients with contagious infection 長澤宏之1, 田口雅彦2, 土屋良成2, 東納重隆2, 小松淳3, 野口邦晴3, 星誠一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-670, 2020. |
|---|
|
|
O32-1. Sialoschesis at nasogastric tube tube long-term custody: Examination with the amitriptyline administration 山岸紀子1,3, 松浦佳代1, 林祥子1,3, 中村優1,3, 中澤実紀1,3, 帆足萌1,3, 島本和巳2,3, 鷹羽頼勝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 671-671, 2020. |
|---|
|
|
O32-2. Study on prehospital drug control and nutritional status 田原温1, 綿屋朋子1, 宮内秀典1, 野口周作1, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 672-672, 2020. |
|---|
|
|
O32-3. Consideration about the use situation of the medicine for the central nervous system in patients with dysphagia and the effect 光武瑞穂1, 金子正博2, 福嶋浩一1, 越智達哉3, 巽弥生1, 尾鼻俊弥4, 岡本知子5, 辻佳穂里6, 後藤昭一7, 河合峰雄8, 西田哲也8, 菅生教文9, 石本学司1, 奥野昌宏1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 672-672, 2020. |
|---|
|
|
O32-4. Efforts to nutrition therapy standardization using a nourishment assessment sheet 只見智恵子1,2, 佐藤美絵1,2, 高橋史織1, 菅原直子1, 柏瀬しのぶ1, 深谷寛1, 浜田幸宏1, 木村利美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 673-673, 2020. |
|---|
|
|
O33-1. Subjective assessment in patients with schizophrenia taking brexpiprazole 横井里奈1, 波多野正和1,2,3, 森田葵1, 福井愛子1, 半谷眞七子1, 津川透2, 山田成樹2, 岸太郎3, 岩田仲生3, 亀井浩行1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 674-674, 2020. |
|---|
|
|
O33-2. Efforts for proper use of sleeping pills combining in-hospital formulary and NDB open data 加藤豊範1, 小暮俊明1, 町田祐実子1, 吉田章悟1, 鈴木絢子1, 酒井美理1, 小田高司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 675-675, 2020. |
|---|
|
|
O33-3. Open-label randomized clinical trial about the effectiveness by the sleeping drug change for the insomnia to be complicated for the depression that is not as effective to a benzodiazepine system sleeping drug 重面雄紀1, 今井哲司1, 中川貴之1, 上田敬太2, 圓東寛基1, 中川俊作1, 村井俊哉2, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 675-675, 2020. |
|---|
|
|
O33-4. Examination of the antidepressant for patients with end-stage cancer which coexisted for a depression symptom 今井一輝1, 二村昭彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2020. |
|---|
|
|
O33-5. Under the antidepressant combination is examined the bleeding risk with the oral anticoagulant drug directly 小島悠輔1, 片田佳希1, 中川俊作1, 重面雄紀1, 圓東寛基1, 山本将太1, 米澤淳1, 中川貴之1, 杉田尚子2, 村井俊哉2, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2020. |
|---|
|
|
O33-6. 3 cases that developed deep vein thrombosis after the lithium poisoning 祖川倫太郎1, 飛田修康1, 村川徹2, 阪本雄一郎3, 門司晃2, 入江裕之1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2020. |
|---|
|
|
O33-7. Effect of the psychology education by the pharmacist for the purpose of the medication self-care in the medical observation method ward 坂本靖之1, 助川鶴平2, 佐藤康一1, 堀浩政1, 槇恒雄1, 山口博之3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2020. |
|---|
|
|
O33-8. The new digital that can realize inhibition of cognitive functional decline, BPSD cera; is medical care application ... of spare examination - VR for the Thich development with a zing 岡本美緒1, 仁木一順1, 矢原恵美1, 上野慶太2, 田中寛之2, 野村麻衣3, 吉田啓太3, 奥田赳視3, 内藤泰男2, 石井良平2, 上田幹子1, 伊藤壽記1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 678-678, 2020. |
|---|
|
|
O33-9. It is ... about efforts ... prospective role of the exclusive duty pharmacist in the psychiatry liaison team and the present problem 高橋治樹1, 仲田明弘2, 齋藤千紘3, 平野桂子1, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 678-678, 2020. |
|---|
|
|
O34-1. Prednisolone, verapamil to a nursing mother, the body kinetic consideration in correspondence and the infants from a specialist in prescription about the advisability to the question with famotidine administration 大久保正1,2, 田中真理子2, 大久保七枝3, 大久保節子4, 大久保美穂5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 679-679, 2020. |
|---|
|
|
O34-2. Relations with the umbilical blood, mother's body blood drug concentration and neonatal drug withdrawal syndrome in the duloxetine remedy pregnant woman 田口怜奈1, 内藤隆文1, 鈴木光路1, 伊東宏晃2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 680-680, 2020. |
|---|
|
|
O34-3. Efforts of the improvement in vaccination rate of the pharmacist in our hospital maternity ward 石橋摩耶1, 堤栄二1, 鈴木伸男1, 佐藤貞子2, 柳田純子3, 佐藤多代3, 鈴木久也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 680-680, 2020. |
|---|
|
|
O34-4. It is the use significance of the change and "the mother's milk instructions vote of 12 years of the medication patients" after the nursing instructions system construction in our center 大津由美子1, 和栗雅子2, 藤川郁世1, 永井絵里子1, 松原侑紀1, 長瀧谷美樹1, 加島朱梨1, 外山真理奈1, 庵森靖弘1, 紺屋まりや1, 渡邊宏美1, 小森桂子1, 望月千枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 681-681, 2020. |
|---|
|
|
O34-5. Efforts of a change and the pharmacist of the pregnant medical treatment in the mental disorder merger pregnancy 桐林美緒1, 佐藤千比呂1, 近藤真寿美1, 金田美咲緒1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 681-681, 2020. |
|---|
|
|
O34-6. It is ... for efforts - pregnancy, the nursing and the medicine consultation outpatient department establishment of a pregnant woman, the nursing mother medical therapy authorization pharmacist in our hospital 上森恵里1, 松岡順子1, 川田桂子1, 海老井佳織1, 野口周作1, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 682-682, 2020. |
|---|
|
|
O35-1. Retrospective cohort study about the effect of the anticoagulant giving it to onset of diabetic peripheral neuropathy 冨田詩織1,2, 田中雅幸1, 打谷和記1, 村中達也1, 川畑篤史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 683-683, 2020. |
|---|
|
|
O35-2. Evaluation of the usefulness of the confirmation of a pharmacist for proper use promotion of the agent for diabetes in the outside Parliament drugstore sheet 小俣江利果1, 長内理大1,2, 小長谷奈美1, 伊野陽子1,2, 玉木啓文1,2, 山下修司2,3, 野口義紘2,4, 井口和弘1,2, 寺町ひとみ2,4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 684-684, 2020. |
|---|
|
|
O35-4. Clinical response for the serum lipid of the Dulaglutide 高橋怜史1, 山口亜矢1, 中村千里1, 大川浩子1, 喜多祐樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 685-685, 2020. |
|---|
|
|
O36-1. Search of urinary biomarker reflecting renal failure in the cancer medical therapy of patients with lung cancer 田島壮一郎1, 渡邊裕之1, 福田未音1, 田川慎二1, 佐田裕子1, 槇原洋子1, 秦晃二郎1, 辻敏和1, 岡本勇2, 増田智先3, 江頭伸昭1, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 686-686, 2020. |
|---|
|
|
O36-2. Development and operation of the side effect long-term management sheet of the immunosuppressive drug for renal-transplant recipients in the ethical pharmacy 小長谷奈美1, 長内理大1,2, 小俣江利果1, 伊野陽子1,2, 玉木啓文1,2, 山下修司2,3, 野口義紘2,4, 井口和弘1,2, 寺町ひとみ2,4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 687-687, 2020. |
|---|
|
|
O37-1. The anticholinergic load has an influence on the eating deglutition function in the convalescent rehabilitation ward 小瀬英司1, 平井利幸2, 関利一2, 安野伸浩1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 688-688, 2020. |
|---|
|
|
O37-2. Search of the effect on renal function factor in patients operated on for the osteoarthritis of elderly people 山元孝俊1, 小瀬英司1, 榎本弘美1, 渡部多真紀1,3, 河村剛至1,3, 安井洋一2, 河野博隆2, 安野伸浩1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2020. |
|---|
|
|
O37-3. Efforts of the prescription adequacy for the drug global assessment adjustment addition calculation situation and the elderly people in our hospital circulatory organ ward 廣田あゆ子1, 新城唯1, 河村茉衣1, 松本和也1, 小池彩子1,2, 黒田忍2, 福家聡一郎3, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2020. |
|---|
|
|
O37-4. Efforts ... as investigation of the use of drug about deglutition function in patients with aspiration pneumonia and team intervention - pharmacist 宮崎雄紀1, 岡本梨江2, 百瀬将晃2, 古清水元子3, 唐澤綾1, 矢嶋直子1, 跡部治1, 登内盛治1, 巨島文子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 690-690, 2020. |
|---|
|
|
O38-1. Comparison of an effective case of the steroid initial treatment in the idiopathic thrombocytopenic purpura and the invalid case 大野峻1, 武田元樹2, 菊池健2, 渡邉大毅2, 北島聖也2, 相馬貴史2, 佐々木啓2, 名達陽一2, 鶴山辰2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 691-691, 2020. |
|---|
|
|
O38-2. The effectiveness and tolerability of the morphine water (hospital preparation) for dyspnea due to the cryptogenic fibrosing alveolitis 南貴之1, 若月淳一郎1, 松本香織1, 花輪和己2, 小林みつ恵1, 小林義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-692, 2020. |
|---|
|
|
O38-3. Examination of oxidative stress before and after the medical treatment in autistic spectrum children coexisting for attention deficit hyperactivity disorder and the evaluation score 森本真仁1, 橋本俊顕1, 津田芳見1, 浜田茂明1, 北岡泰介2, 京谷庄二郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-692, 2020. |
|---|
|
|
O38-4. Making of conversion tables from the use situation and a Parkinson's disease internal use therapeutic drug of the Levodopa injection preparation in Nagoya Memorial Hospital to Levodopa injection preparation 近藤奈央子1, 壁谷めぐみ1, 湯浅周1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-693, 2020. |
|---|
|
|
O38-5. The effectiveness in the long-term use of the hyperammonemia therapeutic drug Rifaximin and safe examination 福井愛子1,2, 川部直人2, 三井有紗2, 宮地洋平2, 宮地小百合2, 越智友花2, 田中浩敬2, 中岡和徳2, 中野卓二2, 葛谷貞二2, 宮原良二2, 橋本千樹2, 吉岡健太郎2, 廣岡芳樹2, 亀井浩行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-693, 2020. |
|---|
|
|
O38-6. About a change of the lipid-related test value with the Elobixibat tablets in patients without a dyslipidemia anamnesis 高多瞭治1, 多賀允俊1, 西佳子1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-694, 2020. |
|---|
|
|
O38-7. Examination of the medication support based on Health Assessment Questionnaire in patients with rheumatoid arthritis 柳原有希1, 佐々木恵一2, 益口賢1, 狭間淳輔1, 加藤貴子1, 木本泰孝3, 堀内孝彦3, 橋本昌文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-694, 2020. |
|---|
|
|
O38-8. Effect of the CYP3A5 genetic polymorphism giving it to renal graft tissue level of tacrolimus in renal-transplant recipients 重松智博1,2, 田島壮一郎1, 張夢雨2, 末次王卓1, 岡部安博3, 増田智先4, 江頭伸昭1,2, 家入一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-695, 2020. |
|---|
|
|
O38-9. The use situation investigation of the morphine for patients with terminal heart failure 高城沙也香1, 鳥山陽子1, 永石浩貴2, 松尾圭祐1, 江崎瞳1, 谷口潤1, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-695, 2020. |
|---|
|
|
O38-10. New treatment strategy for the obliterative bronchiolitis that assumed carbon monoxide a base 渡部佑樹1, 田口和明1, 榎木裕紀1, 酒井宏水2, 丸山徹3, 小田切優樹4, 河野光智5, 松元一明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 696-696, 2020. |
|---|
|
|
O39-1. Rearward controlled trial ... about the effect of DAAs under the enforcement of the multicenter study and the true clinical practice from a manager for study to patients with problems - HCV which we saw 嘉屋道裕1, 中村和代1, 杉山恭平1, 木苗あゆみ1, 山口紘生2, 浮田浩利3, 氏家智香5, 加藤純6, 影山富士人7, 名倉真理子8, 松下久美9, 杉上香織10, 石田紘基11, 名波章子12, 小田切圭一4, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 697-697, 2020. |
|---|
|
|
O40-1. Construction and pharmacist activity of the outside Parliament other types of job cooperation in the local inclusion care system 長谷川豊1, 中本政容2, 駒井壽美3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 698-698, 2020. |
|---|
|
|
O40-2. How do you report bad news to pubertal children? 岡野聡1, 長谷川寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-699, 2020. |
|---|
|
|
O40-4. Success ... of the prescription reduction that polypharmacy formation - pharmacist by the medication assistance suggested 坂本直大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2020. |
|---|
|
|
O40-5. Qualitative study on instruction for patients with life-style related diseases of the drugstore pharmacist of Miyagi 小野寺亮1, 富永敦子1,2, 佐藤健太1,2, 土佐貴弘3, 澁谷和彦3, 男澤貴子4, 北村哲治4, 一條宏2, 平澤典保1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2020. |
|---|
|
|
O40-6. An incident accompanied with the medication assistance in the house 1 institution for elderly people with the service and analysis of the factor 池田百合香1, 佐藤宏樹2, 柳奈津代2, 益子幸太郎3, 木崎速人4, 山本大輔3, 馬来秀行3, 小西ゆかり3, 雨宮潤美3, 堀里子4, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-701, 2020. |
|---|
|
|
O40-7. About usefulness of the pharmaceutical intervention and information sharing in the early stage of the at-home shift 杉浦聡1,2, 北村佳久1,3, 高橋正志2, 千堂年昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-701, 2020. |
|---|
|
|
O40-8. It is efforts of becoming it the outside Parliament prescription of the medical care in remote area organization in connection with a local health insurance drugstore 堀内賢一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 702-702, 2020. |
|---|
|
|
O41-1. Fact-finding about the telephone follow during a medication period 荒井玲美1, 伊藤昌裕1, 渡邉泰崇1, 田井中絹代1, 宮田広樹1, 福岡勝志1, 弓削吏司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 703-703, 2020. |
|---|
|
|
O41-2. We examine illness in the cancer medical therapy and strengthen medicine cooperation 近藤元三1,2,3, 沼田朋和1, 森山健一2, 西千春3, 佐藤みづき3, 中村初美3, 大山高廣4, 田中由起子5, 山室蕗子5, 合澤啓二6, 陣上祥子6, 天方奉子1, 稲葉一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-704, 2020. |
|---|
|
|
O41-3. Evaluation of the usefulness of the tracing report specialized in a regimen in the foreign cancer chemotherapy 有田仁紀1, 宮川ありす1, 菅井瞳1, 柳野紗智子1, 石川曜平1, 渡辺和美1, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-704, 2020. |
|---|
|
|
O41-4. It is ... using efforts - tracing report of the medical cooperation in northeastern Rousaibyoin 菅野和彦1, 麻生敦子2, 新谷裕子2, 塚本弘美2, 小川彰子3, 相澤智子4, 袰岩靖子1, 高松謙1, 熊谷史由1, 中川こはる1, 佐藤真衣1, 横山咲稀1, 駒林幸太郎1, 大友眞菜1, 菊地未由1, 小笠原綾子1, 日野美穂1, 星野祐太1, 伊藤亮太1, 渡邊卓嗣1, 中嶋丈晴1, 穂積史朗1, 大月沢雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-705, 2020. |
|---|
|
|
O41-5. Intervention to the examination for HBV non-enforcement patients utilizing test value notation and the tracing report to a prescription 岩崎真衣1, 糀谷望1, 堀越慶一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-705, 2020. |
|---|
|
|
O41-6. The current situation investigation on the hospital side for the giving and receiving of the information sharing sheet with the health insurance pharmacy for hospitalization and release information sharing 吉良俊彦1, 陣在ひと美1, 本城綾子1, 谷本祐子1, 木下里紗1, 辻井佳代1, 石倉久美子2, 真常美紀3, 村田久枝4,5, 津田宜志6,7, 堀越博一6,8, 小林政彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-706, 2020. |
|---|
|
|
O41-7. Construction and operation of in-hospital formularies in cooperation with university hospital pharmacists and regional hospital pharmacists 渡辺善照1, 菊池大輔1, 三浦良祐1, 栃窪克行2, 佐竹成一3, 遠藤武弘4, 佐藤真由美5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-706, 2020. |
|---|
|
|
O41-9. Usefulness investigation of the advanced course in the inhalational instruction network 竹内まどか1,2, 加藤秀紀1, 後藤佳奈1, 大橋一輝1, 片岡智哉1,3, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 707-707, 2020. |
|---|
|
|
O41-10. Correspondence ... of the prescription issuance with new coronavirus infection spread preventive measures - telephone practice 堀内あす香1, 岡橋孝侍1, 岸本美紀子1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-708, 2020. |
|---|
|
|
O41-11. Patients attitude survey before and after the change to the prescription notebook "Aizu prescription notebook" which we unified in an area 木本真司1, 河原史明1, 香内綾1, 安齊泰裕1, 鈴木涼子2, 小室幹男3, 市橋淳4, 西郷竹次5, 下山田博久6, 塩川秀樹1,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-708, 2020. |
|---|
|
|
O41-13. Making of the protocol for the purpose of doubt inquiry investigation and the duties burden reduction of the outside Parliament prescription in our hospital 橋本知樹1, 眞継賢一1, 濱口良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 709-709, 2020. |
|---|
|
|
O42-1. Making of the drug department manual at the disaster dispatch psychiatric care team (DPAT) advance party dispatch 中山洋輔1, 高田正温1, 矢口武廣1, 渡邉彩友美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 710-710, 2020. |
|---|
|
|
O42-2. Pharmaceutical response to COVID-19 infection that spread in a large Cruise ship 森崎愛夢1, 小松優佳1, 相川実穂1, 渡邉暁洋2, 勝田恵1,3, 中野貴文1, 林稔展1, 江川孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 711-711, 2020. |
|---|
|
|
O42-3. The development of COVID-19 infection situation that spread in a large Cruise ship 小松優佳1, 森崎愛夢1, 相川実穂1, 渡邉暁洋2, 勝田恵1,3, 中野貴文1, 林稔展1, 江川孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 711-711, 2020. |
|---|
|
|
O43-1. Efforts to venous thromboembolism prophylaxis in our hospital 平田備子1,3, 磯弓子1,3, 前岡瑞希4, 林太郎2,3, 木南佐織2,3, 大西尚2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-712, 2020. |
|---|
|
|
O43-2. It is ... for fixation of the medical therapy corresponding to the prevention, the treatment of liaison team activity report - delirium 鶴崎泰史1,2,3,4, 藤田強記2, 中川義浩2, 堂園千代子3, 山下建昭4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-713, 2020. |
|---|
|
|
O43-3. The efforts of the request for medical safe report input for doubt inquiry to an initial clinical resident and the effect 阿部宏志1, 瀬上航平1,2, 山田浩史1,3, 朝野隆之1,2, 大岡正道1,4, 坂上逸孝5, 田中恒明5, 安田宏1,6, 大坪毅人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-713, 2020. |
|---|
|
|
O43-4. Analysis about the inflection situation of the medication reporting book in the drugstore 金子絵里奈1, 小林大介2, 高山浩太郎2, 小柳香織1, 林田論1, 郡司清志1, 鶴田達也1, 脇山えりか2, 古賀友一郎1, 小松公秀1, 高木淳一1, 木原太朗1, 窪田敏夫3, 島添隆雄2, 田中泰三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-714, 2020. |
|---|
|
|
O43-5. Use of sleep inducing drug flowchart introduction for sleeplessness indicator standardization and the evaluation 高砂美和子1, 秋山真里1, 若林和貴1, 税所篤行1,2, 松永和人2, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-714, 2020. |
|---|
|
|
O43-6. Usefulness evaluation of the test value according to the pharmaceutical products which we wrote in outside Parliament prescription 横山威一郎1, 山口洪樹1, 山崎香織1, 関谷美聡1, 新井さやか1, 中村貴子1, 鈴木貴明1, 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-715, 2020. |
|---|
|
|
O43-7. Evaluation about the Distribution of medicine confirmation enforcement by the ward pharmacist 藤里駿1, 生駒結夏1, 横田瑠美1, 岡本裕子1, 小田貴子1, 太田雅俊1, 猪股英幸1, 大橋美由紀2, 竹田克明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-715, 2020. |
|---|
|
|
O43-8. Prediction of the origin of doubt inquiry that accepted a medical institution, a physician using the machine learning 佐藤宏樹1,2, 加藤木俊廣1, 松村敦子3, 月岡良太3, 柳奈津代1, 森澤あずさ3, 大石美也3, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-716, 2020. |
|---|
|
|
O43-9. Of the preparation in the ethical drug package insert is sustained release; to show, and to prevent the accident with investigation - sustained release drug about 長谷部歩1, 山形真一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-716, 2020. |
|---|
|
|
O43-10. Examination of the factor to have an influence on the fall occurrence of the inpatient 松本有加1, 小田真司2, 坂本宜俊1, 渡邉真一1, 田母神淳1, 秋山伸二1,2, 大塚尚2, 奈良敏文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 717-717, 2020. |
|---|
|
|
O43-11. Analysis of the effect that resident background gives to incident occurrence about the medication in the nursing facility 宗方伸樹1, 木崎速人1, 益子幸太郎2, 山本大輔2, 馬来秀行2, 小西ゆかり2, 佐藤宏樹3,4, 澤田康文3, 堀里子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 717-717, 2020. |
|---|
|
|
O43-12. Outcome after a factor to have an influence on the fall of galanthamine treated patients and the pharmaceutical intervention 池口麻由子1, 松田千裕1, 桐生浩子1, 有松冴1, 不破朱里1, 加藤公人1, 森実優1, 橋本陽1, 今西義紀1, 小出哲朗1, 大達清美2, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2020. |
|---|
|
|
O43-13. Construction of the appearance similarity ratio evaluation model of the PTP sheet using the automatic encoder 北村美帆1, 佐藤宏樹2,3, 川上玲3,4, 玉木啓文2, 柳奈津代2, 苗村健3,4, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2020. |
|---|
|
|
O44-1. Of 25 trainees "look back one week"; the role of the instruction pharmacist from the viewpoint of all human medical care in the meeting 奥野昌宏1, 田中詳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 719-719, 2020. |
|---|
|
|
O44-2. For the enforcement system investigation of 8 representative diseases in the pharmacy business training in the 2019 Nagoya Univ. hospital pharmacy and construction 羽田和弘1, 千崎康司1, 宮川泰宏1, 等浩太郎2, 白松貴子3, 吉見陽4, 野田幸裕4, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-720, 2020. |
|---|
|
|
O44-3. Participation experience type training situation third report in the drugstore business training in revision core Cali 松下隼士1, 川尻雄大2, 岸田義博1, 小柳香織1, 吉田理1, 園田正信1, 小林大介2, 高木淳一1, 木原太郎1, 山野徹1, 島添隆雄2, 田中泰三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-720, 2020. |
|---|
|
|
O44-4. Evaluation of the operational system and education effect of the collaboration type medicine pharmacy cooperation class with business training instruction pharmacist and the university teacher 岡田守弘1, 野村政明1, 石川和宏1, 大本まさのり1, 大柳賀津夫1, 杉山朋美1, 岡本晃典1, 高野克彦1, 興村桂子1, 荒川由紀美1, 佐藤栄子1, 多賀允俊2, 坪内清貴3, 川口典子4, 笹山潔5, 長浜潤6, 浜野邦彦7, 杉本智美8, 後藤義之9, 久保杏奈10, 嶋田千穂11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-721, 2020. |
|---|
|
|
O44-5. Effect of the knowledge acquirement on antimicrobial medicine proper use of the pharmacy student by the problem using the true case 中村はづき1, 多賀允俊1, 高瀬文超1, 北川奈津子1, 柘植乙葉1, 二見和由美1, 高橋喜統1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-721, 2020. |
|---|
|
|
O45-1. The extraction of problems by the text mining using the questionnaire about the harmful effect education teaching materials and examination 大和幹枝1, 松野純男2, 土肥弘久1, 長南謙一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 722-722, 2020. |
|---|
|
|
O46-1. Effect to result in in confidence of practice and the medication counseling of the consideration to the hearing person with a disability with the comics brochure 俵口奈穂美1, 鎌内朋子1, 星野正俊2, 窪田敏夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 723-723, 2020. |
|---|
|
|
O46-2. Behavior change investigation of the student attending a lecture two years after the postgraduate training for pharmacist upbringing in the cancer relaxation medical care 葉田昌生1, 山田真裕2, 内田まやこ3, 因間大悟5, 有吉俊二5, 神村英利4,5, 原口亨5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-724, 2020. |
|---|
|
|
O46-3. Introduction and problem of the practice type educational program for new face pharmacists 田村亮1, 山下花南恵1, 室井延之1, 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-724, 2020. |
|---|
|
|
O46-4. Analysis of the "drugstore pharmacist training program (cancer domain) to show extensive pharmacy management function" by the text mining training report 婦川貴博1,2, 毛利順一1,2, 坂倉智子2, 東山倫子1,2, 稲野寛2, 冨澤淳2, 本間雅士2, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-725, 2020. |
|---|
|
|
O46-5. Approach - of the clinical ladder making confluent by construction (the first report) - competency theory of the hospital pharmacist staff education system 小山郁美1, 稲野寛1, 坂倉智子1, 近藤留美子1, 婦川貴博1,2, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-725, 2020. |
|---|
|
|
O46-6. The current situation of the research activities to see inconsistently of the items mentioned in the poster announcement 田中秀和1, 若林進2, 一ノ瀬照子3, 田村かおり4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 726-726, 2020. |
|---|
|
|
O46-7. Attempt of the self-assessment of the pharmacist resident program in the Nagoya University faculty of medicine hospital and the outside evaluation 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 726-726, 2020. |
|---|
|
|
P1-1. Efforts to drug adjustment depending on the renal function in the door front drugstore of the small hospital 吉永里香子1, 柳瀬京子1, 植木香子1, 新山尚子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 728-728, 2020. |
|---|
|
|
P1-2. Elucidation - multivariate analysis and Bayesian net work - of the faith allele to influence prescription suggestion and the teamwork in doubt inquiry and stress 林剛1, 舘知也1, 高岡みらい1, 野口義紘1, 寺町ひとみ1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-729, 2020. |
|---|
|
|
P1-3. The second-year PPT activity in our hospital 手塚博文1, 山本輝代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-729, 2020. |
|---|
|
|
P1-4. Introduction effect by the operational change accompanied with the injection drug withdrawal system update 水野純男1, 村井良平1, 酒井克紀1, 福田英克1, 南波勝栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2020. |
|---|
|
|
P1-5. Examination about all automatic PTP sheet withdrawal device introduction 宮崎美香1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2020. |
|---|
|
|
P1-6. It is evaluated innovativeness and the usefulness of the powdered medicine identification inspection system after the divided powder using far-red spectrometry 亀井健人1, 森山圭2,3, 徳田衡紀1, 赤木晋介1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-731, 2020. |
|---|
|
|
P1-7. The current situation of doubt inquiry at hospitalization prescription change of the bringing medicine and future problem 平川寛之1, 有馬遥太朗1, 柏倉正太1, 高橋将典1, 紫桃裕造1, 渡邊善照1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-731, 2020. |
|---|
|
|
P1-8. An attempt of the doubt inquiry input simplification by the template utilization and the effect 伊藤早織1, 神谷貴樹1, 増田恭子1, 上西幸治1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-732, 2020. |
|---|
|
|
P1-9. The current situation investigation about doubt inquiry utilizing the doubt inquiry sheet in the in-hospital prescription 戸嶋彩乃1, 渡邉美菜子1, 吉田祥子1, 太田小織1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-732, 2020. |
|---|
|
|
P1-10. Doubt inquiry contents of the drug that renal function by the test value notation to a prescription becomes the prescription determinant 宮森伸一1, 吉川明良1, 阿部圭輔1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 733-733, 2020. |
|---|
|
|
P1-11. The effect that is in indication form of the pharmaceutical products in the inspection system using GS1 Data Bar 荒井理乃1, 蝦名勇樹1, 能登数馬1, 福島麻里乃1, 亀井浩二郎1, 和泉秀明1, 三本松泰孝1, 佐藤弘康1, 田村広志1, 渡辺浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 733-733, 2020. |
|---|
|
|
P1-13. Effect of the pharmacy aiming at the improvement of interpersonal duties in ratio vs. the thing duties systematization 横幕香織1,2, 中村真樹1, 山中理3, 米谷領太1, 茂籠邦彦1,4, 近藤博紀1, 安原智久2, 大野勝則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 734-734, 2020. |
|---|
|
|
P1-14. Effect of development and the international standard tube (ISO80369-3) introduction of the formulations support system corresponding to the tube size by the simple suspension method 安藤哲信1, 渡辺智康1, 難波良平1, 高取孝一1, 山崎恵1, 塩飽郁雄2, 飯田寿彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-735, 2020. |
|---|
|
|
P1-15. About the effect on compounding of medicines duties by the setting of the manual attachment standard at formulations 山田宜和1, 岩田真子1, 高村誠1, 渡辺真希1, 仁谷美希1, 関口陽子1, 貝瀬眞由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-735, 2020. |
|---|
|
|
P1-16. The misunderstanding of pharmaceutical products and relative evaluation of a name, efficacy, the appearance similarity 赤澤佑理1, 國津侑貴1, 上田智弘1, 田淵陽平1, 平大樹1,2, 上西幸治1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-736, 2020. |
|---|
|
|
P1-17. About the effect that a universal cassette gives one package to formulations 猪谷朱理1, 金澤沙衣1, 越野早紀1, 晴山知拓1, 津田雅大1, 三本松泰孝1, 佐藤弘康1, 和泉秀明1, 田村広志1, 渡辺浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-736, 2020. |
|---|
|
|
P1-18. Examination ... of the pharmaceutical products exposure at pharmaceutical products exposure investigation - ointment mixed formulations of the pharmacist 前田志津子1, 藤瀬晟1, 佐々木まい1, 田山剛崇1, 杉原数美1, 三宅勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-737, 2020. |
|---|
|
|
P1-19. Efforts to injection drug compounding of medicines duties efficiency 恒川有里1, 岡本奈緒1, 山田知世1, 長水正也1, 佐藤由美子1, 日比陽子1, 中村康夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-737, 2020. |
|---|
|
|
P1-20. Efforts of the injection room for the improvement in productivity 前勇太郎1, 吾妻慧一1, 橋本幸輝1, 渡部秀一1, 川口萌実1, 井上彩花1, 田瀬徹1, 瀧口友美1, 清水久範1, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 738-738, 2020. |
|---|
|
|
P1-21. Examination of the operation by all automatic powdered medicine divided powder planes (Di-32Ct) new introduction and use investigation 吉村和真1, 青井博志1, 谷田彩1, 小川恵美子1, 吉川一吾1, 池田和之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 738-738, 2020. |
|---|
|
|
P1-22. Inspection about the drop prevention effect of the quantity of active ingredient by the difference in light blocking effect of the medicine bag 井上智咲1, 田崎眞生1, 桑原晶子1, 豊原朋子1, 大川恭子1, 辻本勉1, 森良江2, 森本茂文2, 濱宏仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 739-739, 2020. |
|---|
|
|
P1-24. Pharmaceutical consideration about the case conveyed to our hospital by aciclovir encephalopathy 吉田晴菜1, 東野愛1, 高橋佐和1, 宮崎俊明1, 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2020. |
|---|
|
|
P1-25. Comparison of the formulations mistake change by making formulations support system link an electronic medical chart order ring system, and having decreased a care power 海老原貴之1, 伊東美歩1, 竹内英樹1, 馬渡貴之1, 山崎和音1, 矢嶋香歩1, 岡本和也1, 平原一也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2020. |
|---|
|
|
P1-26. A case of preavoid of ultrashort-acting sleeping pills in elderly patients 山本雅裕1, 藤田あゆみ2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-741, 2020. |
|---|
|
|
P1-27. Investigation about the test value information described in outside Parliament prescription 畠山規明1, 川角和彦1, 松野英子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-741, 2020. |
|---|
|
|
P1-28. Development and clinical evaluations of the multifunctional deployment type "pharmacist electronic calculator" based on the pharmaceutical point of view 鈴木茉莉子1, 佐藤淳也1,2, 吉澤博明3, 小山永3, 前澤佳代子1,2, 百瀬泰行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2020. |
|---|
|
|
P1-29. Prescription grounds of cefditoren pivoxil (CDTR-Pl) used for patients with acute otitis media incidence children short bowel syndrome 世古敬一1, 藤田あゆみ2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2020. |
|---|
|
|
P1-30. Comparison before and after the medical treatment plan (PBPM) revision based on the protocol in the in-house prescription 山崎伊織1, 小倉弥生1, 大木孝夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-743, 2020. |
|---|
|
|
P1-31. Problems in the medication of magnesium oxide tablets using the thickness adjustment food 島崎学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-743, 2020. |
|---|
|
|
P1-32. Starting pharmaceutical products and comparison with the generic medicine judging from accuracy of the tablet division 村上雅裕1, 安田恵1, 天野学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-744, 2020. |
|---|
|
|
P1-33. Relation of the pharmacist for patients with a history of convulsions or epilepsy 竹下恵理子1, 今井陽子1, 竹下治範2, 南雅子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-744, 2020. |
|---|
|
|
P2-1. Examination for a return drug and the handling in inside the hospital 藤田健太1, 横山貴幸1, 小田明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 745-745, 2020. |
|---|
|
|
P2-2. Examination about duties burden reduction and the economic effect in the cool place pharmaceutical products management system introduction 升田万祐子1, 大橋正和1, 楠川侑吾1, 藤田博巳1, 村田龍宣1, 村岡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-746, 2020. |
|---|
|
|
P2-3. Usefulness of the pharmaceutical products management using the traceability system 小林亮1, 石田将之1, 山田紘嗣1, 小森善文1, 安田浩二1, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-746, 2020. |
|---|
|
|
P2-4. A generic drug change and non-pharmacist duties in 300 beds of public hospitals 磯貝一成1, 佃尚紀2, 森谷卓子1, 神保雄一1, 細田好宏1, 三國貴子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-747, 2020. |
|---|
|
|
P2-5. A review of the ward fixed number drug for household delivery accompanied with the new hospital move and the effect 綿貫陽一1, 木村麗砂1, 日浦寿美子1, 小林秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-747, 2020. |
|---|
|
|
P2-6. Impact on prescription amount and drug cost by efforts to reduce ARB-adopted items with awareness of formulary creation 神田藍1, 中村和代1, 南智1, 鈴木貴也1, 平野桂子1, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2020. |
|---|
|
|
P2-7. Effect of the pharmaceutical products SPD introduction in the Okayama Red Cross hospital 森英樹1, 花房伸幸1, 小池彩子1, 大道淳二1, 横田幸子1, 石橋真実1, 諏訪耕三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2020. |
|---|
|
|
P2-8. The current situation investigation about the polypharmacy in the JCHO Kurume General Hospital care health center for the elderly 篠崎千尋1, 野田聖奈子1, 柿原圭佑1, 松本美紅1, 原田智子1, 松崎雄1, 白石亘1, 三上忠司1, 藤井裕史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2020. |
|---|
|
|
P2-9. Efforts for the enforcement situation investigation and the manual preparation of the pentamidine isethionate inhalation 南場信人1, 今成拓1, 関口陽子1, 山田宜和1, 矢吹剛1, 五十嵐詠美1, 小森裕1, 勝又稔2, 山田竜2, 飯塚美和子3, 青木香子3, 甲田亮4, 伊藤竜5, 関義信6, 貝瀬眞由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2020. |
|---|
|
|
P2-10. Duties improvement with the simple ordering support seat using Microsoft Corporation Excel 平山武宏1, 市川志穂1, 金井貴充1, 荒義昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2020. |
|---|
|
|
P2-11. Farewell temperature control sheet - Thus, we were released from the temperature control record of pharmaceutical products - 垣内祥宏1, 緑川拓也1, 岡陽子1, 渥美弘美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2020. |
|---|
|
|
P2-12. Progress report after introduction of formulary for erythropoietin preparations 澤田雄太1,2,3,4,5,6,7, 佐藤光2, 金井紀仁3, 安藤正純4, 宮崎美子5, 濃沼政美6, 齋藤俊夫7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-751, 2020. |
|---|
|
|
P2-13. Medical economic evaluation in the efforts for the stock adequacy of the blood clotting factor preparation for hemophilic patients 神農麻里奈1, 岡田直人1, 中村信元2, 三木浩和2, 渡辺浩良3, 合田光寛1, 中馬真幸4, 座間味義人1,5, 桐野靖1, 中村敏己1, 安倍正博2, 石澤啓介1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-751, 2020. |
|---|
|
|
P2-14. Visualization of injection drug return of goods duties using bar code and a section system 磯田和也1, 橋本さつき1, 原祐輔1, 嶋田努1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-752, 2020. |
|---|
|
|
P3-1. Effect on clinical practice by the raw materials change of the ulinastatin vagina bougie 飯塚美帆1, 宮内英俊1, 片桐麻未1, 滝浪由季乃1, 宇津裕章2, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-753, 2020. |
|---|
|
|
P3-2. Comparison between roasting law and IPCD method that it is the way it goes in the Daiokanzoto 津江南瑠海1, 齋藤唯衣1, 天池菜都実1, 白石かれん1, 中村憲夫2, 成橋和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2020. |
|---|
|
|
P3-3. Examination about stability of the chief ingredient shikonin of the Shiunko and the stability at mixture 藏所志穂1, 岩本奈留実1, 中村憲夫2, 成橋和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2020. |
|---|
|
|
P3-4. Examination about the quantity of decoction of the difference in crude drug decoction method of Kakkonto and the glycyrrhizic acid in the extract preparation 齋藤唯衣1, 津江南瑠海1, 末原百萌花1, 中村憲夫2, 成橋和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2020. |
|---|
|
|
P3-5. Examination of the granulating condition to enable the granulating of the tablet crush thing 高田慎一朗1, 宮嵜靖則1, 内野智信1, 賀川義之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2020. |
|---|
|
|
P3-6. Fact-finding of the hospital preparation management situation in medical facilities under Ehime 山本真由香1, 乗松真大2, 飛鷹範明2, 田中守2, 野元裕1, 田中亮裕2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 756-756, 2020. |
|---|
|
|
P3-7. Six months lability test of hospital preparation 0.5% Denosine eye drops 鈴木麻文1, 引地文1, 友田吉則2, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 756-756, 2020. |
|---|
|
|
P3-8. Evaluation of skin irritation characteristics of the 8% hydroquinone ointment which prescribed it, and was improved and percutaneous absorption characteristics 山内理恵1, 大野修司1, 竹場和代2, 小林稔2, 川崎智子2, 北岡晃2, 井上信宏1, 久保元1, 浅井和範1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-757, 2020. |
|---|
|
|
P3-9. Inspection of the usefulness of the injection drug no bacteria mixed preparation by the pharmacist in the satellite 江川奈央1, 村上賢次1, 宅和真由美1, 平田敦宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-757, 2020. |
|---|
|
|
P3-10. The preparation evaluation of the hypodermic injection preparation histidine copper injection drug which we prepared inside the hospital and the clinical effectiveness 伊藤藍1, 榎本弘美1, 土屋雅勇1, 児玉浩子2, 石垣しのぶ3, 古川泰司3, 渡部多真紀1,4, 河村剛至1,4, 安野伸浩1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-758, 2020. |
|---|
|
|
P3-11. Preparation of the solution for the methylcellulose oral cavity for the purpose of stomatitis treatment 下山哲哉1, 赤石結菜1, 田辺将1, 上嶋麻葵1, 伊藤邦彦1, 小林道也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-758, 2020. |
|---|
|
|
P3-12. Preparation evaluation of the childhood silverberry preparation using the 3D bio printer 田上辰秋1, 伊藤恵里奈1, 木田理沙子1, 野田剛弘1, 尾関哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2020. |
|---|
|
|
P3-13. Hospital preparation vancomycin, ganciclovir, stable evaluation in keeping it for a long time of micafungin eye drops 武田真実1, 横山雄太1, 渡邉武明2, 地引綾1, 河添仁1, 鈴木小夜1, 門田佳子2, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2020. |
|---|
|
|
P4-1. Effect - of objective evaluation - PTP of the color change of the pharmaceutical products under the LED light 山下修司1,2, 井口和弘2,3,7, 野口義紘2,4, 玉木啓文2,3, 長内理大2,3, 伊野陽子2,3, 林秀樹1,6,7, 寺町ひとみ2,4,6, 酒向孫市5, 杉山正1,6,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 760-760, 2020. |
|---|
|
|
P4-2. The effect that preservation after the packing opening of the Tulobuterol tape gives to preparation properties 岩波歩実1, 池内由里1, 太田美鈴2, 日高慎二3, 田嶋美幸2, 大西啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-761, 2020. |
|---|
|
|
P4-3. In vitro drug permeability evaluation of the ad usum externum tapes which we kept in a looseness state 阿部康弘1, 臼井明子1, 吉田寛幸1, 伊豆津健一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-761, 2020. |
|---|
|
|
P4-4. Stable examination of the metoclopramide in the dextrose in water 久保儀忠1, 大森仁2, 宮脇梨夏1, 中川勉1, 柴山良彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2020. |
|---|
|
|
P4-5. Quality evaluation of magnesium oxide tablets using the far-red spectrometry 山本佳久1, 鈴木佳菜子1, 深水啓朗2, 小出達夫3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2020. |
|---|
|
|
P4-6. Evaluation about the Mitsuyasu qualitative analysis of the nicardipine hydrochloride parenteral injection 斉藤佑治1, 竹内正幸1, 加藤隆寛1, 野々垣知行1, 齋藤寛子1, 大西正文1, 築山郁人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-763, 2020. |
|---|
|
|
P5-1. What does "the long-term hand washing rate of use" in ward drug duties influence? 高田正弘1, 前田龍人1, 坂井原美希1, 星川果南1, 芳野由奈2, 佐藤岳春1, 國原将洋1, 松久哲章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 764-764, 2020. |
|---|
|
|
P5-3. About the side effect monitoring of the gonarthrosis postoperative pain-killer and the continuation of the antiemetic drug 谷前朝海1, 島田実咲1, 橋本理恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 765-765, 2020. |
|---|
|
|
P5-4. Side effect report to the drug information management room in ward drug duties 渡辺智康1, 難波良平1, 山崎恵1, 高取孝一1, 安藤哲信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 766-766, 2020. |
|---|
|
|
P5-5. Relation of the pharmacist in the at-home self-injection introduction with the human normal immunoglobulin preparation for the subcutaneous injection for chronic inflammatory demyelinating polyneuritis (CIDP) 森あやか1, 福田裕子1, 伊東里紗1, 井岡瑞樹子1, 稲場純子1, 酒井和江2, 中藏伊知郎1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 766-766, 2020. |
|---|
|
|
P5-6. Effective and safe comparison in change examples from an IV preparation for chronic inflammatory demyelinating polyradiculoneuritis (CIDP) to subcutaneous injection preparation 伊東里紗1, 福田裕子1, 森あやか1, 井岡瑞樹子1, 島袋尚紀2, 安田由香2, 高田和城3, 中藏伊知郎1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-767, 2020. |
|---|
|
|
P5-7. Effect inspection - blood internal medicine, digestive organ medical service - of ward duties in the pharmacist two permanent residence 高木昭佳1, 近岡伸悟1, 屋木佑太1, 小野敦央1, 加藤敦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-767, 2020. |
|---|
|
|
P5-8. A feasibility study for the drug global assessment adjustment addition calculation and future efforts 中原萌子1, 糸永昇平2, 山下典子2, 小山田純治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-768, 2020. |
|---|
|
|
P5-9. Efforts to improvement in drug control instruction rate of patients receiving new high-risk medicine using new high risk check list and RPA 景山修介1, 石原裕介1, 島田杏子1, 勝部直美1, 安食健一1, 園山智宏1, 横手克樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-768, 2020. |
|---|
|
|
P5-10. Activity report of PBPM by the task sharing of physician duties 岩田佳菜子1, 栗崎貴啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-769, 2020. |
|---|
|
|
P5-11. Pharmaceutical support for ward pharmacist duties in the future 空田洋祐1, 中尾圭裕1, 野田麻希1, 岡智之1, 山崎博史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-769, 2020. |
|---|
|
|
P5-12. Economic effects of pharmacist-initiated drug reduction 猿谷淳1, 若林厚史1, 辻依利1, 高橋彩1, 田畑寛明1, 向一美1, 地野幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-770, 2020. |
|---|
|
|
P5-13. Efforts by the multi-type of job for patients with heart failure 林あゆみ1, 荒木千香子1, 内山耕作1, 田中佳代2, 村上安香音3, 冨田敦和1, 今西忠宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-770, 2020. |
|---|
|
|
P5-14. The drug fever that use of antimicrobial (MINO) caused is non-the case that became apparent by use of drug for household delivery 酒向聡子1, 亀山聡美1, 今西正人1, 鈴木圭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2020. |
|---|
|
|
P5-15. Efforts of the side effect discovery using a preservation drawing blood specimen 田中伸明1, 沢田俊朗1, 小川英也1, 伊東和真1, 服部芳明1, 坂田洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2020. |
|---|
|
|
P5-16. Template making of the drug control instruction record aiming at improvement of the pharmaceutical patients care 松本宏美1, 石橋楽至1, 倉井由香1, 小祝梓1, 高野尊行1, 中丸朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 772-772, 2020. |
|---|
|
|
P5-17. Efforts to the medication self-care for the discharge 安里祐美1, 平田やよい1, 浜元善仁1, 翁長真一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 772-772, 2020. |
|---|
|
|
P5-18. Examination of the operation of medication monitoring report < renal function > and intervention of the pharmacist 橋詰真緒1, 佐藤渉1, 角谷あい子1, 山元麻衣1, 齋藤祥子1, 青山芳文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2020. |
|---|
|
|
P5-19. The use situation investigation of the drug for chronic subdural haematoma (CSDH) in our hospital neurosurgery 森崎真理子1, 水谷彩伽1, 高橋弘泰1, 大谷寧次郎1, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2020. |
|---|
|
|
P5-20. Consciousness, behavior modification about the clinical reasoning of the pharmacist with the CRP card 竹内祐介1, 小泉祐一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2020. |
|---|
|
|
P5-21. About an investigation of the effect by the antimicrobial review of the obstetrics and gynecology department domain pass of our hospital 水谷汐里1, 荒川泰代1, 高橋弘泰1, 中山潤美1, 大谷寧次郎1, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2020. |
|---|
|
|
P5-22. The patients individualization intervention based on the evaluation of medication compliance measure and the medication adherence influence factor and the effect 鷲見悠介1, 峠雄太2, 飛鷹範明2, 橋本麻央2, 中井昌紀2, 木村博史2, 井門敬子2, 田中守2, 中島光業1, 田中亮裕2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 775-775, 2020. |
|---|
|
|
P5-23. Evaluation of the usage of the morphine preparation for the purpose of the palliative care of the heart failure 西尾洋平1, 古谷一平1, 田中佳子1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 775-775, 2020. |
|---|
|
|
P5-24. Examination of drug duties improvement from hospitalization support to discharge drug reporting 池田朋世1, 大西希1, 越智あいり1, 福嶋杏奈1, 吉川由梨1, 鈴木薫1, 長美保1, 一本木之人1, 島田明彦1, 宮地磨砂美1, 廣畑和弘1, 高田耕蔵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-776, 2020. |
|---|
|
|
P5-25. The delirium assessment using the delirium risk assessment list and efforts of the ward exclusive duty pharmacist 森早紀1, 本多秀俊1, 高尾斎昭1, 稲村澄子1, 林由紀子1, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-776, 2020. |
|---|
|
|
P5-26. About the current situation of pharmacist duties to participate in a local inclusion care ward 横山貴幸1, 藤田健太1, 小田明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2020. |
|---|
|
|
P5-27. Fact-finding of the Chinese medicine jelly sherbet operation in the Chita public welfare hospital 佐藤友世1, 齋藤宏明1, 丹村敏則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2020. |
|---|
|
|
P5-28. Research about duties contents of the hospital pharmacist whom patients seek 長田莉花1, 赤堀真佑子1, 滝浪由季乃1, 松井乃利子1, 上田真隆1, 大和田怜那1, 岡本和之1, 大井優1, 山内拓1, 中道秀徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-778, 2020. |
|---|
|
|
P5-29. Examination of the associated factor influencing the medication management method of patients with heart failure 大和田怜那1, 渡嘉敷俊介1, 江藤公美1, 鈴木志歩1, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-778, 2020. |
|---|
|
|
P5-30. The activity report of the urination care team and role of the pharmacist 林剛史1, 古川大樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-779, 2020. |
|---|
|
|
P5-31. Efforts by ward drug duties for the prevention of the steroidal osteoporosis 瀧内瑛輔1, 中村槙一郎1, 財津孝希1, 長澤欣弘1, 羽生智弘1, 尾形美絵1, 田村和彦1, 新関みどり1, 近藤和宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-779, 2020. |
|---|
|
|
P5-32. Questionary survey about pharmacist duties in the medical service 伊藤史依1, 戸川麻理奈1, 生田知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-780, 2020. |
|---|
|
|
P5-33. Examination of the anti-thing duties efficiency in the ward by the formulations assistant introduction 伊藤晴也1, 高島直樹1, 深津昌弘1, 水野尚章1, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-780, 2020. |
|---|
|
|
P5-34. Evaluation ... of the pharmacist duties that we saw from ... physician about pharmacist duties associated with the physician burden reduction 重成大介1, 渡部正太1, 山下慶人1, 北田衛1, 奥村美佑1, 梅原さくら1, 尾崎良輔1, 山形里奈1, 高橋詩織1, 大村侑平1, 佐賀美裕樹1, 太田明秀1, 岡野翔1, 野田師正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2020. |
|---|
|
|
P5-35. Intervention to the case that renal function aggravated by multiple factors 浦嶋和也1, 井上敬之1, 植田徹2, 中城宏子1, 国府孝敏3, 鈴木朗4, 老田章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2020. |
|---|
|
|
P5-36. Effect on consciousness for the medical treatment of patients by efforts and the instruction of the pharmacist in the heart failure classroom 岩崎睦1, 宮田祐一1, 上野栞1, 須賀明輝1, 大塚秀人1, 小沼俊也1, 橋本貴広1, 中村雅敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 782-782, 2020. |
|---|
|
|
P5-37. Relation to infection treatment of the ward pharmacist in ward drug duties 川口奈緒美1, 荻原陽香1, 刀根理香子1, 近藤健太1, 近藤倫成1, 粟野恵介1, 堀部緑1, 上林愛1, 佐々木暢琢1, 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 782-782, 2020. |
|---|
|
|
P5-38. The effect that epidural anaesthesia composition in the laparotomy gynecology surgery gives for nausea post-operative, vomiting and postoperative pain 舛田悠介1, 中井將人1, 吉川明良1, 宮森伸一1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2020. |
|---|
|
|
P5-39. About the calculation situation of the drug comprehensive evaluation adjustment addition at our hospital and the tendency of the drug to be reduced 坂本卓也1, 齋藤和悦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2020. |
|---|
|
|
P5-40. What is necessary for comprehensive evaluation of pharmacotherapy - Part 2 吉川真央1, 澤口友紀1, 増田博也1, 久岡清子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 784-784, 2020. |
|---|
|
|
P5-41. Look back on the change -5 year of the activity of the pharmacist in the Kusatsu General Hospital; and - 村瀬沙織1, 松浦佳代1, 鷹羽頼勝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 784-784, 2020. |
|---|
|
|
P5-42. What is necessary for comprehensive evaluation of pharmacotherapy - part 1 鹿沼奈央1, 増田博也1, 久岡清子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2020. |
|---|
|
|
P5-43. Utilization and evaluation ... of the construction - bringing medicine assessment sheet of the drug extraction system for the calculation of the drug global assessment adjustment addition 稲葉静香1, 満田正樹1, 岡田雅弥1, 富山志帆1, 藤井美紀1, 中谷亮介1, 奥下梨賀1, 野際俊希1, 松本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2020. |
|---|
|
|
P5-44. Usefulness of Yuyama Co., Ltd.'s Polypharmacy System in Polypharmacy Countermeasures 細田未紀1, 畑将弘1, 石谷理紗1, 山根正也1, 千原里美1, 上田宏1, 伊東範尚2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2020. |
|---|
|
|
P5-45. Investigation of the pharmaceutical intervention contents in the SCU ward 榎本尚哉1, 北村桃子1, 竹田匡志1, 増渕幸二1, 牧瀬英知1, 近藤智幸1, 橋本光生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2020. |
|---|
|
|
P5-46. About the inflection of the brochure for patients with heart failure in the palliative care team of our hospital 藤原舞子1, 佐伯剛史1, 團優子1, 寺崎展幸1, 汐谷恵1, 本間久美子1, 坂下明大2, 大石醒悟3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2020. |
|---|
|
|
P5-47. About a factor to have an influence on study on distance, angle - distance between optimal patients - pharmacists at medication counseling - 仲山千佳1, 渡辺久美子2, 近藤梨央2, 水口日南野2, 牛膓沙織2,3,4, 宮地佑佳2, 大嶋耐之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2020. |
|---|
|
|
P5-48. The need of the pharmacist permanent residence to a local inclusion care ward judging from the drug global assessment adjustment addition 矢倉尚幸1, 小俣文香1, 佐々木喬哉1, 湯本哲郎2, 稲葉健二郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 788-788, 2020. |
|---|
|
|
P5-49. Efforts for the number of discharge drug information management instruction increase in the small and medium size scale hospital and the effect 土屋貴1, 倉田賢生1, 荒木弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 788-788, 2020. |
|---|
|
|
P5-50. It is an example of the pharmaceutical intervention for the infection after the forming procedures 松村真裕1, 長谷川和恵1,2, 西野多江子2,3, 甲斐幸代2,4, 福盛達也2,5, 立石耕介7, 服部英喜2,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2020. |
|---|
|
|
P5-51. Examination for the stocktaking of the inhalational maneuver in the ward and inhalational instruction promotion 島崎沙織1, 西川達也1, 梅下翔1, 清水翔子1, 青木理恵1, 光井彩1, 茶野下貴恵1, 松岡美紗1, 古本真由美1, 岡田久美1, 角紀一郎1, 後藤義之1, 森戸敏志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2020. |
|---|
|
|
P5-52. Effect of the drug duties burden reduction by PBPM of the prescription correction 松木克仁1, 平野淳1, 松岡梨恵1, 前田玲於奈1, 薄雅人1, 中井正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2020. |
|---|
|
|
P5-53. The current situation of the ward pharmacist in the convalescent rehabilitation ward and future problem 前田悠里1, 阪本久未子1, 樺木美香1, 高橋佳代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2020. |
|---|
|
|
P5-54. The ward duties management by the inflection such as a ward log book and the analysis system, and the like 泉川博子1, 八代哲也1, 東海秀吉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-791, 2020. |
|---|
|
|
P5-55. The potentiality effect of the multi-type of job polypharmacy conference 林八恵子1, 山本圭恵1, 徳田嘉仁2, 原将之3, 遠藤正憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-791, 2020. |
|---|
|
|
P5-56. In-hospital oral antithrombotic drug resumption guideline making and evaluation 陸丸幹男1, 佐藤史織1, 大塚愛美1, 福山薫子1, 原尻学志1, 佐藤朋子2, 高倉健3, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 792-792, 2020. |
|---|
|
|
P6-1. About the active intervention of the pharmacist for the operating room duties at the middle scale hospital and the evaluation 栗崎貴啓1, 北窓正孝1, 相方靖史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 793-793, 2020. |
|---|
|
|
P6-2. To the pharmaceutical administrative work improvement by the operating room working full time pharmacist work 日江井和英1,2,3,4, 土本暁斗1, 武冨佳那子1, 新井大地1, 金森祐紀子1, 水野楓子1, 佐藤和也1, 宇佐見文隆1, 塚原民夫1, 甲斐三由紀2, 山崎潤二3, 梶川真樹4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 794-794, 2020. |
|---|
|
|
P6-4. The current situation and evaluation of the operating room no bacteria preparation by the pharmacist 山中洋1, 杉山健二郎1, 河相景子1, 藤田憲一1, 家岡昌弘1, 串崎浩行2, 八本久仁子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 795-795, 2020. |
|---|
|
|
P6-5. About the effect of delirium and the benzodiazepine system medicine for patients with severe infection 赤星璃1, 栗崎貴啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 795-795, 2020. |
|---|
|
|
P6-6. Analysis of the seriously ill hypoglycemia patients in our hospital 青山剛一1, 宮川ありす1, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2020. |
|---|
|
|
P6-7. Usefulness of the buprenorphine in painkilling, the sedative protocol of intubated patients 磯崎僚1, 栗島彬1, 塩田朋子1, 米倉一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2020. |
|---|
|
|
P6-8. Evaluation of the pharmaceutical contribution by the operating room exclusive duty pharmacist 長田一晃1, 吉川昌子1, 森川記道1, 田邊晴香1, 田辺友也1, 原田靖子1, 西原昌幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 797-797, 2020. |
|---|
|
|
P6-10. Securing of adequacy of the medical treatment by the intensive care unit exclusive duty pharmacist and medical security 永倉史子1, 大久保淑子1, 小田慎1, 加藤剛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 798-798, 2020. |
|---|
|
|
P6-11. Examination of the case that received our hospital for drug intoxication 石橋真実1, 甲元大樹1, 向井めぐみ1, 平井淳子1, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 798-798, 2020. |
|---|
|
|
P6-12. Diuresis effect by the low-dose carperitide 宮川泰宏1, 稲垣孝行1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2020. |
|---|
|
|
P6-13. Examination about the timing of the blood level measurement of vancomycin during the sustained hemocatharsis enforcement 小林洋平1, 中川貴弘1, 藪内新平1, 安達晋吾2, 中尾彰太2, 森朝紀文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2020. |
|---|
|
|
P7-1. One case that rheumatoid arthritis improved using Remy check Q in the pharmacist outpatient department 平田一耕1,2, 稲垣孝規3, 六反田諒4, 舟越亮寛3,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 800-800, 2020. |
|---|
|
|
P7-3. Medication support in the drugstore using QR cord 谷田弘1, 赤嶺美奈2,3, 赤嶺有希子2, 加納美知子2,3, 澤井一3, 田中祥子2,3, 姜惠元2,3, 吉原澄吉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 801-801, 2020. |
|---|
|
|
P7-4. Establishment ... of preoperative evaluation - anesthesiology outpatient department by the multi-type of job 島谷桜子1, 高田将季1, 小宮詠子1, 伊藤由香1, 坂下裕子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 802-802, 2020. |
|---|
|
|
P7-5. Investigation of duties contents in the patients support center for the purpose of the duties efficiency 淵田悠一郎1, 森慶喜1, 柴田慎子1, 永嶌一紀1, 野口祥紀1, 三宅知宏1, 谷村学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 802-802, 2020. |
|---|
|
|
P7-6. Pharmacist intervention to the perioperative patients in the patients support center 吉田愛1,2, 田中泉1, 喜多岡洋樹1, 田中由起子1, 楠本将裕1, 橋本知佳1, 山室蕗子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-803, 2020. |
|---|
|
|
P7-7. Relation of the pharmacist to the PCSK9 inhibitor introduction patients in the Saiseikai Futsukaichi Hospital 秀島久美子1, 中野祐樹1, 大竹野久雄1, 岡亜矢子1, 蓮輪博嗣1, 横尾賢乗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-803, 2020. |
|---|
|
|
P7-8. Efforts for cancellation and the benzodiazepine receptor agonist reduction in the psychosomatic medicine outpatient department 渡久川敦子1, 永田和裕1, 芦原睦2, 前田わかな2, 宮崎貴子2, 伊藤功治3, 栗原康彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 804-804, 2020. |
|---|
|
|
P7-10. Efforts of the pharmacist outpatient department for the sleeping drug decrease medicine using PBPM 岡平将志1, 饗庭孝一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-805, 2020. |
|---|
|
|
P7-11. The problem that we were able to see from efforts and the staff questionnaire of the pharmacist in the patients support center 奥田智子1, 山本麻央1, 依藤健之介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-805, 2020. |
|---|
|
|
P7-12. Pharmaceutical intervention in by practice support - surgery front and by endoscopy front by the outpatient department charge pharmacist and evaluation ... 増田博也1, 久岡清子1, 大荒政志1, 佐々木健志1, 間千晴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 806-806, 2020. |
|---|
|
|
P7-13. Examination of Pharmacy Service at Hospitalization and Discharge Support Center - Efforts for Sharing Patient Information - 田中真衣1, 竹内晴香1, 片山聡子1, 池崎友明1, 北澤英徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 806-806, 2020. |
|---|
|
|
P7-14. Examination of the current situation and problems of the inhalational maneuver establishment by the intervention of the foreign inhalational support team 高安芽衣子1, 大宜見真希1, 宮島佳菜子1, 大久保真理1, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-807, 2020. |
|---|
|
|
P7-15. Efforts in the pharmacist outpatient department in our hospital for the cancer medical therapy 吉田茜1, 渡邉貴子1, 藤掛麻希1, 清美奈1, 石原溶子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-807, 2020. |
|---|
|
|
P7-16. A tendency and analysis of the consultation example in "the pregnancy and medicine outpatient department" 中村早織1, 藤井恵1, 松本祐子1, 原伸輔1, 渡邊梓1, 山本智也1, 門脇裕子1, 三宅達也2, 柿ヶ野藍子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-808, 2020. |
|---|
|
|
P7-17. Three months later follow-up of the foreign patients-adaptive workshop student attending a lecture 水沼麻1, 高橋恵美利1, 高橋雄太1, 池浦恵2, 入野真規子3, 大林恭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-808, 2020. |
|---|
|
|
P7-18. The current situation in the smoking cessation outpatient of the Okayama Red Cross hospital 大道淳二1, 花房伸幸1, 甲元大樹1, 別所昭宏2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 809-809, 2020. |
|---|
|
|
P7-19. Efforts of the pharmacist by the support before hospitalization 水落翔太1, 渡邊歩1, 堀部聖1, 瀬尾達朗1, 長谷川匡史1, 池上幸子1, 福本由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 809-809, 2020. |
|---|
|
|
P7-20. The tendency of the pharmaceutical intervention case in the hospitalization support task and the evaluation 國遠孝斗1, 伊藤有美1, 柴田大地1, 滝本典夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2020. |
|---|
|
|
P7-21. Analysis of the factor affecting nausea post-operative, vomiting in the female surgery patients 丸山真一1, 冨永麻里子1, 永瀬怜司1, 今浦将治1, 小西康博2, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2020. |
|---|
|
|
P7-22. Communalization and effect of the instruction record in the foreign cancer chemotherapy 桂川みき1, 湯澤美和2, 中村裕一1, 須藤大雄1, 坂本和央1, 鈴木千波1, 小原秀治1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 811-811, 2020. |
|---|
|
|
P7-24. Patients questionary survey for family pharmacist duties 藤井雅裕1, 安藤伸一郎1, 白澤芙美1, 中村海里1, 新谷祐佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-812, 2020. |
|---|
|
|
P7-25. Search of the factor of patients requiring re-instruction of the inhalational operation 長谷川真由1, 岩永周子1, 伊藤貴博1, 内田美月1, 吉見陽1, 山田清文2, 若原恵子3, 橋本直純3, 野田幸裕1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-812, 2020. |
|---|
|
|
P7-26. Example that clinical practice applied aromatherapy to to a fibromyalgia outpatient 増渕龍一郎1,2, 秋元美咲1, 佐々木信子1, 前澤佳代子2, 佐藤忠章2, 有山淳4, 倉橋清泰3,4, 百瀬泰行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 813-813, 2020. |
|---|
|
|
P7-27. What is necessary for comprehensive evaluation of pharmacotherapy - Part 3 久岡清子1, 大荒政志1, 佐々木健志1, 増田博也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 813-813, 2020. |
|---|
|
|
P7-28. Aggressive intervention (3) to the pharmaceutical management of the perioperative patients in our hospital 山田奈緒1, 左右田和恵1, 滝川亜弥1, 太田久美子1, 田村睦弘2, 清水歩3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 814-814, 2020. |
|---|
|
|
P7-30. Establishment and efforts of the perioperative pharmacist outpatient in our hospital 平原康寿1, 椎葉萌1, 畑中真理1, 岩田円夏1, 高森大樹2, 川谷彩百合3, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2020. |
|---|
|
|
P7-31. The effect that a change gives for the clinical manifestations of patients with asthmatic condition of a patient merger chronic obstructive pulmonary disease on 3 distribution of the ingredients inhalants 浦上勇也1, 山地康文2, 久家哲也1, 河田由紀子1, 原田亜記1, 山本和幸1, 飯原なおみ3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2020. |
|---|
|
|
P7-32. Intervention effect of the pharmacist in the hospitalization and release support center 竹内恵1, 飛田里美1, 末松耕輔1, 森川仁美1, 剣彰彦2, 佐藤清治2, 草葉一友1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2020. |
|---|
|
|
P7-33. Construction of an anti-doping system at Oita City Medical Association Almeida Hospital 河村聡志1, 大塚愛美1, 陸丸幹男1, 沖田美玖1, 松本善企2, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2020. |
|---|
|
|
P7-34. Efforts and problem of the pharmacist to a hospitalization support task in our hospital 片野貴大1, 佐藤美砂1, 荒川正悟1, 木南志朗1, 伊藤功治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2020. |
|---|
|
|
P7-35. Investigation about the cause of the discontinuation instructions unobservance before operation 高橋真理1, 木田有里子1, 今浦将治1, 澤柳ユカリ2, 谷口英喜2, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2020. |
|---|
|
|
P7-36. About problems and the correspondence that we were able to see from the different case example of the approval dose in the health insurance pharmacy 石原千春1, 生田このみ1, 大嶋沙希1, 澤村陽子1, 村田瑠衣1, 伊東公一2, 岩佐治典2, 澤木進2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-818, 2020. |
|---|
|
|
P7-37. Relation of the pharmacist of the Lenvatinib treatment for thyroid cancer in our hospital 廣岡賢輔1, 清水浩幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-818, 2020. |
|---|
|
|
P7-38. Cooperation with hospital pharmacy and the neighborhood ethical pharmacy using prescription notebook about the cancellation medicine before examination, surgery 藤井達郎1, 佐々木静香1, 下口谷貴1, 久保瞳1, 川本康太郎1, 森本雅子1, 門村将太1, 井藤達也1, 馬場隆彰2, 栗田克美3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 819-819, 2020. |
|---|
|
|
P8-1. Community medical care cooperation for dementia early detection in the health insurance pharmacy 早田佳生1, 甲斐麻美子2, 石橋久1,3, 安倉央2,4, 安部綾2, 中野貴文2, 林稔展2, 冨永宏冶2, 高橋正志4, 飯田仁志5, 尾籠晃司6, 川嵜弘詔5, 江川孝2, 園田正信1, 山野徹3, 田中泰三3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 820-820, 2020. |
|---|
|
|
P8-2. One patient who succeeded in famotidine reduction by the healthy practice classroom participation in the drugstore 吉岡遼1,2,3, 水野智博2, 浅井敦子1, 水野祐果1, 梅田洋子3, 梅田孝3, 浅井治行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2020. |
|---|
|
|
P8-3. Intervention based on the multi-theory integration model of the pharmacist in the Kure-shi osteoporosis aggravation prevention project 覚前美希1, 羽山順子2, 松村智子3, 濱崎匡史4, 要田弥生5, 金子富美6, 津田彰7, 大塚幸三8, 三宅勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2020. |
|---|
|
|
P8-4. About usefulness of BSC in the pharmacy management of our hospital 若木麻由1, 佐藤大輔1, 黒田健吾1, 岡田侑子1, 寺島清文1, 加藤菊郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 822-822, 2020. |
|---|
|
|
P8-5. Pilot study (the second report) for the development of the new medication support law of children utilizing Virtual reality 安井麻姫1, 仁木一順1,2, 井口舞香1, 磯野友美1, 影山寛人1, 上田幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 822-822, 2020. |
|---|
|
|
P8-6. Result of the management that we continued a balun strike scorecard in the Yokohama General Hospital and used 高田啓介1, 廣瀬直樹1,2, 倉田武徳1, 仙内光子1, 小町和樹1, 鯉淵寛之1, 南雲史雄1, 金田昌之2, 赤瀬朋秀3, 佐村優1, 谷川浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 823-823, 2020. |
|---|
|
|
P8-7. Task shifting to pharmacists for in-hospital management work 脇田真之1, 波能満理恵1, 星野智美1, 棚田真紀1, 渡辺恵美1, 吉井千菊1, 岡村吏華1, 大坪愛実1, 人見智香子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 823-823, 2020. |
|---|
|
|
P8-8. About effect to give pharmacist duties by the introduction of the drug assistant 沼田諒1, 梶原彩香1, 小野歩1, 阿部和恵1, 比毛有理子1, 折戸融1, 石井勇太1, 片山潤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2020. |
|---|
|
|
P8-9. About enforcement of the continuous medication support utilizing the telephone after the medication attitude survey - of - pharmacist 鬼木薫1, 河口剛之2, 伊佐珠2, 藤井雅裕3, 平田聡美4, 安藤伸一郎5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2020. |
|---|
|
|
P8-10. Inspection of duties contents by the duties introduction of the formulations assistant in the convalescent hospital ソディ保子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2020. |
|---|
|
|
P8-11. Usefulness of being led by a ward pharmacist, and practicing medication based on protocol 大池恵生1, 奥苑朱加1, 杉野晃希1, 山室栄一1, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2020. |
|---|
|
|
P8-12. Consideration vol.2 about the usefulness of the balun strike scorecard in the drug section duties construction 稲葉健二郎1, 古浜健一1, 河野健1, 矢倉尚幸1, 佐々木優1, 大石将義1, 酒井梨帆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-826, 2020. |
|---|
|
|
P8-13. Consideration about the individual making and cascade of a hospital balun strike scorecard and the balun strike scorecard for hospital pharmacist 金田昌之1, 米澤禎貴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-826, 2020. |
|---|
|
|
P9-1. Usefulness evaluation of the prescription check system contraindicated to the name of disease in conjunction with an electronic medical chart system 國津侑貴1, 平大樹1,2, 上西幸治1, 炭昌樹1, 森田真也1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 827-827, 2020. |
|---|
|
|
P9-2. Improvement effect of duties burden and the drug regime of the physician by the communication route introduction from a drug system to an electronic medical chart 内田佳菜子1, 高梨愛1, 越後憲之2, 田中敏幸3, 日野祥幸3, 田中淳4, 山下敦志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2020. |
|---|
|
|
P9-3. The making of the drug dose calculation tool according to the renal function using Microsoft Excel VBA and examination (the third report) of the usefulness 後藤純一1, 菅原拓也1, 荒井浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2020. |
|---|
|
|
P9-4. Promotion (the first report) - formulation study support systems construction of the pharmaceutical products proper use cycle utilizing the ICT and usefulness - 西田基紀1, 川田敬1, 柳澤成佳1, 川添哲嗣1, 船戸裕樹1, 上田真由美1, 門田亜紀1, 常風興平1, 森田靖代1, 宮村充彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2020. |
|---|
|
|
P9-5. Combination contraindications in the University of Occupational and Environmental Health Hospital, efforts of the prescription for the drug allergy 實松絵美子1, 河野紗羅1, 一木孝治2, 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2020. |
|---|
|
|
P10-1. Inquiry analysis of the infusion to use for patients on dialysis put to the infusion DI center 掛水瑞芳1, 竹林佑花1, 松田直子1, 吉岡小都子1, 星泉1, 福田まゆみ1, 河野裕則1, 岩原良晴1, 沢田憲彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 830-830, 2020. |
|---|
|
|
P10-2. Difference in suicide/self-harm association adverse event signal in AMPA receptor blocker Perampanel hydrate and other antiepileptic drugs 堀江美香子1,2, 古関竹直2, 熊澤里美2,3, 山田成樹2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-831, 2020. |
|---|
|
|
P10-3. Reporting of the active injection drug by the intervention of the pharmacist 大竹由莉1, 鈴木善貴1, 野田千笑2, 冨田妙鶴2, 柚原昌典2, 室田智代2, 大沼哲朗3, 定盛理純1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-831, 2020. |
|---|
|
|
P10-4. Reconstruction of the formulary for uric acid production inhibitors 宮本拓也1, 金井紀仁2, 濃沼政美3, 宮崎美子4, 齋藤俊夫5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2020. |
|---|
|
|
P10-5. About an investigation of the blood pressure in the Lenvatinib taking our hospital patients for the hepatocellular carcinoma 近藤理絵1, 田中智啓1, 日生下美紀1, 西窪奈津子1, 吉田直恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2020. |
|---|
|
|
P10-6. Difference in adverse event signal of antipsychotics and signal in non-elderly people, elderly people 古関竹直1,2, 中林哲夫3, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-833, 2020. |
|---|
|
|
P10-7. The improvement of problems of the subset of pharmaceutical products interaction analysis for the signal detection and the inspection 野口義紘1, 林剛1, 高岡みらい1, 舘知也1, 寺町ひとみ1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-833, 2020. |
|---|
|
|
P10-8. Analysis ... according to effect - Gender that the presence or absence of breakfast intake gives to body-mass index (BMI), the generation 初岡玲奈1, 真野泰成2, 鈴木立紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2020. |
|---|
|
|
P10-9. Examination in the association between PSA level change and prostate cancer onset using the administrative data base 西川寛来1, 真野泰成1, 武藤倫弘2, 松山裕2, 石川英樹3, 上村博司4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2020. |
|---|
|
|
P10-10. Examination about the in-hospital formula reintroduction example and pharmaceutical products costs reduction effect in our hospital 川邉桂1, 志村明日香1, 畠山成寛1, 古川大輔1, 小池博文1, 戸谷義幸2, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2020. |
|---|
|
|
P10-11. Usefulness of the inquiry record communalization of the drug information room 飯田彩花1, 小林加寿子1, 日浦寿美子1, 小林秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2020. |
|---|
|
|
P10-12. Research - Rabeprazole about the description about the inhibition style of the proton pump inhibitor in the drug information is reversible, or is it irreversible? - 高島佳央理1, 青山隆夫1, 小茂田昌代1, 斎藤顕宜1, 高橋秀依1, 西川元也1, 嶋田修治1, 鈴木立紀1, 真野泰成1, 尾関理恵1, 高澤涼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2020. |
|---|
|
|
P10-13. The handling of the safe information in the call center of the off patent pharmaceutical products (OPD) maker: Evaluation by KPI (thank you score) 西山悠1, 有賀美穂1, 井上香織1, 河合孝1, 尾崎好夫1, 門田靜明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2020. |
|---|
|
|
P10-14. Search of the encephalopathic inducer based on large-scale side effect database JADER 瀬山友香1, 細谷龍一郎1,2, 加藤智之1, 日野斉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 837-837, 2020. |
|---|
|
|
P10-15. The discontinuation using the drug check list contraindicated to aminolevulinic acid hydrochloride granule combination and investigation of the side effect expression situation 関口陽子1, 寺口敦1, 高村誠1, 今成拓1, 矢吹剛1, 南場信人1, 貝瀬眞由美1, 原昇2, 西山勉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 837-837, 2020. |
|---|
|
|
P10-16. Investigation about mention contents of the inhalational instruction material for patients whom a pharmaceutical company made 中田英夫1, 山田悠加1, 青森達1,2, 望月眞弓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2020. |
|---|
|
|
P10-17. Database ... which can confirm development - intersection allergy medicine of the database which can conduct registration of the drug allergy information appropriately 宮村信輝1, 阿部純子1, 杉平直子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2020. |
|---|
|
|
P10-18. Association analysis of the concomitant drug in patients with Stevens Johnson's syndrome using big data, toxic epidermal necrolysis onset 山崎智久1, 寺薗英之1, 中嶋洋生2, 武田泰生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2020. |
|---|
|
|
P10-20. Examination - using analysis of effect - JADER that antipsychotics give to the onset of the breast cancer and exacerbation and the human breast cancer cultured cell 前島多絵1, 飯島亮介1, 渡邊真知子1, 板垣文雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-840, 2020. |
|---|
|
|
P10-22. "The secant design" of the tablet judging from a package insert, interview form of the mirtazapine preparation 若林進1, 田中秀和2, 藤澤哲也3, 三上彰貴子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2020. |
|---|
|
|
P10-23. Search of the insomnia risk with pharmaceutical products by Sequence Symmetry Analysis using electronic drug history data 佐野由奈1, 酒井隆全1, 近藤貴志2, 横地浩次2, 田辺公一1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2020. |
|---|
|
|
P10-24. Introduction of Formulary in Toda Central Medical Group - Efforts in Totsuka Area - 安藤正純1, 金井紀仁2, 鈴木智3, 濃沼政美4, 宮崎美子5, 齋藤俊夫6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2020. |
|---|
|
|
P10-25. Analysis of the after giving birth depression using American adverse event spontaneous report database (FAERS) 羽根由基1,2, 堀部めぐみ3,4, 阿部純子5, 松井利亘1,6, 加藤大和1,7, 上田夏実1,8, 笹岡沙也加1,9, 元岡佑美1, 畠平春奈1,10, 長谷川栞1,11, 紀ノ定保臣1,12, 原英彰4, 中村光浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2020. |
|---|
|
|
P10-26. Consideration about the usefulness of the new drug information offer tool from the pharmaceutical company under "the guidelines about the sale reporting activity on ethical drug" 田中里和1, 分銅淑1, 五十嵐美和1, 森田健司1, 中島美保1, 佐々木洋1, 塩原ひとみ1, 結城陽二郎1, 串戸徳彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 843-843, 2020. |
|---|
|
|
P11-1. Approach to psycho status of patient for the polypharmacy 原田彩1,3, 岡本禎晃2, 中島園美3, 力武良行3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2020. |
|---|
|
|
P11-2. Investigation of the factor to have an influence on the palliation of patients with glossodynia, the improvement in quality of life 赤嶺美奈1, 佐久間美里2, 田中祥子1, 山本美智子1, 赤嶺有希子1, 吉原澄吉3, 澤井一2,3, 谷田弘3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-845, 2020. |
|---|
|
|
P11-3. Investigation about the recognition about the term to use at medication counseling 赤嶺有希子1, 田中祥子1, 赤嶺美奈1, 山本美智子1, 高木正信1, 加納美知子2, 佐久間美里2, 平野陽子1, 姜惠元2, 吉原澄吉3, 澤井一2, 谷田弘3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-845, 2020. |
|---|
|
|
P11-4. Prescription trend of the oral anticancer agent used for foreign cancer chemotherapy 杉山純子1, 齋藤翔太2, 田中美幸3, 佐藤展宏4, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2020. |
|---|
|
|
P11-5. Effect according to the area of the drug-resistant (AMR) measures action plan to give to prescription meeting a demand of the third generation cephem system antimicrobial 河田直也1, 片山珠季2, 前田守3, 長谷川佳孝3, 月岡良太3, 森澤あずさ3, 大石美也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2020. |
|---|
|
|
P11-6. Use fact-finding of the antimicrobial in the childhood acute respiratory tract infection 伊藤綾花1,2, 阿部久瑠美1,2, 渡邊亜矢子1,2, 江畠麗1,2, 伊波樹1,2, 越塚宏美1,2, 柏原由佳1,2, 田中克巳1,2, 佐々木忠徳2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-847, 2020. |
|---|
|
|
P11-8. If disease insight, medicational self-understanding is not associated even if a pharmacist chooses an individual treatment-related expensive inhalational device as for the lung function of patients with COPD, we do not improve it 塩飽英二1, 土手賢史1, 金子忍1, 野崎歩1, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2020. |
|---|
|
|
P11-9. The choice of the infusion pump for improvement in quality of life of patients 古橋隆久1, 鈴木善貴1, 板垣千華1, 堀部弘子2, 西村千賀子2, 野田千笑2, 定盛理純1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2020. |
|---|
|
|
P11-10. Questionnaire results about the operability of the Teriparatide automatic injector 松嶋奈那美1, 城戸美恵子1, 杉知子1, 松尾昭代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-849, 2020. |
|---|
|
|
P11-11. Use fact-finding of the antiinfluenza medicine in the drugstore 白川貴章1, 白川夕紀子1, 白川加代子1, 白川憲廣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-849, 2020. |
|---|
|
|
P11-12. The use situation investigation of biological drug, the JAK inhibitor to patients with rheumatoid arthritis in our hospital 根橋佳奈1, 橋本浩之1, 松本亜佐美1, 秋本法人1, 江口善美1, 藤井淳平2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2020. |
|---|
|
|
P11-13. A survey on the use of brexpiprazole in our hospital 下地晶1, 高橋嘉寛1, 矢野真弓1, 池田郁子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2020. |
|---|
|
|
P11-15. Investigation about the prescription trend of the oral laxative 廣瀬靖章1, 小山貴史2, 前田守3, 長谷川佳孝3, 月岡良太3, 森澤あずさ3, 大石美也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 851-851, 2020. |
|---|
|
|
P11-17. The use of sleeping drug situation investigation to elderly people before and after the manual introduction 長澤欣弘1, 中村槙一郎1, 財津孝希1, 瀧内瑛輔1, 羽生智宏1, 尾形美絵1, 田村和彦1, 新関みどり1, 近藤和宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 852-852, 2020. |
|---|
|
|
P11-18. The use situation investigation of hydromorphone in the metropolitan Komagome hospital 小林崇史1, 吉田茜1, 宮澤真帆1, 石原溶子1, 田中桂子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-853, 2020. |
|---|
|
|
P11-19. Analysis of the factor giving it to the medication adherence of patients who received hormonal therapies after the breast cancer technique 櫻井雄太1, 武田真央1, 中村裕義1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-853, 2020. |
|---|
|
|
P11-20. About shortening of the anti-thing duties time of the pharmacist by the introduction of the return of goods medicine withdrawal device 深津昌弘1, 高島直樹1, 齊藤将之1, 水野尚章1, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 854-854, 2020. |
|---|
|
|
P11-21. Investigation about the prescription situation of antidepressant and the antianxiety drug in the Nagoya University faculty of medicine hospital psychiatry outpatient 野田幸裕1,2, 野口健1, 磯貝里奈1, 吉見陽1,2, 山田清文2, 尾崎紀夫3, 肥田裕丈1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 854-854, 2020. |
|---|
|
|
P11-22. Tasting party report of the medicine by a physician, the pharmacist aiming at improvement in medication adherence of children 加覧みなみ1, 清水祐一1, 渡邉真菜実1, 甲斐維子1, 加戸奈穂美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 855-855, 2020. |
|---|
|
|
P11-24. It is ... for pharmacist intervention of use situation investigation - perioperative period of iv-PCA after the TKA technique 宮島佳菜子1, 大城匡史1, 國分千代1, 藤村泰三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-856, 2020. |
|---|
|
|
P11-26. Association with HADS and the medication adherence in patients with rheumatoid arthritis 中村郁勝1, 須古杏子1, 森岡淳子1, 高岡宏和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2020. |
|---|
|
|
P11-27. Change of the patients awareness by the pharmaceutical intervention to the patients targeted for percutaneous transluminal coronary angioplasty 大津友紀1,2, 末松保憲3, 神村英利1,2, 三浦伸一郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2020. |
|---|
|
|
P11-28. Role of the new pharmacist to examine from the use situation of the autoimmunity skin disease therapeutic drug 内田和孝1, 須古杏子1, 高濱啓太1, 徳澄亜紀2, 松尾敦子2, 城野昌義2, 今泉文子3, 堀川達史3, 森岡淳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 858-858, 2020. |
|---|
|
|
P11-29. The development of the Child-Resistance container as preventive measures against pharmaceutical products mis-deglutition accidents and questionary survey for the pharmacist for the purpose of the spread enlightenment 山田真由美1, 高藤由紀子1, 岩橋香奈1, 山谷明正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 858-858, 2020. |
|---|
|
|
P11-30. Use of pain-killer investigation after the autoregulation epidural analgesia interruption in the surgery patients 神原弘和1, 池田久雄1, 平田亜紀1, 森岡浩子1, 足立充司1, 野村浩英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2020. |
|---|
|
|
P11-31. Use investigation for the proper use of the magnesium oxide preparation 高橋麻衣1, 山口恵輔1, 新枦義之1, 岩城康子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2020. |
|---|
|
|
P11-32. Fact-finding of the delirium onset in the inpatient 土元研史1, 安田礼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2020. |
|---|
|
|
P11-33. The prescription situation investigation of the number of patients of the acute respiratory tract infection and the oral antimicrobial 平田貴宏1, 池田久雄1, 足立充司1, 野村浩英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2020. |
|---|
|
|
P11-34. The development of the Child-Resistance container as preventive measures against pharmaceutical products mis-deglutition accidents and questionary survey for the protector for the purpose of the spread enlightenment 高藤由紀子1, 山田真由美1, 岩橋香奈1, 山谷明正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 861-861, 2020. |
|---|
|
|
P11-35. Comparison - of 2014 and 2019 by the prescription of current situation analysis - antidementia medicine of the medical therapy of elderly people 田窪真行1, 松本憲昭1, 榊原幹夫1, 白石成明2, 鈴木裕介3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 861-861, 2020. |
|---|
|
|
P11-36. The use situation of the chronic constipation therapeutic drug in our hospital 山野邉裕子1, 栗原直貴1, 角田結菜1, 田村賢士1, 金子智一1, 金子誠1, 寺田伊知郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2020. |
|---|
|
|
P11-37. Speech therapist and efforts for the simple suspension method for the collaboration of the pharmacist 岩井厚希1, 大野峻2, 角谷直志1, 菊池健1, 武田元樹1, 相馬貴史1, 佐々木啓1, 名達陽一1, 鶴山辰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2020. |
|---|
|
|
P11-38. Use fact-finding of the directly oral effect type anticoagulant in the on admission 福浦啓史1, 青孝明1, 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2020. |
|---|
|
|
P11-39. Examination to the prescription situation investigation and drugstore pharmacist intervention in the anticoagulation of the heart failure 山本美智子1, 赤嶺美奈1, 佐久間美里1, 高木正信1, 松尾律子1, 加納美知子1, 田中祥子1, 赤嶺有希子1, 澤井一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2020. |
|---|
|
|
P11-40. Evaluation of clinical efficacy and safety of topiroxostat in patients with severe renal impairment 佐藤加菜1, 菊田絵梨華1, 坂東香織1, 道貝優太1, 高畠弘樹1, 三浦綾華1, 北川裕也1, 寺原史貴2, 中村裕一1, 鈴木千波1, 小原秀治1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-864, 2020. |
|---|
|
|
P11-41. Attitude survey for the Japanese Society of Hospital Pharmacists hospital pharmacy authorization pharmacist system of the Yamanashi hospital pharmacist 橘田文彦1,2, 河田圭司1, 鈴木正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-864, 2020. |
|---|
|
|
P11-43. The use situation of Emicizumab in our hospital adults haemophilia A 近藤旭1, 阿部憲介1, 神尾咲留未1, 後藤達也1, 鈴木美絵子2, 佐々木晃子2, 今村淳治3, 伊藤俊広3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 865-865, 2020. |
|---|
|
|
P11-44. Extraction of the problem about adoption, the prescription at questionary survey - hospital to a specialist about the Biosimilar 青木良子1, 勝田由紀子1, 鈴木美佳1, 佐井君江1, 石井明子2, 斎藤嘉朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-866, 2020. |
|---|
|
|
P11-45. Mainly on drug remedy situation investigation - fall of elderly patients with proximal thighbone bone fracture, the risk measures of the fall - 大塚愛美1, 平賀愛実1, 河村聡志1, 上田由貴1, 稲垣芙美佳1, 原田百華1, 森一生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-866, 2020. |
|---|
|
|
P11-46. About the use of mirogabalin situation of our hospital 沢仁美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 867-867, 2020. |
|---|
|
|
P12-2. Examination about an effect of the pharmacist intervention in patients with foreign cancer pain and the evaluation of the medical economics 沼田裕也1, 松村千佳子1, 山田正実2, 地丸裕美2, 鳥井小莉2, 矢野義孝1, 高橋一栄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 869-869, 2020. |
|---|
|
|
P12-3. The medical expenses inhibitory effect that we can see from the interpersonal duties of the ward pharmacist 高野温志1, 石井志保1, 松井奈々江1, 高野明香1, 伊賀正典1, 町田充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 869-869, 2020. |
|---|
|
|
P12-4. Changes in generic drug usage and drug costs due to in-hospital formulary formulation of proton pump inhibitors 竹下和輝1, 渡辺桃子1, 小野奈緒1, 浜本千明1, 八木心平1, 巽昭代1, 横井尋和1, 松山哲史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 870-870, 2020. |
|---|
|
|
P12-6. Examination of the quantity of exposure at the fixed dose administration of immune checkpoint inhibitor utilizing the Pharmacometrics 岡田章1, 小原真穂1, 永井尚美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2020. |
|---|
|
|
P12-7. Examination about the corporate strategy development of the drug section by the inflection of the balun strike scorecard 松崎貴志1, 安島秀友1, 多田純平1, 森田一1, 小形桂子1, 中薗健一1, 杉村春奈1, 百合野祐子1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2020. |
|---|
|
|
P12-8. Fact-finding of the hypermagnesemia with magnesium oxide in the opioid analgesic remedy patients 飛鷹範明1, 馬塲彩織2, 田中守1, 秋山伸二2, 田中亮裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2020. |
|---|
|
|
P12-9. Investigation (the second report) about the drug intervention by the pharmacist participating in the breathing care team, Observational study after the single institution suitable for 島田萌美1, 吉廣尚大1, 埋橋賢吾1, 櫻谷正明2, 荒田晋二3, 白井敦1, 角井碧1, 向井一樹1, 小野塚和人1, 橋本佳浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2020. |
|---|
|
|
P12-10. Comparison of prescribing conditions, drug costs, and safety of proton pump inhibitors before and after formulary introduction 塩田朋子1, 栗島彬1, 磯崎僚1, 森下慎二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-873, 2020. |
|---|
|
|
P12-11. Cost-effectiveness analysis of baloxavir and marboxil for the treatment of influenza virus infection 原田悟1, 金澤幸訓2, 森川昭正2, 中川直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-873, 2020. |
|---|
|
|
P12-12. It is ... from the situation of cost effect analysis - society of the neuraminidase inhibitor 森田聖仁1, 金澤幸訓2, 森川昭正2, 中川直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-874, 2020. |
|---|
|
|
P12-13. Investigation of the quantity of disposal of the injectable anticancer agent in our hospital and the medical expenses reduction effect of the vial multiple times utilization time 佐藤家恒1, 津嶋那奈1, 清水優依1, 藤島哲大1, 高橋幸1, 小川信二1, 佐藤博樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-874, 2020. |
|---|
|
|
P12-14. Comparison about the use of drug in Japan and France 山田治美1, 加藤芳徳1, 平尾卓也1, 手塚千裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 875-875, 2020. |
|---|
|
|
P12-15. Investigation of the blood test rate of use before the medication with the HBV reactivation risk 北村葵1, 阪井祐介1, 成瀬亮1, 千崎康司1, 山本雅人1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 875-875, 2020. |
|---|
|
|
P12-16. Cost effect analysis of the allergic rhinitis therapeutic drug 江川慧1, 柏原正美2, 高畑篤2, 中川直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-876, 2020. |
|---|
|
|
P12-17. Than simulation of the consumption investigation of the hippopotamus diTaki cell and medical economic evaluation - 40 mg preparation ... 星田唯史1, 森本奈緒美1, 藤原大一朗1, 眞下惠次1, 和田祥明1, 野田明宏1, 多喜和夫1, 阪口勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-876, 2020. |
|---|
|
|
P13-2. We work on analysis for the reduction in the use of bringing medicine days in the Fukuoka Red Cross hospital 竹野智彦1, 橋本華1, 藤永理恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-878, 2020. |
|---|
|
|
P13-3. Effect of the bringing medicine lecture on medical student by the pharmacist 齋藤靖弘1, 民谷健太郎2, 武田清孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-878, 2020. |
|---|
|
|
P13-4. Efforts of the bringing medicine administration cart set duties by the pharmacist 近藤美祥1, 北村渉1, 尾崎昌大1, 林政和1, 添田真司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 879-879, 2020. |
|---|
|
|
P13-5. Efforts to accident evasion at bringing medicine continuation in the orthopedics ward 川本英子1, 大道淳二1, 奈良葵1, 甲元大樹1, 小池彩子1, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 879-879, 2020. |
|---|
|
|
P13-7. Efforts of the bringing medicine for electronic medical chart and bringing medicine management system management by the interlocking movement 城戸美恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-880, 2020. |
|---|
|
|
P13-8. Role of the ward pharmacist in the bringing medicine information communalization by the electronic medical chart 酒井梨帆1, 杉山央輔1, 古浜健一1, 湯本哲郎2, 稲葉健二郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2020. |
|---|
|
|
P13-9. The security utilizing the IT technique and construction and evaluation of the effective bringing medicine differentiation system 岡田雅弥1, 中谷亮介1, 満田正樹1, 稲葉静香1, 奥下梨賀1, 尾崎加織1, 野際俊希1, 藤井美紀1, 本郷志帆1, 松本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2020. |
|---|
|
|
P13-10. The serotonin syndrome that was diagnosed by the drug differentiation at the change ridge by the pharmacist early: Case report 藤野怜美1, 吉廣尚大1, 築家秀和2, 橋本佳浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2020. |
|---|
|
|
P13-11. Enforcement of the bringing medicine prescription representation input by the pharmacist based on the protocol and the evaluation 池田澪樺1, 仲田浩成1, 薮内由里香1, 松元俊博1, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2020. |
|---|
|
|
P13-12. On admission bringing medicine discriminant problem and evaluation in the pediatric special hospital 鈴木美穂1, 鈴木英二1, 小林恵子1, 小口真美1, 上條早奈美1, 石川友貴1, 熊谷静香1, 松澤麻紀子1, 尾坂早苗1, 西條純1, 堀勝幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-883, 2020. |
|---|
|
|
P13-13. The content analysis of the pharmaceutical intervention example performed with bringing medicine differentiation and examination of the countermeasure 加藤千佳1, 杉本浩子1, 水谷栄梨2, 篠木優里1, 白石ちひろ1, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-883, 2020. |
|---|
|
|
P14-1. The higher anthocyanin-containing cassis extract improves behavior disorder of dementia model mouse SAMP8 島田美理1, 前多隼人2, 七島直樹3, 山田清文4, 中島晶2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 884-884, 2020. |
|---|
|
|
P14-3. Arteriosclerosis inhibitory effect of the go stone tea using the Apolipoprotein E loss mouse 石田七生1, 石田智滉1, 森沢惇平1,2, 飯塚美知郎1, 八木祐助1, 常風興平1, 森田靖代1, 受田浩之3, 宮村充彦1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 885-885, 2020. |
|---|
|
|
P15-1. Proposal to inspection and drugstore duties of the proper use situation of the dihydrocodeine-containing antitussive liquid for internal use using drugstore ID-POS data 小林華奈1, 渡邊崇2,3, 菊池千草1,2, 鈴木匡1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 886-886, 2020. |
|---|
|
|
P16-1. Use and application of examination NDB opening data and the financial statements of the choice method of the excellent generic medicine judging from a viewpoint of running it 石坂敏彦1, 安瀬淳1, 遠藤晋吾1, 安井友佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-887, 2020. |
|---|
|
|
P16-2. Attempt of the drug information streaming for employees in the off patent drug (OPD) pharmaceutical products company 筧真実1,2, 林恵理子1, 河合孝1, 伊藤秀明2, 門田靜明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 888-888, 2020. |
|---|
|
|
P17-1. Comparison of infusion reaction frequency in a precedence product and the Biosimilar of rituximab and the disease severity 大谷隼斗1,2, 花井雄貴1, 越川一誠1, 三井ゆりか2, 長瀬大輔2, 入田博史2, 廣田愛2, 名取一彦2, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-889, 2020. |
|---|
|
|
P17-2. Examination about the infusion reaction at the initial rituximab Biosimilar administration in the treatment of patients with first non-Hodgkin's lymphoma 鈴木康之1, 齋藤雅隆2, 遠藤征裕3, 工藤直嗣1, 斉藤匡昭4, 大野謙太郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 890-890, 2020. |
|---|
|
|
P17-3. Therapeutic safe comparison between precedent biomedicine and biofollowing article of the trastuzumab 龍田涼佑1, 炭本隆宏1, 中原良介1, 田中遼大1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 890-890, 2020. |
|---|
|
|
P18-1. One patient whom an erythema multiforme severe form developed in after the influenza HA vaccine inoculation 杉原弘記1, 樫野かおり2, 岡田昌浩1, 岡本伸也1, 村上史承1, 岡崎和子1, 岡田麻衣子1, 田代操1, 竹井英介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 891-891, 2020. |
|---|
|
|
P18-2. Superiority for the current preparation of the change of prescription esflurbiprofen Mentha Oil preparation (SFP tape) 遠藤継良1,2, 佐藤潤一2, 川鰭昌吾2, 有馬和範1, 桐畑佑香1, 寺坂修一1, 今野芳浩1, 山口順一1, 八田羽幾子1, 山田清文3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2020. |
|---|
|
|
P18-3. What is necessary to further increase the adverse event report of the pharmacist? : Consideration judging from the number according to the type of job of JADER of reporters and content 高谷瑞穂1, 豕瀬諒1, 村木優一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2020. |
|---|
|
|
P18-4. The case that developed a side effect by the additive included in pharmaceutical products 田中祥子1,2, 赤嶺美奈1,2, 赤嶺有希子1, 加納美知子1,2, 高木正信1,2, 松尾律子1,2, 澤井一2, 吉原澄吉3, 谷田弘3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-893, 2020. |
|---|
|
|
P18-5. One patient who developed an allergic symptom by multiple antimicrobial 安高勇気1,2, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-893, 2020. |
|---|
|
|
P18-6. Examination of somnolence, the oversedation expression risk in the delirium time Risperidone administration 矢野裕士1,2, 鈴木優司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 894-894, 2020. |
|---|
|
|
P18-7. Acute renal failure and hypoglycemic one patient with the concomitant drug who had the onset just after voriconazole administration 松田翔平1, 水口真利江1, 楢原史子1, 馬屋原慈理1, 木村竜司1, 今津智子1, 下川福子1, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 894-894, 2020. |
|---|
|
|
P18-8. A hypereosinophilic syndrome with pericarditis that occurred with dobutamine: Case report 無漏田香穂1, 吉廣尚大1, 石橋直樹1, 橋本佳浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 895-895, 2020. |
|---|
|
|
P18-9. 1 case of the drug-related pleurisy with mesalazine 柴田健太1, 白川直人1, 中田和宏1, 木村美由喜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 895-895, 2020. |
|---|
|
|
P18-10. The side effect expression situation investigation of pulmonary MAC symptom treatment in central part Rousaibyoin 旭将来1, 荒川正悟1, 平松久典1, 山口智江1, 宮原兼二1, 木南志朗1, 伊藤功治2, 石川真弓3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 896-896, 2020. |
|---|
|
|
P18-11. Elucidation of the uptake mechanism that is skin-specific of the ipragliflozin in human keratinocytes HaCaT cells 高畑洋平1, 辻本雅之1, 伴野靖奈1, 堀優香1, 折方琴音1, 白土恵理1, 辻本美菜1, 河渕真治2, 栄田敏之2, 峯垣哲也1, 西口工司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 896-896, 2020. |
|---|
|
|
P18-12. Examination of the usefulness of ALBI Grade in the occurrence of adverse event prediction by the Lenvatinib 松本由季1, 榎本大智1, 山本和宏1, 大村友博1, 小松昇平2, 矢野嘉彦3, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-897, 2020. |
|---|
|
|
P18-13. Efforts aimed at increasing the number of preavoid reports and their results 甲元大樹1, 横田幸子1, 向井めぐみ1, 花房伸幸1, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-897, 2020. |
|---|
|
|
P18-14. One case with suspected drug-related pulmonary disorder by the Vonoprazan fumarate 五十川達哉1, 中村祐太2, 瀬口優里1, 荒金裕敏1, 三浦光年3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-898, 2020. |
|---|
|
|
P18-15. It is one patient with suspected dihydropyrimidine dehydrogenase deficiency in the capecitabine internal use patients 屋敷大輔1, 田中恭人1, 豊留麻衣1, 北園幸大1, 中野一馬1, 山本梢1, 岸本真1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-898, 2020. |
|---|
|
|
P18-16. Examination and comparison between hemoglobin level and effect on anemia frequencies with the antiandrogen 廣部開斗1, 玉木啓文1,2, 伊野陽子1,2, 長内理大1,2, 山下修司2,3, 野口義紘2,4, 井口和弘1,2, 寺町ひとみ2,4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2020. |
|---|
|
|
P18-17. The serum magnesium densitometry for the magnesium oxide preparation internal use patients which the renal function based on the protocol decreased and chronic constipation measures 田畑真一1, 中島麻有1, 戸塚孝治1, 新井成俊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2020. |
|---|
|
|
P18-18. 1 case that had a diagnosis of dabigatran origin-related esophagitis during hospitalization of the congestive heart failure 川成昂1, 高田正弘1, 景山康二郎1, 氏原弘洋1, 國原将洋1, 松久哲章1, 杉野浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2020. |
|---|
|
|
P18-19. Look at the rear of the risk factor of the onset of impaired renal function by Liposomal-amphotericin B; mark investigation 横田翼1, 吉川直樹1, 有森和彦1, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2020. |
|---|
|
|
P18-20. Reexamination about the adverse event expression including the photo-allergy in the aminolevulinic acid hydrochloride granule internal use patients of our hospital urology department 標真里絵1, 高嶋祥匡1, 大谷寧次郎1, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-901, 2020. |
|---|
|
|
P18-21. Adverse event report contents of hospital pharmacist and the insurance pharmacist 奥村伊代1,2,3, 矢野裕士1, 江川裕之1, 岡本祐二1, 岡安弘樹1, 千葉詩織1, 今井裕久2, 平本要2, 吉澤美香3, 鈴木優司3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-901, 2020. |
|---|
|
|
P18-22. New digital to contribute to side effect prevention, reduction of the TC therapy cera; see the rear about preliminary examination - adverse event for the Thich development with a zing; mark investigation ... 森本彩香1, 仁木一順1, 原伸輔2, 奥田真弘2,3, 上田幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2020. |
|---|
|
|
P18-23. The digestive tract function in patients with intensive care unit admission serious case and internal behavior of blood neuroendocrine system peptide 三宅優美1, 道原あやな1, 高田千明1, 白川真1, 後藤孝治2, 佐藤雄己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2020. |
|---|
|
|
P18-24. Comparison of bleeding frequency between clopidogrel and prasugrel with DAPT therapy after PCI 濱田恵輔1, 門口直仁1, 濱本真歩1, 森田有香1, 田中広大1, 段松雅弘1, 田中聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 903-903, 2020. |
|---|
|
|
P18-25. Examination of the factor to have an influence on the onset of cutaneous symptom that vancomycin is due to 森幸代1, 中蔵伊知郎1, 福田裕子1, 本多美悠1, 吉本咲貴1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 903-903, 2020. |
|---|
|
|
P18-26. Examination of the factor having an influence on weight loss, the cancellation of the dose by the drop of serum Ca level and PTH-intact in the Evocalcet administration 土江学1, 西原昌幸1, 森川記道2, 吉原統1, 伊豆優美子1, 稲艸優生子1, 藤田啓子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-904, 2020. |
|---|
|
|
P18-27. One case that a drugstore pharmacist utilized the prescription test value of the basic hospital, and evaluated the another hospital medical treatment, and fed back 原田祐希1,2, 鈴木渉太2,3, 中川素子1, 中川道昭1, 岡田浩2, 中山健夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-904, 2020. |
|---|
|
|
P18-28. Evaluation of the side effect report system of pharmaceutical products in the Gifu comprehensive medical care center 小寺聖1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-905, 2020. |
|---|
|
|
P18-29. Examination of the hTHTR2 inhibitory action with metronidazole using hTHTR2 expression MDCK II cells 山岸喜彰1, 白坂善之2,3, 鮒井悠汰2,3, 橋本光弘1, 工藤敏之1, 井上勝央2, 伊藤清美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-905, 2020. |
|---|
|
|
P18-30. The effect that NSAIDs gives to healing of wound 長崎裕1, 中居肇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-906, 2020. |
|---|
|
|
P18-31. Examination of the risk factor associated with the acute side effect of nonionic contrast media 鶴見裕美1, 冨田敦和1, 國分祐介1, 飛永あゆみ1, 今西忠宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-906, 2020. |
|---|
|
|
P18-32. It is the onset of immune-mediated adverse event situation until one year after checkpoint inhibitor administration of immunity 岩田一史1, 合澤啓二1, 小野達昌1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 907-907, 2020. |
|---|
|
|
P18-33. The effect that the polypharmacy with the adverse event spontaneous report database gives to the fall risk of elderly people 畠平春奈1,2, 長谷川栞1, 笹岡沙也加1, 加藤大和1, 阿部純子3, 元岡佑美1, 福田昌穂1, 長沼美紗1, 中尾智史1, 向井梨々香1, 島田和代1, 平出耕石2, 加藤武司2, 中村光浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 907-907, 2020. |
|---|
|
|
P18-34. One case that caused metformin-related lactic acidosis after the alcohol large quantity drinking 平識善彦1, 小杉卓大1, 座覇明子2, 嘉数敦3, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 908-908, 2020. |
|---|
|
|
P18-35. Investigation of the observance situation of "asking in case of pharmaceutical products safety information report mention" that PMDA delivered it 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 908-908, 2020. |
|---|
|
|
P18-36. Drug adverse event risk of the elderly people whom we recognized from bringing medicine investigation 大野陽平1, 石川めぐみ1, 吉見猛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-909, 2020. |
|---|
|
|
P18-37. A Case of Hepatitis B Virus Reactivation with Pomalidomide + Dexamethasone Therapy 設楽愛美1, 美馬禎俊1, 村上達也1, 竹田祐加1, 牧瀬英知1, 近藤智幸1, 橋本光生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-909, 2020. |
|---|
|
|
P18-38. Association between expression situation and age of the red man syndrome with vancomycin 富島喜朗1, 古庄弘和1, 渡邊瑛理1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2020. |
|---|
|
|
P18-39. Examination about the association of PK/PD parameter and the lower urinary tract symptom frequency that we calculated using QSAR 伊東岳1, 湯山円晴2, 飯山夏海1, 慶野綾子1, 平岡優里菜1, 荒井裕美子2, 金谷貴行2, 杉山奈津子1, 加藤芳徳1, 前澤佳代子1, 倉本敬二1, 栗原正明2, 百瀬泰行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2020. |
|---|
|
|
P18-40. Efforts for the prescription situation and the mesenterial vein sclerosis early detection of the gardenia fruit-containing Chinese medicine 磯野礼果1, 林彩矢香1, 遠藤秀竜1, 堀浩子1, 山崎崇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2020. |
|---|
|
|
P18-41. Use experience of the Lenvatinib in our hospital 西條由夏1, 大谷綾1, 亀井健人1, 塙久瑠実1, 上田愛梨1, 中尾啓子1, 笹瀬典子1, 藤井貴子2, 金秀基2, 金守良2, 金啓二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2020. |
|---|
|
|
P18-42. Use fact-finding of distigmine bromide tablets in our hospital 山根紗希子1, 山根靖弘1, 梅田清隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2020. |
|---|
|
|
P18-43. Investigation about the introduction of the hyperuricaemia therapeutic drug for patients with chronic kidney disease 山下功祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2020. |
|---|
|
|
P18-45. An example of allergy to α-gal which we experienced in our hospital 小池彩子1,2, 出宮千聖1, 山口麻里2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-913, 2020. |
|---|
|
|
P18-46. An attitude survey about the side effect relief system for the pharmacists of the health insurance pharmacy and examination of the problems 秋山滋男1, 土井信幸2, 淺野未代子3,9, 福澄重泰4,10, 高橋真吾5, 鈴木勝俊6, 小川憲治7,10, 宮本悦子8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2020. |
|---|
|
|
P18-47. The current situation of Adverse Drug Event in the Baptist health center for the elderly and the problem 東原和美1, 梅村道代2, 福田美沙子2, 中田裕久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2020. |
|---|
|
|
P18-48. Examination about the onset risk of the diarrhea by the naldemedine in our hospital 向井淳治1, 坂本竜平1, 小竹優希1, 氏川郁穂1, 奥田広志1, 名徳倫明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-915, 2020. |
|---|
|
|
P18-49. Pediatric case with suspected symptom central at voriconazole administration 小野寛之1, 田中遼大1, 木村裕香2, 平野直樹2, 末延聡一2, 龍田涼佑1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-915, 2020. |
|---|
|
|
P18-50. Fact-finding of the intracranial hemorrhage that occurred during oral anticoagulant drug (DOAC) remedy directly 天野祐太1, 門野健二1, 武田龍馬1, 池田大騎1, 片倉佐都子1, 高橋紀恵1, 野本祐香1, 本間和加子1, 上山憲司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2020. |
|---|
|
|
P18-51. Search of the infusion reaction expression risk factor of the daratumumab 小野達昌1, 岩田一史1, 合澤啓二1, 森優1, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2020. |
|---|
|
|
P18-52. Infection frequencies in EORA and examination of the expression time 西本辰徳1, 千場美奈2, 山部美千子2, 木村修徳2, 小園亜希2, 清水裕彰2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2020. |
|---|
|
|
P18-53. Effect analysis of the antipyretics analgesic giving it to cisplatin-induced acute renal failure using adverse drug reaction database (JADER) 奥村啓樹1, 南島拓矢1, 宮崎雅之1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2020. |
|---|
|
|
P18-54. In vitro assessment of tubular toxicity of the BRAF inhibitor vemurafenib 真川明将1,2, 森菜々香2, 冨田なつみ2, 堀田祐志2, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-918, 2020. |
|---|
|
|
P18-55. The effect that long-term proton pump inhibitor (PPI) internal use gives for the renal function of elderly people 後藤早衿1, 北川佳奈子1, 倉地茜1, 松原匡希1, 宮川泰宏1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-918, 2020. |
|---|
|
|
P18-56. The detection of the pharmaceutical products safety signal about the miscarriage using FAERS 弓長隆太1, 酒井隆全1, 田辺公一1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 919-919, 2020. |
|---|
|
|
P19-1. Examination of circadian variation in xanthine oxidase and xanthine dehydrogenase activity 田山剛崇1, 喜多智生1, 西村さとみ1, 岡本友理香2, 前田志津子1, 杉原数美1, 三宅勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-920, 2020. |
|---|
|
|
P19-2. Steroid hormone hydrocarbon hydroxylase by the human cytochrome P450 3A subfamily 谷美咲1, 岡本綾香1, 成田華苗1, 豊田愛実1, 丹羽俊朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 921-921, 2020. |
|---|
|
|
P19-3. Effect to give to human cytochrome P450 activity of various antimicrobial 石井里沙1, 佐々木笙子1, 丹羽俊朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 921-921, 2020. |
|---|
|
|
P19-4. Effect of steroid hormone and related compounds on testosterone hydrocarbon hydroxylase by the human cytochrome P450 3A subfamily 川崎日向子1, 岡本綾香1, 豊田愛実1, 丹羽俊朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2020. |
|---|
|
|
P19-5. Dopamine generation with human CYP2D6 and effect of steroid hormone and related compounds 田中麻友1, 丹羽俊朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2020. |
|---|
|
|
P19-6. It is effect of various antidepressant on dopamine generation from p-tyramine by human cytochrome P450 (CYP) 2D6 道廣有里奈1, 杉本静也1, 丹羽俊朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2020. |
|---|
|
|
P19-7. Pharmacokinetic examination in the rat of the redie fen relative using the HPLC 角岡映1, 千森隆靖1, 坂本祐輔1, 土谷香穂2, 酒井博遥3, 古川実季1, 小林正樹1, 樋上賀一1, 長原礼宗3, 椎名勇2, 真野泰成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2020. |
|---|
|
|
P19-8. The effect that 5-fluorouracil administration gives to substrate drug metabolism activity of liver CYP3A and the internal change 福野修平1, 藤池麻衣1, 佐々木雄哉1, 長井克仁1, 小西廣己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2020. |
|---|
|
|
P19-9. Effect of the selective serotonin reuptake inhibitor (SSRI) on intracerebral progesterone 21 - hydrocarbon hydroxylase 佐々木笙子1, 丹羽俊朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2020. |
|---|
|
|
P19-10. Establishment and application of the plasma concentration system of measurement of the antidementia medicine by the HPLC-MS/MS method 道原あやな1, 三宅優美1, 白川真1, 山本浩一2, 佐藤雄己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 925-925, 2020. |
|---|
|
|
P20-1. Estimate of the plasma concentration measurement of apixaban in patients with severe impaired renal function and the internal change 市川祐依1, 内田信也1, 小幡由佳子2, 三浦基靖1, 田中紫茉子1, 柏倉康治1, 乾直輝3, 渡邉裕司3, 並木徳之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 926-926, 2020. |
|---|
|
|
P20-2. Pharmacokinetic analysis of vancomycin in patients with childhood febrile neutropenia 海士野恵理乃1, 田中遼大1, 小野寛之1, 龍田涼佑1, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 927-927, 2020. |
|---|
|
|
P20-3. Population pharmacokinetics analysis of gentamicin in Japanese children 石原慎之1, 猪川和朗2, 大仁田哲修1,2, 玉木宏樹1, 矢野貴久1, 森川則文2, 直良浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 927-927, 2020. |
|---|
|
|
P20-4. Investigation about the change of the serum albumin level for initial INR at warfarin introduction and the arrival INR that is in a steady state 西山貴章1, 加藤善章1, 菊田紋華1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 928-928, 2020. |
|---|
|
|
P21-1. Drug interaction potentiation simulation when multiple CYP was inhibited at the same time 伊藤哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 929-929, 2020. |
|---|
|
|
P21-2. Change of low-density lipoprotein cholesterol (LDL-C) by the combination of rosuvastatin and magnesium oxide 高橋尊1, 門田祥吾1, 梅田慎也1, 永井滉士1, 南雲徳昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 930-930, 2020. |
|---|
|
|
P21-4. Validity of the cocktail study as the quantitative rating system in the drug interactions detection 三浦基靖1,2, 内田信也1, 田中紫茉子1, 神谷千明3, 片山直紀3, 袴田晃央3, 小田切圭一3, 乾直輝3, 川上純一2, 渡邉裕司3, 並木徳之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2020. |
|---|
|
|
P21-5. Search of the factor affecting warfarin potassium, PT-INR of the amiodarone hydrochloride combination patients 眞崎晃1, 大津友紀1,2, 梅崎靖弘1, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2020. |
|---|
|
|
P21-6. Interaction of the antiMRSA medicine and warfarin at ventricular assist device wearing 井倉恵1, 中北和樹1, 宇野貴哉1, 竹中裕美1, 松田紗知1, 小田亮介1, 和田恭一2, 中村任2, 服部雄司1, 早川直樹1, 簗瀬正伸3, 福嶌教偉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-932, 2020. |
|---|
|
|
P21-7. A case in which voriconazole pharmacokinetics were affected by changes in letermovir absorption due to vomiting 大石博史1,2, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-932, 2020. |
|---|
|
|
P21-8. Medicine - for study on drug (the second report) - central nervous system which takes it in, and can be inhibited by a combination of magnesium oxide 吉田久博1, 楠本正明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-933, 2020. |
|---|
|
|
P21-9. A color change and content change after a crush, the divided powder with Mercazole tablets (thiamazole) and Magmitt tablets (magnesium oxide) 石田志朗1, 邊恩守1, 鈴江朋子1, 山本曉2, 山岸美貴2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-933, 2020. |
|---|
|
|
P21-10. Examination about the drug interactions of tacrolimus in the childhood hematopoietic stem cell transplantation patients and the azole-based antifungal agent 持田裕子1, 清水祐一1, 宇野倫弘1, 甲斐維子1, 加戸奈穂美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-934, 2020. |
|---|
|
|
P21-11. It is examined the safety of atorvastatin in patients after the kidney transplantation during the cyclosporine internal use 原林六華1, 高橋正也1, 高橋克之1, 杉本崇1, 内田潤次2, 永山勝也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-934, 2020. |
|---|
|
|
P21-12. One case that blood tacrolimus levels increased by vonoprazan internal use after the living renal transplantation 池田ゆり絵1, 中村絢香1, 小阪直史1, 原田俊平2, 牛込秀隆2, 四方敬介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2020. |
|---|
|
|
P21-13. The effect of menthol on killing effect of the paclitaxel with human liver cancer HepG2 cells and vincristine: Association with the CYP3A expression control 長井克仁1, 福野修平1, 大間知杏奈1, 三浦健2, 小西廣己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2020. |
|---|
|
|
P21-14. 1 case that absorption of the cyclosporine micro emulsion preparation was promoted by combination of the bile acid preparation conspicuously 竹島秀美1, 吉川直樹1, 秋月渓一2, 日高智徳2, 下田和哉2, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2020. |
|---|
|
|
P21-15. The establishment and evaluation of the angiotensin II receptor knockout cells using the CRISPR/Cas9 system 本山瑞季1, 池尻朱里1, 伊達和輝1, 小島美駒1, 齋藤僚2, 平大樹1, 上島智1, 蓮元憲祐1, 岡野友信1, 角本幹夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2020. |
|---|
|
|
P22-1. Examination of the drug clearance of vancomycin in patients with malignant tumor 泉澤友宏1,3, 金子知由1, 涌井宣行2, 齋藤大輔3, 今井正彦3, 島崎博士1, 高橋典子3, 長谷川英雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-937, 2020. |
|---|
|
|
P22-2. DAP pharmacokinetics analysis in patients who received CHDF 山科卓也1, 入江健司4, 辻泰弘2, 山本善裕3, 平木洋一4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-938, 2020. |
|---|
|
|
P22-3. Relation - after pharmacist intervention effect - initial formulations in the Teicoplanin initial administration plan based on guidelines 崎山良1, 岡村智文1, 管田彩乃1, 柴田茂貴1, 兼石誠1, 松永愛1, 田口みどり2, 船越幸代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-938, 2020. |
|---|
|
|
P22-4. Comparison between ingredient ratio and measurements between the Teicoplanin preparation by the LATIA method 太田千代枝1, 松永典子1, 里加代子2, 黒崎友亮2, 兒玉幸修1, 佐々木均1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-939, 2020. |
|---|
|
|
P22-5. Attempt of the "vancomycin daily standard quantity" in our hospital development 木村三奈美1, 成田久美1, 吉本咲智子1, 戸田純司1, 室岡邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-939, 2020. |
|---|
|
|
P22-6. Examination of the risk factor that a blood level trough value becomes the high level in the TDM of vancomycin in our hospital 竹田晃輝1, 中井健人1, 田中利夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2020. |
|---|
|
|
P22-7. Examination about the usefulness of the vancomycin initial administration plan nomogram 綿貫真優1, 島崎信夫1, 鈴木洋平1, 梅田清隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2020. |
|---|
|
|
P22-8. Stable examination for the pharmacokinetic pro-evaluation establishment of the meropenem by LC-MS/MS 堀田奈央1, 長瀬泉1, 森光輝1, 種田靖久1, 松岡知子1, 宇佐美英績1, 吉村知哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2020. |
|---|
|
|
P22-9. Evaluation of the bisoprolol patch in patients with sepsis that developed tachycardiac atrial fibrillation 里加代子1, 安藝敬生1, 関野元祐2, 東島潮2, 黒崎友亮1, 内田隆寛1, 兒玉幸修1, 佐々木均1, 北原隆志3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2020. |
|---|
|
|
P22-10. Age-specific investigation about the second trough value of vancomycin 今西嘉生里1, 水本知宏1, 井後星哉1, 宮部貴識1, 佐光留美1, 山内一恭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-942, 2020. |
|---|
|
|
P22-11. 1 case that showed high level by the VCM trough value drawing blood from a periphery insertion central venous catheter 浜元善仁1, 平田やよい1, 東千夏1, 益田菜月1, 親富祖翔太郎1, 岸本卓1, 翁長真一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-942, 2020. |
|---|
|
|
P22-12. Effect examination of the TDM study session in our hospital 石田有希1, 清水善仁1, 長井宏文1, 多賀允俊1, 高瀬文超1, 山本康彦1, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 943-943, 2020. |
|---|
|
|
P22-13. Evaluation of measurements by blood level measuring equipment "LM1010" (evaluation machine) by the HPLC method 尾田一貴1,2, 岩村耕次1, 片野田朋美1, 成田勇樹1,2, 内野翔太2, 黒木香吉2, 堀川真衣2, 松本直也2, 米丸興2, 山口綾水2, 城野博史1,2, 齋藤秀之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 943-943, 2020. |
|---|
|
|
P22-14. 1 example of the renal renal failure attributable to the levetiracetam 水口真利江1, 松田翔平1, 丸本彩加1, 谷本愛花1, 久賀谷幸昌1, 中村護1, 下川福子1, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 944-944, 2020. |
|---|
|
|
P22-15. It is a one case using the levetiracetam for an epileptic seizure complicated for short bowel syndrome 小澤拓1, 吉岡睦展1, 饒平名長武1, 高子優子1, 小川佳美1, 児島正道2, 岡田敏弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 944-944, 2020. |
|---|
|
|
P22-16. Examination about vancomycin initial administration plan using the nomogram and the effect 村田翔1, 川崎亮輔1, 相原敏彦1, 増尾昌則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-945, 2020. |
|---|
|
|
P22-17. Evaluation of the practical usefulness that blood antimicrobial levels measurement order registration and the injection drug temporary registration by the pharmacist bring 村川亜光1,2, 山本和宏1, 石井順子1, 阪上倫行1, 清水倫子1, 槇本博雄1, 大村友博1, 坂根稔康2, 國正淳一2, 宮田興子2, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-945, 2020. |
|---|
|
|
P22-18. Evaluation of the predictive performance in the Japanese patients of the warfarin kinetic-pharmacodynamic model 青山隆彦1, 平井利典2, 辻泰弘3, 宮本葵1, 伊東俊雅2, 松本宜明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 946-946, 2020. |
|---|
|
|
P22-21. Usefulness and problem of the vancomycin administration regimen standardization 加藤渓1, 山下悠希1, 山田和弘1, 中山博文1, 奥村麻佐子1, 阪口勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 947-947, 2020. |
|---|
|
|
P22-24. Making of the dose adjustment nomogram using initial doses in the vancomycin administration and the initial actual survey trough value and the evaluation 種茂いずみ1, 片岡優1, 尾田一貴2, 山田智之3, 小田怜1, 瀬戸崇光1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2020. |
|---|
|
|
P22-25. Improvement of the aim trough value achievement quotient by the standardization of the initial administration plan method of vancomycin 左野亜規子1, 水野裕治1, 西田初博1, 西野隆1, 三嶋一登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2020. |
|---|
|
|
P23-1. The effect that the inflammatory response in patients receiving voriconazole gives to CYP2C19 activity 相内尚也1, 中川潤一1, 上野桂代1, 木村正彦2, 萱場広之3, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 950-950, 2020. |
|---|
|
|
P23-3. Association between trough level change and onset of renal failure situation and CYP3A5 genetic polymorphism after the tacrolimus administration in the autoimmune disease patients 兵藤塁1, 櫻庭裕丈2, 中川潤一1, 蓮井桂介2, 渡邊里奈2, 東野優花1, 福田眞作2, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-951, 2020. |
|---|
|
|
P24-1. Fact-finding of the anticancer agent doses setting in consideration of economy 稲野寛1, 植田茉梨絵1, 菅原充広1, 佐々木治一郎2, 厚田幸一郎1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-952, 2020. |
|---|
|
|
P24-2. Making of the anticancer agent preparation sheet using Microsoft Excel 東島幸道1, 尾崎紗緒理1, 飯田優美1, 吉本有里2, 佐澤卓哉3, 大坪輝行1, 伊南裕子1, 山脇一浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2020. |
|---|
|
|
P24-3. The effectiveness of nivolumab and the Pembrolizumab in patients with lung cancer, safe examination 吉見峻祐1, 加藤博史1, 冨安真史1, 松尾モモ1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2020. |
|---|
|
|
P24-4. It is efforts in our hospital for the cisplatin base regimen promotion in the adjuvant chemotherapy and the effect after the lung cancer technique 高原彩1, 光永義治1, 長門芳2, 田中嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2020. |
|---|
|
|
P24-5. Usefulness evaluation of the injection anticancer medicine check seat in the prescription checking 松尾拓馬1, 原田浩明1, 後藤総太郎1, 石原溶子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2020. |
|---|
|
|
P24-6. The effect that the introduction of the regimen check sheet results in for a doubt inquiry at checking prescription time 堀真悠子1, 吉田幹宜1, 土屋亜祐美1, 長尾嘉真1, 佐藤吉一1, 島貫裕実子1, 田中万穂1, 小川千晶1, 増田純一1, 近藤直樹1, 寺門浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-955, 2020. |
|---|
|
|
P24-7. About duties improvement of the foreign chemotherapy center for patients waiting time cancellation 鈴木敦詞1, 伊東沙紀1, 村山まりこ1, 前田剛司1, 中釜浩美2, 坂田洋1, 服部芳明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-955, 2020. |
|---|
|
|
P24-8. Analysis of doubt introduction contents in the cancer chemotherapy of our hospital 河野大希1, 牧陽介1, 橋本雅司1, 林淳一郎1, 横田千明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 956-956, 2020. |
|---|
|
|
P24-9. Inspection of the significance of prior doubt inquiry in the regimen inspection of the foreign chemotherapy 冨原莉穗子1, 新谷拓也1, 原伸輔1, 山本智也1, 門脇裕子1, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 956-956, 2020. |
|---|
|
|
P24-10. Efforts to the administration of oral pyrimidine system anticancer agent adequacy with the off-period fluoride 村上幸恵1, 桑原玄樹1, 奥井美加子1, 本間健道1, 竹野裕晶2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 957-957, 2020. |
|---|
|
|
P25-1. Efforts and problem for the multiple hospitals in the area in the cancer domain and the cooperation of the health insurance pharmacy 村田稔弥1,2, 淺野未代子1,3, 有井太郎1,4, 井出貴之1,5, 大輪武司1,6, 鬼窪利英1,7, 小野里直彦1,8, 中村久美1,7, 野村充俊1,7, 平林克博1,9, 松澤直樹1,10, 松原重征1,11, 三浦篤史1,12, 向山百合1,7, 吉澤貴代美1,13 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 958-958, 2020. |
|---|
|
|
P25-2. Job evaluation by the RevMate pharmacist outpatient department introduction 河村勇介1, 水上皓喜1, 伊藤実里1, 岡崎夏実1, 妹尾啓司1, 阪田安彦1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2020. |
|---|
|
|
P25-3. Efforts to the cooperation full addition acquisition of "the meeting thinking about the medicine medicine cooperation of the Chita Peninsula area" 小田浩史1, 伴晶子2, 土井直美2, 佐藤知香2, 古田麻衣子2, 森田奨2, 早川裕二3, 加藤雅斗3, 大平勇二4, 石川奈央佳4, 三島江津子5, 永松秀紹5, 奥田佳苗6, 堀崎和美7, 服部聡8, 上地小与里9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2020. |
|---|
|
|
P25-4. Usefulness of PBPM by the cooperation of hospital pharmacist and the drugstore pharmacist for the hand-and-foot syndrome of the capecitabine: Multicenter retrospective study 白岩泰祈1, 中村暢彦1, 春名康裕2, 一島知樹2, 武田智子2, 長谷川晃司2, 矢野義孝1, 楠本正明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-960, 2020. |
|---|
|
|
P25-5. Evaluation of the effect that the cutaneous symptom of the capecitabine remedy patients in the health insurance pharmacy gives in quality of life 喜多日向子1, 中村暢彦1, 春名康裕2, 一島知樹2, 武田智子2, 長谷川晃司2, 矢野義孝1, 楠本正明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-960, 2020. |
|---|
|
|
P25-6. Intervention ... of the pharmacist with the medical institution that there is not efforts - gene therapy specialist job for examination for MSI in central part Rousaibyoin, the BRCA1/2 genetic screening 山口智江1, 鵜飼麻由1, 伊藤功治2, 後藤真澄3, 柴原真由子3, 宿輪和孝4, 坂口憲史5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-961, 2020. |
|---|
|
|
P25-7. Efforts to support patients receiving treatment with oral anticancer agent in an area 上林崇1, 工藤滉大1, 立花慧千2, 平島郁2, 伊藤宏彰2, 奥山裕子3, 佐々木雄太4, 大久保幸子5, 中村一成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-961, 2020. |
|---|
|
|
P25-8. Example of the cooperation of hospitalization support room pharmacist and the chemotherapy center pharmacist 牛膓沙織1,2, 安田愛実1, 新井孝文1, 加藤幾1,2, 野村翔1,2, 丸山あずさ1, 早川正哉2, 池上信昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-962, 2020. |
|---|
|
|
P25-9. Telephone follow-up to patients with Abemaciclib remedy carried out at a health insurance pharmacy 新谷裕子1, 塚本弘美1, 熊谷史由2, 袰岩靖子2, 高松謙2, 麻生敦子3, 菅野和彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-962, 2020. |
|---|
|
|
P25-10. It is ... about efforts - joint conference enforcement with the health insurance pharmacy for the patients information communalization of the cancer medical therapy and the evaluation 青孝明1, 福浦啓史1, 近藤智彦1, 粟野萌1, 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2020. |
|---|
|
|
P25-11. Efforts of making, the operation of the reporting tool for the cooperation full addition calculation 森由佳里1, 齋藤裕子1, 高橋庄太1, 倉田奈央子1, 山内雅仁1, 塩澤誠1, 岡田浩司1,2, 渡邊善照1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2020. |
|---|
|
|
P25-12. The case that led to side effect reduction by an interview before medical examination by the pharmacist 米倉正樹1, 丹羽直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-964, 2020. |
|---|
|
|
P25-13. Example that became the treatment continuation in cooperation with a medical institution by the adverse event management for patients with progress recurrent hepatocellular carcinoma 尾形晶子1, 藤田尚宏1, 櫻井裕子1, 小泉浩司1, 大上満1, 松浦綾子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-964, 2020. |
|---|
|
|
P25-14. Cancer board in Osaka University School of Dentistry Hospital 浦川龍太1, 上田紘子1, 戸田史恵1, 山中佑合子1, 足立亜希子1, 上田幹子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-965, 2020. |
|---|
|
|
P25-15. Examination about the intervention example of the dermatopathy measures team for the anticancer agent of our hospital 山田卓摩1, 伴晶子1, 竹内亜由美2, 伊藤裕子2, 濱本ますみ2, 井上智子3, 野尻基4, 伊藤靖5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-965, 2020. |
|---|
|
|
P25-16. One case that collaborated with a division of cardiovascular disease physician for warfarin control during capecitabine remedy, and contributed to the evasion of the bleeding sign by the warfarin 須賀明輝1, 門谷靖裕1, 宮田祐一1, 中村雅敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-966, 2020. |
|---|
|
|
P25-17. About efforts of the cooperation full addition in the foreign cancer chemotherapy in our hospital 益子里美1, 鎮目晶子1, 藤谷竜磨1, 真柴友紀1, 福山博務1, 塩地園代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-966, 2020. |
|---|
|
|
P26-2. About the use situation of the Residual medicine in the anticancer agent preparation of our hospital 松田真一郎1, 岡林悠1, 田中慎1, 安田優子1, 宮崎大生1, 庄中高哉1, 松尾和馬1, 安原翔大1, 湧上大介1, 小瀬弘尚1, 馬瀬久宜1, 寺本晴美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-968, 2020. |
|---|
|
|
P26-3. Anticancer agent pollution status of the IVR room in the hepatic artery chemistry embolus therapy enforcement institution using the epirubicin 前田章光1, 稲葉吉隆2, 保坂彰子3, 長谷川貴章2, 長谷川彩子1, 稲熊一英1, 梶田正樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-968, 2020. |
|---|
|
|
P26-4. The costs investigation every prescription accompanied with the closed system anesthesia connection appliance introduction and examination of the economic modi operandi 計良貴之1, 小笹英祐1, 湊川紘子1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 969-969, 2020. |
|---|
|
|
P26-5. An investigation of the time required for an anticancer medicine preparation and examination 後藤総太郎1, 木下理恵1, 小林美佳1, 石原溶子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 969-969, 2020. |
|---|
|
|
P26-6. Conduct in-hospital exposure to anticancer medicine investigation (the third report) 長山晃1, 平野雄一1, 森下和美1, 川上典子1, 近藤昌子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 970-970, 2020. |
|---|
|
|
P26-7. Efforts of the pharmacy to an anticancer agent preparation in the liver arterial infusion chemotherapy 柘植雅大1, 安藤洋介2, 伊藤佳織1, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 970-970, 2020. |
|---|
|
|
P26-8. The current situation investigation of the environmental pollution situation utilizing the anticancer medicine quantitative analysis system and evaluation of exposure measures 鈴木寿樹1, 小林美奈子1, 高崎新也1, 横田則子2, 菊地正史1, 前川正充1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-971, 2020. |
|---|
|
|
P26-9. Development of the injection kit preparation in consideration of prevention of exposure, handiness 盛本修司1, 川崎浩延1, 野崎雅男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-971, 2020. |
|---|
|
|
P26-10. Exposure investigation in the anticancer agent preparation environment 中田絵梨1, 渡邉愛悠1, 田中壮周1, 丸山卓哉1, 槙田芳1, 後藤悠1, 小寺隆二1, 久保淳一1, 嘉屋則子1, 和泉秀明1, 田畑裕和1, 小原郁司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-972, 2020. |
|---|
|
|
P26-11. Examination of the cleaning agent at safety cabinet cleaning at use of closed system anesthesia drug transportation system 小笹英祐1, 計良貴之1, 湊川紘子1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-972, 2020. |
|---|
|
|
P26-12. Grasping the contamination status when dispensing 6-mercaptopurine hydrate 10% powder and comparing the residual amount generated by the cleaning method of the powder packing machine 比嘉朋子1, 具志堅優美絵1, 宇地原萌1, 奥野聖子1, 寺本奈都子1, 屋良愛1, 三上まどか1, 比嘉豊1, 古堅直也1, 久場良亮1, 石田浩1, 當真房子1, 又吉拓舟1, 比嘉浩一1, 佐藤雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2020. |
|---|
|
|
P26-13. Effect ... obtained from occupational exposure to anticancer medicine measures (the second report) ... anticancer medicine exposure findings 疋田絵梨1, 大崎真美1, 黒木あかね1, 賀川智子1, 林みどり2, 城田幹生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2020. |
|---|
|
|
P26-14. General efforts of anticancer agent exposure measures using an online self-assessment tool 高山俊輔1, 玉木秀子2, 高山裕樹1, 黒沢由歌理2, 吉井紀子2, 眞壁秀樹1, 前田智也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-974, 2020. |
|---|
|
|
P26-15. Introduction and evaluation of the anticancer agent mixing remote inspection support system 戸田史恵1, 上田紘子1, 山中佑合子1, 足立亜希子1, 浦川龍太1, 大石美奈子2, 上田幹子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-974, 2020. |
|---|
|
|
P26-16. It is ... about CSTD introduction in the preparation, administration of all occupational exposure to anticancer medicine measures (the first report) ... anticancer medicine management 大崎真美1, 疋田絵梨1, 黒木あかね1, 賀川智子1, 林みどり2, 城田幹生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2020. |
|---|
|
|
P26-17. It is ... about use to preparation for examination - subcutaneous injection of the medical economics by the use of CSTD 奥主仁1, 樋口裕樹1, 有山智博2, 今井桂子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2020. |
|---|
|
|
P26-18. Effect to give the medical material cost of an administration appliance accompanied with the coverage expansion of the closed system anesthesia connection appliance and the personal protector 橋本浩季1, 山口恭平1, 宮崎実千芸1, 村上通康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-976, 2020. |
|---|
|
|
P26-19. Efforts to occupational exposure measures 奥村智子1, 岩崎要人1, 三宅佑美1, 大西一嘉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-976, 2020. |
|---|
|
|
P27-1. Pharmacist support to raise the adherence of the oral anticancer agent 里見眞知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-977, 2020. |
|---|
|
|
P27-2. Significance by the relation to cancer treatment of our hospital pharmacist outpatient department 中道秀徳1,2, 都甲海2, 山本圭祐2, 松川陽央2, 北畠千種2, 荒川大輔2, 清水真弓2, 澤昇平2, 飯塚美有2, 瀧口晶子2, 矢部勝茂2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2020. |
|---|
|
|
P27-3. Efforts to calculate "cancer patient guidance management fee c" at Narita Memorial Hospital 鈴木善貴1, 野田千笑2, 神谷厚3, 藤原裕之4, 小林将貴4, 栗本昌明4, 小出修司4, 佐藤寛子5, 定盛理純1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2020. |
|---|
|
|
P27-4. Efforts for the follow-up system construction of the oral anticancer medicine remedy patients 藤田強記1, 眞弓健介1, 鶴崎泰史1, 花田聖典1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2020. |
|---|
|
|
P27-5. Examine intervention and the illness to patients with foreign chemotherapy enforcement in our hospital; efforts to medicine cooperation reinforcement 西千春1, 佐藤みづき1, 井口有紀1, 遠山潤1, 櫻間啓基1, 中村初美1, 古閑悠輝2, 甲斐豊3, 近藤元三4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2020. |
|---|
|
|
P27-6. 2 cases that reached the pharmaceutical intervention by telephone medication support and medicine medicine cooperation in foreign cancer treatment utilizing the feedback report 堀龍太郎1, 武田照幸1, 山崎友里恵1, 田中寿和1, 長沼敬子1, 木下隆市1, 染谷光洋1, 長内泰憲1, 宮岡勝弘1, 谷口亮央1, 中島史雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2020. |
|---|
|
|
P27-7. Aiming to develop medical professionals involved in cancer treatment - Efforts of Ain Pharmacy Nishi-Shinjuku Nishi-Shinjuku Cancer Treatment Research Group - (Fifth Report) 畔柳裕一1, 亀谷奈広1, 友清えりか1, 島津真衣1, 石黒貴子2, 前田守3, 長谷川佳孝3, 月岡良太3, 森澤あずさ3, 大石美也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2020. |
|---|
|
|
P27-8. Operation and evaluation of the use of internal use anticancer medicine report in the respiratory domain 北口梨紗1, 花房伸幸1, 河村茉衣1, 松本和也1, 田村安希1, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2020. |
|---|
|
|
P27-9. Usefulness evaluation of the side effect table for the purpose of the grade evaluation unification in the cancer medical therapy 宍戸桃子1, 辻本高志1, 井上靖隆1, 寺谷俊昭1, 山本明日香1, 加納宏樹1, 上田晃1, 川本由加里1, 後藤仁和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2020. |
|---|
|
|
P27-10. Effect of the pharmacist intervention on oral anticancer agent prescription patients 後藤美穂1, 荒川裕貴1, 桂川健司1, 大田亜希子2, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2020. |
|---|
|
|
P27-11. Usefulness evaluation of the pharmacist outpatient department for patients with Enzalutamide remedy prostate cancer 岩間弓奈1, 池末裕明1, 平畠正樹1, 三浦理恵子1, 入江慶1,2, 室井延之1, 川喜田睦司3, 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2020. |
|---|
|
|
P27-12. Efforts of our hospital for the high then tiger (TM) of patients with blood-forming organ tumor at-home introduction 森本隼多1, 鮎原秀明1, 藤本涼子1, 金子亜希子1, 赤羽大悟2, 竹内裕紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-983, 2020. |
|---|
|
|
P27-13. About the current situation and usefulness of the prescription suggestion in the pharmacist outpatient department 村上賢次1, 橋本恵梨花1, 中川のどか1, 早坂大1, 宅和真由美1, 平田敦宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-983, 2020. |
|---|
|
|
P27-14. Investigation about the effect to give to immune checkpoint inhibitor alone and an immune-mediated adverse event by the killer cells-related anticancer drug combination on lung cancer in our hospital 勝啓子1, 近藤篤1, 中多陽子1, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2020. |
|---|
|
|
P27-15. The current situation and problem of the efforts of the intervention before medical examination of the pharmacist for foreign chemotherapy patients 永峰槙子1, 中垣繁1, 中條倫成1, 杉山理奈1, 鈴木貴也1, 常泉道子2, 多久佳成3, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2020. |
|---|
|
|
P27-16. Efforts of the pharmacist outpatient department for the use of oral anticancer agent patients in the municipal hospital 永井大地1, 小森由理子1, 岡崎周大1, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 985-985, 2020. |
|---|
|
|
P27-17. Example that we utilized a tracing report for exclusive use of the Lenvatinib mesilate preparation and conducted a side effect report 藤田尚宏1, 尾形晶子1, 櫻井裕子1, 小泉浩司1, 大上満1, 松浦綾子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 985-985, 2020. |
|---|
|
|
P27-18. Pharmaceutical intervention for pediatric patients with cervical spinal cord tumor treated with entrectinib 浅葉有紀1, 柊元美優1, 小阪直史1, 四方敬介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-986, 2020. |
|---|
|
|
P27-19. One case that grasp of the onset of low back pain just after the nilotinib remedy start contributed to early CML remission 藤田あゆみ1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-986, 2020. |
|---|
|
|
P27-20. Efforts to medicine medicine cooperation and the cooperation full addition acquisition utilized the pharmacist outpatient department 河原史明1, 木本真司1, 香内綾1, 安齊泰裕1, 原田伸彦1, 平山拓史1, 成田浩気1, 星美奈子1, 山田麻帆1, 木村俊介1, 塩川秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-987, 2020. |
|---|
|
|
P27-21. The effect that the suit of patients gives in discovery of irAE in the nivolumab monotherapy 木村周古1, 高橋典哉1, 及川淳1, 黒田祥嗣1, 及川嵩人1, 工藤琢身1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-987, 2020. |
|---|
|
|
P27-22. One case that we followed up after the medication for patients receiving foreign cancer chemotherapy (XELOX + BV therapy) 吉田達司1, 藤田あゆみ2, 末次加代子1, 矢部和昭1, 庄瀬篤志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-988, 2020. |
|---|
|
|
P27-23. It is efforts for the calculation by the cooperation full addition in our hospital 新行内健一1, 栗原りか1, 川村勇太1, 佐藤亜希穂1, 中沢亜弓1, 葛岡朋代1, 直井隆浩1, 松井雄太1, 根岸由貴1, 海老原卓志1, 飯合等1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-988, 2020. |
|---|
|
|
P28-1. Effect on retching by the abbreviation of the dexamethasone after the second day in the Dose-dense EC therapy 阿部多一1, 住谷達也1, 林哲哉1, 井口恵美子1, 清水大輔2, 猪股克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 989-989, 2020. |
|---|
|
|
P28-2. Evaluation of the digestive organ symptom protective efficacy with aprepitant at paclitaxel + Carboplatin therapy enforcement in gynecologic cancer 渡辺祐子1, 齋藤佳敬1, 加藤信太郎1, 三田村卓2, 武隈洋1, 菅原満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2020. |
|---|
|
|
P28-3. Effect of treatment of olanzapine as the relief therapeutic drug for retching with the hematopoietic stem cell transplantation pre-treatment 宮原強1, 武富光希1, 松永尚1, 草葉一友1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2020. |
|---|
|
|
P28-4. 2 cases that mirtazapine was effective for retching vomiting with the chemotherapy 原田沙枝子1, 林洋平1, 櫻井美由紀1, 川嵜英二1, 鹿間良弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2020. |
|---|
|
|
P28-5. Comparison of granisetron and palonosetron in retching, the vomiting prevention at the GEM + nab-PTX therapy 藤本友季1, 三好孝法1, 堀南奈子1, 松尾尚美1, 平木洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2020. |
|---|
|
|
P28-6. Effect of the NK1 receptor blocker in the side effect expression of the ICE therapy 當麻丹香1, 宮崎雅之1, 中井剛1, 渡邉美菜子1, 石井沙也加1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2020. |
|---|
|
|
P28-7. We look at the rear about the risk factor of crizotinib-induced vomiting and prophylactic antiemesis therapy and examine a mark 熊谷康平1, 畑裕基1, 中野一也1, 山下大輔1, 別府博仁1, 本田芳久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2020. |
|---|
|
|
P28-8. Examination of the usefulness of the side effect management using the liver residual function metrics ALBI score in the gemcitabine + albumin suspension type paclitaxel combination therapy 永松秀紹1, 三島江津子1, 植田明日美1, 榊原洋一1, 竹内由佳2, 村上照幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2020. |
|---|
|
|
P28-9. Comparison of the antiemesis effect before and after the antiemesis supportive care change on TC therapy in gynecologic cancer 内山知乃1, 八島秀明2, 大島宗平2, 高橋恵美利1, 高橋雄太1, 大林恭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2020. |
|---|
|
|
P28-10. Use fact-finding of the peg filgrastim for patients who received FEC therapy in the Kitasato University Hospital 小原悠1, 田村和敬1, 佐々木寿子1, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2020. |
|---|
|
|
P28-11. Antiemesis effect at the dexamethasone mint condition in the antiemesis therapy at highly emetic chemotherapy enforcement for breast cancer 鈴木亘1, 川上和宜1, 青山剛1, 横川貴志1, 杉崎崇人1, 小林一男1, 柴田直樹1, 羽鳥正浩1, 鈴木賢一2, 伊藤良則3, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2020. |
|---|
|
|
P28-12. Of the side effect expression situation and the side effect management with the Olaparib administration in our hospital, actually 福泉智子1, 衛藤智章1, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2020. |
|---|
|
|
P28-13. Examination about the use actual situation of aprepitant in patients who received use of Carboplatin regimen and the effectiveness 先名健太1, 石塚仁保1, 櫻田啓介1, 船田茜1, 友寄旬1, 松本由香莉1, 山下友輝1, 村中一大1, 鈴木千波1, 小原秀治1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2020. |
|---|
|
|
P28-14. Examination of the effect of treatment of aprepitant in the induction therapy for acute myeloid leukemia 武富光希1, 草葉一友1, 宮原強1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2020. |
|---|
|
|
P28-15. Example that a 5-HT3 receptor blocker was effective for vomiting with the IRd therapy 加藤良隆1, 丸浜暢子1, 大坪達弥1, 鹿浦香織1, 野口裕介1, 神田英一郎1, 岡橋孝侍1, 藤田敦夫1, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2020. |
|---|
|
|
P29-1. Examination about the risk factor of the dermatopathy with before docetaxel for the breast cancer or the postoperative chemotherapy 志村裕介1, 菅幸生2, 嶋田努1, 原祐輔1, 辻千明1, 三坂恒1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-997, 2020. |
|---|
|
|
P29-2. Examination of optimal lipid doses in the nourishment management early after the allogeneic hematopoietic stem cell transplantation 筒井佑紀1, 渡部大介1, 中島寿久1, 橋本浩伸1, 牧野好倫1, 金成元2, 福田隆浩2, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2020. |
|---|
|
|
P29-3. One case that a low Ca blood symptom was prolonged in the patients who had ileus after the denosumab administration 野尻雅人1, 清水雅子1, 宮崎徹1, 高瀬美咲枝2, 塚田健一郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2020. |
|---|
|
|
P29-4. Fact-finding about the immune-mediated adverse event of the ipilimumab nivolumab combination therapy in metastatic nephrocyte cancer 増田竜大1,2, 野口祥紀2, 三宅知宏2, 服部公紀2, 中西由衣2, 小川晃宏2, 内田早弓2, 高尾雄介1, 谷村学2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-999, 2020. |
|---|
|
|
P29-5. Examination of the protective efficacy of the Goshajinkigan for peripheral neuropathy by the docetaxel 菅野亮太1, 齋藤佳敬1, 谷口理1, 山下啓子2, 武隈洋1, 菅原満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-999, 2020. |
|---|
|
|
P29-6. The gemcitabine liquid preparations increase vascular pain frequency as compared with lyophilized products: Clinical outcome and suggestion of vascular pain measures 河添仁1, 森奈月2, 井門静香2, 魚住龍史3, 恒岡菊江2, 竹内茜2, 松尾真由美2, 山内美砂子2, 薬師神芳洋4, 吉浦誠海1, 地引綾1, 横山雄太1, 鈴木小夜1, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2020. |
|---|
|
|
P29-7. The side effect expression of immune checkpoint inhibitor situation in the Gifu comprehensive medical care center 眞野翔太1, 宮崎公輔1, 伊藤健史1, 村田庄司1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2020. |
|---|
|
|
P29-8. One case that we showed an immune-mediated adverse event after the Atezolizumab administration and changed a drug of to Pembrolizumab 岡田淳芳1, 中村豪志1, 神原康佑1, 石井一也1, 大塚識稔1, 玄馬顕一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2020. |
|---|
|
|
P29-9. Construction of the Abemaciclib administration system utilizing the medication reporting book 柿原圭佑1, 三上忠司1, 原田智子1, 武田なつか1, 野田聖奈子1, 篠崎千尋1, 松本美紅1, 藤井裕史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2020. |
|---|
|
|
P29-10. About the association between Tumor Proportion Score and immune-mediated adverse event in the Pembrolizumab administration 藤本愛理1, 高武嘉道1, 木村滋1, 川俣洋生1, 福石和久1, 高島伸也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2020. |
|---|
|
|
P29-11. Risk factor search about the onset of neutropenia in patients who received cisplatin + vinorelbine combination therapy 村山三佳1, 丹羽洋介1, 竹内佐織1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2020. |
|---|
|
|
P29-12. An evaluation and measures of the vascular pain with the gemcitabine administration 菅野雄太1, 坂野昌志1, 山田洋治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2020. |
|---|
|
|
P29-13. Examination about the association between neutrophil count and onset of febrile neutropenia before the administration in the EC or FEC therapy 深見安希1, 槙原克也1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2020. |
|---|
|
|
P29-14. Examination of the neutropenic protective efficacy by peg filgrastim administration day in the breast cancer adjuvant chemotherapy 高原悠子1, 吉田弘樹1, 鈴木雅人1, 牧原明秀1, 三屋良太1, 木全司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2020. |
|---|
|
|
P29-15. Examination about the safety of the oral VEGF course inhibitor in the low cardiac activity case 新谷拓也1,2, 横山晴香2, 渡邊梓1, 山本智也1, 門脇裕子1, 藤尾慈2, 奥田雅弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2020. |
|---|
|
|
P29-16. Examination about Infusion reaction measures of Obinutuzumab in our hospital 坂本竜平1, 向井淳治1,2, 小竹優希1, 竹原涼子1, 濱崎淳哉1, 奥田広志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2020. |
|---|
|
|
P29-17. One case that developed severe dermatopathy during chemotherapy including the Pembrolizumab 元茂拓法1, 森永大亮2, 高橋知宏1, 廣崎邦紀3, 須甲憲明2, 内山英二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2020. |
|---|
|
|
P29-18. Associated analysis of a low NA blood symptom and retching that occurred after CDDP administration of patients with head and neck cancer 金澤絵莉1, 橋本雅司1, 田中藤信2, 木村滋3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2020. |
|---|
|
|
P29-19. The onset situation and factor search of the neutropenia in patients who received DLd therapy 野村実由1, 古谷智裕1, 武井秀樹1, 金田公平1, 白木政博1, 北本真一1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2020. |
|---|
|
|
P29-20. The diabetes management at the cancer chemotherapy 中村敏史1, 高橋典男2, 牛膓沙織1,3, 早川正哉3, 吉田昌則2, 池上信昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1007, 2020. |
|---|
|
|
P29-21. One case of autoimmune encephalitis with the Atezolizumab discovered by monitoring of the treatment support application alone 桂英之1, 米田太郎2, 木場隼人2, 坂野ひとみ1, 高田直子1, 石田外樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1007, 2020. |
|---|
|
|
P29-22. Comparison of the dermatopathy frequency of Minomycin and the concomitant drug in patients receiving antiEGFR antibody medicine 馬島務1, 小田剛史1, 山下剛史郎1, 廣瀬孝一1, 鶴田和樹1, 金田典子1, 北村瑞穂1, 稲村勝志1, 浅井茂夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1008, 2020. |
|---|
|
|
P29-23. Use experience of five patients who injected bortezomib in the mantle cell lymphoma hypodermically 伊勢崎竜也1, 湯山聡1, 成田健太郎3, 舟越亮寛1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1008, 2020. |
|---|
|
|
P29-24. Fact-finding at use of mycophenolate mofetil for steroid refractoriness, the intractable allied adverse event of immunity 三浦華歩1,2, 望月伸夫1, 川崎敏克1, 花田和彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2020. |
|---|
|
|
P29-25. Consideration ... of the effect with the association of fact-finding - taste disturbance and serum zinc levels of the taste disturbance at breast cancer AC therapy enforcement and the zinc replacement therapy 坂井由紀1, 山内可南子1, 星野直人1, 永橋昌幸2, 西條康夫3, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2020. |
|---|
|
|
P29-26. Examination of the risk factor of the side effect of Lenvatinib administration expression 石田友規1,2, 宮崎雅之2, 福澤翔太2, 松永安未2, 千崎康司2, 永井拓2, 山田清文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2020. |
|---|
|
|
P29-27. Example that became the treatment continuation by adverse event management by the pharmaceutical medicine cooperation to progress recurrent breast cancer S1 monotherapy patients 松浦綾子1, 尾形晶子1, 藤田尚宏1, 櫻井裕子1, 小泉浩司1, 大上満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2020. |
|---|
|
|
P29-28. It is a 1 case who had autoimmune pancreatitis and the colitis by a therapy with Nivolumab and Ipilimumab 木村竜司1, 一瀬貴史1, 馬屋原慈理1, 山崎美保1, 西園寺真二1, 下川福子1, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2020. |
|---|
|
|
P29-29. About the onset of immune-mediated adverse events, and the like in the nivolumab administration 山田剛1, 筒井洋子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2020. |
|---|
|
|
P29-30. Efforts of the interview before medical examination for patients with foreign cancer chemotherapy enforcement 村上由樹1, 上羽沙綾1, 谷千鶴佳1, 西山翼1, 大西真由1, 四方純子1, 奥村智晴1, 佐賀嘉英1, 谷田有花1, 芦田理沙1, 足立圭司1, 川見里奈1, 足垣亮介1, 宮谷正哉1, 山本真世1, 立道直美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2020. |
|---|
|
|
P29-31. Investigation about relations of the expression situation and the moisturizer consumption of the hand-and-foot syndrome in the capecitabine treated patients using the cutaneous symptom assessment sheet 久保萌美1, 島津智行1, 村上冴美1, 門脇督1, 土井佳子1, 田中悠季1, 三本松泰孝1, 佐藤弘康1, 和泉秀明1, 田村広志1, 渡辺浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2020. |
|---|
|
|
P29-32. Nephropathic risk factor analysis with the cisplatin combination radiotherapy 小出博義1, 野田哲史1, 奥貫裕美1, 中多祐介2, 大脇成広2, 清水猛史2, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2020. |
|---|
|
|
P29-33. About an investigation and measures of the onset of oxaliplatin hypersensitivity situation in the chemotherapy 和田康弘1, 伴晶子1, 岡戸洋1, 森田奨1, 山田卓麿1, 竹内亜由美2, 小林和子2, 野尻基3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2020. |
|---|
|
|
P29-34. Analysis of the risk factor to be involved in protein urine expression by the ramucirumab 廣上典和1, 松野由華1, 舟瀬和美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1014, 2020. |
|---|
|
|
P29-35. Making and inspection of the new metrics for the oxaliplatin origin-related feeling cold hypersensitivity symptom 橋本竜1,2,3, 佐藤淳也1,2,3, 石黒洋4, 杉山奈津子1,3, 伊東岳2,3, 加藤芳徳3, 倉本啓二2,3, 前澤佳代子1,2,3, 百瀬泰行1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1014, 2020. |
|---|
|
|
P29-36. Examination about the use actual situation of the naldemedine tosyl acid salt for the opioid-induced constipation and the effectiveness, the safety 飯田美紅1, 大久保凜花1, 大下瑚姫1, 若松遼介1, 中野裕介1, 小笠原綾香1, 岩本朱史鈴1, 須藤大雄1, 寺原史貴1, 樋浦一哉1, 鈴木千波1, 小原秀治1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1015-1015, 2020. |
|---|
|
|
P29-37. Questionary survey about the onset of nail disorder with the trastuzumab administration 山本龍世1, 草野淳一1, 吉田理1, 赤木秀子2, 嶋田昌彦3, 林誠一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1015-1015, 2020. |
|---|
|
|
P29-38. Through inspection before denosumab administration in efforts - pharmacy to use of aptitude in the denosumab administration - 北本真一1, 古谷智裕1, 白木政博1, 野村実由1, 金田公平1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1016-1016, 2020. |
|---|
|
|
P29-39. The effect that a vascular endothelium growth factor receptor inhibitor gives to a left ventricular dilatation function 横山晴香1, 新谷拓也2,3, 前田真一郎2,3, 廣部祥子2,3,4, 前田真貴子2,4, 藤尾慈2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1016-1016, 2020. |
|---|
|
|
P29-40. Examination of the workaround of the interaction of Fosaprepitant and the epirubicin 山崎美保1, 一瀬貴史1, 胡雅貴1, 前田頼伸2, 小田啓祐3, 森信博3, 村上照夫3, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1017, 2020. |
|---|
|
|
P29-41. Examination of the effect that calcium-channel blocker gives in the ramucirumab + paclitaxel therapy 木本大樹1, 槙原克也1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1017, 2020. |
|---|
|
|
P29-43. The HBV-DNA monitoring enforcement situation investigation after the hematopoietic stem cell transplantation in the HBV history infected person 浅野岳人1, 松村若菜1, 築山奈央1, 志賀有雅1, 野田実希1, 杉浦礼菜1, 杉山惠亮1, 米山英二1, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1018-1018, 2020. |
|---|
|
|
P29-44. Investigation about the effect on renal function by the hydration change in the chemotherapy, radiotherapy simultaneous combination therapy for patients with head and neck cancer 熊崎満菜1, 岩西雄大2, 中野寛之1, 高木麻里1, 吉田智恵1, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2020. |
|---|
|
|
P29-45. Investigation about proteinuria of the bevacizumab 工藤直嗣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2020. |
|---|
|
|
P29-46. Importance of the blood pressure management in the Carfilzomib administration continuation 網野一真1,2, 江口彩香1, 前澤優圭1, 柏原佑香1, 水谷妙子1, 横山征史1, 粟野原幸恵1, 濱至寛1, 登内盛治1, 内山倫宏2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1020, 2020. |
|---|
|
|
P29-47. About correlation of fact-finding of the vocal disorder with the neovascularisation inhibitor administration and VEGF receptor inhibitory action and the frequency 輿石徹1, 西岡菜々子1, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1020, 2020. |
|---|
|
|
P29-48. Examination of the effectiveness of mirogabalin for chemotherapy-induced peripheral neuropathy 吉田真人1, 青木利恵2, 菅谷量俊1, 牧野浩司3, 高瀬久光1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1021-1021, 2020. |
|---|
|
|
P29-49. Use fact-finding of a low Mg blood symptom and the Mg preparation with the antiEGFR antibody medicine in the foreign chemotherapy center 内藤舞1, 本多伸二1, 佐分利美帆子1, 三松史野1, 目黒裕史1, 實光由香1, 大野恵一1, 寸田靖1, 村岡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1021-1021, 2020. |
|---|
|
|
P29-50. Examination about the risk factor of the onset of proteinuria with the bevacizumab administration in patients with gynecologic tumor 村上正樹1, 北郷真史1, 石原慎之1, 玉木宏樹1, 矢野貴久1, 直良浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1022-1022, 2020. |
|---|
|
|
P29-51. 1 case of the prostate cancer which developed SIADH after hippopotamus diTaki cell administration 戸塚弘幸1, 長井宏文1, 高橋喜統1, 中澤佑介2, 近沢逸平2, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1022-1022, 2020. |
|---|
|
|
P29-52. Examination of the adverse event of the Durvalmab therapy for NSCLC 小竹優希1, 向井淳治1, 坂本竜平1, 竹原涼子1, 濱崎淳哉1, 奥田広志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2020. |
|---|
|
|
P29-53. Comparison of the blood toxicity expression situation of RAM+PTX therapy and the RAM+nab-PTX therapy in the progress recurrent gastric cancer 大澤美紗1, 中條倫成1, 多久佳成2, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2020. |
|---|
|
|
P29-54. Examination of the effect with frequency and the concomitant drug of the hypomagnesemia with the antiEGFR medicine in our hospital 川島悠吾1, 村嶋彩加1, 宗本尚子1, 鳥居奈央1, 鶴島真子1, 瓦比呂子1, 徳山洋子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1024, 2020. |
|---|
|
|
P29-55. Comparison of the single institution backsight of the number of follow before and after the observance confirmation intervention of irAE measures by the pharmacist 前田和輝1, 藤田真穂1, 新川実季1, 永井浩章1, 見上千昭1, 本間久美子1, 西尾孝1, 片岡裕貴2, 國東ゆかり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1024, 2020. |
|---|
|
|
P29-56. Examination about the association between taste disturbance and zinc concentration in pancreatic cancer chemotherapy patients 加藤寛子1, 藤井宏典1, 大畑紘一1, 左高史織2, 上村真也2, 岩下拓司2, 清水雅仁2, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1025, 2020. |
|---|
|
|
P29-57. Effect on renal function accompanied with the hydration change in the cancer of the esophagus FP therapy 西馬怜1, 山本幸子2, 中野寛之1, 高木麻里1, 吉田智江1, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1025, 2020. |
|---|
|
|
P29-58. One patient who experienced vocal disorder after the Lenvatinib administration for a hepatocellular carcinoma 西岡菜々子1, 輿石徹1, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2020. |
|---|
|
|
P29-59. It is examined the usefulness of the peg filgrastim primary prophylaxis administration in the AP therapy after the endometrial cancer technique 古川卓也1, 久保田豊1, 深沢健一1, 勝山善彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2020. |
|---|
|
|
P29-60. Examination of the risk factor of Infusion reaction in the trastuzumab initial administration 有原大貴1, 間瀬広樹2, 宗本将義3, 秋山哲平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2020. |
|---|
|
|
P29-61. Immune-mediated adverse event investigation with the immune checkpoint inhibitor at the medical corporation Meiwa hospital 照瀬美紗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2020. |
|---|
|
|
P29-62. Examination of the gemcitabine initial dosage in the adjuvant chemotherapy before total cystectomy 小栗良介1, 大野裕之1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1028, 2020. |
|---|
|
|
P29-63. 1 case that developed salts loss nephropathy by the Carboplatin 生出亘1, 井上靖隆1, 辻本高志1, 奥田衣理1, 宍戸桃子1, 加納宏樹1, 上田晃1, 川本由加里1, 後藤仁和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1028, 2020. |
|---|
|
|
P29-64. Examination about the expression situation of the diarrhea by the bortezomib and the measures 武井秀樹1, 古谷智裕1, 金田公平1, 野村実由1, 白木政博1, 北本真一1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1029, 2020. |
|---|
|
|
P29-65. Search of the risk factor of the liver damage by the regorafenib 田口尋子1, 新谷拓也1, 原伸輔1, 山本智也1, 門脇裕子1, 坂井大介2, 佐藤太郎2, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1029, 2020. |
|---|
|
|
P29-66. The use situation and side effect expression investigation of the Abemaciclib in the Okayama Red Cross hospital 新城唯1, 笠原なつみ1, 奈良葵1, 甲元大樹1, 森川希実2, 原享子2, 吉富誠二2, 辻尚志2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1030-1030, 2020. |
|---|
|
|
P29-67. Examination of the risk factor of the onset of proteinuria with the ramucirumab administration for the progress recurrent gastric cancer 渡部秀一1, 平出誠1, 青山剛1, 川上和宣1, 若槻尊2, 山口研成2, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1030-1030, 2020. |
|---|
|
|
P29-68. Investigation about the nutritional status before a neutropenia with the FP therapy in patients with cancer of the esophagus, the FN onset and the chemotherapy start 村松直幸1,2, 熊澤里美1,2, 古関竹直2, 山田成樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2020. |
|---|
|
|
P29-69. Examination about the effectiveness of the second prophylaxis of the peg filgrastim in patients with non-Hodgkin's lymphoma given R-CHOP and R-THP-COP 小中健1, 斉藤辰彦1,2, 宮森弘子1,2, 森剛志1, 森本美由樹2, 橋本年弘3, 伏谷秀治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2020. |
|---|
|
|
P29-70. Example that the telephone follow of the insurance pharmacist was effective for early detection of decreased visual acuity through S-1 田中越1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1032, 2020. |
|---|
|
|
P29-71. The expression situation and severity evaluation of the adverse event by the ramucirumab in the hepatocellular carcinoma 熊澤里美1,3, 村松直幸1,3, 加藤滉基1,3, 安田顕2, 棚橋義直2, 古関竹直3, 山田茂樹1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1032, 2020. |
|---|
|
|
P29-72. Nutritional status in the EPOCH (-R) therapy and association of the side effect expression 菊池健1,2, 小谷瑠星2, 武田元樹1, 渡邉大毅1, 鶴山辰1, 佐藤秀紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1033, 2020. |
|---|
|
|
P29-73. Efforts of the infection prophylaxis internal use in the hospitalization chemotherapy for blood-forming organ tumor 北野勝義1, 岸本大裕1, 田中嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1033, 2020. |
|---|
|
|
P29-74. Search of the infusion reaction expression situation at the pertuzumab combination cancer chemotherapy administration and the factor 田渕祐輔1, 峯垣哲也3, 清水大生1, 柴田かおり1, 中嶋佑樹1, 小阪直史1, 菅谷和子2, 石川剛2, 辻本雅之3, 西口工司3, 田口哲也2, 四方敬介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1034, 2020. |
|---|
|
|
P29-75. Risk factor analysis about the digestive organ toxicity expression of duloxetine in nab-PTX-induced peripheral neuropathy of patients with unresectable pancreatic cancer 森下滉己1, 鈴木秀隆1, 川崎敏克1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1034, 2020. |
|---|
|
|
P29-76. Preventive measures against hepatitis B reactivation - HBs with the chemotherapy or efforts ... of the pharmacist for the HBV-DNA fixed-quantity examination of the HBc antibody positive case 光家勉1, 中村緑1, 上田豊実1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2020. |
|---|
|
|
P29-77. The current situation investigation of the immune-mediated adverse event with the immune checkpoint inhibitor (the second report) 樋口浩輔1, 斉藤佑輔1, 福田愛弓1, 木村謙吾1, 加藤浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2020. |
|---|
|
|
P29-78. The use situation and safety of the Palbociclib for patients with old breast cancer in our hospital 鈴木拓也1, 遠藤未央1, 畠山智明1, 中田昌樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2020. |
|---|
|
|
P29-79. 1 case of the use of immune checkpoint inhibitor which dissipated by carbocisteine internal use cancellation immediately-related erythema multiforme type drug eruption 成田綾香1, 中積広貴2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2020. |
|---|
|
|
P29-80. Fact-finding of the onset of myelosuppression situation in the castration-resistant prostate cancer docetaxel therapy 赤羽根純1, 魚住真哉1, 門田佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1037, 2020. |
|---|
|
|
P29-81. Inspection of the risk factor for the side effect expression situation and the chronic administration with the ramucirumab administration 渡部智文1,2, 五十嵐信智2, 吉川慧1, 山中光1, 今理沙子2, 酒井寛泰2, 亀井淳三2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1037, 2020. |
|---|
|
|
P29-82. Severity investigation of the dermatopathy in the use of panitumumab patients and search of the risk factor 石田貴啓1, 寺尾勇紀1, 内田将吾1, 高橋弘泰1, 大谷寧次郎1, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2020. |
|---|
|
|
P29-83. A nephropathic evaluation by the cisplatin in patients with lung cancer and search of the risk factor 坪井久美1, 塩入理子1, 井上嘉余子1, 平井さやか1, 松本嵩史1, 亀田谷和将1, 羽鳥椋吾1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2020. |
|---|
|
|
P29-84. Cockcroft-Gault-style estimated Ccr revision in the Carboplatin doses setting for gynecologic TC therapy patients and investigation about the side effect 橋本優里1, 北本真一1, 廣中佑香1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1039, 2020. |
|---|
|
|
P29-85. Dabrafenib, fever by the Trametinib, the CK rise may be caused at high frequency than an existing report 坂口智己1, 山下恭範1, 小野尚志1, 小林直貴1, 谷香苗1, 小竹斗志之1, 松浦泰寛1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1039, 2020. |
|---|
|
|
P29-86. One case that became controllable by oneself by changing an agent type of the antidiarrheal drug for the diarrhea symptom of the Abemaciclib to a tablet 矢部和昭1, 藤田あゆみ2, 杉浦伸哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1040-1040, 2020. |
|---|
|
|
P29-87. Consideration - about the control of Blinatumomab administration example - side effect symptom in our hospital 石嶋麗1, 有原大貴1, 杉村勇人1, 間瀬広樹2, 三村優仁3, 秋山哲平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1040-1040, 2020. |
|---|
|
|
P29-88. Usefulness of the peg filgrastim in the non-Hodgkin's lymphoma chemotherapy 嘉村基樹1, 福島ゆかり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2020. |
|---|
|
|
P29-89. The use situation of the mirogabalin for peripheral neuropathy with the anticancer agent 河原陽介1, 水野奈穂子1, 加藤良治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2020. |
|---|
|
|
P29-90. Example that desensitization introduction made possible readministration for eruption, fever with lenalidomide 多田純平1, 中薗健一1, 松崎貴志1, 田中恒明1, 井上靖之2, 佐野文明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1042, 2020. |
|---|
|
|
P29-91. The use situation investigation of the Palbociclib in the Shizuoka Prefectural general hospital and examination of the factor about neutropenia 佐久間大樹1, 中垣繁2, 嘉屋道裕2, 木村緑2, 常泉道子3, 小林義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1042, 2020. |
|---|
|
|
P29-92. Intervention at the health insurance pharmacy for foreign cancer-treated patients, analysis and evaluation examination of tracing report contents 下村直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1043-1043, 2020. |
|---|
|
|
P29-93. Comparison of the side effect expression situation for the non-small cell lung cancer of the Osimertinib after primary treatment and the second treatment 小橋来海1, 梅原健吾2, 若本あずさ2, 初山多恵2, 佐藤秀紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1043-1043, 2020. |
|---|
|
|
P29-94. Examination of the risk factor of the febrile neutropenia in CHOP therapy, the THP-COP therapy 敦賀剛気1, 輪湖哲也1, 田中弘人1, 井ノ口岳洋1, 久保村優1, 久保田馨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1044, 2020. |
|---|
|
|
P29-95. About usefulness of the supportive care for the hand-and-foot syndrome by the capecitabine 八木聡美1, 片岡智美1, 加藤善章1, 藤野泰孝1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1044, 2020. |
|---|
|
|
P29-96. Approach of the medical department dentistry cooperation in our hospital 宮川貴行1, 梶井孝洋1, 水口敦子1, 形部文寛1, 大倉裕祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1045, 2020. |
|---|
|
|
P29-97. Risk factor search of the serious neutropenia due to CPT-11 鈴木直哉1, 菊地義明1, 藤林遼1, 山田将悟1, 朝倉幹己1, 藤田果那1, 山本翔太1, 庄崎沙耶1, 田中耕太1, 前川英輝1, 高橋誠1, 青田忠博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1045, 2020. |
|---|
|
|
P29-98. Efforts to improvement in bone density measurement in patients during aromatase inhibitor remedy 渡辺富美子1, 下村直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1046-1046, 2020. |
|---|
|
|
P29-99. Examination of the cisplatin inducible nephropathic protective efficacy with the administration before Mg 8mEq 岩村高弘1, 大野晃和1, 尾高登美枝1, 神原史織1, 水馬佑輔1, 森光保武1, 藤井秀一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1046-1046, 2020. |
|---|
|
|
P30-1. One case of the ureter cancer metastases to lung that fentanyl patch was effective for a feeling of dyspnea 中村俊貴1, 田辺就子1, 小林由布子1, 斎藤太寿1, 柴田壮一1, 松原肇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1047-1047, 2020. |
|---|
|
|
P30-2. Examination of the usefulness of various pre-back prediction tools in patients with end-stage cancer 下清水義博1, 小山菜々子1, 松村千佳子1, 佐古守人2, 黒沢秀夫2, 野村剛久2, 江口由紀3, 矢野義孝1, 大場一輝4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1048-1048, 2020. |
|---|
|
|
P30-3. The point of evaluation, item template operation after the drug application and the effect on cancerous pain 伊東美歩1, 海老原貴之1, 岡本和也1, 川本拓馬1, 高柳雅恵1, 竹内英樹1, 小沼由香2, 田中紀子2, 平原一也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1048-1048, 2020. |
|---|
|
|
P30-4. Examination of the timing of the route of administration change of the use of opioid patients and the reason 今中智子1, 鈴木佳寿子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1049, 2020. |
|---|
|
|
P30-5. To support the life like polypharmacy measures ... person in our hospital palliative care unit; ... 宮武望1, 長谷川喜一1,2, 岡田芙美子1,3, 岩谷理佳子1,3, 佃博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1049, 2020. |
|---|
|
|
P30-6. Fact-finding of the situation and the adverse event of the supportive care at oxycodone extended-release introduction to opioid naive patients 萩原諒一1, 小林礼子2, 中山弘道3, 花香淳一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1050-1050, 2020. |
|---|
|
|
P30-7. A relative evaluation of the painful symptom and blood test value in patients with end-stage cancer and examination about the usefulness as the pre-rear predictor 小山菜々子1, 松村千佳子1, 佐古守人2, 黒沢秀夫2, 野村剛久2, 江口由紀3, 矢野義孝1, 大場一輝4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1050-1050, 2020. |
|---|
|
|
P30-8. Examination about the usefulness of the mirogabalin for chemotherapy-induced peripheral neuropathy 淺野肇1, 山脇誉央1, 藤本伸一郎1, 平本志於里1,2, 川口明範1, 藤原季美子1, 月岡康行1, 竹上学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2020. |
|---|
|
|
P30-9. One patient who was treated effectively with the epidural pain relief that we combined with opioid for the pain of lower extremities due to metastases to bone 今関尊司1, 工藤三果1, 古川博則1, 長嶋真美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2020. |
|---|
|
|
P30-10. Investigation of the usefulness of the octreotide 600μg/day administration for the gastrointestinal obstruction in patients with end-stage cancer 矢部雅子1,2, 久間田佳彦1,2, 野澤大輔1,2, 長島智子1, 藤井宏一2,3, 邉見光利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2020. |
|---|
|
|
P30-11. Introduction and effect of the opioid switching assistance system 松木有莉1, 宮村有貴1, 浅見祥崇1, 荒川桃子1, 坂本和央1, 寺原史貴2, 須藤美穂子1, 桂川みき1, 鈴木千波1, 小原秀治1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2020. |
|---|
|
|
P30-12. Analysis of the delirium expression by the oral opioid of patients with cancer using the adverse drug reaction database 石橋廉司1, 杉本智哉1, 高岡龍蔵1, 山室栄一1, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2020. |
|---|
|
|
P30-13. A retrospective study on drug reduction in a palliative care ward - 2nd report - 井口舞香1, 仁木一順1,2, 岡本禎晃2, 田中育子2, 橋本百世2, 大前隆仁3, 松田良信3, 上田幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2020. |
|---|
|
|
P30-14. The pharmaceutical intervention of the pharmacist for the palliative care team intervention patients and evaluation (the second report) of the medical economics 安永大輝1, 飛鷹範明1, 田中守1, 田中亮裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2020. |
|---|
|
|
P30-15. Of the initial dosage of a fentanyl sublingual tablet, buccal tablet and methadone appropriateness-related: National fact-finding using DPC data 染野里奈1, 田辺公一1, 佐藤一樹2, 宮下光令3, 石川ベンジャミン光一4, 森田達也5, 伏見清秀6, 内富庸介7, 酒井隆全1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2020. |
|---|
|
|
P30-16. Investigation about the prescription participation of the pharmacist in the palliative care team 山関智恵1,2, 岩本貴子2, 青木佐知子2, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1055, 2020. |
|---|
|
|
P30-17. Effect on predictive precision by the cancer species of the pre-back prediction using Palliative Prognostic Index for the palliative care team intervention patients 岩津慎次郎1,2, 深津昌弘1,2, 高島直樹1, 寺本真弓1, 熊澤尚美2, 水元弥生2, 山田哲也1, 澤田憲朗3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1055, 2020. |
|---|
|
|
P30-18. 2 cases that suffered from switching of the hydromorphone preparation 宮原兼二1,2, 竹内美緒1,2, 荒川正悟1, 丹村亜梨朱1, 古山しのぶ2,3, 森山裕紀子2,4, 坂口憲史2,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2020. |
|---|
|
|
P30-19. Examination about the prescription suggestion of the pharmacist in the mild medical care of the regular hospital 清川明慶1, 矢田康司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2020. |
|---|
|
|
P30-20. The use fact-finding of the hydromorphone note in the palliation of our hospital and evaluation of the usefulness for the dyspnea symptom 沖田彩1, 土屋裕伴1, 諸橋賢人1, 大登剛1, 新井亘1, 増田裕一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1057, 2020. |
|---|
|
|
P30-21. Pain relief effect for peripheral neuropathy of the cancer chemotherapy with the 1.5% ketamine aqueous cream 久保靖憲1, 山本譲1, 山本香緒里1, 大滝康一1,2, 山下恭範1, 小野尚志1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1057, 2020. |
|---|
|
|
P30-22. Consideration about the use situation investigation of the naldemedine and the prophylactic use 元木孝1, 渡邊清人1, 高柳昌宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1058, 2020. |
|---|
|
|
P30-23. Examination of the usefulness of the side effect of pharmacist monitoring for the methadone initial introduction patients 土田隼之祐1, 川名真理子1, 舟越亮寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1058, 2020. |
|---|
|
|
P30-24. Use situation of the hydromorphone hydrochloride note and side effect investigation 御澤勝将1, 渡部多真紀1,2, 榎本弘美1, 安野伸浩1,2, 有賀悦子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1059, 2020. |
|---|
|
|
P30-25. Examination of the protective efficacy of the antiemetic drug for retching, vomiting by the oxycodone hydrochloride hydrate extended-release 奈良悠汰1, 福原東美1, 渕上俊介1, 車塚千穂1, 今井隆人1, 小林龍1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1059, 2020. |
|---|
|
|
P30-26. Use of fen toss tape fact-finding 岡田悠加1, 小林真弓1, 仲野笑美1, 大前隆広1, 佐倉小百合1, 上田里恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1060, 2020. |
|---|
|
|
P30-27. Factor analysis for the tramadol analgesic effect insufficiency in patients with cancer 島本一志1,2, 戸村和希1,2, 藤宮龍祥1,2, 松井美月1,2, 渡邊徹1,2, 中山博文3, 市川度3, 佐々木忠徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1060, 2020. |
|---|
|
|
P30-28. Effect on use situation of the hydromorphone preparation and dyspnea symptom 奥野亜弓1, 山東真寿美1, 口分田章典1, 岩崎瑛子1, 桂明里1, 戸島心1, 竹田健志1, 井上聡子1, 坂上嘉浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1061-1061, 2020. |
|---|
|
|
P30-29. Survey of usage of hydromorphone hydrochloride extended-release tablets and immediate-release tablets 臼井哲宏1, 土井田愛1, 田中佳子1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1061-1061, 2020. |
|---|
|
|
P30-30. Literature documentation about the use report of the hospital preparation Mohs paste for the purpose of the control of the skin disintegration wound due to the malignant tumor 田口真穂1, 佐藤淳也2, 紅谷梨央1, 清原祥夫3, 山田博章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2020. |
|---|
|
|
P30-31. The effectiveness, safe examination of the naldemedine 野田拓誠1, 村津圭治1, 田中亮1, 山下大輔1, 別府博仁1, 本田芳久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2020. |
|---|
|
|
P30-32. Example that joint instruction made possible the smooth at-home shift of patients with end-stage cancer at a discharge of the multi-type of job cooperation 相宮幸典1, 吉岡聖子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2020. |
|---|
|
|
P30-33. Efforts of the instruction contents standardization in the telephone follow-up of the cancerous pain control 川崎祐介1, 渡辺富美子1, 新谷菜々子1, 関根聖子1, 鈴尾美紗1, 遠藤珠実1, 小溝雪江1, 金子実樹1, 高野幸泉1, 栗原千晶1, 下村直樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2020. |
|---|
|
|
P30-34. About the medication situation in our center palliative care unit 木村佳世1, 木村朋未1, 西山恵理2, 松村早希子1, 多喜和夫1, 筒井一成3, 阪口勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2020. |
|---|
|
|
P30-35. Study on change to the Nrf2 expression in the peripheral-blood mononuclear cells which aromatherapy gives it to for a short term 高木千明1, 堀真紀子1, 岡元ちよみ1, 畔蒜祐一郎1, 平田尚人1, 下枝貞彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2020. |
|---|
|
|
P30-36. Use investigation of fentanyl patch 0.5 mg 高橋智恵子1,2, 後藤愛実1,2, 南愛衣1, 浅石健2, 長えき美奈子2, 今井麻里子2, 西原雅美1, 内山和久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1065, 2020. |
|---|
|
|
P31-1. - close about the nourishment support to the foreign chemotherapy patients in the drugstore as a result of nourishment evaluation by - MUST 熊谷岳文1,2, 山根孝太3, 小畑志保3, 森大輔3, 柴田愛美3, 吉田知香3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1066, 2020. |
|---|
|
|
P31-2. Evaluation of frequencies and the disease severity of peripheral neuropathy in FOLFIRINOX therapy and the GEM+nab-PTX therapy 長田大河1, 松井頌明1, 牧野華子1, 石原慎之1, 玉木宏樹1, 矢野貴久1, 直良浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1067, 2020. |
|---|
|
|
P31-3. Two cases of nephrocyte cancer which developed a serious liver damage after the change to a tyrosine kinase inhibitor from an immune checkpoint inhibitor 北出紘規1, 宮永和美1, 高波太1, 西野正義1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1067, 2020. |
|---|
|
|
P31-4. Use experience of the human mesenchyma system stem cell (hMSC: TEMCELL (R) HS note) for acute GVHD after the childhood hematopoietic stem cell transplantation 小森桂子1, 寺岡知香2, 飯野香菜子1, 浅原章裕1, 辻有梨3, 岩本悠花1, 倉本侑香1, 運天奈緒美1, 澤井勇希1, 大垣智子1, 伊地知政美1, 岸田美和1, 大津由美子1, 望月千枝1, 安井昌博4, 井上雅美4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2020. |
|---|
|
|
P31-5. The current situation of the foreign cancer chemotherapy to see in the meeting a demand situation of the oral anticancer agent in the health insurance pharmacy 田中美幸1, 杉山純子2, 齋藤翔太3, 佐藤展宏4, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2020. |
|---|
|
|
P31-6. Grasp and efforts of the patients needs about patients with cancer for the drugstore function enhancement that considered specialized medical institution cooperation drugstore authorization 澤井一1, 赤嶺美奈1,2, 赤嶺有希子2, 加納美知子1,2, 佐久間美里1,2, 高木正信1,2, 田中祥子1,2, 松尾律子1,2, 山本美智子1,2, 吉原澄吉3, 谷田弘3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2020. |
|---|
|
|
P31-7. Fact-finding (2) of the pharmaceutical intervention in the foreign cancer chemotherapy of the pharmacist 藤井友和1, 澤柳直樹1, 西川隆一1, 荒木寛也1, 坂柳悦章1, 辻博幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2020. |
|---|
|
|
P31-8. Fact-finding of the administration schedule of the regorafenib in our hospital 吉池麻衣1, 杉山昌秀1, 篠原佳祐1, 関口展貴1, 宮田智陽1, 原あや乃1, 渡邉将隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1070, 2020. |
|---|
|
|
P31-9. Recognition of the pharmacist specialized in a cancer judging from ethical pharmacy user questionnaire 斎藤大祐1, 石橋正祥2,3, 関悠斗3, 石井正和3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1070, 2020. |
|---|
|
|
P31-10. The effect that adaptation addition gives for foreign cancer chemotherapy preparation duties on non-small cell lung cancer of the immune checkpoint inhibitor: Joint investigation with this country 4 institution 森元能仁1, 稲野寛2, 石丸博雅3, 河合祐輔4, 長澤知徳5, 尾崎正隆5, 臼井浩明5, 田村勝彦5, 吉田正5, 吉成清志5, 篠原高雄5, 渡部一宏5, 廣原正宜5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2020. |
|---|
|
|
P31-11. We conduct an investigation into administration and the five days administration by azacitidine therapy for myelodysplastic syndrome in our hospital for seven days 蓮尾憲作1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2020. |
|---|
|
|
P31-12. Effect of HBV screening PBPM on cancer chemotherapy application patients 鈴木寛人1, 築田晃直1, 平田亮介1, 上原智博1, 仲本敦2, 河崎英範3, 渡嘉敷崇4, 山形真一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1072, 2020. |
|---|
|
|
P31-13. Problems and countermeasures during administration of blinatumomab in the pediatric ward of our hospital 楠川侑吾1, 田村優衣1, 三松史野1, 本多伸二1, 村田龍宣1, 村岡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1072, 2020. |
|---|
|
|
P31-14. The CDDP administration situation investigation in craniocervical part cancer CCRT and examination about the dose 松尾圭祐1, 鳥山陽子1, 森田真樹子1, 馬場華菜1, 永石浩貴1, 谷口潤1, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1073, 2020. |
|---|
|
|
P31-16. Safe examination in the rapid administration of rituximab 若月淳一郎1, 佐久間大樹1, 松本香織1, 花輪和己3, 飯野昌樹2, 小林みつ恵1, 小林義文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2020. |
|---|
|
|
P31-17. Dosing period and cancellation reason in Pembrolizumab treated patients 75 years or older 石原泰子1, 小林宏太朗1, 亀井健人1, 仁科慎一2, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2020. |
|---|
|
|
P31-18. The case that presented endocrinopathy, various immune-mediated adverse events including the enterocolitis by Nivolumab administration 松浦暢子1, 小西千尋1, 南野智志2, 草薙みか2, 山本倫数2, 大里恭章2, 洪鉉寿3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2020. |
|---|
|
|
P31-19. Prescription trend of the oral anticancer agent for patients with female cancer 齋藤翔太1, 田中美幸2, 杉山純子3, 佐藤展宏4, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2020. |
|---|
|
|
P31-20. Analysis (as part of reduction of the drug-related near miss) of anticancer agent-related doubt inquiry contents in our hospital 石崎文子1, 相原敏彦1, 増尾昌則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2020. |
|---|
|
|
P31-21. The effect of the eribulin administration on patients with progress, recurrent breast cancer and investigation of the neutrophils, lymphocytes ratio 西和哉1, 川田彰彦1, 高橋舞1, 佐々木崇1, 佐賀利英1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2020. |
|---|
|
|
P31-22. Examination of starting dose of ixazomib for relapsed or refractory multiple myeloma 畑中由香子1, 大里勇二1, 瀧真由子1, 島田健1, 平松靖史2, 中村進一郎1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2020. |
|---|
|
|
P31-23. The intervention of the pharmacist is the case of the recurrence after the colon cancer technique which was able to contribute to complete response and long-term continuation of Regorafenib 小西千尋1, 松浦暢子1, 南野智志2, 草薙みか2, 山本倫数2, 大里恭章2, 村上修3, 洪鉉寿4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2020. |
|---|
|
|
P31-24. It is an investigation about the successful execution situation of the XELOX therapy as the adjuvant chemotherapy after the colon cancer technique in elderly people 脇由香里1, 江原亜沙子1, 松田浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2020. |
|---|
|
|
P31-25. Role of the genome charge pharmacist in the Kyushu cancer center cancer genomic medicine system 衛藤智章1,2, 高崎紘臣2, 田中麻紀子1,2, 松元俊博2, 薦田正人3, 織田信弥1, 江崎泰斗1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2020. |
|---|
|
|
P31-26. Association of a blood pressure change and the effect of treatment before and after the administration in the ramucirumab paclitaxel combination therapy 森田真樹子1, 鳥山陽子1, 松尾圭祐1, 江崎瞳1, 谷口潤1, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2020. |
|---|
|
|
P31-27. Accumulation of the immune-mediated adverse event that led to cancellation after the use of immune checkpoint inhibitor single agent in the Ariake district 小薮真紀子1, 緒方進2, 陣内優3, 前田健一4, 川瀬大輝5, 出水みいる6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2020. |
|---|
|
|
P31-28. Search of the risk factor to affect the side effect expression of Osimertinib 前野有紀1, 大井隆広1, 柿花美沙紀1, 貝野裕也1, 坂野玲子1, 中藏伊知郎1, 北澤文章1, 中村孝人2, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2020. |
|---|
|
|
P31-29. Comparison of the acceptability of pancreatic cancer recurrent after the operation in the Gemcitabine+nab-Paclitaxel therapy and the unresectable progress pancreatic cancer 有馬絵美1, 梅村拓巳1, 深津昌弘1, 水野貴仁1, 伊藤聡一郎1, 小崎耕自1, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2020. |
|---|
|
|
P31-30. The effect that initial dose setting in consideration of renal function of S1 and the capecitabine gives to effect of treatment and adverse event expression 三宅真史1, 久保木千晴1, 松島彩音1, 佐々木健介1, 亀尾剛士1, 山下真史1, 藤井哲英1, 二宮洋子2, 小林美代子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1081-1081, 2020. |
|---|
|
|
P31-31. Treatment fact-finding of the CapeOX therapy that we provided as adjuvant chemotherapy after the colon cancer technique in our hospital 土屋亜祐美1, 吉田幹宜1, 長尾嘉真1, 佐藤吉一1, 島貫裕実子1, 田中万穂1, 小川千晶1, 増田純一1, 近藤直樹1, 寺門浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1081-1081, 2020. |
|---|
|
|
P31-32. Example that caused a myocardium harm-related event of immunity by the nivolumab ipilimumab combination therapy that we used for patients with progressive renal cell carcinoma 田井達也1, 渡邊政博2, 山下紗矢佳1, 水岡大策1, 元木貴大1, 山口佳津騎1, 鈴木聖1, 田中裕章1, 芳地一3, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1082, 2020. |
|---|
|
|
P31-33. Examination about the validity of FOLFIRINOX therapy and the GEM+nabPTX therapy in the primary treatment for unresectable pancreatic cancer 荒川裕貴1, 桂川健司1, 後藤美穂1, 大田亜希子2, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1082, 2020. |
|---|
|
|
P31-34. Consideration about the application patients in the initial transplantation of autologous hematopoietic stem cells of the multiple myeloma 島田惇司1, 五十嵐貴之1, 岡田和博1, 島崎博士1, 鈴木一史2, 西脇嘉一2, 長谷川英雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2020. |
|---|
|
|
P31-35. Efforts of the pharmacist for the examination for HBV compliance with the cancer chemotherapy 福田愛弓1, 稲塚菜摘1, 斉藤佑輔1, 樋口浩輔1, 木村謙吾1, 加藤浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2020. |
|---|
|
|
P31-36. Investigation about the drug-related interstitial lung disease onset in patients receiving immune checkpoint inhibitor 岩下昂平1, 山田成樹1, 熊澤里美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2020. |
|---|
|
|
P31-37. Comparison of the side effect of Pembrolizumab single agent in the non-small cell lung cancer and cytotoxic anticancer agent combination 大野裕之1, 田中佳子1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2020. |
|---|
|
|
P31-38. The decreased renal function deteriorates the blood toxicity of the Carboplatin 高木賢太郎1, 南一典1, 上田要一1, 真下聡文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1085-1085, 2020. |
|---|
|
|
P31-39. 2 cases that low-dose gemcitabine succeeded for a long term 桂川健司1, 荒川裕貴1, 後藤美穂1, 遠山幸男1, 久田達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1085-1085, 2020. |
|---|
|
|
P31-40. Reports of the side effect occurrence situation such as the use situation investigation of the Lenvatinib for the unresectable hepatocellular carcinoma and TSH rise, and the like 川崎彰彦1, 林洋平1, 福澤正隆1, 川嵜英二1, 鹿間良弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1086-1086, 2020. |
|---|
|
|
P31-41. Progressive form type I diabetes mellitus slow during Durvalumab administration and 1 case that was diagnosed 堀友紀1, 的場美香1, 口分田章典1, 高橋愛未1, 井上聡子1, 山東真寿美1, 坂上嘉浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1086-1086, 2020. |
|---|
|
|
P31-42. 4 cases that was treated with cancer chemotherapy to patients on dialysis 新居亜里紗1, 和田祐一郎1, 坂井裕美1, 穂積廣1, 加藤香奈1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2020. |
|---|
|
|
P31-43. Search of the factor to give it to a relative dose intensity of the breast cancer adjuvant chemotherapy in the North Kyoto area 山本皓介1, 峯垣哲也2, 越野勝博3, 坂下透子1, 堀口裕美1, 田渕祐輔4, 新宮秀昭1, 小阪直史4, 西口工司2, 四方敬介4, 土淵尚也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2020. |
|---|
|
|
P31-44. Search of the treatment target which paid its attention to the carbohydrate metabolism Reprography and Consultant gram in the cells of chronic myelogenous leukemia cells at exposure to Bcr-Abl tyrosine kinase inhibitor 平尾卓也1, 齊藤諒1, 青木重樹2, 加藤芳徳1, 手塚千裕1, 山田治美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2020. |
|---|
|
|
P31-45. Examination of the effect to give to pazopanib and the treatment of the sarcoma under the gastric-acid secretion antagonist combination 菅野仁美1, 伊勢崎竜也1, 安室修1, 舟越亮寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2020. |
|---|
|
|
P31-46. The current situation investigation at chemotherapy new introduction in elderly people 三沢あずさ1, 水谷妙子1, 粟野原幸恵1, 網野一真1, 浜至寛1, 登内盛治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1089, 2020. |
|---|
|
|
P31-47. Efforts of "the NCGM pharmacy cancer drill" for the improvement in knowledge about the anticancer medicine 永田麻子1, 吉田幹宜1, 熊木絵美1, 土屋亜祐美1, 長尾嘉真1, 島貫裕実子1, 佐藤吉一1, 田中万穂1, 小川千晶1, 増田純一1, 近藤直樹1, 寺門浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1089, 2020. |
|---|
|
|
P31-48. Examination ... about the association of analysis ... anticancer agent and PIMs prescription of the cancer medical therapy for elderly people 松本憲昭1, 榊原幹夫1, 白石成明2, 鈴木裕介3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1090, 2020. |
|---|
|
|
P31-49. Comparison of the physiological response of the person of anticancer agent preparation using two kinds of gowns 五月女拓也1, 外山智章1, 日向野理輝1, 押坂勇志3, 石濱洋美2, 臼井悟1, 本田雅巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1090, 2020. |
|---|
|
|
P31-50. Search (interim report) of the risk factor about the neutropenia in the ramucirumab + albumin suspension type paclitaxel 永田彩加1,2, 足立茂樹2, 大池恵生2, 小田浩史2, 川原田祐貴2, 小玉幸与1,2, 佐久間晶基2, 杉野晃希2, 中井剛2, 永松秀紹2, 間瀬広樹2, 宮崎雅之2, 中根茂喜2, 今西忠宏1, 久田達也2, 板倉由縁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1091, 2020. |
|---|
|
|
P31-51. Examination of the effect on hepatocellular carcinoma factor about the treatment continuation of the Lenvatinib therapy 柴野雅仁1, 高橋克之1, 高橋正也1, 永山勝也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1091, 2020. |
|---|
|
|
P31-52. 1 consideration about the role of the specialized medical institution cooperation pharmacist in the cancer medical therapy 泊口豊1,2, 徳山尚吾2, 浅野涼子1, 前田竜太郎1, 小松正典1, 福森淳1, 寺脇康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1092, 2020. |
|---|
|
|
P31-53. Questionary survey to the health insurance pharmacy in the cancer chemotherapy regimen seal pasting to prescription notebook 宮崎晃臣1, 米村匡平1, 新岡琢也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1092, 2020. |
|---|
|
|
P31-54. Construction and practice of preventive measures against HBV reactivation by the pharmacist 天川佳洋1, 足立匠1, 徳留雄太1, 武井優輝1, 土屋雅勇1, 榎本弘美1, 渡部多真紀1,2, 河村剛至1,2, 安野伸浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1093, 2020. |
|---|
|
|
P31-55. Exploration study in the association of castration acquisition of fastness of the prostate cancer and the clinical factor 林友典1, 宮本朋佳2, 平田敦士1, 長井紀章3, 川畑篤史3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1093, 2020. |
|---|
|
|
P31-56. We look at the rear about the onset of hand-and-foot syndrome of the use of sorafenib patients in the pediatric domain and examine a mark 時澤秀明1, 宇野倫弘1, 清水祐一1, 甲斐維子1, 加戸奈穂美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2020. |
|---|
|
|
P31-57. Analysis about the risk factor of the neutropenia by the Osimertinib 黒部健太郎1,2, 塩川裕美1, 岩永健太郎2, 松永尚1, 草葉一友1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2020. |
|---|
|
|
P31-58. About infusion reaction in the first time of cetuximab and the reintroduction 大里勇二1, 島田健1, 石井雅人1, 畑中由香子1, 上野聖子1, 中村進一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2020. |
|---|
|
|
P31-59. Effect of the checkpoint inhibitor history of treatment to give to the effectiveness of the DTX+RAM combination therapy in patients with non-small cell lung cancer and safety of immunity 松尾モモ1, 片岡智美1, 熊倉康郎1, 加藤善章1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2020. |
|---|
|
|
P31-60. Relative investigation with a hand-and-foot syndrome and the capecitabine consumption in the health insurance pharmacy 當真房子1, 三上まどか1, 阿嘉さゆり1, 鬼木華歩1, 砂川信子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1096-1096, 2020. |
|---|
|
|
P31-61. A neutropenic risk factor search with the oil xanthan gum + gemcitabine (GnP) therapy in patients with unresectable progress pancreatic cancer and effect on antitumor effect 道家雄太郎1, 野田哲史1, 平大樹3, 前平博充2, 谷眞至2, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1096-1096, 2020. |
|---|
|
|
P31-62. Job analysis by having started pharmacist dental auxiliary duties for patients with chronic myelogenous leukemia of the blood internal medicine outpatient department 高橋典哉1,2, 及川淳1, 木村周古1, 及川嵩人1, 山澤望1, 村井一範2, 菊池英1, 菊地英行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2020. |
|---|
|
|
P31-63. Investigation according to the foreign hospitalization of incident/accident evasion example by the chemotherapy room charge pharmacist using the effect degree classification 三井満里奈1, 森田一1, 平田藍1, 松崎貴志1, 田中恒明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2020. |
|---|
|
|
P31-64. We look at the rear of the predictor about the extension for duration of treatment of the Palbociclib by the multicenter combination and search for a mark 小川喜通1, 小倉千奈2, 亀岡春菜2, 宮前文明1, 槙恒雄3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2020. |
|---|
|
|
P31-65. Pharmaceutical intervention for the Abemaciclib in the cancer pharmacist outpatient department 米谷頼人1, 石井隆義1, 松田亜希子1, 藤谷千紘1, 坂本佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2020. |
|---|
|
|
P31-66. Examination of dose intensity of the Lenvatinib in the hepatocellular carcinoma 魚井みゆき1, 杉本理恵2, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2020. |
|---|
|
|
P31-67. Example that we finished passing and exchanged oral from hypodermic injection sustained by the home care start of the uterine cancer terminal patient 砂川信子1, 當真房子1, 石田浩1, 三上まどか1, 阿嘉さゆり1, 鬼木華歩1, 坂本政文1, 喜屋武芳美1, 佐藤雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2020. |
|---|
|
|
P31-68. Examination of the Infusion reaction expression of trastuzumab risk factor 森本奈緒美1, 阪口勝彦1, 多喜和夫1, 野田明宏1, 和田祥明1, 眞下惠次1, 藤原大一朗1, 星田唯史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2020. |
|---|
|
|
P31-69. Investigation of the factor to give adjuvant chemotherapy introduction after the pancreatic cancer technique 菊地義明1,2, 鈴木直哉1, 朝倉幹己1, 藤田果那1, 庄崎沙耶1, 田中耕太1, 木下愛1, 山本翔太1, 山田将悟1, 前川英輝1, 藤林遼1, 高橋誠1, 青田忠博1, 上野峰2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2020. |
|---|
|
|
P31-70. 1 case that reintroduced Afatinib into Osimertinib after the change from Afatinib for reasons of other than the drug resistance, and continued a partial response 岸本真1,2, 屋敷大輔1,2, 田中恭人1,2, 森永崇史2, 池沢若菜2, 豊留麻衣2, 北園幸大2, 中野一馬2, 山本梢2, 淵脇ゆかり2, 徳丸章佳2, 長ヶ原琢磨2, 荻尾夕起子2, 三阪高春1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2020. |
|---|
|
|
P31-71. Fact-finding of the lung cancer medical therapy after the checkpoint inhibitor approval in the foreign cancer medical therapy of immunity 藤原大一朗1, 星田唯史1, 森本奈緒美1, 眞下惠次1, 和田祥明1, 野田明宏1, 多喜和夫1, 阪口勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2020. |
|---|
|
|
P31-72. It is current situation and problem ... of ... pharmaceutical intervention about a reason of the direct hospital admission of emergency in cancer chemotherapy patients 木元慎一郎1, 木村佳弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1102-1102, 2020. |
|---|
|
|
P32-1. Investigation about antimicrobial proper use guidelines 阪野和重1, 中西俊介1, 谷畑悠起子1, 武内恭範1, 奥本真巳1, 篝忠宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1103-1103, 2020. |
|---|
|
|
P32-2. For the patients with CDI initial infection about 2 cases received the Fidaxomicin 平野貴志1, 安部一秀1, 畑伸一1, 長澤雄大2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1104-1104, 2020. |
|---|
|
|
P32-3. Approach for the antimicrobial proper use in our hospital 安田陽子1, 福山博務1, 松元謙治2, 眞柄雄樹2, 小倉健一3, 高田淳子4, 杉田知妹5, 塩地園代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1104-1104, 2020. |
|---|
|
|
P32-4. A case where tedizolid (TZD) was effective in persistent MRSA bacteremia 瀬戸崇光1, 片岡優1, 小田怜1, 杉田裕貴1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1105-1105, 2020. |
|---|
|
|
P32-5. As a result of proper use of the perioperative infection prophylaxis antimicrobial in the surgery 小関崇文1,2, 大貫敏明1,2, 日向早苗1,3, 足立智子1,3, 大場雄一1,4, 鈴木由佳2, 加藤由紀2, 田紗永子2, 小舛修三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1105-1105, 2020. |
|---|
|
|
P32-6. The effect that cefazolin understock resulted in 佐多照正1,2, 八汐祥恵1, 堀之内志織1, 鶴永大貴1, 中村有莉恵1, 赤星真広1, 上原友美1, 池増鮎美1,2, 秋山久美2,3, 副島賢忠2,3, 宮原宏典3, 徳重浩一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1106, 2020. |
|---|
|
|
P32-7. Effect by the empiric treatment enforcement of vancomycin on patients with bacterial meningitis 中野貴文1,2, 水野寧子1, 江口幸臣1,2, 池内忠宏1, 兼重晋1, 緒方憲太郎1,2, 神村英利1,2, 林稔展1,2, 江川孝2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1106, 2020. |
|---|
|
|
P32-9. Efforts to oral antibiotic deescalation in patients with hospitalizing pyelonephritis 村上礼隆1, 菅原隆文2, 吉川明良2, 宮森伸一2, 開浩一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1107, 2020. |
|---|
|
|
P32-10. Cross-sectional study about the quantity of duties necessary for an antimicrobial use of medicine case and proper use support activity 川崎祥平1,3, 小林義和1,3, 松倉拓哉1,3, 伊藤靖2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1108-1108, 2020. |
|---|
|
|
P32-11. The effect that quick PCR introduction gives in the antimicrobial prescription trend of patients with staphylococcus aureus bacteremia 渡邊雅史1, 酒井幹康1, 三宅芳男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1108-1108, 2020. |
|---|
|
|
P32-13. Efforts to vancomycin initial trough blood level adequacy by the antimicrobial proper use support team (AST) exclusive duty pharmacist intervention 木賀田亮介1, 丸山晴生1, 金子泰也1, 小沼恵莉1, 勝山善彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1109, 2020. |
|---|
|
|
P32-14. An example of the necrotising fasciitis by Aeromonas hydrophila caused by the wound part infection related to West Japan heavy rain disaster 池本雅章1, 藤本孝則1, 宮田絵莉加1, 横田智美1, 岡村和彦1, 佐々木雄啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2020. |
|---|
|
|
P32-15. Association of a period and the treatment prognosis to deescalation in the substrate specific expansion type β - lactamase (ESBL)-producing Enterobacteriacae bacteria bacteremia case 中蔵伊知郎1, 田中裕貴子1, 森幸代1, 森あやか1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2020. |
|---|
|
|
P32-16. Effect of the patients with bacteremia all cases intervention by the antimicrobial proper use support team working full time pharmacist 須山由佳子1,2, 伊藤健太3, 神戸宏憲1, 佐々木理恵4, 鈴木清美2, 袴田康弘2,5, 平野桂子1, 木村緑1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1111, 2020. |
|---|
|
|
P32-17. It is the 1 case receiving the colistin for meningitis by the multidrug-resistant Acinetobacter 吉原涼子1, 橋本雅司2, 吉野裕統1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1111, 2020. |
|---|
|
|
P32-18. Pharmacist-led approach ... to realize antimicrobial proper use support team - speedy yellow staphylococcemia treatment 古川大樹1, 伊藤嘉英1, 大橋武司1, 林房江2, 菱田志乃3, 長谷川雅哉1, 中尾彰宏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1112, 2020. |
|---|
|
|
P32-19. Effect on use situation of the specific antimicrobial by the registration system introduction of TAZ/PIPC 松田理湖1, 久田瑛吉1, 加藤洋介1, 前田直希1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1112, 2020. |
|---|
|
|
P32-20. The effect that AS activity of MEPM using the length of therapy (LOT) /t > MIC gave in use of MEPM frequency of the low-dose level 小林義和1,2,3, 川崎祥平1,2,3, 松倉拓哉1,2,3, 伊藤靖1,2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2020. |
|---|
|
|
P32-21. It is compared administration and the 2nd administration after the operation of the Total Knee Arthroplasty on cefazolin 1st in the infection prophylaxis 田川誠二1, 小林俊介1, 安武夫2, 小倉敬史1, 柳澤克昭3, 松原正明3, 北岡晃1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2020. |
|---|
|
|
P32-22. Examination and evaluation of the intervention effect by AST 片山聡子1,2, 松木悠平3, 池崎友明1,2, 村上真樹1,2, 坂東翔1,2, 北澤英徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1114, 2020. |
|---|
|
|
P32-23. Efficacy and safety of tenofovir alafenamide for hepatitis B virus reactivation due to treatment for malignant lymphoma 谷口潤1, 松尾圭祐1, 櫻井一宏2, 尾之江剛樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1114, 2020. |
|---|
|
|
P32-24. Involvement of Newly Appointed Pharmacists in the Proper Use of Antibiotics - From a Study of Preavoid Cases - 牧田亮1, 古谷一平1, 田中佳子1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2020. |
|---|
|
|
P32-25. Antimicrobial choice to substrate specific expansion type beta lactamase (ESBL)-producing bacteria-positive patients in the urine culture 杉田裕貴1, 小田怜1, 片岡優1, 瀬戸崇光1, 松村友和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2020. |
|---|
|
|
P32-26. The effect that supply restrictions of ampicillin sulbactam gave for aspiration pneumonia treatment 関口愛1, 内田裕之1, 杉沢拓麿1, 中島美治1, 本郷偉元2, 丹羽一貴3, 河井良智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2020. |
|---|
|
|
P32-27. Efforts of the pharmacist of the antimicrobial proper use in the medical treatment ward of our hospital 重里幸枝1, 滝川亜弥1, 太田久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2020. |
|---|
|
|
P32-30. Usefulness of GNRI in the VCM trough aim area individualization 松木祥彦1, 松本遥奈2, 佐古兼一2, 矢嶋美樹3, 渡部多真紀4, 渡辺茂和5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1118-1118, 2020. |
|---|
|
|
P32-32. AST activity in our center 山下悠希1, 山田和弘1, 中山博文1, 阪口勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2020. |
|---|
|
|
P32-33. Can the result index be accomplished by use situation investigation - 2020 of the oral antimicrobial targeted for AMR action plan in our hospital? ... 南波勝栄1, 尾崎絢果1, 吉田朱里1, 尾花祥世1, 福田英克1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2020. |
|---|
|
|
P32-34. Analysis of the clinical outcome for the AS activity in the small and medium size hospital for 2 years 沢田佳祐1, 中谷丈之1, 上山孝太2, 篠原晃子3, 福田康二4, 河野修治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1120, 2020. |
|---|
|
|
P32-35. Intervention effect of AST on antimicrobial supply difficulty 中村麗紗1, 喜多洋嗣1, 喜多幸子1, 仲村亮太1, 森智子1, 駒井勇太1, 人見百合子1, 田仲祐子1, 近藤理美1, 府川祥子1, 坂口結斗1, 久田潤平1, 宮川千珠1, 水野康平1, 山中愛美1, 吉村美菜1, 岸本実優1, 北池祥子1, 小久保綾乃1, 白木萌1, 有銘千賀子1, 宇根良祐1, 石木仁美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1120, 2020. |
|---|
|
|
P32-37. A change of the antimicrobial consumption accompanied with the cefazolin supply stop and investigation about the chemosensitivity 田子尚史1, 國分真理1, 鈴木達宙1, 新後閑俊之2, 武谷洋子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1121-1121, 2020. |
|---|
|
|
P32-38. Correspondence of our hospital accompanied with the cefazolin supply stop and the inspection 岩田真子1, 山田宜和1, 山岸宏和1, 五十嵐詠美1, 鈴木さくら1, 寺口敦1, 種村瞭1, 貝瀬眞由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2020. |
|---|
|
|
P32-39. Effect of the Time above MIC calculation in Meropenem 畑中祐磨1, 本舘諭1, 田村麻衣1, 中居肇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2020. |
|---|
|
|
P32-40. The construction of the oral antimicrobial prescription grasp system in the outpatient department and the current situation report of the prescription situation 小川暁生1, 三上友寛1, 門居久嗣1, 淵上尚彦1, 桐畑美里1, 近澤秀己1, 伊庭雅代1, 遠藤正憲1, 高橋良一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1123-1123, 2020. |
|---|
|
|
P32-41. About a factor affecting it during the antibiotic exposure period (Duration of Antimicrobial Treatment: DAT) of blood culture-positive patients 安原昌子1,2, 栗原晋太郎1,2, 井上雄平1,2, 佐藤一求1,2, 藤本雅宣1,2, 江草徳幸2, 本田智洋1,3, 徳本和哉2, 堀川俊二1,2, 佐和章宏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1123-1123, 2020. |
|---|
|
|
P32-42. Efforts to oral antimicrobial proper use 田中博和1, 安永実沙1, 松浦徹1, 山下大貴1, 立石裕樹1, 安部由起子1, 後藤貴央1, 與田賢作1, 秋吉正貴1, 宮津大輔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1124, 2020. |
|---|
|
|
P32-43. Examination about the initial therapeutic drug choice about the MRSA bacteremia 吉田三矢1, 土江亜季1, 白崎佑磨1, 辰巳晃造1, 田路章博1, 吉野宗宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1124, 2020. |
|---|
|
|
P32-44. Antimicrobial proper use investigation for acute cholangitis, cholecystitis treatment judging from a viewpoint of the TAZ/PIPC consumption reduction 長山優介1,2, 高橋英加1,2, 藤垣俊介1, 村田久枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2020. |
|---|
|
|
P32-45. By a supply stop of the cefazolin, we changed the prophylactic antimicrobial of surgical-site infections, but anti-VAIO gram of MSSA did not have the change 長野響1, 平田貴大1, 小野寺隆記2, 黄前尚樹3, 起塚美沙1, 中村美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2020. |
|---|
|
|
P32-46. Examination of the effect of Antimicrobial Stewardship on bacteremia with the Enterococcus genus 伊藤亮太1, 渡邊卓嗣1, 星野祐太1, 菊地未由1, 大月沢雄1, 菅野和彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1126, 2020. |
|---|
|
|
P33-1. About a usage review and efforts of the surgical-site infections (Surgical site infection: SSI) prevention antimicrobial in our hospital cardiovascular surgery 久保悠1, 今田深雪1, 岩朝静子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1127-1127, 2020. |
|---|
|
|
P33-2. Surveillance of the use of antimicrobial in the area guessing from a trend of the antimicrobial consumption of the prescription 坪内理恵子1, 谷合英太郎2, 吉住和樹2, 小林岳3, 大倉輝明4, 宮崎美子5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2020. |
|---|
|
|
P33-3. Evaluation of the disease severity classification using the MN standard for the patients with suspected the Clostridioides difficile infection 山田楊太1, 宮崎元康1, 松尾宏一1, 内山将伸1, 小宮ゆきえ2, 永田忍彦3, 今給黎修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2020. |
|---|
|
|
P33-4. About the effect of the third generation oral cephalosporin antimicrobial adoption cancellation suggestion on pediatrician by the antimicrobial proper use support team 池田浩幸1,2, 松島実2, 池田恵子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1129, 2020. |
|---|
|
|
P33-5. For CEZ supply stop, it is evaluated AS utilizing ABPC/SBT for the perioperative period 伊藤悠里子1,3, 高野純希1,3, 塩谷光彦2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1129, 2020. |
|---|
|
|
P33-6. Efforts to consumption reduction of the third generation oral cephalosporin medicine 森田眞由1, 大橋正和1, 本多あずさ1, 村田龍宣1, 村岡淳二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1130, 2020. |
|---|
|
|
P33-7. Examination about the usefulness of the participation of AST at antimicrobial supply restrictions 佐々木貴之1,2, 加藤恵一1, 佐々木香織1, 山川智一1, 中園裕利華1, 福本真己1, 白木克哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1130, 2020. |
|---|
|
|
P33-8. Correspondence of our hospital AST for the supply stop of the cefazolin sodium antimicrobial 蔵地章仁1, 高桑実希1, 二宮茂光2, 寺西太3, 早川繁子4, 石黒早織4, 都築菜美5, 棚田愛5, 南條明徳5, 河内若代1, 三宅浩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2020. |
|---|
|
|
P33-9. Consideration about the evaluation of the AST activity by the point of view of the AWaRe classification and the future action program 田中雄大1, 山口諒1, 山本武人1,2, 鈴木洋史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2020. |
|---|
|
|
P33-10. Efforts to fact-finding and improvement for the hand hygiene of the ward charge pharmacist in enforcement 仲俣桃華1, 玉城哲子1, 城間盛彦1, 浦崎清美1, 武富美貴子1, 仲吉亜依美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1132, 2020. |
|---|
|
|
P33-11. After the operation by the prophylactic oral antimicrobial cancellation in the cataract surgery about the effect of the adverse event incidence 高橋有1, 小林和博1, 上田覚1, 岡田麻佑1, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1132, 2020. |
|---|
|
|
P33-12. Inspection of the improvement in number of hand washing by the enlightenment activity for the pharmacist 檜山洋子1, 鴫田江理嘉1, 小澤智紀1, 久保有子1, 冨田隆志1, 佐伯康之1, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2020. |
|---|
|
|
P33-13. Foreign prescription fact-finding of the oral antimicrobial for acute respiratory tract infection and the acute diarrhea 南真進1, 松浦直嗣1, 小杉隆祥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2020. |
|---|
|
|
P33-14. Relationship of the use situation and the drug resistant bacterium detection situation of the finger disinfectant in our hospital 佐藤智功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2020. |
|---|
|
|
P33-15. Efforts for the efficiency of AST duties 横手克樹1, 伊藤太一1, 雫文子1, 森山史就1, 安食健一1, 園山智宏1, 松原康博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2020. |
|---|
|
|
P33-18. About the effect that the issue of steady supply of the antibiotic gave 仲井修一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1136, 2020. |
|---|
|
|
P33-21. Examination of the perioperative prophylactic antimicrobial in the orthopedics domain with the cefazolin supply difficulty 坂梨綾香1, 高田百合菜1, 植竹宣江1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1137, 2020. |
|---|
|
|
P33-22. Changes such as the hospitalization, and the like by the change of the clinical path with the supply difficulty of the antibiotic cefazolin 長濱藍1, 和泉勝一1, 喜友名侑舞1, 生野夢子1, 白木萌1, 小久保綾乃1, 北池祥子1, 岸本実優1, 吉村美菜1, 山中愛美1, 水野康平1, 宮川千珠1, 久田潤平1, 坂口結斗1, 近藤理美1, 府川祥子1, 田仲祐子1, 人見百合子1, 駒井勇太1, 森智子1, 仲村亮太1, 喜多幸子1, 喜多洋嗣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2020. |
|---|
|
|
P33-23. Change of the De-escalation rate by the antimicrobial proper use support intervention to blood culture-positive patients 上村真由1, 河村一郎2, 澤井祐樹1, 立川奈保美1, 長谷川聡司1, 中野寛之1, 高木麻里1, 吉田智江1, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2020. |
|---|
|
|
P33-24. Effect on prescription trend by the in-hospital manual revision of influenza treatment 宮内英俊1, 渡嘉敷俊介1, 大井優1, 加賀正基1, 志智大介2, 山内拓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2020. |
|---|
|
|
P33-25. Efforts for oral antimicrobial proper use in our hospital outpatient department section and the effect 倉田賢生1, 堀内寿志2, 井上昇3, 斧沢京子4, 荒木弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2020. |
|---|
|
|
P33-26. Effect on surgical-site infections of the chemosensitive rate of the microbe by the cefazolin supply stop and the cardiovascular surgery 迫田英樹1,2,3, 馬場華菜1, 栗脇千春2, 山下正治3, 山口俊3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2020. |
|---|
|
|
P33-27. The procalcitonin for sepsis of the intensive care unit admission patients or the pre-back prediction and usability of the pre-sepsine 伊部裕太1, 石郷友之1, 清治翔伍1, 稲村広敏1, 藤居賢1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2020. |
|---|
|
|
P33-28. Intervention of AST for patients with MRSA bacteremia in Nagoya Memorial Hospital and the result 吉田祐理1,2, 岡本千晴1,2, 長岡雅敏1,2, 鈴木道雄2,3, 関原恵利子2,4, 北原陽子2,5, 湯浅周1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1141, 2020. |
|---|
|
|
P33-29. Factor analysis of Clostridioides difficile infection recurrence 木下大夢1, 岡崎椋子1, 御牧夕紀子1, 帖佐弘子1, 松山淳史1, 鬼丸俊司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1141, 2020. |
|---|
|
|
P33-30. Intervention and evaluation to the pneumonia inpatient in the antimicrobial proper use support team 竹内陽亮1,2,3,4, 高橋雄也1, 辻文生2, 東浦壮志2, 高鷲智美3, 砂田梨穂4, 大谷将弘4, 長島裕樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1142-1142, 2020. |
|---|
|
|
P33-31. Comparison of the use of antimicrobial situation before and after the antimicrobial proper use support team start in our hospital 海野亜実1, 久保田綾乃1, 北村修1, 牧野和也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1142-1142, 2020. |
|---|
|
|
P33-32. One patient whom ventriculitis to assume Corynebacterium striatum origin bacteria developed in 松下永利子1, 戸田智美1, 太田雄一郎2, 荒木勇人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1143-1143, 2020. |
|---|
|
|
P33-33. Evaluation of the AST activity of the pharmacist in the staphylococcal bacteremia 中市里実1, 澤田美穂2, 溝端友希1, 三浦絢1, 前田智佳子1, 藤本明由美1, 岡本悠紀1, 山本紗世1, 楠本臣彌1, 台野佳代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1143-1143, 2020. |
|---|
|
|
P33-34. Having been understood from a medical interpreter, the questionary survey by the tuberculosis workshop for staff of Japanese school 山崎彬史1, 中浴伸二1, 森本茂文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2020. |
|---|
|
|
P33-35. Construction ... of the prescription situation investigation system of the oral antimicrobial accompanied with prescription situation investigation - medical service fees revision of the foreign oral antimicrobial for acute respiratory tract infection and the acute diarrhea 中谷亮介1, 満田正樹1, 岡田雅弥1, 太田かおり2, 奥野千晶3, 松本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2020. |
|---|
|
|
P33-36. Relation Vol.2 of the hospital pharmacist to vaccination recommendation 渡辺智之1, 大石将義1, 古浜健一1, 湯本哲郎2, 稲葉健二郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2020. |
|---|
|
|
P33-37. Examination of the factor associated with the onset of Clostridioides difficile-related loose bowels 沢田裕介1, 古畑光司1, 三戸香央里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2020. |
|---|
|
|
P33-39. The current situation of the bundle observance rate of the staphylococcus aureus bacteremia in Rousaibyoin, China 今津智子1, 大上亜樹1, 福田結彩1, 濱崎浩一1, 福原伸治1, 下川福子1, 小濱邦彦2, 前田頼伸3, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1146-1146, 2020. |
|---|
|
|
P33-40. Analysis of the factor involved in the resistant bacteria detection in the acute pyelonephritis 島田茉侑1, 堀川洋平2, 柳田真樹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1147, 2020. |
|---|
|
|
P33-41. Infection measures about environment and the hand hygiene in the dispensary 小西寿子1,2, 橋本直人1, 海老原文哉1, 前浩史1, 浜田幸宏1, 木村利美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1147, 2020. |
|---|
|
|
P33-42. The effect that acute nephropathic disease severity gives to a pre-sepsine level 石郷友之1, 伊部裕太1, 藤居賢1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2020. |
|---|
|
|
P33-43. It is the change of the AST (antimicrobial proper use support team) activity by becoming it the working full time of the pharmacist 植竹宣江1, 竹之内誠1, 立川文崇1, 松本俊治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2020. |
|---|
|
|
P33-44. Examination of a pollution status and the contact infection prophylaxis of the medication window by the adenosine triphosphate assay 瀬山翔史1, 山吉康子1, 津田壮一郎1, 池谷修2, 柏村祥子3, 西村知泰4, 高野八百子2, 長谷川直樹2, 村松博1, 青森達1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2020. |
|---|
|
|
P33-45. Examination of the use of hand hygiene evaluation application for the evaluation of the hand hygiene 清水智也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2020. |
|---|
|
|
P33-46. The current situation and problem in the scale hospital out of one of Clostridioides difficile infection 安田美奈子1, 河本大輝1, 五藤里奈1, 白川舞1, 熊田克幸1, 岡田美智代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2020. |
|---|
|
|
P33-47. Adequacy of Clostridioides difficile infection treatment by use of antimicrobial aptitude support team (AST) and the examination 中野祐樹1,2, 大竹野久雄1,2, 船津康弘2, 井上真太郎2, 末安禎子2, 横尾賢乗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2020. |
|---|
|
|
P33-48. Usefulness of infection measures cooperation common platform (J-SIPHE) in the use of antimicrobial situation investigation 遠藤美緒1, 早川佳代子1,2, 田島太一1, 藤井直樹1, 坂口みきよ1, 浅井雄介1, 都築慎也1, 松永展明1, 大曲貴夫1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2020. |
|---|
|
|
P33-49. Examination of the patients with Candida bacteremia outcome that use of antifungal agent aptitude in the scale hospital (Antifungal Stewardship: AFS) gives 星貴薫1, 浅利伸朗1, 井畑理沙1, 大島美保1, 西條正二1, 冨所愛佳1, 松田まなぶ1, 宮腰恵生1, 和田直樹1, 中川麗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2020. |
|---|
|
|
P33-51. Successive change of the practice guidelines on perioperative antimicrobial conformity rate by the AST intervention 高野雅己1, 稲垣孝行1, 南島拓矢1, 松原匡希1, 渡部亨平1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1152, 2020. |
|---|
|
|
P33-52. Fact-finding of the use of perioperative antimicrobial in the childhood spinal fusion 栗島彬1, 塩田朋子1, 磯崎僚1, 田島幸子2, 小野貴司3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2020. |
|---|
|
|
P33-53. The current situation investigation about the infusional antimicrobial proper use for nurses of our hospital 後藤義之1, 角紀一郎1, 岡田久美1, 古本真由美1, 松岡未紗1, 茶野下貴恵1, 光井彩1, 島崎沙織1, 青木理恵1, 清水翔子1, 西川達也1, 梅下翔1, 森戸敏志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2020. |
|---|
|
|
P33-54. Can put it in our hospital; and quantity of oral antimicrobial prescription investigation of the next acute respiratory tract infection 花房伸幸1, 小池彩子1, 廣田あゆ子1, 河村茉衣1, 奥格2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2020. |
|---|
|
|
P33-55. Efforts to the antimicrobial proper use of the AST pharmacist in the Matsusaka center general hospital 木平香織1, 飯田拓真1, 森章哉1, 福永浩也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2020. |
|---|
|
|
P33-56. The current situation and problem for the foreign antimicrobial proper use 西村清孝1, 山本貢1, 清水浩幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1155, 2020. |
|---|
|
|
P33-58. Activity report for the new coronavirus infection in the pharmacy service under health insurance drugstore Japan pharmacy 中村翔吾1, 赤木太一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1156-1156, 2020. |
|---|
|
|
P34-1. A Case of Pharmacological Management in Dolutegravir + Lamivudine Dual Therapy as Initial Treatment for AIDS Patients with Decreased Renal Function 松本慎太郎1, 石田茂1, 渡邊裕之1, 辻敏和1, 松本佑慈2, 江頭伸昭1, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1157, 2020. |
|---|
|
|
P34-2. Effect of change to dolutegravir on intra-individual variation in estimated glomerular filtration rate 日笠真一1, 島袋翔多1, 秀田恭子1, 日笠聡2, 澤田暁宏2, 徳川多津子2, 田中邦佳1, 柳井美奈1, 木村健1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1158, 2020. |
|---|
|
|
P34-3. Investigation about the malignant tumor merger HIV patients in our hospital 合原嘉寿1,2,3, 大石裕樹1,2,3, 高島伸也1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1158, 2020. |
|---|
|
|
P34-4. A Case of Renal Dysfunction Caused by Dolutegravir + Tenofovir Alafenamide/Emtricitabine Combination Therapy 齋藤巨樹1,4, 三原智2, 大石裕樹3, 小森敦正4, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1159, 2020. |
|---|
|
|
P34-5. Making of the hearing questionnaire by the pharmacist to aim at the improvement in quality of life of patients with HIV infection with unheated blood products (harmful effect HIV infection victim) 阿部憲介1, 近藤旭1, 神尾咲留未1, 赤木麻衣2, 鈴木美絵子2, 佐々木晃子2, 鈴木智子2, 今村淳治2, 後藤達也1, 伊藤俊広2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1159, 2020. |
|---|
|
|
P35-1. Examination about the carnitine supplement in the seriously disabled child person 小野美沙紀1, 室博也1, 垣越咲穂1, 中村曜子1, 服部昇二1, 吉田知由1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1160-1160, 2020. |
|---|
|
|
P35-3. A side effect, an effect and effect factor of the oral phosphorus preparation administration for the hypophosphatemia of adults 土川拓也1, 古谷一平1, 田中佳子1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1161-1161, 2020. |
|---|
|
|
P35-4. Study on association of lipid microsphere administration and the malnutrition risk in the childhood TPN patients 池田隆史1, 藤田紀子1, 安河内尚登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1162, 2020. |
|---|
|
|
P35-6. Application to NST duties using an action card 青木まりあ1, 山本高範1, 谷口朋子2, 長田文子2, 前田篤史3, 松田明敏4, 阿部康治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1163, 2020. |
|---|
|
|
P36-1. About the burden on patients degree in diabetes treatment with the mental disorder examination - using - Problem Areas In Diabetes Survey 福山雄卯介1, 宮崎敦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1164-1164, 2020. |
|---|
|
|
P36-2. Attempt of the antipsychotics decrease medicine for patients with dementia 大谷達郎1, 藤渕大樹1, 田中文江1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2020. |
|---|
|
|
P36-3. Example that a pharmacist intervened in for the weight loss of the high-dose benzodiazepine receptor agonist remedy patients early 植田有希1, 原田学1, 宇野葉子1, 杉本貴洋1, 下村好子1, 大橋郷子2, 仲谷佳高3, 四方佳美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2020. |
|---|
|
|
P36-4. Investigation about the usability of the blonanserin patch in patients with schizophrenia 當真菜央1, 竹内一平3, 波多野正和1,2,4, 横井里奈1, 半谷眞七子1, 宇野準二3, 藤田潔3, 岩田仲生4, 亀井浩行1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1166, 2020. |
|---|
|
|
P36-5. The actual situation of the consultation behavior for the drugstore pharmacist of patients with depression and the interference factor 野田久美子1, 後藤奨一1, 櫻井秀彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1166, 2020. |
|---|
|
|
P36-6. About the effectiveness of the schizophrenia therapeutic drug blonanserin patch in the true clinical practice 宇佐美伶奈1, 竹内一平1,2, 半谷眞七子1, 宇野準二2, 藤田潔2, 亀井浩行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2020. |
|---|
|
|
P36-7. The effect that efforts for the proper use of the sleeping drug gives for the fall fall incident of the inpatient 坂田将貴1, 堀田彰悟1,5, 奥村啓樹1, 村上佳人1, 肥田裕丈1,5, 太田小織1, 山本雅人1, 梅村朋2,5, 長尾能雅2, 鈴木裕介3, 尾崎紀夫4, 野田幸裕5, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2020. |
|---|
|
|
P36-8. Investigation about the current situation of the stigma for patients with schizophrenia of the pharmacist working in the health insurance pharmacy in Aichi 成瀬友葵1, 藤井知郎1,2, 室谷健太3, 半谷眞七子1, 亀井浩行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2020. |
|---|
|
|
P36-9. A case of an alcoholic patient who became bromo-poisoning due to an overdose of the over-the-counter drug Wutt 高見澤誠1, 市川裕平1, 篠原徹1, 箕輪勇紀1, 池田知也1, 島谷晴美2, 渡邉将隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2020. |
|---|
|
|
P36-10. Use experience of trazodone for the delirium in our hospital 谷口結基1, 森智世1, 田中美帆1, 太田達也1, 田中章郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2020. |
|---|
|
|
P36-11. Examination of the fall risk with the medicine before sleep in the inpatient 中原友1, 後藤志典1, 林幹也1, 赤崎淳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2020. |
|---|
|
|
P36-12. Investigation of the drug causing the delirium onset in the ICU admission patients after the cardiovascular surgery technique 中田麻里1,2, 喜田昌記1,2, 越塚宏美1,2, 柏原由佳1,2, 田中克巳1,2, 佐々木忠徳2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2020. |
|---|
|
|
P36-13. Rehospitalization of the bipolar disorder and participation of the pharmacist 山内茜1, 酒井要1, 西嶋長1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2020. |
|---|
|
|
P36-14. It is the examination of the risk factor in the delirium after the operation that produced opening type stent graft interpolation postoperatively 石川めぐみ1, 大野陽平1, 菅原依里1, 吉見猛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2020. |
|---|
|
|
P36-15. Examination of the risk factor of a white blood cell, the neutropenia in Clozapine treated patients 竹内小百合1, 中村奈央1, 幸邦憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2020. |
|---|
|
|
P36-16. Examination about the patients adherence judging from the change of the antipsychotics prescription dose before and after the sustained-release parenteral injection introduction in schizophrenia treatment 阿部友江1, 落合理路2,3, 河合真理子1, 榎本了三2, 梁川剛生2, 早坂俊亮4, 鈴木立紀1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1172, 2020. |
|---|
|
|
P37-1. Relation to the perinatal medical care of the pharmacist specialized in a pregnant woman, a nursing mother in the general hospital 香西祥子1,2, 河西邦浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1173-1173, 2020. |
|---|
|
|
P37-2. Examination about the thyroid disease merger pregnancy 木藤一美1, 橋本隆信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2020. |
|---|
|
|
P37-3. 1 case that was given a transplacental prenatal treatment for fetal congenital heart block which antiSS-A antibody-positive pregnant woman had 長瀧谷美樹1, 加島朱梨1, 外山真理奈1, 渡邊宏美1, 紺屋まりや1, 松原侑紀1, 永井絵里子1, 庵森靖弘1, 藤川郁世1, 大津由美子1, 石井陽一郎2, 和栗雅子3, 望月千枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2020. |
|---|
|
|
P37-4. Trend of the antiepileptic drug for women of the childbearing age in our hospital 伊藤有美1, 佐藤寛子1, 鈴木秀明1, 滝本典夫1, 池田昇平2,3, 丹羽央佳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1175, 2020. |
|---|
|
|
P37-5. Using study - fetal movement acceleration measurement recorder (FMAM recorder) of the effect that ritodrine hydrochloride tablets give to fetal movement - 世永由里子1,2, 梁栄治2, 八木慶太2, 森田政義2, 瀬戸理玄2, 鎌田英男2, 渡辺達也1, 伊東明彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1175, 2020. |
|---|
|
|
P37-6. Examination of the effect that a DHA-containing supplement gives to postpartum bleeding 佐藤寛子1, 伊藤有美1, 鈴木秀明1, 滝本典夫1, 石川優子2, 長船綾子3, 梅津朋和3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2020. |
|---|
|
|
P37-7. The effect that the nursing in our hospital and the current situation and counseling of the foreign counseling about the medicine give in a mother's milk childcare choice 小澤秀介1, 小岩井祥1, 山折大1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2020. |
|---|
|
|
P37-8. Relations with BMI and the insulin resistance in the carbohydrate metabolism abnormality pregnant woman and the secretion ability 相馬まゆ子1, 野木山史恭1, 山崎布美子1, 佐々木洋一1, 今田愛也2, 山本浩史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2020. |
|---|
|
|
P37-9. Outcome investigation after the reporting by "the pregnancy, the nursing and medicine consultation duties" 清宮啓介1, 小谷宙1, 三浦あす美1, 鈴木靖奈1, 村松博1, 青森達1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2020. |
|---|
|
|
P38-1. Questionary survey about the "insulin preparation, GLP-1 receptor agonist chart" making 亀岡大樹1, 金子玲美2, 小幡舞2, 谷聡美2, 宮前文明3, 中野良4, 才野壽子5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1178, 2020. |
|---|
|
|
P38-2. The effect that metformin and proton pump inhibitor combination give to glycemic control 石田翔1, 吉川明良1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1179, 2020. |
|---|
|
|
P38-3. The effectiveness of the SGLT2 inhibitor supplementation in patients with type I diabetes mellitus and safe examination 正村怜那1, 早川伸樹1,2, 津川透1,3, 福井愛子1, 亀井浩行1, 桑原宏貴3, 公文尚子2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1179, 2020. |
|---|
|
|
P38-4. About the introduction of the osteoporotic allied lecture in the diabetes education inpatient 加藤泉希1,2,3, 石丸隆之1, 野中敏治1, 渡邉洋子2, 馬渡太郎3, 平松真祐2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1180, 2020. |
|---|
|
|
P38-5. One patient who conducted the medication counseling of patients with foreign diabetes that had difficulty in Japanese communication デニヤ智子1, 荒木良介1, 山田英紀1, 石田悠人2, 高橋謙一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1180, 2020. |
|---|
|
|
P38-7. Example that led to healing by medicine for external application therapy and harness wearing for the ulcer of the sole part 西村博之1, 吉田陽1, 塩山由紀1, 守田彩文1, 高田雅文1, 鈴木知子2, 栗並昇2, 稗島州雄2, 梶原敬三2, 杉山正悟2, 陣内克紀2, 陣内冨男2, 陣内秀昭2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1181-1181, 2020. |
|---|
|
|
P38-8. Effect to give a fact and patients of the glycemic control of patients with type 2 diabetes using the FreeStyle livret 宮田絵莉加1, 佐々木雄啓1, 岡村和彦1, 高橋栄子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1182, 2020. |
|---|
|
|
P38-9. Examination of the effectiveness for the liver function improvement of the dapagliflozin and the contributing factor 西村功史1, 花井雄貴1, 山西由里子1, 志村翔大1, 伊藤優紀1, 原敬一3, 松尾和廣2, 坂本真紀1, 西澤健司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1182, 2020. |
|---|
|
|
P38-10. Search of the fact-finding of the clinical inertia in patients with type 2 diabetes and effect factor 喜多力1, 真井雄規1, 村上智香1, 石田陽美1, 金住麻子1, 三本松泰孝1, 佐藤弘康1, 和泉秀明1, 田村広志1, 渡辺浩明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1183, 2020. |
|---|
|
|
P38-11. Dispatch ... to the area that it merged on efforts 2019 - world diabetes day in our hospital for diabetes 河村紳介1, 丸井志織3, 原田雅子3, 中村正光4, 芝原裕和4, 鈴木聡史5, 安江誠人5, 山下香織6, 朝井康雄7, 槇野裕也2, 大石裕子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1183, 2020. |
|---|
|
|
P38-12. Difference in recognition degree between the multi-types of job in the insulin consultation in the team approach in medical care 氏川郁穂1, 向井淳治1,2, 竹原涼子1, 木村実央1, 奥田広志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2020. |
|---|
|
|
P38-13. One case of patients with type 2 diabetes that developed diabetic ketoacidosis during SGLT2 inhibitor internal use 新屋友理1, 太田充2, 野村暢彦1, 安田浩一朗2, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2020. |
|---|
|
|
P38-14. Attitude survey about the internal use drug control in our hospital diabetes education inpatient 田口諒1, 高柳昌宏1, 渡邊清人1, 元木孝1, 綱島道子1, 目谷莉紗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2020. |
|---|
|
|
P38-16. Establishment of the exact assay of diabetes marker 1,5-anhydroglucitol by the high-speed liquid chromatograph tandem mass spectrography 本橋秀之1, 木村遥華1, 井辻真由1, 竹林裕美子1, 永井純也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1186, 2020. |
|---|
|
|
P38-17. Examination about the stability under a high temperature bottom of insulin glargine and the non-shading 辻本勉1, 井上智咲1, 田崎眞生1, 濱宏仁1, 大川恭子1, 豊原朋子1, 桑原晶子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1186, 2020. |
|---|
|
|
P38-19. Investigation about the effect of oral hypoglycemics on sugar toxicity cancellation in patients with type 2 diabetes 丹代恭太1, 工藤晋1, 鈴木弘文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1187-1187, 2020. |
|---|
|
|
P39-1. Evaluation of the PCSK9 inhibitor Evolocumab for dyslipidemia in chronic kidney disease (CKD) patients 田杭直哉1, 佐藤淳子1, 近藤匡慶1, 菅谷量俊1, 高瀬久光1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1188-1188, 2020. |
|---|
|
|
P39-2. Examination of renal function evaluation after administration of romosozumab subcutaneous injection 田村悟1, 中村智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1189-1189, 2020. |
|---|
|
|
P39-3. Examination of the usefulness in the pharmacist company of foreign maintenance dialysis rounds 伊藤真史1, 木下照常2, 近藤洋一2, 滝本典夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1189-1189, 2020. |
|---|
|
|
P39-4. Investigation about the phosphorus content in pharmaceutical products prescribed for haemodialysis patients 柏倉康治1, 内田信也1, 茂木麻里奈1, 瀬戸川陸1, 鈴木寛1,2, 田中紫茉子1, 山内克哉2, 影山慎二3, 並木徳之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1190-1190, 2020. |
|---|
|
|
P39-5. Questionary survey about the medical cooperation using the CKD seal 佐藤淳子1,2,3, 田杭直哉1, 柴田まり子2, 浅井梨沙3, 菅谷量俊1, 金子朋広3, 高瀬久光1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1190-1190, 2020. |
|---|
|
|
P39-6. Association between effect on patients with childhood nephrotic syndrome and side effect of the mycophenolate mofetil 小林未佳1, 長嶺歩1,2, 八島秀明2, 高橋恵美利1, 高橋雄太1, 大林恭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1191, 2020. |
|---|
|
|
P39-7. Roxadustat use experience in hospitalized patients 乙竹慧未1, 寺尾育恵1, 穂積廣1, 加藤香奈1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1191, 2020. |
|---|
|
|
P39-8. Effect on renal function of the SGLT-2 inhibitor in patients with diabetic nephropathy third 北條文啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2020. |
|---|
|
|
P39-9. Effect of the pamphlet in the CKD prophylactic enlightenment exercise 中澤幸恵1, 石川若菜2, 高木春香2, 小路麻梨恵2, 菊池舞子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2020. |
|---|
|
|
P39-10. The elucidation of the multifaceted effect of the Neurotropin and application to renal disease 門脇大介1,2, 福永雅樹1,3, 内田朱美1, 末吉美優1,3, 前田仁志3, 成田勇樹3, 渡邊博志3, 丸山徹3, 瀬尾量1,2, 平田純生3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1193, 2020. |
|---|
|
|
P40-1. Brochure making and understanding degree investigation for elderly people for frailty common knowledge 杉山朋美1, 布井祥映1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1194-1194, 2020. |
|---|
|
|
P40-2. Examination of confirmation of the drug-taking behavior of the elderly patients by the pharmacist using the electronic medication calendar and the effect 田中李奈1, 菊池千草1,2, 小田切州広1, 松波晋平3, 鈴木匡1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1195, 2020. |
|---|
|
|
P40-3. Efforts to polypharmacy improvement using STOPP criteria in our hospital convalescent rehabilitation ward 三島直也1, 猪木摩耶子1, 坂本健太郎1, 光山忠史1, 桶東愛史1, 桑田益希1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1195, 2020. |
|---|
|
|
P40-4. Efforts to the benzodiazepine receptor agonist consumption decrease in patients with old cancer 橋本未雷1, 松藤敬佑1, 薮内由里香1, 池田澪樺1, 松元俊博1, 三角紳博1, 西嶋智洋2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1196-1196, 2020. |
|---|
|
|
P40-5. Participation of the pharmacist in bringing medicine hearing in the local inclusion care ward and medical security 新見奈々1, 川上恭弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1196-1196, 2020. |
|---|
|
|
P40-6. Relations with frailty and the medical therapy in local elderly people: Nakajimacho study 吉川由華1, 丸一泰雅1, 石田奈津子1, 菅幸生1, 松下良1, 石崎純子1, 横川正美2, 篠原もえ子3, 駒井清暢4, 山田正仁3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2020. |
|---|
|
|
P40-7. Association between blood vessel function (CAVI) and frailty in the medical examination testee 櫻井穂香1, 新木美枝1,2, 高橋恵美利1, 高橋雄太1, 林邦彦3, 大林恭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2020. |
|---|
|
|
P40-8. Of the polypharmacy team activity in the acute phase hospital where is specialized in elderly people, actually 小原朋也1, 片原憂斗1, 瀧川美和1, 島崎良知1, 森淑子1, 石川讓治2, 岩切理歌3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1198, 2020. |
|---|
|
|
P40-9. Fact-finding of the drug global assessment addition in the acute phase hospital 宮田知世1, 伊藤有美1, 小笠原理恵1, 木下照常1, 本間崇正1, 林睦菜1, 柴田大地1, 菅原さやか1, 滝本典夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1198, 2020. |
|---|
|
|
P40-10. The effect that the polypharmacy of elderly people gives to hospitalizations 中野智尋1, 宇夛裕基1, 竹田和喜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1199, 2020. |
|---|
|
|
P40-11. Factor analysis to influence multiple drug prescription and prescription complexity in the medical therapy of elderly people 亀田敬子1, 佐古渚1, 小川沙織1, 木本信介1, 山田周平1, 西田直史1, 福澤祐幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1199, 2020. |
|---|
|
|
P40-12. Adequacy and economic effect of the medication in the care health center for the elderly 浅野志津1, 川上隆弘1, 日浦亜実2, 江尻東伍3, 近藤昭3, 横山祐二3, 森英樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2020. |
|---|
|
|
P40-13. One case that medication compliance and ADL improved by the home medical treatment management instruction by the community pharmacy pharmacist 早川貴司1, 田中淳2, 藤田あゆみ3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2020. |
|---|
|
|
P41-1. Background investigation of patients with acute acetaminophen poisoning in our hospital 平良木由布1, 波多野亘1, 島田祐子1, 川上陽介1, 寺島達也1, 五十嵐大輝1, 堀寧1, 広瀬保夫2, 吉田暁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2020. |
|---|
|
|
P41-2. Questionary survey about the medication adherence of the patients with the cardiovascular system disease 菅原隆文1, 吉川明良1, 薮田理子1, 洲山佳寛1, 開浩一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2020. |
|---|
|
|
P41-3. It is an example with suspected adrenal insufficiency onset with the internal use cancellation of betamethasone/d- chlorpheniramine maleate combination drug (celestamine combination tablets) 宮下博幸1, 斎藤太寿2, 松原肇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2020. |
|---|
|
|
P41-4. Five examination that were able to achieve the LDL-C management that continued by PCSK9 inhibitor administration 山本高範1, 田中剛史2, 阿部康治1, 後藤浩之2, 福岡秀介3, 川崎敦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2020. |
|---|
|
|
P41-5. Examination about the heart failure improvement effect of the tolvaptan 松尾有美1, 宮川泰宏1, 岸里奈1, 千崎康司1, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2020. |
|---|
|
|
P41-7. Search of the background factor of patients with upper gastrointestinal bleeding that required endoscopic treatment in our hospital 藤田謙1, 朝倉美加1, 鈴木結利花1, 大竹満博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1204-1204, 2020. |
|---|
|
|
P41-8. The effectiveness, safe comparison of Linaclotide and the agate Pross ton in elderly people 下坪達人1, 石郷友之1, 北川学1, 木明智子1, 中田浩雅1, 宮本篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1205, 2020. |
|---|
|
|
P41-9. Effect of the nitrosylation of the Protein disulfide isomerase substrate binding domains in nerve cells 小倉次郎1,2, Lloyd Ruddock2, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1205, 2020. |
|---|
|
|
P41-10. For lower limbs ischemia-related chronic pain of the peripheral arterial disease, it is a case using the fen toss (R) tape 大荒政志1, 坂本真衣1, 増田博也1, 久岡清子1, 勝田真理2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1206, 2020. |
|---|
|
|
P41-11. Examination of the measurement of the inspiratory flow rate by in-checkDIAL and the inhalational management 西村淳1, 玉井典子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1206, 2020. |
|---|
|
|
P41-12. Investigation of the GI bleeding onset situation in patients who underwent PCI 朝倉美加1, 藤田謙1, 鈴木結利花1, 大竹満博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2020. |
|---|
|
|
P41-13. It is an investigation about the non-proper use of the oral anticoagulant drug directly 石福奈々1, 今浦将治1, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2020. |
|---|
|
|
P41-14. Examination of the initial starting dose of the Elobixibat 荒川正悟1, 旭将来1, 小野元久1, 片野貴大1, 徳田富妃子1, 山口智江1, 宮原兼二1, 木南志朗1, 伊藤功治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1208-1208, 2020. |
|---|
|
|
P41-15. Problem ... of the pharmacist by acute phase hospital and polypharmacy measures ... multi-type of job team 小倉弥生1, 松本知之1, 下田麻祐子1, 江原可成子1, 大木孝夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1208-1208, 2020. |
|---|
|
|
P41-16. About a change of the gut flora in the social defeat stress load depression model mouse 吉本和佳1, 上村祐介1, 桑垣衣里奈1, 濱野咲佳1, 高畑祐香1, 安川岳志2, 森本博俊2, 魚住嘉伸2, 高山健太郎1, 長澤一樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1209, 2020. |
|---|
|
|
P41-17. Protective efficacy of magnesium oxide for the inflammatory bowel disease onset in the mouse 大嶋廉之1, 浅田あゆみ1, 河本実季1, 宮永佳代1, 高山健太郎1, 長澤一樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1209, 2020. |
|---|
|
|
P41-18. The usefulness evaluation of the standard manual in the inhalational maneuver acquisition and examination of the pit hall 齋藤友里菜1, 高橋恵美利1, 前田恵里1, 岡田裕子1, 高橋雄太1, 土井信幸1, 堀江健夫2, 大林恭子1, 根本明日香3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1210-1210, 2020. |
|---|
|
|
P41-19. About safety of the anticoagulation after the transcatheter left auricle closure technique 友納保幸1, 波多江沙織1, 木原慶子1, 北島聖也1, 前田朱香1, 富田敏章1, 入江利行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1210-1210, 2020. |
|---|
|
|
P41-20. The effect that use of metformin results in for the ADL evaluation of elderly patients admitted to the convalescent rehabilitation ward 花岡峻輔1, 丸野翠1, 林宏行1, 平井利幸2, 関利一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1211-1211, 2020. |
|---|
|
|
P41-22. The role of the pharmacist in the heart failure conference and the future prospects 松田有加1, 萩野佑紀1, 森塚亮太1, 宮崎俊明1, 筒井由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1212-1212, 2020. |
|---|
|
|
P41-23. It is an example receiving the Empagliflozin for heart failure to assume expansion phase hypertrophic cardiomyopathy primary disease 松村泰斗1, 安島秀友1, 中薗健一1, 松崎貴志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1212-1212, 2020. |
|---|
|
|
P41-24. It is two patients using the continuous intravenous infusion of oxycodone for patients with terminal heart failure who had the severe impaired renal function 高橋未來1, 中田和宏1, 木村美由喜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1213-1213, 2020. |
|---|
|
|
P41-25. Efforts to the edoxaban proper use in a thighbone trochanter part, the cervical bone fracture surgery pass 西倉教子1, 内海敦志1, 吉川昌子1, 横山匠太1, 長田一晃1, 田中正宏2, 三保成正3, 原田靖子1, 西原昌幸4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1213-1213, 2020. |
|---|
|
|
P41-26. Analysis about the PT-INR level under the warfarin introduction after the prosthetic replacement 森岡朝美1, 清水倫子1, 山本和宏1, 大村友博1, 井上武2, 岡田健次2, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1214, 2020. |
|---|
|
|
P41-27. Use fact-finding of the mirogabalin 佐藤智香1, 寺西真凜1, 高橋直也1, 八木遥1, 大橋史嵩1, 岩堀真弓1, 田中あさ子1, 坂本華代1, 東修司1, 齊藤俊一郎1, 和泉秀明1, 田畑裕和1, 小原郁司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1214, 2020. |
|---|
|
|
P41-28. Examination of the objective pain evaluation of pregabalin using the pain degree measurement for the anal pain derived from neuropathy 猿渡康宏1, 丸田佐知子1, 伊藤由希1, 寺本拓哉1, 水本智子1, 平井裕子1, 中島みどり2, 小林伸行3, 高野正太4, 高野正博4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1215-1215, 2020. |
|---|
|
|
P41-29. Verification of the effect of promoting the use of generic drugs, etc. by formulating in-hospital formularies 森木邦明1, 安達真紀子1, 金田達也1, 島田美樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1215-1215, 2020. |
|---|
|
|
P41-30. Comparison of the analgesic effect of ad usum externum NSAIDs using PainVision 寺山和利1, 渡部多真紀1,2, 安野伸浩1,2, 榎本弘美2, 土屋雅勇2, 渡辺茂和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2020. |
|---|
|
|
P41-31. One case that hydromorphone immediate-release was effective for dyspnea of patients with terminal heart failure 中村眞梨1, 芝崎由美子1, 中村智弘2, 野村淳1, 石田岳史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2020. |
|---|
|
|
P41-32. A serum zinc level in front of the art is ... examining significance of the zinc supplement in addition investigation - preoperation about relations with the hospitalization after the operation 山本文哉1, 金田知詞2, 蟻川勝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1217-1217, 2020. |
|---|
|
|
P41-33. Role of the sea lion microglia as the sensitivity determinant of the mouse for the social defeat stress to induce depression-like behavior and the gut flora 桑垣衣里奈1, 上村祐介1, 濱野咲佳1, 高畑祐香1, 吉本和佳1, 西村周泰2, 高田和幸2, 安川岳志3, 森本博俊3, 魚住嘉伸3, 高山健太郎1, 長澤一樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1217-1217, 2020. |
|---|
|
|
P41-34. Examination of the factor associated with the eye drops adherence in patients with glaucoma 大江泰1,2, 柴谷直樹1,2, 平野達也1,2, 宮坂萌菜1,2, 藤原雅史3, 室井延之1,2, 橋田亨2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1218-1218, 2020. |
|---|
|
|
P41-35. Comparison about the effectiveness, the safety between the JAK inhibitor 白崎佑磨1, 土江亜季1, 吉田三矢1, 辰己晃造1, 田路章博1, 吉野宗宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1218-1218, 2020. |
|---|
|
|
P41-36. Visualization of the evidence of the pharmacist professional ability 高倉和茄1, 酒井隆全1, 田辺公一1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1219-1219, 2020. |
|---|
|
|
P41-37. The prescription situation of the dyslipidemia therapeutic drug for the coronary disease history case before and after the guidelines revision 米屋安佳里1, 小泉桂1, 飯田遼1, 黒澤亮太1, 色川正憲1, 堀越建一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1219-1219, 2020. |
|---|
|
|
P42-1. Approach at trial case arrangement of our hospital 小野田稔久1,2, 佐久間清1, 佐藤啓1, 西澤健司2, 増田雅行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1220-1220, 2020. |
|---|
|
|
P42-2. The case that a clinical experimental medicine and the causation judgment of the adverse event were carried out appropriately 齊田翌美1,2, 市下由美1, 白澤宏美1,2, 宮本聖子1,2, 吉井薫1, 宮本美穂1, 正代敦子1, 花田聖典2, 鶴崎泰史5, 藤本和輝3, 中川義浩1,2, 富田正郎4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1221-1221, 2020. |
|---|
|
|
P42-3. Introduction of the point list for the purpose of the appropriate calculation of the clinical experimental medicine administrative expense 佐藤佑樹1,2, 角山政之1,2, 深川恵美子1,2, 井廻裕美1,2, 木村優美1,2, 小林真理1,2, 上代大地1,2, 田中惇子1,2, 西垣内亮1,2, 村瀬哲也1, 梅本誠治2, 松尾裕彰1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1221-1221, 2020. |
|---|
|
|
P42-4. Investigation about the examination of the prevention of narcotic abuse preparation for the medical care in the United States 松崎哲郎1, 奥村啓樹1, 永井拓2, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1222-1222, 2020. |
|---|
|
|
P42-5. The current situation and problem of the clinical experimental medicine management in the clinical studies core hospital 浅野智央1, 久保晶子1, 佐々木真緒1, 住吉愛1, 平山久美子1, 今泉克明1, 橋本浩伸1, 近野健一1, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1222-1222, 2020. |
|---|
|
|
P42-6. Examination about the temperature change of the cooling box (cubic) equipped with a traceability system in the clinical experimental medicine administrative work 遠又未佐子1, 松井周一1, 岡村央1, 勝亦秀樹1, 後藤洋仁1,2, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1223-1223, 2020. |
|---|
|
|
P42-7. Approach for the prevention of protocol deviation in the clinical experimental medicine administrative work of the university hospital 中村夏季1,2, 家田正子1, 川瀬智子1, 井上真理也1, 若林巨樹1, 木寺康裕1, 嶋野裕人1, 福岡和也1, 竹上学2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1223-1223, 2020. |
|---|
|
|
P43-1. Dilemma regarding drug therapy in home palliative care - Possibility of questionnaire survey and gamification 工藤信孝1, 柴田弘子2, 山田貴代加3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1224-1224, 2020. |
|---|
|
|
P43-2. One case that was given the switching from an oxycodone note to a morphine note in the home care of the cancer terminal patient 出口昌孝1, 石橋祐子1, 山本真希1, 伊藤朋子2, 山際健太郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1225-1225, 2020. |
|---|
|
|
P43-3. Observational study of the medication situation in being at home 加納美知子1,2, 阿部智子3, 赤嶺有希子2, 田中詳子1,2, 澤井一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1225-1225, 2020. |
|---|
|
|
P43-4. About the way of the reporting at infection problem occurrence for foreign inhabitants with the language barrier 池浦恵1, 入野真規子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1226-1226, 2020. |
|---|
|
|
P43-5. Questionary survey for the person of health insurance pharmacy next situation for the purpose of the treatment at home promotion, and the like 興村桂子1, 大柳賀津夫1, 岡本晃典1, 木下慧1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1226-1226, 2020. |
|---|
|
|
P43-6. Efforts by the pharmacist to choose the optimal thickness agent along the needs of the caregiver 松原つばさ1, 水口真咲美1, 朝倉恵美子1, 武山則行1, 大橋千加1, 大橋哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1227-1227, 2020. |
|---|
|
|
P43-7. 1 case that was given pain control by the dose change that the distribution of the drug for the medical care grieved at for New Year holidays 木村拓哉1, 堀里圭2, 田村章子2, 渡邉佐智代2, 安井久美2, 輪嶋美幸2, 櫻井真理子1,2, 森厚司1, 山本有人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1227-1227, 2020. |
|---|
|
|
P43-8. Investigation about the enforcement situation of the online medication counseling in the national strategy special ward 廣部祥子1,2,3,4, 犬飼萌乃2, 横山俊之5, 大門力男5, 松浦伸史5, 田中亮太5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1228-1228, 2020. |
|---|
|
|
P43-9. Role of the drugstore pharmacist by the community medical care to examine from needs of the Care manager 村木紗1, 本舘秀樹2, 永井亜矢子1, 青木雅和1, 山本歩実1, 堀祐輔3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1228-1228, 2020. |
|---|
|
|
P43-10. Education support to the care staff by the pharmacist aiming at pharmaceutical products proper use promotion 伊東佳美1, 坂東勉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1229-1229, 2020. |
|---|
|
|
P43-11. Association between social index and medical drug consumption about home medical treatment person, the home dead according to the metropolis and districts 杉野若菜1, 田辺公一1, 市橋亮一2, 西城卓也3, 酒井隆全1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1229-1229, 2020. |
|---|
|
|
P43-13. Efforts to osteoporotic risk assessment using FRAX in the Fukugami ethical pharmacy 光岡ゆり1, 安藤伸一郎1, 小庄修明1, 堤葵1,2, 竹尾正典1,3, 大光正男2, 石丸隆之3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1230-1230, 2020. |
|---|
|
|
P43-14. Practice ... of the community medical care cooperation in efforts - NICU/GCU of the pharmacist in the growth medical care 大西知絵1, 溝口和代1, 阿部康治1, 内薗広匡2, 栗本淳子3, 林眞砂子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1231-1231, 2020. |
|---|
|
|
P43-15. Appropriateness-related inspection (the second report) of constipation and the use in at-home adult patients of laxative 櫻澤恵里香1, 神山瑛美1, 柳澤沙織1, 高橋恵美利1, 高橋雄太1, 岡部美保2, 棚橋さつき2, 大林恭子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1231-1231, 2020. |
|---|
|
|
P43-16. Utilize ICT (hydrangea net) in the terminally ill patients and the low caregiver of Functional status; the efforts case from a discharge to a shift at home that is No stress 鈴木智香子1, 小徳由梨絵1, 岩高美帆1, 大島聖也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1232-1232, 2020. |
|---|
|
|
P43-17. Fact-finding of the inhalational instruction to the home care patient in the Minamikawachi, Osaka district 松下一樹1, 和田宜久1, 木村貴1, 木澤成美1, 金銅葉子1, 松野治2, 源誠二郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1232-1232, 2020. |
|---|
|
|
P43-18. Role (the first report) of the insurance pharmacist in the care conference of the care pay nursing home belonging to 塚本賢児1, 徳山智治2, 磯尾優子2, 穴見江梨子3, 坂本豊伸4, 天方奉子5, 稲葉一郎5, 宮野恭彰6, 木戸宏幸6, 湯川栄二6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1233-1233, 2020. |
|---|
|
|
P43-19. About 1 case that felt importance of the medicine medicine cooperation again to connect to being at home 島袋優花1, 浜元善仁1, 翁長真一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1233-1233, 2020. |
|---|
|
|
P43-20. The development of the at-home pharmacy management standard vote to evaluate the duties of the pharmacist by the treatment at home and the current situation investigation 角明香里1,2,3,4, 柴田賢三2, 宇野達也2, 室谷健太3, 坂巻弘之4, 亀井浩行1, 半谷眞七子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1234-1234, 2020. |
|---|
|
|
P43-21. One case that was able to prevent becoming severe by the periodical visit of the community pharmacy pharmacist 土井武司1, 田中淳2, 堀高之1, 三久裕子1, 藤田あゆみ3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1234-1234, 2020. |
|---|
|
|
P43-22. Control improvement case by the device choice of the inhalant in elderly people 飯征士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1235-1235, 2020. |
|---|
|
|
P43-23. One case that saw symptom improvement by suspecting a side effect in the elderly patients whom culf edema appeared, and prescribing it, and having suggested it 新井尚1, 藤田あゆみ2, 八木澤恭子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1235-1235, 2020. |
|---|
|
|
P43-24. Usefulness of the Parkinson notebook (symptom diary) in the advanced Parkinson's disease patients 中野雄介1, 藤田あゆみ2, 吉岡聖子2, 杉浦伸哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1236-1236, 2020. |
|---|
|
|
P43-25. Example that we were able to conduct appropriate medication by the cooperation with the care job in the local inclusion care system 荻野純基1, 吉岡聖子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1236-1236, 2020. |
|---|
|
|
P43-26. One case that medication management became appropriate by the home visit to the elder-to-elder nursing household by the community pharmacy pharmacist 宮田成康1, 吉岡聖子2, 藤田あゆみ3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1237-1237, 2020. |
|---|
|
|
P43-27. As a member of all human supporters in local palliative care and medicine medicine cooperation - palliative care ... 白石丈也1, 笠原庸子2, 谷川大夢3, 廣原正宜4, 串田一樹4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1237-1237, 2020. |
|---|
|
|
P44-1. Establishment of Drug-Drug Collaboration in Cancer Chemotherapy -Through the Chemo x Cross Roundtable - 嶋田紘也1, 博田舞子1, 藤田美涛1, 荻野未希1, 王恵理佳1, 宮崎有紀2, 大町由佳3, 江島彩子4, 佐久間理紗5, 野村貴一6, 中畔勇一7, 平岩知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1238-1238, 2020. |
|---|
|
|
P44-2. Regimen information to outside Parliament prescription, change of the patients outcome by the indication of the clinical test value 川口文誉1, 常木隆史1, 金子憲太郎1, 川村僚一朗1, 土井路子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1239-1239, 2020. |
|---|
|
|
P44-3. It is ... for the effect of the prescription notebook pasting regimen that we made in "a meeting thinking about the medicine medicine cooperation of the Chita Peninsula area" and the altitude pharmacy management practice of problem - area 奥田佳苗1, 伴晶子2, 土井直美2, 佐藤知香2, 古田麻衣子2, 森田奨2, 早川裕二3, 加藤雅斗3, 大平勇二4, 石川奈央佳4, 小田浩史5, 三島江津子6, 永松秀紹6, 堀崎和美7, 服部聡8, 上地小与里9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1239-1239, 2020. |
|---|
|
|
P44-4. Evaluation after the setup of the local cancer medicine medicine cooperation workshop and the operational start 片桐将志1, 佐野嘉容子1, 中西順子1, 篠永浩1, 原田典和1, 加地努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1240-1240, 2020. |
|---|
|
|
P44-5. We investigate a problem to improve the telephone medication follow approval rate to the foreign cancer medical treatment patients in the health insurance pharmacy assuming the medicine medicine cooperation 西村碧1, 横田恵子1, 田中真美1, 難波春香1, 松本久美子1, 田島香1, 門温子1, 吉留実慧子2, 尾上雅英3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1240-1240, 2020. |
|---|
|
|
P44-6. Efforts of "the Sapporo Higashi-ku cancer medical care pharmacist workshop" and usefulness evaluation - medicine medicine cooperation and local overall efforts ... 徳留章1,2,3, 鈴木直哉3,4, 辻裕太3,5, 藤村拓也3,6, 谷口亮央3,7, 菊池健3,8, 武田清孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1241-1241, 2020. |
|---|
|
|
P44-7. Examination ... of the usefulness of the tracing report in the cooperation reinforcement (3) - Swertia Herb station of a health insurance pharmacy and the hospital 清水有由実1, 後藤政之1, 岩井久美子1, 森厚司2, 舩木志保3, 石原祥子4, 大谷寧次郎4, 三浦毅4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1241-1241, 2020. |
|---|
|
|
P44-8. Construction of the drug control instruction record on the basis of drug control summary and PIMs 田畑寛明1, 若林厚史1, 辻依利1, 高橋彩1, 猿谷淳1, 向一美1, 地野幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1242-1242, 2020. |
|---|
|
|
P44-9. The effect that a prior agreement protocol gives to the duties reduction of the physician 間瀬広樹1,2, 有原大貴3, 矢野涼子4, 坂野由宇希5, 乙田雅章5, 綿谷敏彦5, 室谷理沙3, 山方基寛3, 齋藤讓一3, 秋山哲平3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1242-1242, 2020. |
|---|
|
|
P44-10. Evaluating the usefulness of holding a pharmaceutical-pharmaceutical-collaboration group work-type workshop for the dissemination of the "fava bean sticker", a notification sticker for patients with decreased renal function 飯塚康人1, 佐藤邦宣2, 村井華代3, 藤田雄一4, 溝井武尊5, 永田隆之1, 鈴木隆広6, 赤津雅美5, 吉川真一1, 渡邉義久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1243-1243, 2020. |
|---|
|
|
P44-11. Efforts to the medicine medicine cooperation using the inhalational instruction manual 吉本有里1, 飯田優美1, 東島幸道1, 佐澤卓哉1, 尾崎紗緒理1, 大坪輝行1, 大丸素子1, 伊南裕子1, 山脇一浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1243-1243, 2020. |
|---|
|
|
P44-12. About the duties burden reduction effect of the outside Parliament prescription doubt inquiry simplification protocol in the Kyoritsu Kanbara General Hospital 渡辺俊輔1, 竹下秀司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1244-1244, 2020. |
|---|
|
|
P44-13. Outcome inspection of the pharmacist cooperation by the interactive information sharing through the tracing report 河本由紀子1,2, 佐久間美佐緒2, 奥貞智2, 増本憲生2, 池末裕明2, 室井延之2, 橋田亨2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1244-1244, 2020. |
|---|
|
|
P44-14. Usefulness of the telephone follow-up for the Lenvatinib remedy patients in the health insurance pharmacy 岡水涼1, 春日真由1, 櫻下弘志2, 佐伯康之2, 畝井浩子2, 松尾裕彰2, 重留佳代子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1245-1245, 2020. |
|---|
|
|
P44-15. The prior agreement doubt inquiry protocol introduction effect in the outside Parliament prescription and personnel expenses reduction effect of the physician 内山将伸1, 宮崎元康1, 佐々木宏子2, 隠地智也3, 田宮彰子4, 横枕正隆5, 鵜木亜矢子1, 後藤美和1, 松尾宏一1, 今給黎修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1245-1245, 2020. |
|---|
|
|
P44-16. The operation of the practical participation type group discussion pattern study session using the virtual prescription of the cancer domain and the evaluation 三浦篤史1,2,3, 淺野未代子2, 鬼窪利英1,2, 大輪武司2, 中村久美1,2, 野村充俊1,2, 松原重征2, 向山百合1,2, 村田稔弥2, 吉澤貴代美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1246-1246, 2020. |
|---|
|
|
P44-17. The current situation investigation of the discharge teachers' textbook in the medicine medicine cooperation 稲葉未来1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1246-1246, 2020. |
|---|
|
|
P44-18. It is ... for the current situation investigation and the revision of cooperation reinforcement (1) - inhalation instruction request book, the report of a health insurance pharmacy and the hospital 野村祥子1, 石原祥子1, 大谷寧次郎1, 村松秀樹2, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1247-1247, 2020. |
|---|
|
|
P44-19. Evaluation of the physician for "the prior agreement protocol in the outside Parliament prescription" 山方基寛1, 間瀬広樹2, 矢野涼子3, 室谷理沙1, 齋藤讓一1, 秋山哲平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1247-1247, 2020. |
|---|
|
|
P44-20. Operational findings of the offer book such as medication information, and the like in the Kyoritsu Kanbara General Hospital 松本すずか1, 渡辺俊輔1, 竹下秀司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1248-1248, 2020. |
|---|
|
|
P44-21. Efforts (the second report) of the medicine medicine cooperation through foreign cancer treatment in our hospital 塚原邦浩1, 原田晃典1, 小倉秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1248-1248, 2020. |
|---|
|
|
P44-22. Evaluation of an investigation and the study session of feelings and the understanding degree of the insurance pharmacist before and after the medicine medicine cooperation study session of the cancer domain 小澤有輝1, 猪狩賢蔵1, 草野淳一1, 山本龍世1, 吉田蘭子1, 林誠一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1249-1249, 2020. |
|---|
|
|
P44-23. Efforts ... which collaborated in a health insurance pharmacy pharmacist, hospital pharmacist about health insurance pharmacy and cooperation reinforcement (2) - foreign inhalational instruction of the hospital 山洞直樹1,4,6, 清水有由実1,4, 増田博一1,5, 山田安夫1,4, 前田深佳子1,4, 圓城寺和胤1, 鳥飼明生1, 飯田昭宏1,2, 石原祥子1,2, 濱浦弘光1,2, 野村祥子1,2, 水野彩1,2, 木澤翠1,2, 高橋果歩1,2, 三浦毅1,2, 村松秀樹1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1249-1249, 2020. |
|---|
|
|
P44-24. Efforts report (the second report) - of the meeting thinking about medicine medicine cooperation activity - KAMAKURA medicine medicine cooperation in Kamakura-shi in 2019 宮田祐一1, 門谷靖裕1, 岩崎睦1, 小川亮子2, 鈴木大介2, 金林茂2, 中村雅敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1250-1250, 2020. |
|---|
|
|
P44-25. An evaluation of the medicine medicine cooperation business in the cancer domain and future problem 大澤友裕1, 安田昌宏1, 梅田道1, 渡邉久高1, 牧野哲平1, 長屋雄大1, 甲田明英1, 堀晃代1, 田中和秀1, 水井貴詞1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1250-1250, 2020. |
|---|
|
|
P44-26. Efforts aiming at improvement of the quality of the prescription notebook seal in the foreign cancer chemotherapy 其田学士1, 岩井裕香1, 森本明美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1251-1251, 2020. |
|---|
|
|
P44-27. Efforts of the hospital pharmacist for the childhood treatment at home 西川真璃絵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1251-1251, 2020. |
|---|
|
|
P44-28. Cooperation example after the hospital transfer utilizing the drug control summary with the writing a postscript of the multiple drug adjustment system 根上朋子1, 吉岡睦展1, 杉生雅和1, 石津智司1, 若松雄太1, 小澤拓1, 高子優子1, 馬淵英一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1252-1252, 2020. |
|---|
|
|
P44-29. Usefulness of the outside Parliament prescription doubt inquiry simplification protocol 野田聖奈子1, 柿原圭佑1, 原田智子1, 篠崎千尋1, 三上忠司1, 松尾琴美2, 城野美奈子3, 藤井裕史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1252-1252, 2020. |
|---|
|
|
P44-30. About the cooperation of a health insurance pharmacy and the medical institution utilizing the CKD seal 遠藤大介1, 木元慎一郎1, 和田泰明2, 鈴木岳瑠1, 加藤寛史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1253-1253, 2020. |
|---|
|
|
P44-31. Examination of stocktaking and the problem after the doubt inquiry simplification protocol introduction 北田絢子1, 飯塚由佳1, 天野正康1, 富田歩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1253-1253, 2020. |
|---|
|
|
P44-32. Questionary survey about the test value indication in the outside Parliament prescription 福澤美夕1, 西本辰徳1, 益崎和也1, 山崎恵子1, 清水裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1254-1254, 2020. |
|---|
|
|
P44-33. The making of the illness medicine cooperation tool in the follow-up to the use of drug patients for the medical care and the effect 山根孝太1, 熊谷岳文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1254-1254, 2020. |
|---|
|
|
P44-34. About the operation of the local inhalational instruction cooperation system to work on altogether in a hospital, a medical office, the health insurance pharmacy 江口彩香1, 水谷妙子1, 田中文1, 榊間絢子1, 横山征史1, 前澤優圭1, 浜至寛1, 登内盛治1, 蜂谷勤2, 浜峰幸2, 木本昌伸2, 平林太郎2, 高林康樹3, 小松佳道4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1255-1255, 2020. |
|---|
|
|
P44-35. An example of the regional alliances that made at-home return be successful from a local inclusion care ward 川村大輔1, 増田博也1, 久岡清子1, 高塚陽子2, 川口怜子2, 三浦朗子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1255-1255, 2020. |
|---|
|
|
P44-36. Establishment of Akabeko Net, a local pharmacist network 成田浩気1, 木本真司1, 河原史明1, 香内綾1, 安齊泰裕1, 原田伸彦1, 平山拓史1, 星美奈子1, 山田麻帆1, 木村俊介1, 塩川秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1256-1256, 2020. |
|---|
|
|
P44-37. Efforts to the cooperation full addition acquisition for improvement in quality of the foreign cancer chemotherapy 竹田優作1, 川瀬洋次1, 浅野寿規1, 杉野善彦1, 大島有美子1, 堀田敏之1, 桜田宏明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1256-1256, 2020. |
|---|
|
|
P44-38. Count investigation of the doubt inquiry contents for the outside Parliament prescription in our hospital 西澤英之1, 堀智貴1, 吉岡奈津恵1, 福森洋之1, 水川恵2, 生島繁樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1257-1257, 2020. |
|---|
|
|
P44-39. Construction of the local inhalational instruction cooperation system to work on altogether in a hospital, a medical office, the health insurance pharmacy 横山征史1, 水谷妙子1, 田中文1, 榊間絢子1, 江口彩香1, 前澤優圭1, 網野一真1, 登内盛治1, 蜂谷勤2, 濱峰幸2, 木本昌伸2, 平林太郎2, 高林康樹3, 小松佳道4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1257-1257, 2020. |
|---|
|
|
P44-40. A medical institution and the cooperation promotion DVD making of the health insurance pharmacy and evaluation by the audience questionnaire 川澄賢司1, 松井礼子1, 下村直樹2, 縄田修一3, 村田勇人4, 長久保久仁子5, 片倉法明6, 田中康裕7, 遠藤一司8, 安原眞人9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1258-1258, 2020. |
|---|
|
|
P44-41. Recognition investigation of the family drugstore in the Gifu comprehensive medical care center 田中佳子1, 渡部実咲1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1258-1258, 2020. |
|---|
|
|
P44-42. Allergic information sharing using the outside Parliament prescription 畑山未来1, 中野有瑛1, 工藤滉大1, 馬場啓貴1, 西舘尚子1, 坂口修治1, 中村一成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1259-1259, 2020. |
|---|
|
|
P44-43. The effect that a test value mention gives for use dose adequacy based on renal function on outside Parliament prescription 中野剛志1, 石坂敏彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1259-1259, 2020. |
|---|
|
|
P44-44. Usefulness of the medicine medicine cooperation of the pharmacist in patients with heart failure 萩野佑紀1, 筒井由佳1, 宮崎俊明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1260-1260, 2020. |
|---|
|
|
P44-45. Efforts for the cooperation full addition accompanied with the 2020 medical service fees revision 上淵未来1, 土井裕美子1, 志間裕介1, 伊藤裕美1, 泉勇成1, 西村秀洋2, 市川康子1, 藤井憲一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1260-1260, 2020. |
|---|
|
|
P44-46. Effect of the doubt inquiry prior agreement protocol introduction 鈴木剛1, 中居肇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1261-1261, 2020. |
|---|
|
|
P44-47. Efforts about the tracing report spread in Iwakuni-shi 尾崎誠一1,2, 廣子真大2, 河田尚己2, 渡辺宗男2, 松久哲章2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1261-1261, 2020. |
|---|
|
|
P44-48. Early effect on in-house prescription issuance of drugstore rate by the establishment in the hospital site 山田哲也1, 河村隆登1, 勝野晋哉1, 小崎耕自1, 水野尚章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1262-1262, 2020. |
|---|
|
|
P44-49. Is the doubt inquiry simplification protocol introduction useful? 小島一晃1, 松永富美代2, 山村裕佳子1, 森川智子1, 林愛華1, 松本弘誠1, 小西史子1, 仲忠士1, 美和孝之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1262-1262, 2020. |
|---|
|
|
P44-50. Practice second report of the medical treatment management based on the protocol that the hospital pharmacist for doubt inquiry from the health insurance pharmacy receives 工藤滉大1, 中野有瑛1, 馬場啓貴1, 坂口修治1, 中村一成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1263-1263, 2020. |
|---|
|
|
P45-1. Investigation about the disaster prevention awareness of the drugstore one year after the massive blackout caused by the typhoon 尾関佳代子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1264-1264, 2020. |
|---|
|
|
P45-2. The prospects of a pharmacist activity report of the quarantine inspection 14th day in the Cruise ship diamond Princess number and future pharmacist duties 坂口晋哉1, 福石和久1, 川俣洋生1, 高島伸也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1265-1265, 2020. |
|---|
|
|
P45-3. Effect as the multi-type of job cooperation disaster medical training of refuge administration game (HUG) 永田実沙1, 安原智久1, 上田昌宏1, 串畑太郎1, 曾根知道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1265-1265, 2020. |
|---|
|
|
P45-4. Upbringing - diabetes edition ... of the pharmacist who can contribute to disaster relief 滝澤康志1,2, 近藤智之2, 追木正人2, 井上陽平2, 雪本恵理子2, 安藤和佳子2, 下石和樹2, 細谷龍一郎2, 小林映子2, 谷村学2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1266-1266, 2020. |
|---|
|
|
P45-5. The current situation of the anti-disaster measures of the Okayama hospital pharmacy gate after the July, 2018 heavy rain and future problem 槇枝大貴1,2,3, 益本周治1,2,4, 崎代英樹1,2,5, 村川公央1,2,3, 森英樹1,2,6, 千堂年昭1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1266-1266, 2020. |
|---|
|
|
P45-6. Activity of our hospital drug department in Cruise inboard new coronavirus (COVID-19) outbreaks 生地美菜1, 篠田聡1, 野々下拓真2, 橋口宏司1, 有馬一成1, 中島研1, 關野長昭3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1267-1267, 2020. |
|---|
|
|
P46-1. Relationship of a BZD, non-BZD system sleeping drug and a fall, the fall in our hospital 中嶋丈晴1, 菅野和彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1268-1268, 2020. |
|---|
|
|
P46-2. Association of the VTE incidence after risk of developing clot score and the total hip replacement with the VTE prevention enforcement table of our hospital 針木志織1, 赤嶺聡彦1,4, 高平尚伸2,4, 冨澤淳1, 厚田幸一郎1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1269-1269, 2020. |
|---|
|
|
P46-4. - to think from the efficiency of the swing return marks of structure "duties not to put a burden on the duties of" days and the rebuilding of examination - manual which we are apt to leave unattended of the usefulness 野村真里1, 吉田明弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1270-1270, 2020. |
|---|
|
|
P46-5. Examination of the dispensing error decrease effect by the inspection using the pharmaceutical products authentication system 山本恭平1, 奥平正美1, 川井正光1, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1270-1270, 2020. |
|---|
|
|
P46-6. Contribution to the doubt inquiry content analysis to a resident and medical security 吉田ミチル1, 會澤玲奈1, 嶋田紘也1, 遠藤修司1, 後藤亨2, 平岩知子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1271-1271, 2020. |
|---|
|
|
P46-7. Side effect, the effect that the uniform management system of the allergic information gives in safety of the medical therapy 荒木良介1, 加藤加奈恵1, 長谷康史1, 山村翔1, 宇野崇之1, 浜本知之2, 田中恒明3, 山田英紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1271-1271, 2020. |
|---|
|
|
P46-8. The prior efforts which does not make the medical accident by pharmaceutical products or materials, and the like had 伊東健一1, 倉永高樹2, 田中美枝3, 松尾剛志4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1272-1272, 2020. |
|---|
|
|
P46-9. Evaluation from efforts using the OMOTENASHI application to the foreign patients in the health insurance pharmacy and the foreign patients 山川紘希1, 鈴木渉太2,3, 建山和代1, 諏訪由利香1, 垂井由季1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1272-1272, 2020. |
|---|
|
|
P46-10. Drug information offer construction and evaluation for nurses using SafeMaster 森岡淳子1, 須古杏子1, 山田美穂2, 杉松睦美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1273-1273, 2020. |
|---|
|
|
P46-11. Decision ... of the graded medication management method by efforts (the second report) - nursing department and the collaboration for the decision of an evaluation and the education of the oral medicine management method of the inpatient 小野歩1, 比毛有理子1, 阿部智恵子2, 武山陽子2, 守屋幸江2, 梶谷香奈子2, 石井勇太1, 片山潤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1273-1273, 2020. |
|---|
|
|
P46-12. The cause of the picking error for the human error prevention and consideration of the background factor 國分祐介1, 冨田敦和1, 羽田勝彦1, 今西忠宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1274-1274, 2020. |
|---|
|
|
P46-14. Change (the first report) of the number of the people of remedy situation by the fixed number storage medicine for sleeping drug change and fall, fall 奥鈴花1, 関恭子1, 大西政典1, 長井円香1, 芝本奈々1, 足立聡子1, 宮西有紗1, 盛重あずさ1, 池田咲樹1, 岸井加代子1, 先崎健造1, 長田知子1, 石本昌裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1275-1275, 2020. |
|---|
|
|
P46-15. To examine medicine targeted for efforts - doping in our hospital pharmacy for Kagoshima national polity 2020 quickly; ... 中野一馬1, 池沢若菜1, 森永崇史1, 豊留麻衣1, 田中恭人1, 北園幸大1, 山本梢1, 屋敷大輔1, 徳丸章佳1, 淵脇ゆかり1, 長ヶ原琢磨1, 荻尾夕起子1, 岸本真1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1275-1275, 2020. |
|---|
|
|
P46-16. Change of the contents of doubt inquiry by sharing it in a medical safe section 川崎文雄1,2, 若林沙季1, 瀬戸梓1, 与那城知夏1, 奥西美奈1, 小室寿子2, 兒島正裕2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1276-1276, 2020. |
|---|
|
|
P46-17. Examination of the development prevention effect of the medicine blunder by the GS1 cord authentication system introduction 道内玲奈1, 西田承平1, 小森善文1, 丹羽隆1, 津村直樹2, 矢島睦門3, 太田雅弘3, 丹羽道夫3, 飯原大稔1, 小林亮1, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1276-1276, 2020. |
|---|
|
|
P47-1. Examination about the duties burden on enforcement situation and staff of the pharmacy education model core curriculum 2013 revised edition pharmacy student business training in the middle scale hospital 宗像千恵1,2, 村山裕一2, 執行優希2, 江口功一2, 西村信弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1277-1277, 2020. |
|---|
|
|
P47-2. Investigation about the simple suspension method training in a drugstore, the hospital business training 青山京介1, 舘知也1, 高岡みらい1, 久保賢晃1, 林剛1, 野口義紘1, 寺町ひとみ1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1278-1278, 2020. |
|---|
|
|
P47-3. Research about the basic nature sought as a pharmacist of the student in the business training 久保賢晃1, 舘知也1, 高岡みらい1, 青山京介1, 林剛1, 野口義紘1, 寺町ひとみ1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1278-1278, 2020. |
|---|
|
|
P47-4. Investigation about efforts and the learning turn of eventss for the inclusion of 8 representative diseases 小森智也1, 勝亦秀樹1, 山下美乃里1, 森直樹1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1279-1279, 2020. |
|---|
|
|
P47-5. The investigation that understanding deepens for the local action of the pharmacist by a pharmacy student acting as the lecturer of the patients briefing session in the long-term business training and examination 森厚司1, クロスビー智美1, 吉田和美1, 櫻井真理子1, 山本有人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1279-1279, 2020. |
|---|
|
|
P47-6. It is a learning effect using refuge administration game (HUG) for a revision pharmacy education model core curriculum "disaster medical care and pharmacist" 徳田衡紀1, 益本周治1, 松山祐1, 谷口恵美1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1280-1280, 2020. |
|---|
|
|
P47-7. The instruction situation investigation of 8 representative diseases in the pharmacy business training 山中俊哉1, 田中佳子1, 関谷泰明1, 井上壽江1, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1280-1280, 2020. |
|---|
|
|
P47-8. Change of the understanding degree of the pharmacy school business trainee through the antitumor agents preparation training 飯塚俊介1, 佐々木祐樹1, 鶴崎大1, 北野徹1, 菊池憲和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1281-1281, 2020. |
|---|
|
|
P47-9. Examination about 8 representative disease learning opportunities by confirmation of the bringing medicine of the pharmacy student 伊賀正典1, 高野温志1, 高野明香1, 前田華奈子2, 横山未来2, 藤掛佳男2, 町田充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1281-1281, 2020. |
|---|
|
|
P47-10. Other types of job experience-based training introduction to revision pharmacy education business training and the evaluation 小泉盛1, 新井優1, 横田敬之1, 土谷真幹1, 竹沢卓也1, 林良行1, 岸野亨1, 谷島成子2, 川村利江子3, 小峰美仁4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1282-1282, 2020. |
|---|
|
|
P47-11. Drugstore, medication counseling enforcement situation - pharmacist of 8 representative diseases in the hospital training can teach the approach method to a compound disease to a student; or ... 渡邉正教1, 中沢修司1, 日比徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1282-1282, 2020. |
|---|
|
|
P47-12. Attitude survey of the business trainee for 8 representative diseases of the revision pharmacy education model core curriculum 前川祐美1, 高橋功一1, 立道貴清1, 辻繁子1, 加地雅人1,2, 田中裕章1, 二宮昌樹3, 芳地一1,3, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1283-1283, 2020. |
|---|
|
|
P47-13. After inspection - business training of the hospital training curriculum change with the revision model core curriculum from a comparison of the questionary survey - 高橋里奈1, 本多秀俊1, 林由紀子1, 服部裕子2, 杉浦宗敏2, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1283-1283, 2020. |
|---|
|
|
P47-14. Questionnaire analysis about the understanding degree of the trainee in the drugstore business training in conformity with the revision pharmacy education model core curriculum and the satisfaction 吉田都1, 内田享弘1, 大川恭子1, 笠井眞二1, 政田啓子1, 原口珠実1, 藤原由梨1, 池上咲枝里1, 井上智咲1, 波多江崇2, 森山賢治1, 中村一基1, 篠塚和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1284-1284, 2020. |
|---|
|
|
P47-15. Questionnaire analysis about the understanding degree of the trainee in the hospital business training in conformity with the revision pharmacy education model core curriculum and the satisfaction 小島穂菜美1, 吉田都1, 内田享弘1, 桑原晶子1, 豊原朋子1, 濱宏仁1, 辻本勉1, 片岡和三郎1, 綿本有希子1, 田崎眞生1, 波多江崇2, 森山賢治1, 中村一基1, 篠塚和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1284-1284, 2020. |
|---|
|
|
P47-16. Than outcome and factor analysis - student questionary survey that learned in hospital business training most ... 片岡憲昭1, 倉地果純1, 窪田理沙1, 坂井紀水1, 鈴木典子1, 西原雅美1, 角山香織2, 中村敏明2, 内山和久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1285-1285, 2020. |
|---|
|
|
P47-17. The construction of the program that pointed to the exhaustive learning of 8 representative diseases and the inspection 麻那古信之1, 嶺尾里奈1, 廣部祥子1,2, 山本智也1, 前田真一郎1,2, 渡邊梓1, 門脇裕子1, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1285-1285, 2020. |
|---|
|
|
P47-18. Efforts and the usefulness for the business training in conformity with the revision pharmacy model core curriculum in the middle scale hospital 蛯子卓也1, 山田航輔1, 高橋雅也1, 船木映二1, 橋本義宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1286-1286, 2020. |
|---|
|
|
P47-19. Introduction and evaluation of physical assessment education in long-term practical training 川崎元弘1, 尾崎誠一1, 三好浩一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1286-1286, 2020. |
|---|
|
|
P47-20. Investigation about the current situation and the problem of the long-term business training in our hospital accompanied with the start of the revision model core curriculum 伊東千佳1, 成田勇樹1, 城野博史1, 内田隆1, 伊藤祐子1, 清住友香1, 山下諒祐1, 山辺雄太1, 大坪謙一1, 林明佳1, 榎田裕紀1, 新屋諒1, 吉井美香1, 近藤昭志1, 政賢悟1, 田中順子1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1287-1287, 2020. |
|---|
|
|
P48-1. Research design for formulary workshops aimed at improving ability to evaluate drug information 金井紀仁1, 宮崎美子2, 宮本拓也3, 永瀬真理子4, 安藤正純5, 佐藤光6, 吾妻隼斗7, 澤田雄太8, 奈良部修弘9, 下館桃子10, 吉岡克幸11, 小田慎12, 矢嶋美樹13, 高橋邦雄14, 稲生和彦15, 勝俣はるみ16, 齋藤俊夫17 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1288-1288, 2020. |
|---|
|
|
P48-2. Effect on ability for thought, solution to the problem by the simulation training 福井里佳1, 松田雅史1, 巖西真1, 池田義人1,2, 長谷川千晶1, 日置三紀1, 平大樹1,3, 戸川香代4, 川口晃4, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1289-1289, 2020. |
|---|
|
|
P48-3. About the cooperation with the veterinary school in the pharmacist education that aimed at professional ability expansion 杉山育美1, 佐塚泰之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1289-1289, 2020. |
|---|
|
|
P48-4. Fourth-year students' awareness survey on drug information and initiatives for formulary education 上田昌宏1, 向井啓2, 串畑太郎1, 永田実沙1, 安原智久1, 曽根知道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1290-1290, 2020. |
|---|
|
|
P48-5. Usefulness of "the medicine classroom" about the proper use of the medicine as the local community enlightenment activity 中村真理子1, 佐治凪帆1,2, 河西初音1,2, 野口健1,2, 間宮隆吉3,4, 鍋島俊隆4, 野田幸裕1,2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1290-1290, 2020. |
|---|
|
|
P48-6. ... which behavior of the MR was turned into by a visit to example - pharmacy of the rapid effect that we took example by in the MR education by lube Rick evaluation 日比徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1291-1291, 2020. |
|---|
|
|
P48-7. A comparison between actual situation and prevention of drug abuse education of the drug abuse in Japan and foreign countries and attitude survey of the student 網岡克雄1, 等浩太郎1, 山下史佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1291-1291, 2020. |
|---|
|
|
P49-1. About efforts of the introduction of IT in the Saitama hospital pharmacist society 田村賢士1,2, 金子智一1,2, 近藤正巳1,3, 中村房子1, 北澤貴樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1292-1292, 2020. |
|---|
|
|
P49-2. Questionary survey for the purpose of the activity support of the healthy support drugstore 本田桃佳1, 水野智博2, 大島秀康3, 梅田孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1293-1293, 2020. |
|---|
|
|
P49-3. New face educational program - result and reflection ... from a business training curriculum 日比陽子1,2, 長水正也1, 神田光司1, 久田宜範1, 諸角一成1, 佐藤由美子1, 中村康夫1, 森下修行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1293-1293, 2020. |
|---|
|
|
P49-4. Attempt of the postgraduate education training of the hospital pharmacist by the collaboration with the pharmacy school 坂倉智子1, 稲野寛1, 小山郁美1, 婦川貴博2, 毛利順一2, 岩澤真紀子2, 堀井剛史2, 東山倫子2, 瀬戸良教1, 寺松洋美1, 山本悠樹1, 近藤留美子1, 平山武司1,2, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1294-1294, 2020. |
|---|
|
|
P49-5. Usefulness evaluation about the germfree preparation practical skill seminar for health insurance pharmacy pharmacists 音窪麻衣1, 内田まやこ1, 井上薫1, 金美惠子1, 河合悦子2, 中村敏明1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1294-1294, 2020. |
|---|
|
|
P49-6. Focus on upbringing - member of society basic skills of the non-expert skill through the clinical ladder; and ... 新井亘1, 土屋裕伴1, 中里健志1, 増田裕一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1295-1295, 2020. |
|---|
|
|
IP02. A HPLC method for analysis of methotrexate in human cerebrospinal fluid and comparison with the chemiluminescence immunoassay Naoki Yoshikawa1, Ai Yamada2, Tsubasa Yokota1, Hiroshi Moritake2, Yasutoshi Hirabara1, Ryuji Ikeda1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1297-1297, 2020. |
|---|
|
|
IP03. The lifecycle management of pharmaceuticals by using barcodes and RFID tags Takao Orii1,2, Kouichi Uemura2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1298-1298, 2020. |
|---|
|
|
IP04. Effects of dopamine uptake inhibitors and dopamine receptor agonists on motivational behavior using the runway model of intracranial selfstimulation behavior in rats Satoru Esumi1, Yoshihisa Kitamura1,2, Soichiro Ushio1, Yudai Wada1, Yutaka Gomita1, Toshiaki Sendo1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1299-1299, 2020. |
|---|
|
|
IP05. Study for mechanisms of Hochuekkito against inflammation-induced anxiety-like behavior Soichiro Ushio1, Yudai Wada1, Satoru Esumi1, Makoto Kajizono1, Yoshihisa Kitamura1,2, Toshiaki Sendo1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1300-1300, 2020. |
|---|
|
|
IP06. Survey on the Pharmaceutical Industry's Contribution and Perspective for Improving Access to Medicines and Global Health Yukino Yoshida1, Hisashi Urushihara1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1300-1300, 2020. |
|---|
|
|
IP07. Reinforced collaboration between community pharmacies and hospital for the management of oral anti-cancer therapy using information sharing tools and team-based learning Risa Ueda1, Masaaki Tanda1, Takahiro Ito1, Ayaka Enomoto1, Masashi Iida1, Naomi Mizuta1, Kazuhiro Yamamoto1, Hiroo Makimoto1, Tomohiro Omura1, Eikuko Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1301-1301, 2020. |
|---|
|
|
IP08. Effects of pharmacist-led antimicrobial stewardship programme in urological patients Atsushi Uda1, Katsumi Shigemura2,3,4, Koichi Kitagawa3,5, Kayo Osawa3,6, Ken-Ichiro Onuma2, Shigeaki Inoue7, Joji Kotani7, Yonmin Yan4, Yuzo Nakano4, Tatsuya Nishioka1, Takayuki Miyara2, Masato Fujisawa4, Ikuko Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1301-1301, 2020. |
|---|
|
|
IP12. Association analysis of coadministrated drugs in patients with serotonin syndrome using big data Hideyuki Terazono1, Tomohisa Yamasaki1, Taiyo Arima1, Takayuki Takahashi1, Yasuo Takeda1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1303-1303, 2020. |
|---|
|
|
... that the concentration of the "front line of the team approach in medical care in the cancer chemotherapy" - pharmacist power improves patients power 木本真司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1305-1305, 2020. |
|---|
|
|
The characteristic of the bony formation accelerating agent and future problem 齋藤琢1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1306-1306, 2020. |
|---|
|
|
Clinical ... opioid proper use and side effect management ... of the cancer pain demanded from a generalist 里美絵理子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1307-1307, 2020. |
|---|
|
|
Interim report - from the methodology development - Atsushi trouble special study Imai group of the formula reenforcement of our country 今井博久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1308-1308, 2020. |
|---|
|
|
The problem of polypharmacy measures and the future prospects 溝神文博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1309-1309, 2020. |
|---|
|
|
Type 2 diabetes treatment - condition of a patient grasp, improvement of the quality of the treatment, reduction - of the patient's share of medical expenses in consideration of patients background 飯塚勝美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1310-1310, 2020. |
|---|
|
|
Role ... of the pharmacist in the tips - HIV team approach in medical care to play an active part as a pharmacist 平野淳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1311-1311, 2020. |
|---|
|
|
Practice from tomorrow! - What pharmacists can contribute to in HIV treatment and what they aim to achieve - 石原正志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1312-1312, 2020. |
|---|
|
|
About the capecitabine treatment of elderly patients 安藤雄一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1313-1313, 2020. |
|---|
|
|
Light and shadow of the antithrombotic therapy 石井秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1314-1314, 2020. |
|---|
|
|
Policy ... to improvement in bottom line ... patients satisfaction of the GERD practice 春日井邦夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1315-1315, 2020. |
|---|
|
|
We think about an effective dose of TM alfa for the sepsis-related DIC 今浦将治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1316-1316, 2020. |
|---|
|
|
It is ... about the proper use of insomnia treatment strategy - sleeping drug 内村直尚1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1317-1317, 2020. |
|---|
|
|
Through an appropriate prescription choice based on Chinese medicine - scientific evidence to contribute to side effect reduction of cancer treatment of patients with cancer - 上園保仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1318-1319, 2020. |
|---|
|
|
... which thinks about guidelines of the antiemesis therapy Up to Date - world 村上通康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1320-1320, 2020. |
|---|
|
|
The basics and clinical practice of the compound immune therapy 三浦理1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1321-1321, 2020. |
|---|
|
|
irAE measures of the compound immune therapy 吉野真樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1322-1322, 2020. |
|---|
|
|
Challenge to the medical innovation using Muse cells 出澤真理1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1323-1323, 2020. |
|---|
|
|
The current situation and the prospects of the dementia practice 羽生春夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1324-1324, 2020. |
|---|
|
|
Medical system ... to aim at than online practice under the infection spread and cooperation ... past proof example of the online medication counseling in COVID-19 in the future 高野秀雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1325-1325, 2020. |
|---|
|
|
New Developments in Treatment Strategies for HER2-Positive Inoperable or Recurrent Breast Cancer - Ingenuity to bring out the POTENTIAL of Enhertu(R) - 中山貴寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1326-1326, 2020. |
|---|
|
|
It is ... mainly on management of the pharmacist outpatient department ... Abemaciclib to begin from tomorrow 橋本直弥1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1327-1327, 2020. |
|---|
|
|
Evidence of Verzenio and experience of its use at our hospital - What pharmacists should know about hormone receptor-positive metastasis and recurrent breast cancer treatment - 吉村章代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1328-1328, 2020. |
|---|
|
|
It is ... from a comparison with clinical ... inborn character-related hemophilia of acquired hemophilia 朝倉英策1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1329-1329, 2020. |
|---|
|
|
With the role that a pharmacist fulfils for safe cancer treatment? From ... occupation characteristics exposure measures to COVID-19 土屋雅美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1330-1330, 2020. |
|---|
|
|
Role of the multi-type of job team approach in medical care for improvement in patients power in cancer treatment 上野直人1, 小室雅人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1331-1331, 2020. |
|---|
|
|
It is ... through utilization of the pharmacist outpatient department in role - IMiDs prescription patients of the pharmacist in the ambulatory practice of patients with blood-forming organ tumor 大橋養賢1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1332-1332, 2020. |
|---|
|
|
Role of the JAK inhibitor in rheumatoid arthritis treatment 森信暁雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1333-1333, 2020. |
|---|
|
|
The herpes zoster as the side effect of the JAK inhibitor and the management 渡辺大輔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1334-1334, 2020. |
|---|
|
|
Treatment of osteoarthritis, spondylosis: Domestic and foreign guidelines and paradigm shifts 川口浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1335-1335, 2020. |
|---|
|
|
Heart failure team approach in medical care (including palliative care) in the super aging society 佐藤幸人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1336-1336, 2020. |
|---|
|
|
ICT and AI (artificial intelligence) which are utilized in the way and the healthcare setting of the drug information in the corona in after 木村隆夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1337-1337, 2020. |
|---|
|
|
The database construction of the own institution is easily possible in digital information administration - AI-PHARMA to bring about valuable information! - 神崎浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1338-1338, 2020. |
|---|
|
|
Effect of the equol on development and problem ... women health care of the reproductive medicine 杉浦真弓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1339-1340, 2020. |
|---|
|
|
It is ... that is necessary for contribution - super-aged society of the pharmacist to the town planning that is kind to dementia 遠藤英俊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1341-1342, 2020. |
|---|
|
|
About a quality drop and prevention of the biomedicine 内山進1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1343-1343, 2020. |
|---|
|
|
We overlook the pharmaceutical products proper use in consideration of renal function in the outpatient department 近藤悠希1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1344-1344, 2020. |
|---|
|
|
Let's start TDM - Construction and prospects for a new blood concentration measurement system - 尾田一貴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1345-1346, 2020. |
|---|
